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1. Introduction 
Aldehyde dehydrogenases (ALDH) belong to the oxidoreductase family, which catalyze the 
conversion of aldehydes to their corresponding acids. As a group of NAD(P)+-dependent 
enzymes, aldehyde dehydrogenases (ALDHs) are involved in oxidation of a large number of 
aldehydes into their weak carboxylic acids (Moreb, et al., 2012). ALDH is found in every 
subcellular region such as cytosol, endoplasmic reticulum, mitochondria, and the nucleus, 
with some even found in more than one location (Marchitti, et al., 2008). 
ALDH is also found in stem cells. During early life and growth, stem cells (SCs) have a 
spectacular potential to develop into several cell types in the body. In many tissues, SCs 
behave as a kind of internal repair system, dividing essentially without limit to replenish 
other cells (Fuchs & Segre, 2000). Stem cells are distinguished from other cell types by two 
important characteristics: (1) Their unspecialized properties and renewal potencies; and (2) 
differentiation into other cell types under certain physiologic or experimental conditions 
(Discher, et al., 2009, Solis, et al., 2012). These cells are identified by their expression of a 
particular panel of surface molecules, with the presence of CD73, CD90, CD105, and the 
absence of CD14, CD34, CD45, and HLA-DR. They show no proliferative response from 
alloreactive lymphocytes because of the negligible levels of extracellular MHC class I and II 
determinants and they also have important immunomodulatory functions in all the cells 
involved in both the innate and adaptive immune responses (Nauta & Fibbe, 2007). On the 
other hand, cancer stem cell theory is supported by biological reason for aging. The theory 
postulates that cancer SCs, a small subset of tumor cells also have stem cell-like properties 
(epithelial-to-mesenchymal progression, differentiation and self-renewing capacity). ALDH 
expression has demonstrated itself to be a possibly relevant prognostic marker. For this 
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reason, the subpopulation of cancer SCs (CSCs) can present a therapeutic target for poor-
prognostic, treatment-resistant and recurrent breast cancer. Through its role in oxidizing 
retinol to RA, which is a modulator of cell proliferation, ALDH1 might have a role in early 
differentiation of SCs and stem cell proliferation (Mieog, et al., 2012). 
There are several isoforms of ALDH (ALDH1A1, ALDH1A2, ALDH1A3 and ALDH8A1) 
that play a role in RA formation by oxidation of all-trans-retinal and 9-cis-retinal in RA cell 
signaling, which has been related to the “stemness” characteristics of SCs (Marcato, et al., 
2011). ALDH1 is better as a marker of breast cancer SCs than CD44+/CD24- (Tanei, et al., 
2009). While cellular markers including CD133 have been used to identify tumor SCs, 
especially for glioblastomas (GBMs) ALDH1 was desrcribed as a marker for the 
identification of non-neoplastic SCs and tumor stem cells (TSCs) (Corti, et al., 2006, 
Ginestier, et al., 2007, Huang, et al., 2009).  
After CD133- GBMs are characterized to behave as brain TSCs(Beier, et al., 2007). ALDH1 
has also been described as a stem cell marker in various solid neoplasms including lung 
cancer (Jiang, et al., 2009), breast carcinoma (Ginestier, et al., 2007), colorectal cancer (Huang, 
et al., 2009), and GBM. ALDH1B1 and ALDH1A1 are differentially expressed in normal 
human tissues. ALDH1B1 is expressed at higher levels than ALDH1A1 in human epithelial 
cancers. ALDH1B1 was abundantly expressed in adenocarcinomas originating from the 
tissue and particularly in colonic adenocarcinoma (Chen, et al., 2011).  
ALDHbr cells can be detected with ALDEFLUOR reagent by using flow cytometry or 
fluorescent microscopy. Aldefluor assay is based on the conversion of fluorescent non-toxic 
substrate for ALDH substrate to the fluorescent reaction product. Non-toxic substrate for 
ALDH can freely diffuse into intact, viable cells. The BODIPY aminoacetaldehyde is 
converted to the fluorescent product BODIPY aminoacetate by ALDH activity. These cell 
populations, which are known as ALDH bright (ALDHbr) cells are isolated from adult 
tissues by flow sorting. ALDHbr cells were also found in various cancer tissues including 
breast, liver, colon, pancreas, prostate, lung, ovarian and acute myelogenous leukemia and 
are related to cancer chemo resistance (Siclari & Qin, 2010). 
ALDHbr population may play an important role in regenerative medicine. The regenerative 
potential of ALDHbr cells obtained from different tissues was investigated in various disease 
models such as ischemic tissue damage, hind limb model, brain damage (spinal motor 
atrophy, etc.) and pancreatitis.  
Thus, as mentioned above, ALDH is an important enzyme for cancer and stem cells. This 
chapter aims to represent the important role of aldehyde dehydrogenases in stem cells, 
cancer stem cells, therapy and regenerative medicine. 
1.1. Aldehydes 
Aldehydes are formed in various physiological processes such as catabolism of transmitters 
like GABA, serotonin, adrenaline, noradrenaline and dopamine, as well as catabolism of 
amino acids. In addition, there are more than 200 different aldehydes that are produced 
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through lipid, and aldehydic intermediates through carbohydrate metabolism. Along with 
these endogenous aldehydes, there are also exogenously present aldehydes in a variety of 
industrial processes, including the production of polyester plastics (formaldehyde, 
acetaldehyde, acrolein, etc.), polyurethane, smog, cigarette smoke or motor vehicle exhaust. 
With their malodorous properties, some dietary and aromatic aldehydes are accepted as 
additives in food and cosmetics (e.g., citral, cinnamaldehyde, benzaldehyde, and retinal), 
though many others are cytotoxic (Chen, et al., 2010). Aldehydes could interact with thiol 
compounds of some proteins, leading to structural and functional alterations of these 
molecules (Weiner, et al., 2008). In order to protect the human body from the deleterious 
effects of aldehydes in general, and myocardium and the brain in particular, a fast aldehyde 
detoxification mechanism is essential. Aldehydes are significantly reactive and possess high 
diffusion capacities in cells, thus they can easily form complexes with DNA, proteins and 
lipids, of which they can alter the function and cause their inactivation. As a result of DNA 
damage induced by these complexes, many aldehydes are classified as mutagenic or 
carcinogenic, including acetaldehyde, which is derived from ethanol consumption. Over–
consumption of ethanol has been related to liver disease and several gastrointestinal and 
upper aerodigestive cancers. Numerous other cytotoxic and reactive aldehydes have been 
shown to be linked with other types of diseases (Hofseth & Wargovich, 2007, Perluigi, et al., 
2009, Chen, et al., 2010). 
1.2. Aldehyde dehydrogenases 
Aldehyde dehydrogenases [EC 1.2.1.3; systematic name: aldehyde: NAD(P)+oxidoreductase] 
catalyze aldehyde conversion into their matching acids by NAD(P)+-dependent nearly 
irreversible reaction. In 1949, mammalian ALDH was first discovered in ox liver. After that, 
many types of ALDH were distinguished according to their physico-chemical 
characteristics, enzymological properties, subcellular localization, and tissue distribution 
(Oraldi, et al., 2011). They are involved in several cell functions such as proliferation, 
differentiation, survival as well as cellular response to oxidative stress (Jackson, et al., 2011). 
ALDHs are commonly delivered from bacteria and humans (Moreb, 2008). Based on their 
physico-chemical characteristics, subcellular localization, tissue distribution and 
enzymological properties, a number of types of ALDH have been distinguished since the 
1960s, around the time when mammalian ALDH activity was observed in ox for the first 
time. In 1985, 2 ALDH genes were cloned and characterized. Genes or cDNAs for more than 
50 animals, fungi and bacterial ALDHs in addition to protein sequences have been 
discovered (Yoshida, et al., 1998).  
The human genome contains 19 ALDH functional genes and 3 pseudogenes (Black, et al., 
2009).  At least 5 ALDH isozymes function in the mitochondria, and all the ALDH genes are 
encoded in the nucleus (Chen, et al., 2010). 
All of the ALDH gene superfamily plays an important role in the enzymic detoxification of 
endogenous and exogenous aldehydes. They are also involved in the formation of molecules 
that are important in cellular processes like RA, betaine and gamma aminobutyric acid 
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formation. Furthermore, ALDHs also have several non-enzymic functions such as binding 
to some hormones and other small molecules and decreasing the effects of ultraviolet 
irradiation in the cornea (Pappa, et al., 2003, Wymore, et al., 2004). The most important role 
of ALDHs is detoxification of aldehydes, which caused cytotoxicity, mutagenicity, 
genotoxicity, and carcinogenesis in healthy cells. Mutations in ALDH genes cause severe 
diseases including Sjögren-Larsson syndrome, pyridoxine-dependent seizures, and type II 
hyperprolinemia, and also plays a role in cancer and Alzheimer's disease (Black, et al., 2009). 
Functions of some of these ALDHs in endobiotic and xenobiotic metabolisms have been 
highly reviewed before and the distinctive metabolic pathways' influences have been 
depicted. Because of their chemical reactivity, many distinct aldehydes are pervasive in 
nature and are toxic at low levels. Hence, levels of metabolic-intermediate aldehydes should 
be cautiously regulated. The presence of several distinct ALDH families in most studied 
organisms seem to have wide fundamental tissue distribution. A wide range of allelic 
variants within the ALDH gene family have been identified, leading to heterogeneity in 
pharmacogenetic characteristics between individuals, resulting distinctive phenotypes 
including intolerance to alcohol and increased risk of ethanol-induced cancers in most cases 
(ALDH2 and ALDH1A1), Sjogren-Larson Syndrome (ALDH3A1), type II hyperprolinemia 
(ALDH4A1), 4-hydroxybutyric aciduria, mental retardation and seizures (ALDH5A1), 
developmental delay (ALDH6A1), hyperammonemia (ALDH18A1), Pyridoxine-dependent 
epilepsy (ALDH7A1), and late-onset Alzheimer’s disease (ALDH2). 
ALDH dysfunction could also be caused by drugs and environmental substances, substrate 
inhibition, as well as oxidative and metabolic stress. ALDH activity in drug resistance to 
oxazaphosphorines is one of the most vigorously studied pathways. The role of ALDH1A1 
in drug resistance has been studied first in hematopoietic progenitors and more recently in 
lung cancer (Marchitti, et al., 2008). 
2. Stem cells  
During early life and growth, SCs have a spectacular potential to develop into several cell 
types in the body. In many tissues, SCs behave as a kind of internal repair system, dividing 
essentially without limit to replenish other cells (Weissman, 2000). Stem cells are 
distinguished from other cell types by two important characteristics: First, they are 
unspecialized cells and, sometimes after long periods of inactivity, they can renew 
themselves through cell division; second, under certain physiologic or experimental 
conditions, they are naturally sensitive to their environment, responding to chemical, 
physical, and mechanical features of their matrices or substrates (Discher, et al., 2009, Solis, 
et al., 2012).  
Until recently, scientists primarily worked with two kinds of SCs from animals and 
humans: embryonic SCs and non-embryonic "somatic" or "adult" SCs (Feng, et al., 2009). 
In 1981, scientists discovered ways to derive embryonic SCs from mouse embryos. In 1998, a 
detailed study of the biology of mouse SCs led to the discovery of a method to derive SCs 
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from human embryos and grow the cells in the laboratory, and these cells are called human 
embryonic SCs.  
In 2006, genetically "reprogrammed" stem-cell-like cells were identified by using specialized 
adult cells. This new type of stem cell is called induced pluripotent SCs (iPSCs) (Krishna, et 
al., 2011). 
2.1. Cancer stem cells  
Cancer is a class of diseases characterized by unregulated cell growth(Deisboeck, et al., 
2011). Cancer initiation depends on genetic mutations in series that affects cellular 
programming. Many cancer researches have focused on the identification and 
characterization of these genetic and molecular properties of cancer cells (Balmain, et al., 
2003). Tumors are also heterogeneous cellular entities whose growth is dependent upon 
dynamic interactions among the cancer cells themselves, and between cells and the 
constantly changing microenvironment (Bissell & Radisky, 2001). That kind of interaction is 
depent on signaling through cell adhesion molecules and different cell responses to growth 
factors and other external signals. All of these interactive processes act together to control 
cell phenotypic behaviors such as proliferation, apoptosis, and migration. There are over 100 
different types of cancer, and each is classified by the type of cell that is initially affected 
(Lakshmi Prasanna & Sathish Kumar, 2011). 
According to recent statistics, cancer accounts for about 23% of the total deaths in the USA 
and is the second most common cause of death after heart disease (Jemal, et al., 2007).  
Cancer is caused by many internal and external factors. Inherited mutations, hormones, 
and immune conditions are internal factors while tobacco, diet, radiation, and infectious 
organisms are environmental/acquired factors (Kalluri & Weinberg, 2009, Nagy, et al., 
2010, Langley & Fidler, 2011, Mantel & Schmidt-Weber, 2011, Noman, et al., 2011). In 
recent years, a particular sub-population of tumor cells are said to have a critical role in 
cancer; these cells are commonly called CSCs or tumor initiating cells (TICs). In most 
cancer types, CScs have been identified. CSCs are characterised by their two important 
properties: (1) Enhanced tumorigenicity; and (2) the capacity for self-
renewal/differentiation (Bonnet & Dick, 1997, Al-Hajj, et al., 2003). Thus, isolating CSCs is 
important in analyzing their characteristics in vitro. The isolated CSC population will not 
only give rise to de novo tumors with high efficiency, but will also recapitulate the tumor 
with both CSC and non-CSC populations.  
One potential human CSC marker is the membrane antigen CD133 (Prominin) identified in 
subpopulations of cells in brain, colon and lung tumors (Singh, et al., 2004, Ricci-Vitiani, et 
al., 2007, Eramo, et al., 2008). CD133+ tumor cells are also a marker identifying lung CSCs 
(Wang, et al., 2008, Salnikov, et al., 2010). 
The expression and activity of ALDHs is determined as another potential CSC marker 
(Ginestier, et al., 2007). ALDH1 is a marker of normal and malignant human mammary SCs 
and a predictor of poor clinical outcome (Huang, et al., 2009). Aldehyde dehydrogenase 
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enzymes participate in cellular detoxification, differentiation and drug resistance through 
the oxidation of cellular aldehydes (Moreb, et al., 1996).  
The functional activity of ALDH has been widely used to identify and isolate CSCs found in 
the bone marrow (Ran, et al., 2009), breast (Ginestier, et al., 2007), lung (Ucar, et al., 2009), 
ovary (Deng, et al., 2010), colon (Huang, et al., 2009), prostate (van den Hoogen, et al., 2010), 
and pancreas (Dembinski & Krauss, 2009). 
2.2. Stem cell markers 
The derivation of SCs from adult tissues, their relative ease of isolation and enormous 
expansion potential in culture make them attractive therapeutic candidates (Prockop, et al., 
2010). These cells are identified by their expression of a particular panel of surface 
molecules, with the presence of CD73, CD90, CD105, and the absence of CD14, CD34, CD45, 
and HLA-DR. They show no proliferative response from alloreactive lymphocytes because 
of the negligible levels of extracellular MHC class I and II determinants. SCs also have 
important immunomodulatory functions in all the cells involved in both the innate and 
adaptive immune responses (Nauta & Fibbe, 2007). 
3. ALDH as a stem cell marker 
In theory, ALDH isozymes including ALDH1A, ALDH1A2, ALDH1A3, and ALDH3A1, 
which are involved in drug resistance and RA formation, are vital in protecting SCs against 
toxic endogenous and exogenous aldehydes and for SCs' ability to differentiate, 
respectively. It is unknown what ALDH isozymes are responsible for the ALDH activity 
that are used to identify stem cell progenitors. In the overlap gene profile of different stem 
cell populations, ALDH7A1, known as antiquitin, and ALDH2 were identified, 
consequently, and are worthy of further investigation. There is more about ALDH to be 
explored as a cause of its full physiological function has remained elusive. ALDH7A1 is a 
green pea 26g protein, which has function in regulation of turgor pressure, and has ≥50% 
amino acid identity with the 3 pseudogenes in the ALDH family. It also has 69% equity with 
ALDH2, but nevertheless has considerably lower affinity for acetaldehyde than ALDH2. 
However, ALDH2, which is a mitochondrial enzyme, has been widely studied mostly for its 
affilitation with ethanol metabolism. Yet, there might be an extent of confusion as to how 
ALDH2 is associated in gene profiling studies. According to the nomenclature, this enzyme 
indeed is ALDH1A, related to a series of events linked to the development of dopaminergic 
neurons through its ability to produce RA. It was reported that ALDH2 or AHD2 expression 
changes during differentiation of NIH-3T3 cells into adipocytes. These studies continue to 
focus on ALDH1A1’s role in SCs and stem cell differentiation. For hematopoietic stem cell 
progenitors, ALDH1A1 has been a thoroughly established marker for many years. Reseach 
on the role of RA in granulocyte differentiation of hematopoietic SCs discovered that 
ALDH1A1 and ALDH1B1 catalyze cellular RA synthesis and are expressed in CD34+ 
hematopoietic progenitors (Russo, et al., 2002, Luo, et al., 2007).They also showed that 
ALDH1A2 or 1A3 do not show those characteristics. For the differentiation to mature 
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granulocytes, these 2 enzymes' expressions are necessary, however their expressions are lost 
once the differentiation is complete. The in vitro disulfiram treatment in which disulfiram 
acts as an ALDH inhibitor may inhibit granulocytic differentiation. ALDH1A1 is found in 
erythrocytes and has been pointed to contribute to the aldophosphamide detoxification. A 
study that inhibited ALDH and retinoid signaling with diethylamino-benzaldehyde (DEAB) 
that reported the expansion of human HSCs probably by blocking differentiation and 
assisting self-renewal and HSC expansion (Marchitti, et al., 2008). 
The cancer stem cell theory is supported by current evidence in tumor biology, which may 
also provide a biological reason for the age-related survival difference. The theory 
demonstrates that CSCs, a small subset of tumor cells with stem cell-like properties such as 
epithelial-to-mesenchymal progression, are capable of differentiation and self-renewal, after 
which leads to formation of a heterogeneous tumor cell population. Including aldehyde 
dehydrogenase-1 (ALDH1) activity, CD44+/CD24-, CD133, and ITGA6, a wide range of 
putative breast cancer stem cell markers have been proposed. ALDH1 expression has 
especially demonstrated an assurance of a clinically relevant prognostic marker. In addition, 
the subset of CSCs is shown to be relatively insusceptible to chemo and radiotherapy by 
various studies. For this reason, the subpopulation of CSCs can present a statement and a 
therapeutic target for poor-prognostic, treatment-resistant and recurrent breast cancer. 
Through its role in oxidizing retinol to RA, which is a modulator of cell proliferation, 
ALDH1 might have a role in early differentiation of SCs and stem cell proliferation (Mieog, 
et al., 2012). 
It is possible to isolate leukemia SCs depending on the elevated ALDH activity by using the 
aldefluor assay. In patient samples, the researchers encountered a population of ALDH+ 
acute myeloid leukemia (AML) cells (Rollins-Raval, et al., 2012). In most cases, the ALDH+ 
AML cells coexpressed CD34+ (formerly determined leukemia stem cell marker), and were 
introduced considerably better than the ALDH- AML cells in immunocompromised mice. In 
the same year, ALDH+ cells from breast cancers, which had the tumorigenic and self-
renewal features of CSCs, were shown to be possibly isolated. This innovative study 
displayed the potential applicability of quantifying ALDH activity in solid tumors. ALDH 
activity would be used successfully as a CSC marker for abundant cancers including liver, 
colon, lung, bone, prostate, pancreatic, head and neck, thyroid, bladder, brain, cervical and 
melanoma in the proceeding years. With one exception of a current study for melanoma, 35 
demonstrate growing evidence recommending ALDH’s activity to be a universal CSC 
marker. Nonetheless, as amounted by the aldefluor assay in various tissues and cancers, the 
cause of ALDH activity may differ. Essentially, determination of specific ALDH isoforms 
carried out commonly in certain cancers might have prognostic suitability. Besides their 
valuable function in detoxification of aldehydes, ALDHs carry out other functions such as 
serving as binding proteins for various molecules (e.g., androgens and cholestorol), 
potentially act as antioxidants by NAD(P)H production, ultraviolet light absorption and/or 
hydroxyl radical scavenging and ester hydrolysis. 
Lastly, several isoforms (ALDH1A1, ALDH1A2, ALDH1A3 and ALDH8A1), take place via 
RA formation by oxidation of all-trans-retinal and 9-cis-retinal in RA cell signaling, which 
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has been related to the “stemness” characteristics of CSCs. Consequently, its supported by 
widening evidence that ALDH may be more than just a CSC marker and have an 
accomplishable role in CSC biology (Marcato, et al., 2011). 
3.1. ALDH family members as stem cell markers 
ALDH proteins can be found in every subcellular region such as cytosol, endoplasmic 
reticulum, mitochondria, and the nucleus, with some even found in more than one location. 
ALDH isozymes found in organelles besides cytosol carry signal or leader sequences that 
make their translocation to specific subcellular regions possible. After translocation or 
import, while nuclear and microsomal signals remain intact, mitochondrial sequences might 
be removed (causing mature proteins to be shorter). Most of the ALDHs have a large tissue 
distribution and show distinct substrate specificity (Marchitti, et al., 2008). 
3.1.1. ALDH1A1 
ALDH1A1 encodes a homotetramer that is ubiquitously distributed in the adult epithelia of 
several organs such as brain, testis, kidney, eye lens, retina, liver and lungs. ALDH1A1 takes 
its position among the three highly-conserved cytosolic isozymes (see ALDH1A2 and 
ALDH1A3), which catalyze the oxidation of the retinol metabolite, retinal (retinaldehyde), 
to RA. ALDH1A1 has great affinity for the oxidation of both all-trans-(Km < 0.1 μM) and 9-
cis-retinal. By serving as a ligand for nuclear RA receptors (RAR) and retinoid X receptors 
(RXR), RA regulates gene expression; therefore its synthesis is crucial for normal growth, 
differentiation, development and the maintenance of adult epithelia in vertebrate 
animals. In retinoid-dependent tissues (including the retina), retinal-oxidizing ALDHs have 
been shown to display differential expression patterns during organogenesis in rodents, 
reflecting that RA signaling is indeed important for embryogenesis. The in vivo function of 
ALDH1A1 in RA synthesis is proven by the fact that after retinol treatment, 
while Aldh1a1−/−mice are viable and possess normal morphology of the retina, the livers of 
Aldh1a1−/− mice have reduced RA synthesis and increased serum retinal levels. Surprisingly, 
it appeared that Aldh1a1−/− mice are protected against both diet-induced obesity and insulin 
resistance and this demonstrates that retinal might regulate the metabolic response to high-
fat diets transcriptionally, and that the ALDH1A1 could be a candidate gene for therapeutic 
targeting. Supression of ALDH1A1 in cultured hepatocytes reduces both the omega-
oxidation of free fatty acids and the production of reactive oxygen species (ROS). Liver 
ALDH1A1 levels were shown to be decreased in RXRα−/− mice, which suggests that RA 
binding is an activating factor in ALDH1A1 gene expression. The androgen receptor might 
also be included in modulation of ALDH1A1, which is recognized to be an androgen 
binding protein. RA is required for testicular development and ALDH1A1 is absent in 
genital tissues of humans with androgen receptor-negative testicular feminization. 
ALDH1A1 is significantly expressed in dopaminergic neurons that are known to require RA 
for their differentiation and development in the human brain. In these neurons, ALDH1A1 is 
under the control of Pitx3, a homeodomain transcription factor that, possibly 
through ALDH1A1 upregulation, regulates the particularization and maintenance of 
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disassociated populations of dopaminergic neurons. Decreased levels of ALDH1A1 takes 
place in dopaminergic neurons of the substantia nigra of patients with Parkinson’s disease 
(PD), as well as the ventral tegmental area in schizophrenic patients. In the central nervous 
system (CNS), monoamine oxidase (MAO) metabolizes dopamine to aldehyde, as it's 
metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), which growing evidence suggests 
might be neurotoxic, and it may lead to cell death in relation to neurological pathologies 
when accumulated. In maintaining low intraneuronal levels of DOPAL, ALDH1A1 may 
undertake a critical role by catalyzing its metabolism to 3,4-dihydroxyphenylacetic acid 
(DOPAC). Being one of 139 genes that are differentially expressed in primary human HSCs, 
and through the production of RA, ALDH1A1 has been shown to promote their 
differentiation. 
These data suggest that for the therapeutic amplification of HSCs, ALDH1A1 inhibition 
could potentially be used (Marchitti, et al., 2008, Moore, et al., 2009).  
3.1.2. ALDH1A2 
ALDH1A2 is a cytosolic homotetramer expressed in several embryonic and adult tissues 
such as brain, kidney, intestine, testis, liver, retina, lung. As ALDH1A1, ALDH1A2 also 
catalyzes the reaction in which both all-trans-retinal and 9-cis-retinal oxidize to RA. 
However, when compared with other ALDH isozymes, ALDH1A2 appears to acquire the 
highest specificity (Vmax/Km = 49 nmol·min−1·mg−1·μM−1) for all-trans-retinal. This 
characteristic may be because of an uncommon discreate loop in its active site that binds all-
trans-retinal in a unique manner. 
Taking action in several developmental processes, ALDH1A2 might be a key regulator of 
RA synthesis in developing tissues. Due to defects in early heart 
morphogenesis, Aldh1α2−/− mice die in early embryonic stages in which they seem to lack 
axial rotation, incomplete neural tube closure, reduction of the trunk region and many of the 
properties of human DiGeorge/velocardiofacial syndrome, a disorder characterized by cleft 
palate, heart abnormalities and learning disabilities. During early vascular development, 
aberrations in endothelial cell cycle progression have also been determined 
in Aldh1α2−/− embryos. Aldh1a2 has been determined as a key regulator in the development 
of many tissues including kidney, retina, lung, forebrain, pancreas, and spinal cord by 
miscellanous animal models (Marchitti, et al., 2008, El Kares, et al., 2010).  
3.1.3. ALDH1A3 
ALDH1A3 is a cytosolic homodimer that participates in RA synthesis, oxidizes both all-
trans-retinal and 9-cis-retinal (Km 0.2 μM for all-trans-retinal) to RA, and has an important 
role in embryonic development; including brain, retina, skeletal muscle, tooth buds, 
intestine, kidney, prostate, lung, liver and pancreas, it is expressed in various late-stage 
embryonic and adult rodent tissues. In humans, ALDH1A3 expression has been noted in 
stomach, salivary gland, breast, kidney and fetal nasal mucosa. Aldh1a3−/− mouse embryos 
die as a result of defects in nasal development. 
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It’s been shown that ALDH1A3 takes part in the development of the eye, nucleus 
accumbens and olfactory bulbs, the forebrain, hair follicles and the cerebral cortex. 
ALDH1A3 deficiency has been shown to play a critical role in cancer by a number of 
studies. For instance, in human breast cancer MCF-7 cells, ALDH1A3 expression is 
downregulated, whereas in cultured human colon cancer cells, ALDH1A3 is one of two 
genes that are upregulated by induction of wild type p53. In mammary tumor-susceptible 
BALB/cJ mice that are heterozygous for p53, Aldh1a3 is one of five candidate genes located 
within a region determined for its linkage to mammary tumorigenesis. In mice resistant to 
induced mammary tumors, (C57BL/6J), Aldh1a3 is one of the two upregulated 
genes. ALDH1A3 is silenced by methylation in gastric cancer cells, whereas in glioblastoma 
cells, it is triggered by the antitumor agent IL-13 cytotoxin (Marchitti, et al., 2008). 
3.1.4. ALDH2 
ALDH2 is a tetrameric enzyme expressed profusely in lungs and liver; it is also present in 
organs that obligate high mitochondrial capacity for oxidative ATP generation including 
heart and brain. Apart from that, ALDH2 is also important in the aldehydic substrate 
oxidation such as 4-HNE, acrolein, and short-chain, aromatic or polycyclic carbons. To add 
to its dehydrogenase activity, depending on the substrates, ALDH2 can function as an 
esterase and reductase. More recent attention has also been focused on ALDH2 in regards to 
its function in the biotransformation of nitroglycerin, reducing it to 1,2-glyceryl dinitrate for 
the production of nitric oxide, which is a critical vasodilator (Chen, et al., 2010).  
3.1.5. ALDH7A1 
ALDH7A1 is a homotetramer that's expressed in a large number of tissues; in rat heart, liver 
and kidney, increased levels of ALDH7A1 are noted, whereas in black seabream fish 
(sbALDH7A1), ALDH7A1 is significantly formed in the liver and the kidney, excluding the 
heart. In human fetal tissues, ALDH7A1 has been encountered at elevated levels in the 
cochlea, eye, ovary, heart and kidney. In contrast, balanced levels are detected in the liver, 
spleen, muscle, lung and brain. 
Human ALDH7A1’s primary role happens in the pipecolic acid pathway of lysine 
catabolism, in which it catalyzes the oxidation reaction of alpha-aminoadipic semialdehyde 
(AASA) (Km180 μM) to alpha-aminoadipate. ALDH7A1 mutations form the molecular basis 
for pyridoxine-dependent epilepsy (PDE), an autosomal recessive disorder characterized by 
the aggression of tenacious seizures during infancy and early childhood and are avoidable 
by daily use of high-dose pyridoxine (Vitamin B6) supplementation.  
Remarkably, ADH7A1 expression in the cochlea of the ear, the region dependent on the 
healthy upkeep of internal hydrostatic pressure, clarifies that mammalian ALDH7A1 might 
have an accomplishable function in osmotic regulation and in hearing disorders. However, 
no connection has been revealed yet, including patients with the inner-ear disorder 
Ménière's disease, which effects hearing and balance. 
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ALDH7A1 is notably and differentially expressed within the first and second meiotic stages 
of porcine oocyte development. Screening of the promoter region sbALDH7A1 has 
discovered cis-elements linked with cell cycle regulation (Marchitti, et al., 2008). 
4. ALDH in cancer and cancer stem cells 
4.1. Adenocarcinoma  
Adenocarcinoma is an epithelium cancer that is generated from glandular tissue. Epithelial 
tissue includes, but is not limited to, the surface layer of skin, glands and a variety of other 
tissues that line the cavities and organs of the body. Epithelium can be derived from the 
three germ layers ectoderm, mesoderm and endoderm during embryologic period. 
Adenocarcinoma classification depends on not only being a part of the gland, but also 
depends on having the same secretory characteristics. But, this form of carcinoma can occur 
in some higher mammals, including humans (Fauquier, et al., 2003).  
Adenocarcinomas can arise in many tissues of the body due to the ubiquitous nature of 
glands within the body. While each gland may not be secreting the same substance, as long 
as there is an exocrine function to the cell, it is considered glandular and its malignant form 
is therefore named adenocarcinoma. Endocrine gland tumors, such as a VIPoma, 
an insulinoma, a pheochromocytoma, etc. are typically not referred to as adenocarcinomas, 
but rather, are often called neuroendocrine tumors. If the glandular tissue is abnormal, but 
benign, it is called an adenoma. Benign adenomas typically do not invade other tissues and 
rarely metastasize, whereas malignant adenocarcinomas do both. Colon, urogenital (cervical 
(Tewari, et al., 2002), prostate, urachus and vagina), breast (Buchholz, 2009), esophagus, 
pancreas, stomach and throat are several examples of adenocarcinoma (Subramanian & 
Govindan, 2007).  
It is reported that ALDH expression marks pancreatic cancer stem cells. Also, they have 
mentioned that the enhanced clonogenic growth and migratory properties of ALDH-
positive pancreatic cancer cells suggest a key role in the development of metastatic disease 
that negatively affects the overall survival of patients with pancreatic adenocarcinoma 
(Rasheed, et al., 2010). 
4.2. Breast cancer 
From high-grade, absence of hormone receptor expression to positive HER2 status and the 
basal-like molecular subtype, the expression of ALDH1 is in direct relation with undesired 
tumor characteristics in breast cancer (Mieog, et al., 2012). 
Breast cancer cells with stem-cell-like properties are suggested to be responsible for 
metastatic spread. Aldehyde dehydrogenase 1 (ALDH1) and cluster of differentiation 44 
(CD44) in addition to RhoC GTPase are among the stem cell markers that are expressed by 
these cells (Chaterjee & van Golen, 2011). 
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Breast CSCs were initially isolated, established on cell surface marker with 
CD24/lowCD44 expression. More currently, ‘‘functional’’ markers depending on stem cell 
properties are investigated for their plausible applications in the breast CSCs isolation. By 
this method, applying the aldefluor assay (Stemcell Technologies), originally designed to 
isolate viable HSCs and is an enzyme-based assay that recognizes ALDH activity, 
Ginestier et al. isolated breast CSCs. The assay is thought to precisely recognize ALDH 
isoform ALDH1A1 activity degree. Besides its application as a prognostic and CSC 
marker, ALDH activity that is primarily carried out by ALDH1A3 might be functional in 
breast cancer progression. 
Expression of genes and tumor sphere formation in self-renewal and differentiation could 
be changed by adding chemical RA signaling inducers or inhibitors in breast cancer cell 
lines (Marcato, et al., 2011).  
ALDH1 could work as a marker of breast CSCs better than CD44+/CD24-. Though we could 
not maintain a conclusion that ALDH1 expression was significantly related with any 
conventional clinicopathologic attributes, nevertheless, there is a compelling relation 
between ALDH1-positive breast tumors and resistance to neoadjuvant chemotherapy, 
because of the pCR rates being obtained, which are lower in ALDH1-positive tumors (9.5%) 
than ALDH1-negative tumors (32.2%). Moreover, after neoadjuvant chemotherapy, a 
considerable increase in the proportion of ALDH1-positive tumor cells was observed. These 
results are an indication of ALDH1-positive tumor cells playing an important role in 
resistance to chemotherapy. Because of tumor cells being more tumorigenic than 
CD44+/CD24-, tumor cells of breast CSCs are thought to be richer in ALDH1-positive tumor 
cells than in CD44+/CD24- tumor cells. As a matter of course, we have shown that ALDH1-
positive, in contrast with CD44+/CD24-, is closely associated with colony formation in the 
collagen gel as well. The subset of ALDH1-positive and CD44+/CD24- tumor cells has been 
reported to contain the largest proportion of breast cancer stem cells (BCSCs); consequently, 
it is speculated to have the strongest resistantance to chemotherapy. However, in our 
current study, pCR rates in the ALDH1-positive and CD44+/CD24- high subset (20%, 2 of 
10), are not the lowest among all the subsets consisting of the ALDH1-positive and 
CD44+/CD24- low subset (0%, 0 of 11), the ALDH1-negative and CD44+/CD24- high subset 
(34.1%, 15 of 44), and the ALDH1-negative and CD44+/CD24- low subset (30.2%, 13 of 43). 
Adding CD44/CD24 status to ALDH1 status does not seem to positively improve the 
prediction of response to chemotherapy. Together, these results direct us to assume that, at 
least for the prediction of resistance to chemotherapy, ALDH1-positive tumor cells serve as 
a better marker for BCSCs than CD44+/CD24- tumor cells. Because such tumors contain a 
higher proportion of CSCs, we suppose that ALDH1- positive tumors are resistant to 
chemotherapy. However, because ALDH1 has been shown to play an important role in the 
resistance to chemotherapy in hematopoietic cells, ALDH1-positive tumor cells might be 
involved in resistance to chemotherapy, regardless of whether they are CSCs or not. In 
addition to deeper illumination of ALDH1’s function in chemotherapy resistance in breast 
cancers, obtaining a significantly specific marker for BCSCs is necessary to enlighten an 
authentic role of BCSCs’ chemotherapy resistance. 
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ALDH1-positive, in contrast to CD44+/CD24-, was tremendously related to sequential 
paclitaxel- and epirubicin-based chemotherapy resistance, and the expression of ALDH1 
increased after neoadjuvant chemotherapy, which stands for an indication of BCSCs, 
determined by ALDH1, indeed having played a significant role in chemotherapy resistance. 
This means that ALDH1-positive appears to be a better marker than CD44+/CD24- in 
identifying BCSCs, at least for the prediction of resistance to chemotherapy (Tanei, et al., 
2009). 
4.3. Lung cancer 
Each year, approximately 171,000 new cases of lung cancer are diagnosed, and 160,000 
individuals do not survive from the disease in the United States. This high incidence and 
mortality makes lung cancer one of the most common cancers and the leading cause of 
cancer death in men. Lung cancer is still the leading cause of death from malignant diseases 
worldwide in spite of the advances in surgical treatment and multimodality treatments 
(Hibi, et al., 1998). 
Cancer stem cells have attributed resistance of a smaller fraction of cells in the tumor bulk 
against chemotherapeutics. The isolation of CSCs is important for these reasons and have 
been isolated using a variety of stem cell markers and phenotypes. CD133 has recently been 
reported to identify tumor-initiating cells in non-small cell lung cancer (NSCLC). ABCG2 is 
also a stem cell marker of a variety of tissues and transporter responsible for the multidrug-
resistance phenotype. However, it was demonstrated that many cells in NSCLC and SCLC 
cell lines show tumorigenic potential, regardless of ABCG2 and CD133 expression. Recently, 
ALDH activity has been used for isolation of these kinds of cells. Normal SCs were shown to 
contain higher levels of ALDH activity than their more differentiated progeny. ALDH-
positive cells of tumors have higher proliferation rates, migration and adhesion ability, and 
metastatic potential than ALDH-negative cells. This may occur because that RA product of 
ALDHs is thought to participate in cellular differentiation and stem cell self-protection 
(Serrano, et al., 2011).   
4.4. Ovarian cancer 
Epithelial ovarian cancer is the sixth most common cancer in women worldwide and it is 
still the most lethal gynecologic malignancy (Iorio, et al., 2007). Application of new 
technologies for detection of ovarian cancer could have an important effect on public health, 
but to achieve this goal, specific and sensitive molecular markers are essential (Petricoin, et 
al., 2002). Aldehyde dehydrogenase-1A1 (ALDH1A1) has been a valid marker among 
several malignant and non-malignant tissues in spite of several stem cell markers to identify 
CSCs. ALDH plays a role in the biology of TICs as well as being a stem cell marker. Because 
ALDH1A1 is implicated in chemo resistance pathways, it is questioned that targeting 
ALDH1A1 can effect cells resistant to chemotherapy and represent a potential target for 
cancer stem-cell-directed therapy. In a study, ALDH1A1 was investigated in ovarian cancer 
cell lines and patient samples and examined whether targeting ALDH1A1 sensitizes cells to 
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chemotherapy in both in vitro and in vivo ovarian cancer models. They showed that 
ALDH1A1 expression and activity have increased chemo resistant ovarian cancer cell lines. 
Most importantly, down-regulation of ALDH1A1 expression has sensitized normally chemo 
resistant tumors to both docetaxel and cisplatin in vitro and in mouse models. Besides being 
a stem cell marker, ALDH1A1 is also a viable target for therapy and a mediator of the 
aggressive phenotype (Landen, et al., 2010). 
4.5. Pancreatic cancer 
Pancreatic adenocarcinoma is a highly lethal disease, which is usually diagnosed in an 
advanced state, and for which there is little or no effective therapies (Li, et al., 2007). Therefore, 
finding markers to detect a malignant cell transformation at an early stage is very important. 
Researches demonstrated that the pancreas possesses ALDH activity, and ALDH is also 
present in the pancreatic cancer cells. Different from other cancer tissues (such as ovarian and 
lung cancer), the activity of ALDH does not differ in pancreatic carcinoma tissue compared to 
normal pancreatic tissue. Additionally, serum levels of ALDH were not significantly elevated 
in patients with pancreatic cancer in comparison to healthy controls (Jelski, et al., 2011). 
4.6. Prostate cancer 
The latest estimates of global cancer incidence show that prostate cancer has become the 
third most common cancer in men, with half a million new cases each year, constituting 
almost 10% of all cancers in men (Quinn & Babb, 2002). Identifying the origin of cells in 
prostate cancer and its distant metastases may be important for the improvement of more 
effective treatment strategies and preventive therapies. Measurement of ALDH activity 
provides great contribution to functional identification and characterization of normal SCs 
and their malignant counterparts. ALDH activity is important for drug resistance, cell 
proliferation, differentiation, and response to oxidative stress of prostate cancer like other 
important cancers.  
ALDH enzyme activity is used for the isolation of “stem-like” cells based on a developmentally 
conserved stem/progenitor cell function. In a study, high ALDH activity was used to isolate 
human prostate cancer cells with significantly enhanced clonogenic and migratory properties 
both in vitro and in vivo. Similar to other cancer tissues, the percentage of ALDHhi cells in 
prostate cancer cell lines are also related to tumorigenicity and metastatic behavior.  
Although high expression of ALDH7A1 is shown in prostate cancer cell lines, primary 
cultures, and in primary prostate cancer tissue and matched bone metastases, ALDH3A2 
and ALDH18A1 are not observed high ALDH activity in human prostate cancer (van den 
Hoogen, et al., 2010).  
4.7. Brain cancer 
Glioblastoma (GBM) is the most common primary brain tumor in adults with an 
approximately 15-month survival (Stupp, et al., 2005). Although there are several studies to 
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improve the postoperative therapeutic applications within the last few years, there is not 
enough succes for this highly aggressive tumor. After resection, radiation, and 
chemotherapy regimens, relapses occur regularly. Thus, it is thought that this can be a clue 
to the presence of tumor stem cells (TSCs). This cellular subfraction within GBM causes 
continuous tumor growth and resistance to drugs and radiation (Rasper, et al., 2010). TSCs 
are believed to nestle in the tumor, keeping it alive and growing, providing pluripotency, 
self-renewal, and resistance to chemo and radiation therapy(Reya, et al., 2001). The first 
malignancies from which cells could be isolated and showed the potential to self-renew and 
to drive tumor formation and growth were leukemias (Bonnet & Dick, 1997). After that, a 
stem cell subfraction was described in brain tumors (Singh, et al., 2003). This was the first 
study that identified and showed a population with stem cell properties in pediatric solid 
brain tumors. Those cells were identified by their ability to proliferate under serum-free cell 
culture conditions and by the expression of CD133 and nestin. CD133 has long remained the 
most important TSC marker in malignant glioma. On the other hand, ALDH1 is a 
cytoplasmatic stem cell marker in a variety of malignant tumors and catalyzes the oxidation 
of intracellular aldehydes including the transformation of retinol to RA. As mentioned 
above, RA is a modulator of cell proliferation and differentiation that possibly contributes to 
the maintenance of an undifferentiated stem cell phenotype. Jones et al. presented a method 
to isolate human cells via flow cytometry depending on the amount of cytosolic ALDH 
(Jones, et al., 1995). Recently, Ginestier et al. found ALDH1 to be a stem cell marker in breast 
carcinoma associated with poor clinical outcomes (Ginestier, et al., 2007). Since then, ALDH1 
has been described as a marker of stemness in other solid malignancies including lung 
cancer (Jiang, et al., 2009) and colorectal cancer (Huang, et al., 2009).  
Therefore, identification and isolation of these cells seem crucial for a better understanding 
of tumor behavior, origin, and therapy. Recently, ALDH1 has been described as a marker for 
the identification of non-neoplastic SCs and TSCs (Ginestier, et al., 2007).  
So far, cellular markers including CD133 have been used to identify TSCs in GBMs, but 
recently, CD133-negative GBMs are characterized to behave as brain TSCs (Beier, et al., 2007).  
Therefore, ALDH1 has also been described as a stem cell marker in various solid neoplasms 
including lung cancer (Jiang, et al., 2009), breast carcinoma (Ginestier, et al., 2007), and 
colorectal cancer (Huang, et al., 2009) and GBM (Rasper, et al., 2010).  
4.8. Colon cancer 
Most colon cancers are adenocarcinomas that release mucus and other cellular secretions. In 
the United States in 2012, estimated new cases and deaths from colon and rectal cancer are 
reported as: 103,170 colon cancers and 51,690 deaths (Levin, et al., 2008). Studies showed that 
ALDH1B1 and ALDH1A1 are differentially expressed in normal human tissues, but 
ALDH1B1 is expressed at higher levels than ALDH1A1 in human epithelial cancers. 
ALDH1B1 was abundantly expressed in adenocarcinomas originating from the tissue and 
particularly in colonic adenocarcinoma (Chen, et al., 2011). Thus it can be deduced that 
ALDH1B1 may be a marker for colon cancer diagnosis. 
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5. Aldefluor activity in stem cells and cancer stem cells 
ALDHbr (ALDH-bright) cells can be detected with ALDEFLUOR reagent by using flow 
cytometry or fluorescent microscopy. These ALDHbr cell populations are isolated from adult 
tissues by flow sorting.  
ALDH activity was shown in human and mouse bone marrow hematopoietic progenitor cells 
(HPCs) by Jones et al. for the first time (Jones, et al., 1995). ALDH was assayed by using a new 
substrate with low light scatter properties with flow cytometry. Now this method was 
improved and known as Aldefluor assay. Aldefluor assay can be used for to measure ALDH 
activity of adult tissue cells, primary cancer cells and cultured cells. Aldefluor assay is based 
on the conversion of fluorescent non-toxic substrate for ALDH substrate to the fluorescent 
reaction product. Non-toxic substrate for ALDH freely diffuses into intact and viable cells. The 
BODIPY aminoacetaldehyde is converted to the fluorescent product BODIPY aminoacetate by 
ALDH activity (Figure 1). In this assay, a specific inhibitor of this reaction 
(diethylaminobenzaldehyde-DEAB) is used to control for background fluorescence. Aldehyde 
dehydrogenase plays a role as a cancer stem cell marker comes down to the specific isoform. 
Stem and progenitor cells are identified as cells with low side scatter and high expression of 
ALDH. DEAB allows to distinguish between ALDH-bright cells and cells with low ALDH 
activity. Generally, 105-106 cells are suspended in Aldefluor assay buffer containing BODIPY 
aminoacetaldehyde with/without DEAB. Aldefluor was excited at 488 nm and fluorescence 
emission was detected at 530/30 (van den Hoogen, et al., 2010). This assay provides a 
successful isolation of viable HSCs and more recently ALDH positive CSCs. However, 
aldefluor assay detects the ALDH activity of several ALDH isoforms expressed in the cells. 
ALDH1A1 is not the only isoform responsible from aldeflour activity. In some studies, it 
was demonstrated that ALDH1A1-deficient hematopoietic cells showed aldefluor activity 
owing to ALDH2, ALDH3A1 and ALDH9A1 isoforms (Marcato, et al., 2011). 
6. ALDH bright (ALDHbr) cell 
Intracellular ALDH enzymes are responsible for oxidizing aldehydes to carboxylic acids in 
the cell. ALDHbr cells from different tissues express high ALDH activity and have 
progenitor cell activity (Gentry, et al., 2007). Firstly, HSC were defined as SSCloALDHbr – 
reflecting their low orthogonal light scattering and bright fluorescence intensity by using 
flow cytometry (Lioznov, et al., 2005). After that, high levels of the enzyme ALDH (ALDHbr) 
have proven to be a novel marker for the identification and isolation of SCs (Mitchell, et al., 
2006). In the same time angiogenic activity of ALDHbr cells were discovered and these cells 
were used for regenerative medicine with preclinical models and have been used safely to 
treat patients in early clinical trials (White, et al., 2011).  
ALDHbr cells were found in various cancer tissues including breast, liver, colon, and acute 
myelogenous leukemia and related with cancer chemo resistance. Human and murine HSCs 
and neural stem and progenitor cells have increased ALDH activity compared to non-stem-
cells (Siclari & Qin, 2010). 
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Therefore, recently the importance of ALDH activity in normal and malignant stem cell 
functions, and the potential diagnostic and therapeutic implications gain importance 
(Moreb, 2008). 
 
Figure 1. The Aldefluor® Assay. Firstly, ALDH positive cell will uptake BODIPY-aminoacetaldehyde 
by passive diffusion and then convert BODIPY-aminoacetaldehyde into BODIPY-aminoacetate. Then 
BAA is retained inside cells, causing the subset of ALDHhi cells to become highly fluorescent (Marcato, 
et al., 2011). 
7. Aldehyde dehydrogenase in regenerative medicine 
Until today, studies showed that BM ALDHbr populations may be useful in several cell 
therapy applications (Gentry, et al., 2007). According to this information, ALDHbr population 
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may play an important role in regenerative medicine owing to RAs ALDH product (Balber, 
2011). Retinoic acids could influence tissue repair by binding to transcription factors and 
regulating developmental programs, especially ALDH1A1 and ALDH3A1 of enzyme 
isoforms that produce RAs from oxidize retinaldehyde (Moreb, 2008). Therefore, ALDH1a1 
and ALDH1A3 may influence cell activity and proliferation by controlling intracellular 
retinoid concentrations and play important roles in stem cell biology (Balber, 2011). 
The studies about value of ALDHbr cells in regenerative medicine were conducted by 
different researchers. The regenerative potential of ALDHbr cells obtained from different 
tissues were investigated in various disease models such as ischemic tissue damage hind 
limb model, brain damage and pancreatitis (Balber, 2011).  
In the beginning of studies, ALDHbr cells were obtained from bone marrow and umbilical 
cord blood and normal peripheral blood (Sondergaard, et al., 2010). Multipotent 
mesenchymal progenitors and endothelial progenitor cells are concentrated in human 
ALDHbr populations. Because of potential progenitor and paracrine activities of ALDHbr 
cells, these cells especially obtained from bone marrow are important for tissue repair. 
Manipulation of the graft to selectively concentrate or expand hematopoietic and/or neural 
stem cells prior to transplant may be a potential strategy in the future. UCBT using ALDH 
bright cells from the CB units have shown faster and higher engraftment in preliminary 
study and is being explored further (Prasad & Kurtzberg, 2010). One of these studies 
showed that human cord blood progenitors with high ALDH activity improve vascular 
density in a model of acute myocardial infarction. In this study, ALDHbr cells were homed 
to the infracted anterior surface of the heart, while ALDH-low cells were in the spleen after 
intravenously administration.   
Another study with animal model of hindlimb ischemia demonstrated that the isolated 
ALDHbr cells effectively restored blood flow to ischemic areas by mediation of local 
formation of new blood vessels with largeer diameter and increasing capillary density even 
if there was no improvement in cardiac functions (Keller, 2009).  
The reason for the restoration of tissue perfusion by ALDHbr cells were attempted to be 
explained with angiogenic properties of these cell groups. Angiogenic factors secreted by 
transplanted ALDHbr cells stimulate formation of new blood vessels at sites of ischemic 
injury (human cord blood progenitors with high ALDH activity improve vascular density in 
a model of acute myocardial infarction). Paracrine mechanisms of ALDHbr cells can protect 
endothelial cells from ischemic damage and respond to ischemic tissue damage (Balber, 
2011, White, et al., 2011).  
Another exciting finding is that ALDHbr cells improve formation of new vessels and increase 
capillary density, while ALDHbr cells together with ALDH-low cells did not restore tissue 
perfusion at all. It is suggested that ALDH-low cells can inhibit the homing and/or 
angiogenic activity of ALDHbr cells. This situation showed the importance of isolating 
ALDHbr cells from bone marrow tissue for therapeutic uses (Balber, 2011). As a result, 
ALDHbr cells may be promising for patients with ischemic heart failure and critical limb 
ischemia (Keller, 2009).   
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TISSUE OBTAINED FROM BENEFITS
 
 
Neural Tissue 
Rat embryonic neural tube 
Fetal mouse brain 
Subventricular and 
subcortical zones of adult 
mouse brain 
Ability to form neurospheres and retained 
multipotency 
Transplantation significantly ameliorated 
disease progression and extended life, but did 
not rescue the animals. 
 
Skeletal 
Muscle 
Biopsies or primary 
explants of human skeletal 
muscle 
Strong myogenic potential 
on IM transplantation 
 
Mammary 
Epithelium 
Mammary epithelium Myoepithelial, luminal epithelial and mixed 
colonies, and ducts, when transplanted into 
mammary fat pads. 
 
 
Pancreatic 
Cells 
Central acinar/terminal duct 
cells from peripheral 
acinar duct units of adult 
mice 
Contributed to both exocrine 
and endocrine lineages in the developing 
pancreas 
 
 
Prostate 
Epithelium 
 
- 
Express basal epithelial and characteristic 
prostate progenitor 
cell markers  
Corneal 
Limbic Cells 
Cadaveric 
human limbic tissue 
Protects the cornea 
from oxidative damage 
Table 1. Different tissue repair models including human ALDHbr cells (Balber, 2011). 
8. Conclusion 
Since ALDH enzyme has been proven to possess a vital role in somatic cells and their 
deficiency cause various diseases, research has focused on the presence and functions of the 
enzyme in SCs. It was demonstrated that ALDH is an important marker for identification of 
SCs and has several functions in these cells just as they possess in somatic cells.  
Exploring some of the isoforms of ALDH for use as a marker of CSCs improved the 
importance of ALDH. Thus, there are several methods to detect ALDHs and their levels 
(Marcato, et al., 2011). After the discovery of ALDH activity in human and mouse bone 
marrow hematopoietic progenitor cells (HPCs) by Jones et al. (Jones, et al., 1995), the 
properties and locations of ALDH-positive cells have started to be investigated.  
Recently, ALDHbr cells were found in cancer tissues including breast, liver, colon, and acute 
myelogenous leukemia. It was demonstrated that proliferation rates, migration and 
adhesion ability, and metastatic potential of ALDHbr CSCs were more than ALDH low cells 
and ALDHbr cells related with cancer chemo resistance. ALDHbr cells became one of new 
therapeutic target against cancer and anti-cancer studies based on targeting ALDHbr cells 
have started recently (Serrano, et al., 2011). It is expected that the anti-cancer studies with 
this perspective may intensively continue.  
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On the other hand, studies showed that BM ALDHbr populations may be useful in several 
cell therapy applications (Gentry, et al., 2007). It is suggested that ALDHbr population may 
play an important role in regenerative medicine owing to Ras, which are one of the ALDH 
products. Paracrine effects of products of ALDH activity may influence tissue repair by 
binding to transcription factors and regulating developmental programs (Balber, 2011).  
Therefore, regenerative potential of ALDHbr SCs were investigated in various disease 
models such as ischemic tissue damage hind limb model, brain damage and pancreatitis 
(Balber, 2011).  
Studies on ALDHbr cells provide restoration of tissue perfusion and stimulation of formation 
of new blood vessels in ischemic tissue damage (Keller, 2009). These promising findings 
showed that ALDHbr cells may gain importance in different areas; however, there are still 
many things to investigate about potential properties of ALDHbr cells for use in regenerative 
medicine. Thus, ALDH have many roles such as a marker of many disease and cell lines for 
detection of them also can using for therapy and have potential for use in regenerative 
medicine. 
However, there are few studies about ALDH as a marker of SCs and potential usage in 
regenerative medicine. Therefore, we suggested that studies should focus on this and this 
review aims to consider the roles of ALDH in SCs and their potential use in regenerative 
medicine. We believe that constructing a review including current studies related to this 
subject will guide future studies. 
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1. Introduction 
Self-monitoring blood glucose (SMBG) is an important component of modern therapy for 
diabetes mellitus. SMBG has been recommended for people with diabetes and their health 
care professionals in order to achieve a specific level of glycaemic control and to prevent 
hypoglycaemia. The goal of SMBG is to collect detailed information about blood glucose 
levels at many time points to enable maintenance of a more constant glucose level by more 
precise regimens. It can be used to aid in the adjustment of a therapeutic regimen in 
response to blood glucose values and to help individuals adjust their dietary intake, 
physical activity, and insulin doses to improve glycaemic control on a day-to-day basis. 
SMBG can aid in diabetes control by: (http://www.diabetes.co.uk/blood-glucose/blood-
glucose-self-monitoring.html) 
 facilitating the development of an individualized blood glucose profile, which can then 
guide health care professionals in treatment planning for an individualized diabetic 
regimen; 
 giving people with diabetes and their families the ability to make appropriate day-to-
day treatment choices in diet and physical activity as well as in insulin or other agents; 
 improving patients’ recognition of hypoglycaemia or severe hyperglycaemia;  
 enhancing patient education and patient empowerment regarding the effects of lifestyle 
and pharmaceutical intervention on glycaemic control. 
 helps to determine which foods or diet are best for one’s control 
 helps inform the patient and doctor about how well the medication regime is working  
 reduces anxiety about, and increases understanding of, hypoglycaemia. This is because 
if untreated hypoglycaemia can result in coma for diabetic patients and is therefore a 
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condition that diabetics try to avoid through proper action. To this end, regular testing 
can predict dangerous drop in blood glucose concentration which can lead to 
hypoglycaemia.  
 is important for undertaking dangerous tasks which could be influenced by high or low 
blood sugar, such as driving and handling dangerous machinery 
Disadvantages are mainly seen when either the patient lacks motivation to test or does not 
have sufficient education on how to interpret the results to make sufficient use of home 
testing equipment. Where this is the case, the following disadvantages may outweigh the 
potential benefits: 
 anxiety about one’s blood sugar control and state of health 
 the physical pain of finger pricking 
 expense to the NHS or other medical body 
Numerous trials have been carried out to determine the true impact of SMBG on glycaemic 
control. Some, including randomized, controlled trials, have demonstrated the efficacy of 
SMBG. Among patients with type 1 diabetes, SMBG has been associated with improved 
health outcomes. [1] Specifically, increasing frequency of SMBG was linearly correlated with 
reductions in HbA1c among type 1 patients in Scotland. [2] Among patients with type 2 
diabetes, a higher frequency of SMBG was associated with better glycaemic control among 
insulin-treated patients who were able to adjust their regimen. [3]  
SMBG works by having patients perform a number of glucose tests each day or each week. 
The test most commonly involves pricking a finger with a lancet device to obtain a small 
blood sample, applying a drop of blood onto a reagent strip (typically an enzyme electrode), 
and determining the glucose concentration by inserting the strip into an electronic meter for 
an automated reading. Test results (a measure of the glucose concentration in the blood 
sample) are then recorded either in a logbook or stored in the glucose meter’s electronic 
memory. People with diabetes can be taught to use their SMBG results to correct any 
deviations out of a desired target range by changing their carbohydrate intake, exercising, or 
using more or less insulin. 
The frequency with which patients with diabetes should monitor their blood glucose level 
varies from person to person. Most experts agree that insulin-treated patients should monitor 
blood glucose at least four times a day, most commonly fasting, before meals, and before bed. 
In addition, patients using insulin can benefit by obtaining postprandial blood glucose 
readings to help them more accurately adjust their insulin regimen. A positive correlation 
between frequency of SMBG and glycaemic control among patients with insulin-treated type 
1 or type 2 diabetes has been demonstrated. [1-3] Patients treated with intermediate, short-
acting, or rapid-acting insulin may benefit from SMBG data to make adjustments in their 
regimen. 
For patients with type 2 diabetes, optimal SMBG frequency varies depending on the 
pharmaceutical regimen and whether patients are in an adjustment phase or at their target 
for glycaemic control. If a patient is on a stable oral regimen with HbA1c concentration 
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within the target range, infrequent SMBG monitoring is appropriate. In such cases, patients 
can use SMBG data as biofeedback at times of increased stress or changes in diet or physical 
activity. [4, 5]  
It is important to point out however that this debate is not straightforward, however. One 
factor that is often overlooked is that the numbers obtained by testing are only one part of 
the picture, which requires additional data to be complete. For example, it is important to 
relate the number to what and when the patient last ate. The patient’s exercise regime must 
also be considered, as well as when and how much medication has been taken. If this were 
not complicated enough, the patient (and physician) need to consider factors such as 
whether the patient has recently been ill, or even subjected to high levels of stress, which can 
distort the picture. 
Blood glucose meters which utilise an enzyme electrode (a term first coined by Updike and 
Hicks in the late sixties [6]) as the glucose sensing element are particularly suitable medical 
devices for SMBG. 
All the commercial electrochemical meter systems typically comprise two components. The 
meter - applies potential differences in a programmed sequence to the sensor, collects 
current data and analyses the current time response of the sensor, records and displays 
results. The enzyme electrode (or biosensor) test strip - collects the blood sample, the sample 
undergoes an enzymatic chemical reaction followed by an electrochemical detection step. 
The patient simply inserts the enzyme electrode into the meter and applies a small drop of 
blood to the sensor. After a short delay (typically 5 seconds) the blood glucose value is 
displayed by the meter in mg/dL or mmol/L. 
The advantages offered by biosensors in SMBG arise for the following reasons. Blood is a 
complex fluid and glucose levels vary widely over time in a single patient, many factors 
besides glucose vary in blood from healthy, patients (haematocrit, oxygen levels, and 
metabolic by-products) therefore great specificity is a prime requirement. In addition, 
patients with diabetes may have a wide range of other medical problems creating even 
greater variation in their blood. Finally, biosensors can be used directly in the blood without 
requiring major modifications to the biological sample (increased temperature or pressure, 
dramatic pH changes, addition of highly reactive chemicals, etc).  
The enzyme electrodes commonly used in SMBG can be defined as a combination of any 
electrochemical probe with a thin layer of enzyme based reagent that is selective for glucose 
(or other important analytes such as β-hydroxybutyrate). In these devices, the function of the 
enzyme is to provide selectivity by virtue of its biological affinity for a particular substrate 
molecule. For example, an enzyme is capable of catalysing a particular reaction of a given 
substrate even though other isomers of that substrate or similar substrates may be present.  
Typically, the progress of the enzyme reaction (which is related to the concentration of 
analyte) is monitored by the rate of formation of product or the disappearance of a reactant. 
If either the product or reactant is electroactive, then the progress of the reaction can be 
monitored directly using amperometry. In this technique, current flow is measured in 
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response to an applied voltage. The resultant current is monitored by the meter and then 
interpolated into an accurate measurement of glucose using on-board software algorithms 
giving the user a concentration value in typically less than 7 seconds. 
The final method of analysis used will ultimately depend on several properties of the 
enzyme. The main considerations are; 
1. does the enzyme contain redox active groups 
2. are the products of the biochemical reaction electroactive 
3. is one of the substrates or cofactors electroactive 
4. what is the required speed of response 
5. what will be the final application of the sensor 
The answer to the first three criteria will depend largely on the system under investigation. 
The answer to the latter three depends on the requirements and application of the sensor 
under consideration. If the enzyme does not contain any redox groups, then the method of 
analysis will be restricted to monitoring either the release of products or the consumption of 
substrate by their reaction at the transducing electrode. The current produced can then be 
related to the concentration of analyte. Of particular relevance to this article, are the devices 
that incorporate nicotinamide adenine dinucleotide (NAD), flavin adenine dinucleotide (FAD) 
or pyrroloquinoline quinone (PQQ) dependent dehydrogenase enzymes. 
2. Electrochemical oxidation of NAD(P)H 
Given that the nicotinamide coenzymes are electron carriers, and therefore by definition 
electroactive, it would appear at first sight (points 2 and 3 above) that these systems would 
be ideal candidates for commercial enzyme electrode devices. The electrochemical oxidation 
of NADH to NAD+ is however both chemically and kinetically complicated at common 
electrode surfaces such as gold, platinum or glassy carbon. 
The electrochemical detection of NADH has generated great interest because the pyridine 
nucleotides NAD+ and NADP+ are ubiquitous in all living systems and are required for the 
reactions of more than 450 oxidoreductases. [7] Although the formal potential of NADH/ NAD+ 
couple in neutral pH at 25 C is estimated to be 0.56 vs. SCE [8, 9] significant over-potential is 
often required for the direct oxidation of NADH at bare electrodes. [10] Unlike in nature where 
the oxidation of NADH occurs as a 1-step hydride transfer, on bare electrodes the reaction has 
been shown to occur via a different and higher energy pathway which produces biologically 
inactive NAD. radicals as intermediates. The large amount of energy required to produce these 
intermediates is the origin of the large overpotential (typically 1 Volt) required at bare 
electrodes. As a result, the direct electrochemical oxidation of NADH has been shown to 
produce a mixture of products including biologically active NAD+, (NAD)2 dimers and 
products from the side reactions of the electrogenerated NAD. radicals.  
In addition, the direct oxidation of NADH is often accompanied by electrode fouling due to 
the polymerisation oxidation products on the electrode surface. [11] The fouling of the electrode 
surface can occur by two mechanisms. First, the NAD. radicals interact directly with oxide 
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functionalities on the surface of the electrode and second the reaction product, NAD+, adsorbs 
onto the electrode surface. Both of these processes are irreversible and result in the gradual 
blocking of the electrode during continued oxidation. It is this electrode fouling that results in 
the irreproducibility of the analytical signal from bare electrodes. In addition, if this method 
were to be used in commercial glucose sensors for SMBG, the high over potentials required 
would result in the response being a combination of signals from the oxidation of both NADH 
and common interferents, e.g. ascorbic acid, uric acid, paracetamol etc. found in blood. 
The problems mentioned above can be overcome by using small catalytic molecules called 
mediators. These molecules can transfer charge from the reduced coenzyme directly to the 
electrode thereby bypassing the direct oxidation of NADH. The use of this approach has three 
potential advantages when compared to the direct oxidation of the reduced nicotinamide. First, 
by judicious choice of the mediator problems associated with electrode fouling or competing 
reactions can be avoided (especially true if he chosen mediator has a site for hydride transfer). 
Virtually 100% of the oxidation product via this mechanism is biologically active NAD. Second, 
the rate of electron transfer between the NADH molecule and the mediator can be enhanced 
resulting in a more stable increased signal. The rate at which NADH is chemically oxidised will 
governed to a large extent by the potential difference between the formal redox potential of the 
two species. Finally, a mediator can be selected with a redox potential that will limit the effects 
of interference. This is particularly relevant in cases where the bio-analyte is present in blood at 
low concentrations as in the case of beta-hydroxybutyrate (0.0 – 0.3mEq/L). The electrocatalytic 
oxidation of NADH at a modified electrode is shown schematically in Figure 1. Of particular  
 
Figure 1. Cyclic voltammograms of the o-AP modified GC electrode in phosphate buffer (a) in the 
absence and in the presence of increasing concentrations of NADH/mM: (b) 0.1, (c) 0.3 and (d) 0.5; and 
(e) 0.6 at bare GC in phosphate buffer (0.1 M, pH 7.0). Scan rate = 10 mV/s. Note, the peak oxidation for 
NADH at the bare electrode occurs at 0.6 Volts. When the electrode is modified, in this case with o-
amino phenol the oxidation of NADH is concomitant with the oxidation of the immobilised redox 
couple (traces b – d). Figure and data adapted from reference 11. 
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interest are voltammograms a and e. These show the direct oxidation of NADH (e) at the glassy 
carbon electrode and the cyclic voltammogram (a) of the immobilised species. Addition of 
NADH to the solution causes an increase in 1. Note that the signal due to the oxidation of 
NADH now occurs at the potential of the mediator resulting in a decrease in the operating 
voltage of approximately 0.3 V. 
Among the mediators used so far are quinones, diimines, ferrocene, thionine oxometalates, 
polymetallophthalocyanines, ruthenium complexes, pyrroloquinoline quinone, fluorenones, 
and quinonoid redox dyes such as indamines, phenazines, phenoxazines and 
phenothiazines.11 A generalised reaction schematic for the mediated oxidation of NADH is 
shown below in Figure 2.  
 
Figure 2. Scheme showing the mediated oxidation of NADH. In this context, the mediator reacts with 
NADH in a chemical step to oxidise it (a) and is itself reduced. The mediator is then itself reoxidised at 
the electrode surface (step b). The chemical oxidation of NADH by this mechanism bypasses the 
problems associated with the direct oxidation at a bare electrode surface.  
To design an NADH sensor, the mediator is normally immobilized on the electrode surface 
or within the electrode material. Mediators can be immobilized by chemisorption by 
covalent attachment directly electrode surface or by electrochemical polymerisation of the 
mediators at the electrode surface or, alternatively via covalently attached/physically 
entrapment in polymers, incorporation in carbon paste grown at electrode surface or 
deposited on the electrodes by drop coating. The method that is ultimately chosen to 
produce the modified electrode depends upon the method of mass production (for 
commercial sensors) and the materials used in the device. For example, in sensors that 
utilise screen printed carbon based electrodes (screen-printing technology is a kind of low-cost 
thick film technology which allows to deposit thick films, a few to hundreds micrometers and is well 
suited for mass production and portable devices. Such a micro fabrication route offers high-volume 
production of extremely inexpensive and yet highly reproducible disposable enzyme electrodes – this 
will be discussed further in the text) it is convenient to incorporate the mediator directly into 
the carbon ink particularly if the mediator contains delocalised aromatic rings, as found in 
quinine and phenoxazine dye based mediators, which form strong chemisorbed bonds with 
the carbon and graphite plates. The mediator loading, activity stability etc can all be 
investigated using conventional electrochemical techniques such as DC cyclic voltammetry. 
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It is important that modified electrodes designed for the reoxidation of NADH are stable 
over their stated shelf-life, respond only to NADH and not to any other species present in 
the blood sample satisfy the following kinetic requirements; i) the reaction between the 
NADH molecule and the mediator is fast, ii) the transfer of charge within the mediating 
layer is fast and iii) the electron transfer between the reduced mediator and the electrode is 
also fast. 
3. Kinetic modelling of NADH oxidation at chemically modified 
electrodes. 
In the scientific literature, NADH oxidation at chemically modified electrodes is most 
commonly suggested to occur via a two-step reaction mechanism. In the first step, NADH 
forms a charge transfer complex with the oxidised form of the mediator bound to the electrode 
surface. In the second step, electron exchange takes lace and the complex breaks down 
producing NAD+ and a reduced mediator site. Because the electrode is polarised, the reduced 
mediator site is reoxidised in a non-rate limiting electron exchange to the bulk electrode 
material. This scheme is shown in Figure 3. The important kinetic constants are also 
represented.  
 
Figure 3. Two-step mechanism commonly proposed for the oxidation of NADH at chemically modified 
electrodes. The mediator and NADH form a charge transfer complex that dissociates to give rise to the 
reduced mediator and biologically active NAD+.  
For this type of mechanism, the catalytically limiting current (ik) observed under controlled 
hydrodynamic conditions can be expressed as: ik = nFAKcatCNADH/KM where CNADH is the 
bulk concentration of NADH and  represents the concentration of binding sites in the 
immobilised film. This type of model assumes that the rate of electron transfer between the 
mediating species in the film and the NADH is sufficiently fast so as not to be rate limiting, 
the NADH freely diffuses into the film whereupon it adsorbs to the catalytic site and it 
undergoes oxidation to NAD+. Also, the expression for ik is valid only for thin films where 
the concentration of NADH is insufficient to saturate the binding sites.[12] 
Due to the formation of the charge-transfer complex, this reaction scheme is commonly 
analysed using Michaelis-Menten kinetics. From figure 3 it is possible to construct the 
following kinetic argument. 
This is now a straight line plot. From the slope of such a plot, values of k+2 can be calculated. 
By extrapolation of zero NADH concentration, i.e. the intercept, values of KM can be 
estimated. Values for kObs can be obtained from Koutecky-Levitch plots under steady state  
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Scheme 1.  
oxidation conditions as described by Compton and Hancock.[12] Typically, values of kObs 
tend to be in the range 10-3 to 10-1 cm s-1. Thus it is possible using such laboratory techniques 
to ensure that the surface coverage of mediator (moles/cm2) is optimised to achieve 
favourable measurement linearity and speed of response. 
4. Commercial sensors for SMBG incorporating NAD(P)-linked 
dehydrogenase enzymes 
Commercial examples of this type of device are the “Abbott Optium Xceed glucose and -
ketone test strips” (http://www.abbottdiabetescare.com/precision-xtra-blood-glucose-and-
ketone-monitoring-system.html). These strips make use of the NAD+ dependent glucose 
dehydrogenase (EC 1.1.1.47) and NAD+ dependent -hydroxybutyrate dehydrogenase (EC 
1.1.1.30). Exogenous NAD+ is incorporated into the reagent ink which is deposited onto the 
individual electrode by screen printing. The mediator molecule that is used to recycle the 
reduced form of the coenzyme is phenanthroline quinone (Manufacturers own vial insert data 
sheet). Advantages often cited with this type of chemistry include good selectivity and no 
reaction with oxygen. 
5. Screen printing as a means of mass-manufacturing enzyme sensors 
Screen printing is arguably the most versatile of all printing processes. It can be used to print 
on a wide variety of substrates, including paper, paperboard, plastics, glass, metals, fabrics, 
and many other materials including paper, plastics, glass, metals, nylon and cotton. Some 
common products from the screen printing industry include posters, labels, decals, signs, and 
all types of textiles and electronic circuit boards. The advantage of screen printing over other 
print processes is that the press can print on substrates of any shape, thickness and size. 
A significant characteristic of screen printing is that a greater thickness of the ink can be 
applied to the substrate than is possible with other printing techniques. This allows for some 
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very interesting effects that are not possible using other printing methods. Because of the 
simplicity of the application process, a wider range of inks and dyes are available for use in 
screen printing than for use in any other printing process. The major chemicals used include 
screen emulsions, inks, and solvents, surfactants, caustics and oxidizers used in screen 
reclamation.  
Screen printing consists of three elements: the screen which is the image carrier; the 
squeegee; and ink. The screen printing process uses a porous mesh stretched tightly over a 
frame made of wood or metal. Proper tension is essential to accurate colour registration. The 
mesh is made of porous fabric or stainless steel mesh. A stencil is produced on the screen 
either manually or photochemically. The stencil defines the image to be printed in other 
printing technologies this would be referred to as the image plate. 
 Screen printing ink is applied to the substrate by placing the screen over the material. Ink 
with a paint-like consistency is placed onto the top of the screen. Ink is then forced through 
the fine mesh openings using a squeegee that is drawn across the screen, applying pressure 
thereby forcing the ink through the open areas of the screen. Ink will pass through only in 
areas where no stencil is applied, thus forming an image on the printing substrate. The 
diameter of the threads and the thread count of the mesh will determine how much ink is 
deposited onto the substrates. Figure 4 shows an example of an image for an electrochemical 
cell consisting of a working, a counter and a reference element. This type of structure can be 
easily produced by screen printing. 
 
Figure 4. Example of a screen printed electrochemical cell (screen image) showing the Reference element 
(A), the working electrode (B) and the counter electrode (C). Comercially available screen printed 
electrodes for research purposes can be obtained from DropSens, Edificio CEEI - Parque Tecnológico de 
Asturias - 33428 Llanera (Asturias) Spain. http://www.dropsens.com/en/screen_printed_electrodes_pag.html 
Many factors such as composition, size and form, angle, pressure, and speed of the blade 
(squeegee) determine the quality of the impression made by the squeegee. At one time most 
blades were made from rubber which, however, is prone to wear and edge nicks and has a 
tendency to warp and distort. While blades continue to be made from rubbers such as 
neoprene, most are now made from polyurethane which can produce as many as 25,000 
impressions without significant degradation of the image. 
If the item was printed on a manual or automatic screen press the printed product will be 
placed on a conveyor belt which carries the item into the drying oven or through the UV 
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curing system. Rotary screen presses feed the material through the drying or curing system 
automatically. Air drying of certain inks, though rare in the industry, is still sometimes 
utilized. 
The rate of screen printing production was once dictated by the drying rate of the screen 
print inks. Due to improvements and innovations the production rate has greatly increased. 
Some specific innovations which affected the production rate and have also increased screen 
press popularity include: 
 Development of automatic presses versus hand operated presses which have 
comparatively slow production times.  
 Improved drying systems which significantly improves production rate.  
 Development and improvement of U.V. curable ink technologies  
 Development of the rotary screen press which allows continuous operation of the press. 
This is one of the more recent technology developments.  
There are three types of screen printing presses. The flat-bed (probably the most widely 
used), cylinder, and rotary. Flat-bed and cylinder presses are similar in that both use a flat 
screen and a three step reciprocating process to perform the printing operation. The screen 
is first moved into position over the substrate, the squeegee is then pressed against the mesh 
and drawn over the image area, and then the screen is lifted away from the substrate to 
complete the process. With a flat-bed press the substrate to be printed is positioned on a 
horizontal print bed that is parallel to the screen. Rotary screen presses are designed for 
continuous, high speed web printing. The screens used on rotary screen presses are 
seamless thin metal cylinders. The open-ended cylinders are capped at both ends and fitted 
into blocks at the side of the press. During printing, ink is pumped into one end of the 
cylinder so that a fresh supply is constantly maintained. The squeegee is a free floating steel 
bar inside the cylinder and squeegee pressure is maintained and adjusted by magnets 
mounted under the press bed.  
Screen printing inks are moderately viscous inks which exhibit different properties when 
compared to other printing inks such as offset, gravure and flexographic inks though they 
have similar basic compositions (pigments, solvent carrier, toners, and emulsifiers). There 
are five different types of screen ink to include solvent, water, and solvent plastisol, water 
plastisol, and UV curable.  
5.1. UV curable inks 
UV curable inks consist of liquid pre-polymers, monomers, and initiators which upon 
being exposed to large doses of U.V. Radiation instantly polymerize the vehicle to a dry, 
tough thermosetting resin. They also require less energy, overall, to dry or "cure" compared 
to gas or electric driers. The down side of UV inks is they can cost as much as three times 
that of regular inks and must be handled differently than conventional inks due to safety 
issues. Additionally, solvents are required for clean-up which results in some VOC 
emissions. 
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5.2. Plastisol Inks 
Plastisol inks (both solvent and water based) are used in textile screen printing. Plastisol ink 
is a PVC (polyvinyl chloride) based system that essentially contains no solvent at all. Along 
with UV ink used in graphic screen printing, it is referred to as a 100% solid ink system. 
Plastisol is a thermoplastic ink in that it is necessary to heat the printed ink film to a 
temperature high enough to cause the molecules of PVC resin and plasticizer to cross-link 
and thereby solidify, or cure. The temperature at which most plastisol for textile printing 
cures at is in the range of 149 °C to 166 °C (300 °F to 330 °F). Plastisol inks are commonly 
used for printing graphics on articles such as tee shirts. 
5.3. Solvent inks & water inks 
Solvent and water based screen printing inks are formulated with primarily solvent or 
water. The solvent evaporates and results in VOC emissions. Water based inks, though they 
contain significantly less, may still emit VOC's from small amounts of solvent and other 
additives blended into the ink. The liquid waste material may also be considered hazardous 
waste. Water-based inks are a good choice when a “soft hand” is desirable. Water-based 
inks also have the advantage of being an excellent ink system for high speed roll-to-roll 
yardage printing. Such printing is done on large sophisticated equipment that has very large 
drying (curing) capacity. Finally, because of the fragility of the components used in the 
manufacture of enzyme electrodes, e.g. enzymes, co-enzymes and mediators water based 
inks tend to be the ink of choice when formulating the reagent ink component of the device. 
Screen (or image transfer) preparation includes a number of steps. First the customer 
provides the screen printer with objects, photographs, text, ideas, or concepts of what they 
wish to have printed. The printer must then transfer a "picture" of the artwork (also called 
"copy") to be printed into an "image" (a picture on film) which can then be processed and 
eventually used to prepare the screen stencil. Once the artwork is transferred to a positive 
image that will be chemically processed onto the screen fabric (applying the emulsion or 
stencil) and eventually mounted onto a screen frame that is then attached to the printing 
press and production begins. Screen mesh refers to the number of threads per inch of fabric. 
The more numerous the threads per inch the finer is the screen. Finer mesh will deposit a 
thinner ink deposit. This is a desirable affect when printing a very fine detail and halftones. 
Typically a fabric should be 200-260 threads per inch. Water based inks work best on finer 
mesh. These are generally used in graphic and industrial printing. Course mesh will deposit 
a heavier ink deposit. This type of screen is used on flatter, open shapes. Typically a course 
screen mesh will be 160-180 threads per inch. These are generally used in textile printing. An 
example artwork for a multi-layered screen printed device. Each colour represents a 
different layer requiring different screens and artworks. 
Enzyme electrodes are normally built up in layers using different art works and different 
inks. The inks range from; conducting carbon and silver inks (to generate the conducting 
pathways and/or the reference half cell of the device), inks containing the various chemical 
and biochemical components of the device (enzyme, buffer salts, mediator, stabilisers etc) 
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and inks that are used to define structural components of the device (insulating inks to 
define the electrode areas and geometries, adhesive inks to provide three dimensional 
elements such as capillary spacers and coloured inks to provide branding and product 
identification.) Each of these individual layers normally requires a separate screen and is 
carried out at a separate printer/dryer station.  
The blood monitors (the systems that the user receives) are made up of three main parts: the 
Optium meter, the Optium Plus blood glucose electrodes, and the Optium blood ß-Ketone 
electrodes. When the blood sample is applied to the electrode, the glucose or ketone (ß-
hydroxybutyrate) in the blood reacts with the chemicals on the electrode. This reaction 
produces a small electrical current that is measured and the result is displayed by the 
sensor. Optium Xceed monitors are designed for testing blood obtained from a finger prick, 
but you can also use it to test blood from other, less painful, sites such as the base of the 
thumb, forearm or upper arm. A recent study published in Clinical Chemistry and Laboratory 
Medicine [13] concluded that the Optium Blood glucose test strip had a within-run 
imprecision coefficient of variation (CV) of 4.2%. Good response linearity was found in 
glucose concentrations in the range 31–444 mg/dL (1.7–24.7 mmol/L). In the concentration 
range studied, the glucose meter error was 5.14% and the linear regression equation was y = 
0.91x +6.2 (r=0.984) against a Modular P clinical analyzer. The Passing-Bablok agreement test 
indicated good concordance of results. However, for glucose concentrations <100 mg/dL (5.6 
mmol/L) (n=69) the error was 6.82% with regression equation y=0.86x+5.9 (r=0.757). 
Between-lot differences amounted to 0.7%–18.2%. The authors concluded that meter had 
good precision and accuracy when compared to the laboratory method and met the quality 
recommendations of the National Committee of Clinical Laboratory Standards (NCCLS, 
currently the Clinical Laboratory Standards Institute), the National Academy of Clinical 
Biochemistry (NACB) and the International Organization for Standardization (ISO). 
6. Ketone sensors which incorporate a NAD-linked dehydrogenase 
In addition to glucose, another important analyte which is of particular relevance to diabetic 
patients is the ketone body, -hydroxybutyrate. Diabetic ketoacidosis (DKA), a condition 
were the level of ketone bodies in the blood are elevated, is a problem that occurs in people 
with diabetes. It occurs when the body cannot use sugar (glucose) as a fuel source because 
there is no insulin or not enough insulin. Fat is used for fuel instead. People with type 1 
diabetes do not have enough insulin, a hormone the body uses to break down sugar 
(glucose) in the blood for energy. When glucose is not available, fat is broken down instead. 
As fats are broken down, acids called ketones build up in the blood and urine. In high levels, 
ketones are poisonous. This condition is known as ketoacidosis. Blood glucose levels rise 
(usually higher than 300 mg/dL) because the liver makes glucose to try to combat the 
problem. However the cells cannot pull in that glucose without insulin. Diabetic ketoacidosis 
is often the first sign of type 1 diabetes in people who do not yet have other symptoms. It can 
also occur in someone who has already been diagnosed with type 1 diabetes. Infection, 
injury, a serious illness, or surgery can lead to diabetic ketoacidosis in people with type 1 
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diabetes. Missing doses of insulin can also lead to ketoacidosis in people with diabetes. 
People with type 2 diabetes can develop ketoacidosis, but it is rare. It is usually triggered by a 
severe illness. In ketoacidosis, the body fails to adequately regulate ketone production 
causing such a severe accumulation of keto acids that the pH of the blood is substantially 
decreased. In extreme cases ketoacidosis can be fatal. 14 Despite considerable advances in 
diabetes therapy, key epidemiological figures related to DKA remained nearly unchanged 
during the last decades at a global level. Prevention of DKA – especially in sick day 
management – relies on intensive self-monitoring of blood glucose and subsequent, 
appropriate therapy adjustments. Self-monitoring of ketone bodies during hyperglycemia 
can provide important, complementary information on the metabolic state. Both methods for 
self-monitoring of ketone bodies at home are clinically reliable and there is no published 
evidence favouring one method with respect to DKA prevention. 
Ketone sensitive test strips can be manufactured using NAD-linked enzyme, -hydroxybutyrate 
dehydrogenase and chemically modified electrodes like the ones described above. It is 
interesting to note however that in the case of this particular enzyme representatives of the 
common classes of quinoid NADH redox mediator, including Meldola Blue, 4-methyl-1,2-
benzoquinone, 1-methoxy phenazine methosulphate and 2,6-dichloroindophenol, were shown 
to inhibit the NAD-dependent enzyme -hydroxybutyrate dehydrogenase, severely limiting 
their utility in the construction of a stable biosensor electrode for the ketone body -
hydroxybutyrate. [14] The authors speculated that this was due to 1,4-nucleophilic addition 
with enzyme amino acid residues such as cystine present on the enzyme. Consequently, this 
mode of inhibition is overcome through the use of mediators such as 1, 10-phenanthroline 
quinone (Figure 5.)  
 
Figure 5. Chemical structure of 1,10 Phenanthroline quinone (oxidised form). The oxidation potential of 
this molecule is 0.1 Volt vs Ag/AgCl. The electrochemical reduction of 1,10-phenanthroline-5,6-quinone, 
like other quinones, is reversible and occurs by 2e- transfer in a single step in aqueous solution and by 
two 1 e-transfer steps in aprotic media. 
This technology resulted in the launch of the MediSense® Optium™ β-Ketone electrode. 
The strip was stable, (≤10% loss in response at 30 C versus 4 C) with a long shelf life of 18 
months. Diabetics were able to determine their -hydroxybutyrate level with good 
precision (0.43 mM 3-OHB, 10.5% CV; 1.08 mM, 5.9%; 3.55 mM, 3.2%; n = 20 per level) and 
accuracy (versus reference assay: slope = 0.98; intercept = 0.02 mM, r = 0.97, n = 120) over the 
range 0.0–6.0 mM in 30 s using a small volume of blood (5 μl). The electrode had a low 
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operating potential (+200 mV versus Ag/AgCl) such that the effect of electroactive agents in 
blood was minimised. [15-18] 
7. Alternative approaches to ketone sensing using Diaphorase 
The diaphorases (EC1.6.99.3) are a ubiquitous class of flavin-bound enzymes that catalyze the 
reduction of various dyes which act as hydrogen acceptors from the reduced form of di- and 
tri- phosphopyridine nucleotides, i.e. NADH, NADPH. They catalyse the following reaction: 
NADPH  H  acceptor NADP  reduced acceptor      
Either NADH or NADPH may be used as reductants. However, no exchange of 
hydrogen between the coenzymes is catalysed. Typical acceptor molecules include dyes 
such as 2, 6- dichlorophenolindophenol and tetrazolium dyes and redox couples such as 
ferricyanide anions and ferricinium cations. The Expasy entry for diaphorase is 
http://enzyme.expasy.org/EC/1.6.99.3 
 
Figure 6. Calibration curve (B) for the diaphorase based ketone sensor developed and manufactured in 
house (unpublished results). The calibration characteristics are shown over the physiologically relevant 
range 0 – 2.5 mmol/L -hydroxybutyrate spiked into a whole blood sample. Each concentration 
determination is 16 repetitions. The reaction scheme for the sensor is shown in (A). Here, the mediator 
is the ferricyanide anion. HBA in the blood was measured using the Randox RX Monza Chemistry 
Analyser, http://www.randox.com/rx%20monza.php. The test time was 7 seconds. 
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In this configuration, NAD+, Diaphorase, acceptor molecule and -hydroxybutyrate 
dehydrogenase are all formulated together in the enzyme ink and laid down on the test strip 
using an appropriate manufacturing method. Data generated in-house (unpublished results) 
using this kind of prototype test strip (with ferricyanide as the acceptor) is shown below for 
the clinically relevant concentration range of -hydroxybutyrate. The strip was 
manufactured by screen printing (cf above). Ferricyanide, buffer salts, NAD+, binders, 
diaphorase and -hydroxybutyrate dehydrogenase were mixed into a suitable enzyme ink 
and printed onto carbon electrodes. The operating voltage was 0.4 Volts. 
8. Glucose test strips using PQQ linked and FAD-linked glucose 
dehydrogenase 
PQQ-GDH (pyrrolo quinoline quinone glucose dehydrogenase) belongs to a class of 
enzymes called quinoproteins which require ortho-quinone cofactors to oxidize a wide 
variety of alcohols and amines to their corresponding aldehydes and ketones. The soluble 
quinoprotein Glucose Dehydrogenase, EC 1.1.99.17, (sGDH), systematic name D-glucose: 
(pyrrolo-quinoline-quinone)1-oxidoreductase, uses pyrrolo-quinoline quinone (PQQ) as a 
cofactor. sGDH is a strongly basic (pI = 9.5) dimeric enzyme of identical subunits. One 
monomer (50 kDa, 454 residues) has been reported to bind one PQQ molecule and two 
Ca(II) ions. One of the Ca(II) ions is required for activation of the cofactor; the other is 
needed for functional dimerisation of the protein. sGDH oxidizes a wide range of mono-and 
disaccharides and is able to donate electrons to several neutral or cationic artificial electron 
acceptors, including short artificial ubiquinone homologues. The natural electron acceptor of 
PQQ-GDH is ubiquinone although the enzyme will react with a variety of artificial 
acceptors such as the ferricyanide anion ion and the ferricinum cation. The oxidised form of 
PQQ can be converted into the reduced form PQQH2 by the transfer of 2 electrons and two 
protons from the substrate molecule. [19-21]  
There are two types of PQQ-GDH enzymes that can be considered for biosensor design. One 
is intracellular and soluble (sPQQ-GDH) whereas the other molecule is insoluble and firmly 
bound to the outer surface of the cytoplasmic membrane (mPQQ-GDH). mPQQ-GDH is 
very selective for glucose but has the disadvantage that it requires extensive solubilisation 
and stabilisation with detergent molecules[22] . For these reasons, mPQQ-GDH has not been 
successfully commercialised for biosensor application. It can oxidise a number of 
monosaccharides, in addition to glucose, such as maltose, mannose and lactose. 
Consequently, patients that have high levels of, for example maltose in the blood (which 
could result as a side effect of peritoneal dialysis) or have an inbred genetic disorder 
resulting in impaired carbohydrate metabolism, would obtain an inaccurate high reading 
when testing with glucose electrodes incorporating this enzyme. The increasing demand for 
dialysis and slower growth in capacity for haemodialysis has reinforced the need for an 
integrated approach to providing dialysis. Peritoneal dialysis is the preferred option for a 
proportion of patients with end stage renal failure. Peritoneal dialysis fluid usually contains 
glucose as an osmotic agent to enable water to pass across the peritoneum. Some patients 
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lose the osmotic effect of glucose quickly, but large icodextrin molecules, which are not 
easily transported across the peritoneal membrane, maintain an osmotic gradient. Icodextrin 
is not metabolised in the peritoneal cavity, but the polymer can move into the blood stream 
via the lymphatic system. During systemic circulation, icodextrin is mainly metabolised into 
maltose which accumulates due to a lack of circulating maltase. It is the accumulation in the 
systemic circulation of these metabolites of icodextrin that may lead to the disparity 
between finger stick and formal blood glucose measurement. Maltose interferes with 
glucose assays that use glucose dehydrogenase with cofactor pyrroloquinolinequinone 
(PQQ-GDH) leading to falsely increased readings. 
Because of the oxygen insensitivity of PQQ-GDH however, there is much commercial 
interest in producing a mutant form of the enzyme that retains its non-reactivity to oxygen 
but improving its specificity with respect to D-glucose. Recently, Roche have reported the 
successful production of a mutant strain of PQQ-GDH which shows no cross-reactivity with 
maltose. [23]  
Finally, it is worth mentioning that PQQ containing proteins lend themselves to an 
interesting electrode configuration. Whilst flavoproteins such as glucose oxidase exchange 
electrons with an electrode surface via small molecular weight mediators such as ferrocene, 
ferricyanide etc, PQQ containing enzymes can exchange electrons via cytochrome b562. This 
cytochrome will exchange electrons directly with the electrode surface without the need for 
any mediator molecule. [24] Information on PQQ-GDH can be found on the EXPASY 
Proteomics server at: http://expasy.org/enzyme/1.1.5.2. 
A new enzyme on the market which has just recently become commercially available to the 
biosensor industry is the flavo-protein FAD-GDH [25] (Toyobo Develops FAD-GDH Enzyme, 
produced by Aspergillus for SMBG http://www.toyobo.co.jp/e/press/press31072009.htm). As 
its name suggests, the enzyme catalyses the oxidation of glucose but does not utilise 
dioxygen as a co-reactant. It can react with a number of artificial electron acceptors such as 
the ferricyanide anion and the ferricinium cation. The enzyme, which is isolated from 
Aspergillus terreus shows good thermal stability and high selectivity for glucose. Its absorption 
spectrum is typical of flavoproteins showing two distinctive peaks corresponding to the 
oxidised flavin cofactor at 465nm and 385 nm. In the presence of glucose the enzyme is 
bleached and these characteristic absorption bands disappear. [26] According to the data sheet 
from the manufacturer (Toyobo, Japan) the enzyme has a pH optimum of 7.0 and a KM for 
glucose of 67.6mM. The information on the EXPASY proteomics server relating to this 
enzyme is at: http://expasy.org/enzyme/1.1.99.10. 
This enzyme is currently used in a number of glucose test strips including the OneTouch 
Verio family of test strips produced and supplied by LifeScan. The design of the OneTouch 
Verio BG test strip is shown in Figure 7. The test strip incorporates gold and palladium 
electrodes which are orientated in a co-facial manner. The dimensions of the two electrodes 
are defined and controlled during the manufacturing process by a die-punch process. The 
electrodes are separated from each other by a thin plastic spacer that has a nominal 
thickness of 95 μm. The glucose-sensitive reagents, citraconate buffer salts, potassium 
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ferricyanide mediator and flavo-protein glucose dehydrogenase (FAD-GDH), are laid down 
on the ‘bottom’ palladium electrode. FAD-GDH enzyme was selected for its high substrate-
specificity and non-reactivity towards oxygen. The strip may be defined as a ‘side-fill strip’ 
because blood may be applied to the 400 nL sample chamber from either the left or the right 
side of the test strip (Figure 7). The levels of glucose in the sample are determined within 5 
seconds, the BG value being shown on the meter display in geographically appropriate units 
(mg/dl or mM). 
 
Figure 7. Architecture of the OneTouch Verio glucose test strip. The test strip incorporates gold and 
palladium electrodes that are orientated in a cofacial manner. The dimensions of the two electrodes are 
defined and controlled during the manufacturing process by a die-punch process. The electrodes are 
separated from each other by a thin plastic spacer that has a nominal thickness of 95 μm. The glucose-
sensitive reagents, citraconate buffer salts, potassium ferricyanide mediator, and flavoprotein glucose 
dehydrogenase, are laid down on the “bottom” palladium electrode. The user can apply blood to the 
test strip either from the right hand side or the left hand side. The glucose level is reported within 5 
seconds of the start of the test procedure. 
Manufacturing process controls and built-in signal processing compensation mechanisms 
eliminate the need for user calibration coding, thus reducing the potential for user error. The 
meter uses a novel multi-pulse signal and has an improved glucose-Hct-temperature-
antioxidant compensation algorithm for higher accuracy and precision over a wide range of 
blood samples. The OneTouch Verio BG test strip is designed to work with meters that are 
technically equivalent but have different user interfaces. Currently available meters include 
OneTouch Verio, OneTouch VerioPro, and OneTouch VerioIQ. The performance 
characteristics of the OneTouch VerioPro BGMS are summarized as follows: plasma 
equivalent calibration; 0.4 μl sample size; FAD-GDH enzyme; 20–600 mg/dl glucose range; 
20–60% Hct range; 10–90% humidity range (non-condensing); 6–44°C temperature range; 
and up to 3048 m altitude use. A summary of the dehydrogenase enzymes currently used in 
commercial enzyme electrodes is shown in Table 1. 
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Enzyme Reacts with O2? Reacts with maltose?  
PQQ-Glucose Dehydrogenase No 
Yes (Not Genetically Engineered 
variant [23] ) 
NAD-Glucose Dehydrogenase No No 
NAD--hydroxybutyrate 
dehydrogenase 
No No 
FAD-Glucose Dehydrogenase No No 
Table 1. Commonly used dehydrogenase enzymes for Commercial Self testing Biosensors 
Shown below are examples of commercially available test strips for home use which 
incorporate dehydrogenase based enzymes. 
 
a. The Roche Accu-Check Aviva test strip. This test strip uses PQQ-GDH as the enzyme of choice. 
http://www.roche.com/products/product-details.htm?type=product&id=2  
b. The Abbott Optium Xceed glucose test strip. This strip uses NAD-Glucose dehydrogenase in the sensing 
chemistry. http://www.abbott-diabetescare.com/AU/ProductDetail.aspx?product=57 
c. The Abbott Optium Xceed ketone test strip. This strip uses NAD+ linked β-hydroxybutyrate dehydrogenase. 
Because it uses the same mediator chemistry as B, and hence operates at the same potential, the two strips can be 
used in the same meter. http://www.abbott-diabetescare.com/AU/ProductDetail.aspx?product=57 
d. The LifeScan OneTouch Verio test strip. This strip incorporates FAD-GDH in the strip chemistry to measure 
glucose in whole blood. http://www.lifescan.co.uk/ourproducts/teststrips/onetouchveriopro 
(Photograph courtesy of Mr Christopher Leach, LifeScan Scotland Ltd., Inverness, UK). 
Figure 8. Examples of commercially available test strips for self-testing utilising dehydrogenases.  
9. Biosensors using dehydrogenase enzymes for continuous monitoring 
9.1. FAD-GDH biosensor for continuous glucose monitoring 
It has been well established that many of the diabetic complications leading to both chronic 
and acute health problems, such as adult blindness, end-stage renal disease, lower-limb 
amputations, and heart disease or stroke, can be reduced or even prevented through intensive 
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blood glucose control. [27-29] Effective glycaemic control requires frequent measurements of 
blood glucose in order to take necessary therapeutic interventions. Such an approach is 
exemplified by the use of so-called ‘continuous glucose monitoring’ (CGM) apparatus and 
methodologies that are used by a growing number of patients to monitor their diabetes 
condition. Such systems are composed of a probe that is inserted into the body such that it 
contacts glucose containing liquids in the body, such as interstitial fluid. These CGM 
systems are designed to operate over extended periods of time, typically over a number of 
days or longer. In reality CGM is a misnomer, inasmuch as the device samples in an 
episodic manner, but on a sufficiently high frequency to distinguish such devices from 
single measurement episodic systems. Nevertheless, compared with episodic self-
monitoring blood glucose (SMBG), CGM follows blood glucose dynamics and hence, 
provides patients and healthcare professionals with not only current blood glucose levels, 
but also real-time rate and direction of changes. Blood glucose thresholds can be set to alert 
for possible dangerous trends, for instance rapid blood glucose descents that may lead to 
hypoglycemia. Advances in CGM research and development are also critical to realize 
“artificial pancreas” of a closed-loop system in conjunction with an insulin pump.  
Enzyme catalysed electrochemical biosensors have been the most successful technology for 
the commercialized SMBG products (as discussed in the preceding part of this chapter). For 
CGM, enzymes are also employed as the means of target analyte recognition, coupled to 
electrochemical transduction methods for determination of the analyte of interest. 
Correspondingly, such systems have been so far limited to the use of a redox enzyme, such 
as glucose oxidase (GOx) in which the prosthetic group is intimately associated with the 
enzyme, such that it cannot diffuse or leach away over the duration of sensor operation.[30] 
Recently commercialized flavin adenine dinucleotide-dependent glucose dehydrogenase 
(FAD-GDH, EC 1.1.99.10), where the FAD moiety forms an integral part of the enzyme, has 
attracted great attention for blood glucose monitoring because of its advantages over GOx in 
terms of insensitivity to molecular oxygen. However, like many redox enzymes, direct 
electron transfer between FAD-GDH and electrode surface cannot occur because the active 
centre FAD is insulated by the large proteins. Therefore, mediators are usually employed to 
shuttle electron between the FAD moiety and electrode surface. An example of such 
mediators is potassium ferricyanide used for LifeScan OneTouch Verio family of SMBG 
products. However, use of small molecular mediators in biosensors faces tremendous 
technical challenges for CGM which requires essentially all the reactive reagents 
immobilized without leaching out from the electrodes to achieve long-term measurement 
stability and to meet biocompatibility requirements, in particular for in-vivo applications. 
An attractive approach to tackle this challenge is to use a polymeric mediator which has 
mediator moieties chemically attached to polymer chains. Because of its large molecular 
size, the polymeric mediator can be co-immobilized with enzyme at electrode by various 
means, including surface grafting, [31-34] layer-by-layer surface adsorption, [35-37] retention 
behind semi-permeable dialysis membranes,[38-40] physical entrapment [41-43] or cross-link in 
hydrogels, [44-47] entrapment in electropolymerized [48,49] or chemically formed layers [50] or in 
inorganic layers,[51,52] and blend in carbon pastes. [53]  
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At LifeScan Scotland Limited, we have synthesized a ferrocene polymeric mediator which is 
a copolymer of vinylferrocene, acrylamide and 2-(diethylamino)ethyl methacrylate.[54] Like 
small molecular mediators, an effective polymeric mediator for biosensors should be able to 
exchange electrons with enzyme prosthetic group and then be re-oxidized/re-reduced at 
electrode in a reversible manor at a sufficient low potential to avoid or minimize 
interferences resulting from oxidation/reduction of other components in the sample fluid, 
such as uric acid, ascorbic acid etc. in a bodily fluid. Figure 9 shows cyclic voltammograms 
of the ferrocene polymeric mediator and FAD-GDH (from Toyobo Co. Ltd., Japan) in 
phosphate buffered saline (PBS). In the absence of glucose, cyclic voltammetry shows almost 
symmetric anodic and cathodic peaks which are attributed to oxidation and reduction of the 
ferrocene moieties of the polymeric mediator. After adding 2.5 mM glucose, the cyclic 
voltammogram changed dramatically, with a large increase in the anodic peak and a 
significant decrease in the cathodic peak. This was a typical phenomenon of enzyme-
dependent catalytic reduction of ferrocenium generated during the oxidation half-cycle in 
the presence of glucose. The cathodic peak increased further as glucose concentration 
increased to 5.0 mM. These results clearly indicated that the ferrocene polymeric mediator 
exhibited preferential redox properties with respect to transfer of electrons from the reduced 
enzyme prosthetic group FADH2 to the glassy carbon electrode surface. The ferrocene 
moieties are reduced to ferrocenium moieties upon accepting the electrons from FADH2 and 
then are re-oxidized on transfer of electrons to the electrode.  
 
Figure 9. Cyclic voltammograms: 1.5mg/mL FAD-GDH, 9 mg/mL ferrocene polymeric mediator in 
0.01M pH7.4 PBS, scan rate 5 mV/s, without (solid line), with 2.5 mM glucose (broken line) & 5.0 mM 
glucose (dotted line) 
We have also developed a technique for co-immobilization of FAD-GDH and the ferrocene 
polymeric mediator in modified electrodes which were fabricated by screen-printing a water-
based carbon ink containing both the enzyme and the ferrocene polymeric mediator. The ink 
contained graphite particles as conductive pigments and a pH sensitive copolymer as a binder. 
[55] The copolymer binder was water-soluble in the presence of ammonium hydroxide and 
hence, the ink was miscible with dissolved FAD-GDH and the ferrocene polymeric mediator 
during the ink formulation. As ammonia evaporated upon drying a screen-printed ink pad, the 
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binder copolymer became water-insoluble and the ink layer evolved to form a 3-dimensional 
nano-porous structure which effectively entraps the large molecules of the enzyme and the 
ferrocene polymeric mediator whilst allows free diffusion of glucose and water molecules. [54] 
Figure 10 shows scanning electron microscopy image of the electrode surface.  
 
Figure 10. Scanning electrode microscopy image of an electrode with immobilized FAD-GDH and the 
ferrocene polymeric mediator 
The main advantages of these electrodes are 
 The enzyme and ferrocene polymeric mediator are co-immobilized in vicinity of the 
electrode graphite particles, which is beneficial for fast electron transfer.  
 The 3-dimensional nano-porous structure enables higher loading of the redox species 
and provides larger electrode surface area than a planar electrode with an enzyme layer.  
 No chemical reactions are involved throughout the immobilization and hence, potential 
enzyme denaturing is avoided.  
 The screen-printing technique suits mass production and has low manufacturing cost.  
Because of the presence of ammonium hydroxide, the water-based carbon ink was basic in 
nature. FAD-GDH stability in the wet ink was studied by comparing glucose sensitivity of 
the modified electrodes fabricated from the same batch of formulated ink with varied stand-
out time. The glucose sensitivity of the electrodes was assessed by testing current responses 
of a 3-electrode setup to glucose in a concentration range of 0 to 20 mM. The test conditions 
and results are presented in Figure 11. It is clearly seen that 2-day stand-out of the wet ink 
significantly reduced glucose calibration slope of the test. During the stand-out period, the 
wet ink containing FAD-GDH and the polymeric mediator was kept in a fridge at 4 C and 
negligible changes in ink rheology and solid content were detected. For comparison, the 
stand-out was also investigated for an ink using GOx as an enzyme and insignificant effect 
on glucose calibration slope was found. Therefore, the reduction in glucose sensitivity of the 
FAD-GDH working electrodes is attributed to decrease in the enzyme activity probably 
resulting from the enzyme denaturing in the basic wet ink.  
Since Clark and Lyons reported the first enzymatic electrode for glucose measurement in 
1962, [56] molecular oxygen has been involved in the enzymatic redox reactions as an electron 
acceptor for the first generation of biosensors. However, this type of biosensors is based on 
measuring generation of hydrogen peroxide or depletion of oxygen and hence, exhibits  
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Figure 11. Calibration plots for screen-printed electrodes prepared by using the ink printed after ink 
formulation without delay (☐) and the ink printed 2 days (■) after ink formulation, tested in 0.01M 
pH7.4 PBS by using an Ag/AgCl reference electrode and a platinum counter electrode, 0.3 V potential, 
room temperature, the error bars are first standard deviation of 7 electrodes 
fundamental limitations. Measurement of hydrogen peroxide requires relatively high 
operational potential (normally >0.45V) and suffers from significant interference resulting from 
oxidation of other substances in the bodily fluid. [57, 58] For oxygen measurement, the test result 
is sensitive to the variations in oxygen supply and test conditions. [59] The second generation 
biosensors use mediators to shuttle electrons between the enzyme prosthetic groups and 
electrodes. Typically, mediators have the attractive property of being selected for a particular 
desirable redox potential at which the mediators readily undergo redox reactions at the 
electrode whilst the redox reactions of the interferents are insignificant. However, for some 
enzymes, such as GOx, oxygen can compete with the mediators to accept electrons from the 
reduced prosthetic group FADH2 to form hydrogen peroxide which cannot be oxidized at the 
electrode under the applied potential for the mediator re-oxidation. As a result, the biosensor 
response to the analyte is dampened in the presence of oxygen. As shown in Figure 12, tested 
in PBS with a 3-electrode setup, the current response to 5 mM glucose for the screen-printed 
electrode modified with GOx and the ferrocene polymeric mediator decreased almost 60% as 
blood oxygen content increased from 8 Kpa to 23.14 Kpa. In contrast, the screen-printed 
electrode modified with FAD-GDH and the ferrocene polymeric mediator had little change in 
the current response in a range of the blood oxygen content from 9.8 Kpa to 20.1 Kpa.  
The oxygen insensitivity of FAD-GDH makes the enzyme very attractive for the development 
of CGM biosensors. This is because the biosensors using an oxygen-sensitive enzyme in 
general has more profound response dampening effect at low glucose concentrations due to 
the generation of hydrogen peroxide, which can contribute to significant accuracy error for the 
CGM and impose critical challenges for CGM to provide patients and healthcare professionals 
with a true picture of ambient glycemia profile which is critical for reliable detection and/or 
prediction of hypoglycemia, an important step to good diabetes management.  
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Figure 12. Effect of oxygen content on current response to 5 mM glucose in 0.01M pH7.4 PBS for 
screen-printed electrodes containing FAD-GHD (☐) and GOx (■), tested by using an Ag/AgCl reference 
electrode and a platinum counter electrode 
Like many medical devices, CGM biosensors normally need sterilization, in particular for in 
vivo or ex-vivo applications to eliminate any harmful contaminants such as fungi, bacteria, 
viruses, and spore forms etc. There are different established methods for sterilizing medical 
devices. Some of them involve the use of high energy means which can cause damages to 
materials in certain circumstances. It is essential that the key redox species, including FAD-
GDH and the ferrocene polymeric mediator in the biosensor are not subject to any significant 
damages during a chosen sterilization process. Figure 13 shows comparison of glucose 
calibration plots for the same batch electrodes fabricated by screen-printing the water-based 
carbon ink containing FAD-GDH and the ferrocene polymeric mediator before and after 25 
KGy e-beam sterilization. The results indicate 10-16% reduction in steady state current in the 
tested range of glucose concentrations. A sample of the ferrocene polymeric mediator also went 
through the sterilization process alongside the electrodes. 1H nuclear magnetic resonance and 
size exclusion chromatography indicated no change to the composition and molecular weight 
of the ferrocene polymeric mediator after the e-beam sterilization. The reduction in the current 
responses to glucose is probably attributed to e-beam induced decrease in the enzyme activity.  
 
Figure 13. Calibration plots for screen-printed electrodes before (☐) and after (■) 25 KGy e-beam 
sterilization, tested in 0.01M pH7.4 PBS by using an Ag/AgCl reference electrode and a platinum 
counter electrode, the error bars are first standard deviation of 7 electrodes 
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CGM biosensors were fabricated by sequentially screen-printing and drying a carbon ink, an 
Ag/AgCl ink and the water-based carbon ink containing FAD-GDH and the ferrocene 
polymeric mediator on the same plane of a plastic foil to form two carbon tracks, a pseudo-
reference electrode and a working electrode, respectively. Then the plastic foil was heat-
laminated onto a plastic disc which had pre-formed micro-channels (typical channel 
dimension: width x depth = 0.3 x 0.3 mm) in a way that the micro-channel runs over the two 
electrodes with the working electrode upstream of the pseudo-reference electrode. Surface 
areas exposed to the micro-channel are 0.3 x 2.0 mm and 0.3 x 5.5 mm for the working 
electrode and the pseudo-reference electrode, respectively. [54] For comparison, biosensors 
with GOx were also fabricated in the same way except for replacing FAD-GDH with GOx in 
the water-based carbon ink. Loadings of the two types of enzymes in the water-based 
carbon inks were identical in weight.  
The two types of biosensor discs were tested side-by-side at room temperature. Human 
blood samples were collected on the same day for the test. Upon testing, a continuous flow 
of the human blood samples were pumped from blood sample reservoirs through the 
channels of each biosensor at 15 μL per minute by using a peristaltic pump (Ismatec). Sensor 
current responses to blood glucose were recorded by using a potentiostat (Uniscan 
Instruments) operated at 0.3 V potential. Step changes of blood glucose concentration were 
realized by switching the blood sample reservoirs which were open to the atmosphere and 
under gentle magnetic agitation. Low glucose blood samples were prepared by standing the 
blood sample reservoirs in a 37 C water-bath to accelerate glucose consumption by blood 
cells, whilst high glucose blood samples were prepared by spiking with a 20% wt/wt glucose 
stock (from Sigma-Aldrich). YSI measurements (YSI 2300 STAT Glucose Analyzer) of 
glucose concentrations were performed for the blood samples as references. In order to 
minimize error caused by blood mixing in the disc channel upon changing glucose 
concentration, the YSI measurements were performed by taking a sample from the reservoir 
when the previous blood sample in the biosensor micro-channel was completely depleted 
indicated by steady sensor current. Given the slow decrease in blood glucose concentration 
with time at room temperature, two YSI measurements were normally performed for each 
blood sample during the period it flowed through the biosensor disc channel. 
In a typical test, the two types of biosensors were tested continuously over 54 hours with daily 
changes of blood samples from different donors. The disc channels were flushed with PBS 
(0.01 M, pH7.4) prior to the blood changes. Figure 14 shows typical recorded current responses 
of one FAD-GDH and one GOx biosensors to the same blood samples with varied glucose 
concentrations in a range of 2.29 to 25.64 mM between 23 and 30 hour test time. YSI measured 
blood glucose concentrations are also shown. For both biosensors, the currents clearly 
followed the step-changes in blood glucose concentration and reached “steady-state” in 3 to 5 
minutes. It is expected that the real response time of the biosensors to the blood glucose 
concentration changes is shorter than 3 to 5 minutes because the recorded steady-state currents 
can only be obtained after complete depletion of the “old” blood samples from the disc 
channels upon the reservoir switching. By a close look, the current response of the GOx 
biosensor clearly drifted whilst the current response of FAD-GDH sensor did not between 28.5 
 
Amperometric Glucose Sensors for Whole Blood Measurement Based on Dehydrogenase Enzymes 343 
and 30 hour test time. This is probably due to the oxygen effect on the GOx biosensor as 
oxygen content of the blood sample gradually increased under continuous agitation. 
The steady-state current responses of the two biosensors over the 54-hour test are plotted 
against the YSI measured blood glucose concentration in Figure 15. For both of the 
biosensors, the test results demonstrated good linear correlations between the current 
responses and blood glucose concentration over the tested glucose concentration range. 
However, the FAD-GDH biosensor had significantly higher current responses than the GOx 
biosensor, leading to higher sensitivity to glucose concentration variations and hence, 
potentially better measurement accuracy. This suggests that FAD-GDH has higher activity 
than GOx given that the enzyme loadings were the same for the two types of biosensors.  
 
Figure 14. Current response variations of sensors with screen-printed working electrodes containing 
FAD-GDH (solid line) and GOx (dotted line) and Ag/AgCl reference electrode, with varied blood 
glucose concentrations (), tested with continuous flow of human blood at a flow rate of 15 μL/min 
 
Figure 15. Calibration plots of sensors with screen-printed working electrodes containing FAD-GDH  
(□) and GOx (■) respectively and Ag/AgCl reference electrode, tested with continuous flow of human 
blood at a flow rate of 15 μL/min 
Because the blood cells continuously consumed glucose and result in gradual decrease in 
blood glucose concentration at room temperature, direct assessment on measurement 
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stability of the biosensors by recording sensor response change with time at a fixed glucose 
concentration proved to be unreliable. Nevertheless, closely aligned data points to the linear 
regression line in Figure 15 illustrate stable biosensor response during the 54-hour test, 
suggesting good FAD-GDH stability during the continuous measurement. 
9.2. NAD and ferrocene polymeric mediator redox couple  
As a coenzyme for hundreds of oxidoreductases, NAD has attracted great attention for 
biosensor development. Because its direct oxidation at electrode surface requires high 
applied potential and involves side reactions leading to the formation of electrochemically 
inactive by-products (see the preceding section), NAD is normally coupled with mediators 
for its application in biosensors. In the literature, ferrocenium and its derivatives have been 
reported as mediator for oxidation of NADH to NAD+. [60-63] As mentioned in the preceding 
section, small molecular mediators are not normally suitable for continuous monitoring 
biosensors. The effective immobilization of the ferrocene polymeric mediator in the screen-
printed carbon electrode developed at LifeScan Scotland Limited holds potentials for 
development of continuous monitoring biosensors using NAD-dependant oxidoreductases. 
To investigate electrochemical communication between NAD and the immobilized 
ferrocene polymeric mediator, 0.3 V potential (ECOChemie PGSTat Autolab, Type III) was 
applied to an electrochemical cell containing 3.0 mL 0.01M pH7.4 PBS and equipped with a 
screen-printed carbon electrode (approximately dimension length x width = 10 x 5 mm) with 
immobilized ferrocene polymeric mediator (about 12.5% wt/wt), an Ag/AgCl reference 
electrode and a platinum counter electrode to oxidize the ferrocene moieties of the 
polymeric mediator to ferrocenium moieties. After the current of ferrocene oxidation 
reached a steady level, PBS in the cell was replaced with 0.3 mM NADH (from Sigma-
Aldrich) in 3.0 mL 0.01M pH7.4 and a step increase in current was detected, which indicated 
oxidation of NADH by the ferrocenium moieties of the polymeric mediator. The NADH 
oxidation was followed by measuring absorbance of the solution at 340 nm wavelength by 
UV/vis spectroscopy (Cecil Instruments, CE9500) at different time intervals. The result 
shown in Figure 16 illustrates gradual decrease in NADH concentration (E340 = 6,330) with 
the oxidation time, which can be attributed to continuous oxidation of NADH by the 
ferrocene polymeric mediator immobilized in the carbon electrode. 
0.65 mL above oxidized NADH solution was collected and mixed with 0.25 mL 99.5% 
ethanol (EtOH, Sigma-Aldrich) in a UV cuvette (l = 1cm). UV spectra of the solution in the 
cuvette were recorded before and after addition of 0.4 mg alcohol dehydrogenase (ADH, 
Sigma-Aldrich). As shown in Figure 17, the addition of EtOH and ADH increased the 
absorbance peak at around 340 nm to almost the same level as the control solution which 
contained 0.3 mM NADH in 0.01M pH7.4 PBS and did not subject to the oxidation process. 
This suggests that NADH oxidation by the immobilized ferrocene polymeric mediator 
predominantly, if not completely produced electrochemically active NAD+ that was reduced 
to NADH by EtOH in the presence of ADH. 
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Figure 16. Variation of UV absorbance at 340 nm of 0.3 mM NADH in 0.01 M pH7.4 PBS by carbon 
electrode with immobilized ferrocene polymeric mediator at 0.3 V potential, by using an Ag/AgCl 
reference electrode and a platinum counter electrode, at room temperature  
 
Figure 17. UV spectroscopy monitoring reduction of oxidized NADH in the presence of ADH and 
EtOH, 0.65ml NADH (0.2 mM) + 0.25ml EtOH (99.5%) + 20ul ADH (control) (solid line), 0.65ml oxidized 
NADH + 0.15mL EtOH (before reduction) (broken line), 0.65ml oxidized NADH + 0.25ml EtOH + 20 ul 
ADH (4mg/ml) (dotted line) 
For continuous monitoring, use of native NAD as a coenzyme apparently is not ideal due to its 
low molecular weight and high water-solubility. Direct immobilization of free NAD at electrode 
has been a long-standing challenge. [64, 65] There are a large number of publications in the literature 
concerned with NAD retention for various purposes. In the field of biosensors, one promising 
approach is covalently attaching NAD moieties to polymer chains which can be immobilized at 
electrode by different means. This can be achieved by directly coupling NAD to an electrode 
modified with a polymer bearing functional groups,[66] entrapping polymeric NAD in semi-
permeable membranes [67, 68] or synthesizing a charged polymeric NAD which was then 
physically adsorbed at electrode surface in conjunction with counter-charged polymer(s) in a 
manner of layer-by-layer. [69] At LifeScan Scotland Limited, we intend to develop continuous 
monitoring biosensors using NAD-dependent enzymes by immobilizing all the redox species, i.e. 
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an enzyme(s), the ferrocene polymeric mediator and a polymeric NAD in an electrode with the 3-
dimentional nano-porous structure (see Figure 10). A polymeric NAD is normally synthesized by 
two routes. One is coupling NAD or NAD analogue with a polymer bearing functional groups. 
[66, 70-73] The other route involves synthesis of a NAD monomer and then its copolymerisation with 
another co-monomer(s). One of the challenges for NAD immobilization is to keep NAD 
coenzymic activity while achieving effective retention at electrode. Yamazaki et al synthesized 
three NAD monomers (N6-[N-(6-methacrylamidohexyl)carbamoylmethyl]-, N6[N-[2-[N-(2-
methacrylamidoethyl)carbamoyl]ethyl] carbamoylmethyl]-, and N6-[N-[N-(2-hydroxy-3-
methacrylamidopropyl) carbamoylmethyl] carbamoylmethyl]-NAD) and then copolymerized 
them with various co-monomers (acrylamide, N-(2-hydroxyethyl)-, N-ethyl-, N,N-diethyl-, and 
N,N-dimethylacrylamide, acrylic acid, and 6-methacrylamidohexylammonium) by free radical 
polymerisation to form a series of polymeric NADs. [74] Their studies revealed that hydrophilicity 
and length of the spacers linking NAD moieties and the polymer backbone had the most 
important effects on coenzymic activity of the polymeric NADs. This suggests that keeping 
mobility of the NAD moieties covalently attached to a polymer chain is critical to NAD 
coenzymic activity. Chemically modification to native NAD is required to tailor chemical 
properties of the spacers. N6-amino group on the adenine ring of NAD (see Figure 18) is 
normally selected as the site for this purpose. [75, 76] Lindberg et al reported alkylation of NAD+ 
with iodoacetic acid followed by alkaline rearrangement to give N6-carboxymethyl-NAD+.[75] 
However, the reaction between NAD+ and iodoacetic acid took 10 days in the dark at room 
temperature. We successfully synthesized N6-carboxymethyl-NAD+ by a modified method with 
a dramatic reduction in the reaction time.  
 
Figure 18. Chemical structure of NAD+ 
9.4. Synthesis of N1-carboxymethyl-NAD+ (compound 1 in Figure 19) 
1.0g NAD+ (1.51mmol) was dissolved in 3.5mL 0.1M pH 7.0 sodium phosphate buffer in a 5ml 
Biotage microwave reaction tube. Then, 1.5 g (8.06mmol, 5.34eq) iodoacetic acid was added 
and pH was adjusted to 7.0 by using 5.0M NaOH aqueous solution. The reaction vessel was 
sealed and the mixture was heated to 50°C for 10 minutes by using microwave irradiation. 
After that, the pink solution (c.a. 5.0 mL) was acidified to pH3.0 using 5M HCl aqueous 
solution before being poured into 25 mL pre-cooled (-5°C) mixture of acetone/IMS (1:1). The 
resulting precipitate was filtered, washed first with 5.0 mL IMS, then 15 mL dry diethyl ether 
before air drying under dry nitrogen for 10 minutes. Further drying overnight in a desiccator 
over fused CaCl2 gave 1.62 g crude N1-carboxymethyl-NAD+ as a pink amorphous solid.  
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9.5. Synthesis of N6-carboxymethyl-NADH (compound 2 in Figure 19) 
9.1g (c.a. 10.57mmol) above prepared crude N1-carboxymethyl-NAD+ was dissolved in 
1.3% w/v NaHCO3 in 450 mL aqueous solution and the solution was deoxygenated by 
sparging with nitrogen for 10 minutes. 3.5 g (20.1mmol) sodium dithionite was added in 
one portion and the mixture was stirred at ambient temperature to affect reduction of the 
nicotinamide moiety. After 1.0 hour, the solution colour changed from pink to yellow. The 
solution was then sparged with air for 10 minutes to destroy any excess dithionite and the 
pH was brought to 11.0 by using 5M NaOH aqueous solution. The mixture was heated at 
70°C for 90 minutes, to promote Dimroth rearrangement to N6-carboxymethyl-NADH, 
before cooling to 25°C. Thin-layer chromatography (silica gel, isobutryic acid/water/32% 
NH4OH (aq), 66/33/1.5 by volume) showed no evidence for the presence of N1-
carboxymethyl-NADH. 
9.6. Oxidation of N6-carboxymethyl-NADH to N6-carboxymethyl-NAD+ 
(compound 3 in Figure 19) 
The reaction mixture containing N6-carboxymethyl-NADH was treated with 17.5 mL 3M 
Tris buffer (pH7.0) and the pH was adjusted to 7.5 using 5M HCl aqueous solution. 3.5 mL 
acetaldehyde (62.6mmol) was added, immediately followed by 10.5 mg yeast alcohol 
dehydrogenase (saccharomyces cerevisiae) (~300U/mg) before allowing agitating at ambient 
temperature to deoxidize the nicotinamide moiety. After 18 hours, the reaction mixture (c.a. 
485 mL) was concentrated in vacuo (30°C/10-15bar) to approximately 1/3 volume and poured 
into 1800 mL pre-cooled (-5°C) mixture of acetone/IMS (1:1). The fine slurry was left to age 
for 18 hours at 3°C. The resulting precipitate was collected by centrifugation and washed on 
a glass sinter with 40 mL IMS then 120 mL dry diethyl ether before air-drying under dry 
nitrogen for 10 minutes. Further drying overnight in a desiccator over fused CaCl2 afforded 
3.99g crude N6-carboxymethyl-NAD+ as a tan coloured hygroscopic solid.  
1.0 g of the above-prepared crude N6-carboxymethyl-NAD+ was taken up in 20 mL water 
and passed through a Sephadex G10 gel filtration column (2x10cm, 20 mL). All eluted 
fractions containing UV active material were combined (60 mL total volume) and added to a 
column of Dowex 1-X2 ion exchange resin (Cl-, 4x50cm, 200 mL) which had been pre-
equilibrated with water. A linear gradient of 0-50 mM LiCl (buffered to pH 3.0), at 10 mL 
per minute over 65 minutes, was applied using “Presearch Combiflash Companion” 
chromatography equipment. The fractions eluted between 25-35 mM were combined (c.a. 
100 mL), neutralized to pH 7.0 with 5M LiOH and evaporated to approximately 1/3 volume 
and poured into 300 mL pre-cooled (-5°C) mixture of acetone/IMS (1:1). The fine slurry was 
left to age for 18 hours at 3°C. The resulting precipitate was collected by centrifugation and 
washed on a glass sinter with 30 mL IMS then 50 mL dry diethyl ether before air-drying 
under dry nitrogen for 10 minutes. Further drying overnight in a desiccator over fused 
CaCl2 afforded 0.307g purified N6-carboxymethyl-NAD+ as a cream coloured hygroscopic 
solid.  
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Figure 19. Synthesis of N6-carboxymethyl-NAD+ 
The synthesized N6-carboxymethyl-NAD+ is an important intermediate for NAD 
immobilization at electrodes for continuous monitoring biosensors. An extension of this 
work could involve synthesis of various polymeric NADs with tailor-made chemical 
properties to meet biosensor requirements for continuous monitoring of different analytes. 
10. Conclusions 
In this article we have outlined various strategies for the electrochemical exploitation of 
dehydrogenase enzymes in sensor devices. The techniques used ultimately depend upon the 
class of dehydrogenase enzyme used. For enzymes that are NAD(P)+ linked it is essential to 
develop a base transducer (a modified electrode) that efficiently reoxidises the reduced 
coenzyme. Alternatively, sensing schemes can be designed which utilize Diaphorase thereby 
facilitating the biochemical oxidation of reduced coenzyme. With FAD and PQQ dependent 
enzymes the most successful strategy has been to utilize mediator molecules such as the 
ferricyanide anion to couple the enzymatic activity to the electrode. Although not yet 
exploited commercially, dehydrogenase enzymes could also have a role in continuous 
monitors. With the NAD+ dependent enzymes there is the additional complication of 
immobilizing the chemical components of the sensor to prevent drift in the device over time. 
This also includes the coenzyme molecule and we have illustrated how the synthesis of the 
N6-carboxymethyl derivative of NAD can be an important intermediate in achieving this. 
Attachment of suitable ligands at this position, with sufficient flexibility, should allow the 
development of stable reagents which will facilitate the development of continuous devices. 
The electrochemistry of NADH oxidation has been well researched over the last 30 years. 
Also, over 250 enzymes use this ubiquitous coenzyme so schemes which utilize NAD 
dependent enzymes should allow for the measurement of a range of analytes in blood. In 
spite of this, it is interesting to note that with the exception of Abbott, none of the other 
major biosensor manufacturers have embraced this technology. The reason for this could be 
due to the fact that glucose SMBG is still the largest biosensor market worldwide and it is 
adequately served by enzymes such as glucose oxidase, FAD-GDH and PQQ-GDH, none of 
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which require any exogenous coenzyme to function. This makes the manufacture of the 
sensor relatively straight forward compared to those that require a modified electrode, an 
enzyme and in addition exogenous coenzyme added to the enzyme ink. In addition, 
switching to a NAD-dehydrogenase system may be incompatible with the manufacturing 
equipment currently used by manufacturers and thus prevent the adoption of this 
technology.  
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1. Introduction 
Glutamate dehydrogenase (GDH) is present in all domains of life and is one of the most 
extensively studied enzymes at the biochemical and structural levels. These enzymes are 
generally reversible and catalyse either the reductive amination of 2-oxoglutarate (2-OG) to 
yield glutamate using NAD(P) as a cofactor, or the oxidative deamination of glutamate [1] 
(Fig. 1). Because of the reaction it catalyses, the main role of GDH is glutamate catabolism 
and ammonium assimilation. However, other physiological roles for GDH have been 
described in some organisms, as we will see below.  
 
Figure 1. Reaction catalysed by glutamate dehydrogenase 
The synthesis of both glutamate and glutamine are key steps in the cell metabolism in all 
organisms, because they represent the only means of incorporating inorganic nitrogen into 
carbon backbones. Inorganic nitrogen is assimilated in the form of ammonium, which is 
incorporated as an amino group to glutamate or an amido group to glutamine. These amino 
acids in turn act as amino group donors for the synthesis of most nitrogen-containing 
compounds in the cell. In particular, the amino group of glutamate is used in the synthesis 
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of purines, pyrimidines, amino sugars, histidine, tryptophan, asparagine, NAD and p-
aminobenzoate. Therefore glutamate is a key element in the nitrogen flow, as it plays a role 
of nitrogen donor and acceptor.  
Glutamate can be synthesized by two alternative routes: one involves catalysis of GDH in 
the aminating direction, but ammonium assimilation is also possible by the participation of 
two enzymes: glutamine synthetase (GS), and glutamate synthase, also named glutamine 
oxoglutarate aminotransferase or GOGAT (Figure 2). The disadvantage of this pathway is its 
extra energy requirement. Although GDH catalyses the reductive amination of 2-OG, it is 
noteworthy that because of its overall high Km for ammonium, this reaction can only be used 
for the synthesis of glutamate when the ammonium concentration is high (>1 mM). When 
the ammonium concentration is lower, ammonia is incorporated to glutamate mainly via the 
GS-GOGAT pathway. Generally, GDH activity is not necessary for cell growth, since most 
organisms can synthesize glutamate from glutamine and 2-OG using GOGAT. In fact, some 
bacteria naturally lack GDH and are neither glutamate auxotrophs nor affected in nitrogen 
assimilation. While the amination reaction provides nitrogen required for many biosynthetic 
pathways, the oxidative deamination reaction of GDH provides carbon to the tricarboxylic 
acid cycle (TCA) by conversion of L-glutamate to 2-OG and probably contributes to 
balancing the glutamine to glutamate ratio.  
Plants and microorganisms can utilise several inorganic nitrogen sources with different 
oxidation states such as N2 (by nitrogen-fixing bacteria and archaea), nitrate or nitrite, by 
reducing them to ammonium, which is subsequently assimilated. After formation of 
glutamate, the α-amino group can be transferred to a wide variety of 2-oxo acceptors to give 
rise to amino acids. Also, the α-amino group can be transferred again to glutamate, when 2-
oxoglutarate and other amino acids are available. These reactions are carried out by the 
reversible activity of aminotransferases (EC 2.6.1.x) (Figure 2). Plants and microorganisms 
can synthesize all carbon skeletons for their amino acids and incorporate the amino group to 
them by transamination using glutamine and glutamate as nitrogen donors. Incorporation 
of ammonium in animals also occurs through the GDH and GS/GOGAT pathways. 
However, higher organisms are unable to reduce oxidized forms of nitrogen to ammonium, 
to synthesize the structures of some branched or aromatic amino acids such as tryptophan 
or phenylalanine, or to incorporate sulphur into covalently bonded structures. They are, 
therefore, totally dependent on other organisms to convert oxidized forms of nitrogen into 
forms available for the organism, as well as to provide some essential amino acids (Figure 
2). These are supplied in the diet or are provided by bacteria from the intestinal tract.  
In plants and microorganisms, the physiological roles of GDH include nitrogen assimilation 
[2], glutamate catabolism [1, 3], but also osmotic balance [4] and tolerance to high 
temperatures [5, 6]. In vertebrates, multiple biochemical pathways involve glutamate, which is 
also used as a neurotransmitter. The imbalance of the GDH activity may lead 
to disturbances of clinical relevance for humans [7]. Free ammonia is highly toxic to organisms 
that excrete urea as the main nitrogenous waste such as mammals, fish and adult amphibians, 
leading to inhibition of brain respiration and an excess ketone body formation from acetyl-
CoA in the liver. To prevent these deleterious effects, GDH and some of the other enzymes 
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that yield amino groups into the urea cycle are localized in the mitochondria. In the liver, 
glutamate is the source of excess ammonium release, and the concentration of glutamate 
modulates the rate of ammonia detoxification into urea. In pancreatic β-cells, the GDH is 
involved in insulin homeostasis, and oxidation of glutamate mediates amino acid-stimulated 
insulin secretion [8]. In the central nervous system, glutamate serves as a neurotransmitter and 
also as the precursor of the inhibitory neurotransmitter γ-aminobutyric acid (GABA), as well 
as glutamine, a potential mediator of hyperammonemic neurotoxicity [7]. Also, excessive 
glutamate signalling can lead to excitotoxicity, a phenomenon where over-activation of 
glutamate receptors initiates neuronal death [9]. The clinical importance of glutamate 
metabolism in β-pancreatic cells has been highlighted by the recent discovery of a dominantly 
expressed defect in glutamate metabolism, the hyperinsulinism/hypermmonemia syndrome 
(HHS). HHS was one of the first diseases that clearly linked GDH regulation to insulin and 
ammonia homeostasis [10]. Affected children suffer from recurrent hypoglycemia due to 
inappropriate secretion of insulin [10-12]. This syndrome is caused by the loss of the human 
glutamate dehydrogenase allosteric regulation (see below). 
 
Figure 2. Flow of nitrogen in the biosphere. Molecular nitrogen, nitrites and nitrates are reduced to 
ammonium and assimilated by microorganisms and plants, whilst higher eukaryotes assimilate these 
nitrogenated compounds as protein in their diets. 
2. Classification, evolution and structure of GDHs 
Several GDH classifications have been done according to their size, oligomerisation state, 
coenzyme specificity or organism, among others. According to their cofactor specificity, 
there are three basic types of GDH: those that are cofactor specific for NAD (EC 1.4.1.2), 
those that are specific for NADP (EC 1.4.1.4) and those that can use either cofactor (EC 
1.4.1.3) (dual coenzyme-specific GDHs). Lower eukaryotes and prokaryotes usually have 
GDHs that only function with one coenzyme whilst the enzymes that have dual coenzyme 
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specificity are commonly found in higher eukaryotes. However, some dual-GDHs, have also 
been described in prokaryotes [5, 13-15]. Glutamate dehydrogenases from non-vertebrate 
animals differ from the GDHs of vertebrates in that they are mono-coenzyme specific and 
are not regulated by nucleotides [16]. In higher plants GDH is ubiquitous and also very 
abundant. A number of isozymes are usually present in a single species, some of them being 
inducible, which correlate with their abundance depending on environmental or nutritional 
conditions [17]. GDHs have also been characterized from a number of eukaryotic 
microorganisms with different coenzyme specificity such as fungi, (NAD+ or NADP+) [18], 
algae (NAD+, NADP+ or dual), protozoa (NAD+ or NADP+) and also different intracellular 
localizations (i.e. cytoplasmic, mitochondrial or in the chloroplasts) [19]. 
According to the molecular weight of the monomer, three groups of GDHs can be 
distinguished: GDH50s (MW around 50 KDa), GDH115s (MW around 115 KDa) and 
GDH180s (MW around 180 KDa). All NADP and dual-GDHs reported so far belong to the 
GDH50 group, whereas there are representatives of NAD-GDHs in all of these groups. 
GDH115s have been found only in lower eukaryotes [20-22], whilst the largest GDHs are 
present only in bacteria. GDH180s were first identified in actinomycetes [23], but recently 
they have been also described in other Gram positive and Gram negative bacteria (see table 
1). Most GDHs reported so far are homo-oligomeric enzymes, but they differ in the number 
of monomers that compose them. The majority of GDHs have a hexameric structure, as is 
the case of vertebrate GDHs, but tetrameric and even dimeric enzymes have also been found 
(see table 1 and references therein). Particularly, the most recently discovered family of 
prokaryotic GDH180s, have representatives of either hexameric [23, 24], tetrameric [25, 26] 
and dimeric [27] enzymes. In addition, a couple of GDH50s composed of two different 
subunits in the form of a hetero-hexamer have been reported [28, 29]. 
Analysis of the distribution pattern of gdh genes from all available sequenced genomes in 
the three domains of life reveal that all classes of gdh have been found in eubacteria and 
archaea and all but the large GDH have been found in eukaryotes. Both NAD+- and NADP+-
dependent forms of GDH have been reported in higher plants, located in mitochondria and 
chloroplasts, respectively. The GDH enzyme is abundant in several plant organs, and its 
isoenzymatic profile can be influenced by dark stress, natural senescence or fruit ripening 
[30]. Genes coding for GDH seem to be absent in some archaeal genomes as well as in some 
of the smaller eubacterial and eukaryotic genomes. Among the organisms that do encode 
GDH, several genes coding for GDH may be found in the same genome. However, just one 
or two classes are represented, no genome has yet been shown to encode all classes. 
 
Organism cofactor 
MW 
enzyme 
(KDa) 
MW 
subunit 
(KDa) 
subunit 
number
Km NH4
(mM) 
Km 2-OG
(mM) 
Km glu 
(mM) 
Ref. 
Archaea   
Archaeglobus fulgidus NADP 263 47 6 4 0.5 3.9 [31] 
Halobacterium 
halobium 
NAD    450 20.2 4 [32] 
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Organism cofactor 
MW 
enzyme 
(KDa) 
MW 
subunit 
(KDa) 
subunit 
number
Km NH4
(mM) 
Km 2-OG
(mM) 
Km glu 
(mM) 
Ref. 
Halobacterium 
halobium NADP       [33] 
Thermococcus strain 
AN1 NADP 204 47 4 15.5 1.7 9.12 [19] 
Pyrococcus furiosus NAD/NADP 270-290 48 6 6, 27b 0.33 0.6 [34] 
Thermococcus 
profundus NADP 263 43 6 1.6, 22
b 0.2, 0.87b 6.8 [6] 
Eubacteria   
Gram negative   
Capnocytophaga 
ochraea NAD    3.33 1.44 2.44 [35] 
Escherichia coli B/r NADP 300 50 6 1.1 0.64  [36] 
Escherichia coli PA340 NADP 2.5 0.2 2.3 [37] 
Janthinobacterium 
lividum NAD 1065 170 6   7.1 [24] 
P. aeruginosa NAD 180 4 15 1.6  [25, 38] 
P. aeruginosa NADP 110 7 1  [38, 39] 
Psychrobacter sp 
TAD1 NAD 290 160 2 24.6 2.36 28.6 [27] 
Psychrobacter sp 
TAD1 NADP 290 47 6 4 ND 67.4 [37] 
Salmonella enterica NADP 0.29 4 50 [40] 
Thermus termophilus NAD 289 46.5, 48a 6  [29, 41] 
Thiobacillus novellus NADP 130 50-55 2? 7.5 7.4 35.5 [42] 
Thiobacillus novellus NAD 120 50-55 2? 7.4, 0.5d 6.7, 0.67d 11.8, 13.3d [43] 
Gram positive   
Bacillus macerans NADP 2.2 0.38  [44] 
Bacillus polymyxa NADP 2.9 1.4  [45] 
Bacillus subtilis NAD 6  [46, 47] 
Clostridium 
symbiosum NAD 282 49 6    [48, 49] 
Corynebacterium 
glutamicum NADP  49 6?    [50] 
Mycobacterium 
smegmatis NAD  180 4?    [26, 51] 
Mycobacterium 
smegmatis NADP 245.5 40 6 33 5 62.5 [52] 
Lactobacillus 
fermentum 
NADP 300 50 6 6.76 5.6 79 [53] 
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Organism cofactor 
MW 
enzyme 
(KDa) 
MW 
subunit 
(KDa) 
subunit 
number
Km NH4
(mM) 
Km 2-OG
(mM) 
Km glu 
(mM) 
Ref. 
Peptostreptococcus 
asacharolyticus 
NAD 266 49 6 18.4 0.82 6 [54] 
Streptomyces 
clavuligerus 
NAD 1100 179 6    [23] 
Streptomyces fradiae NADP 200 49 4 30.8 1.54 28.6 [55] 
a NAD+-GDH of Thermus thermophilus is a heterohexamer composed by two types of subunits: GdhA (46, 5 KDa) and 
GdhB (48 KDa) 
b The Km depends on the substrate concentration 
c The kinetic constants determined for each cofactor in enzymes with dual cofactor specificity are separated by slashes 
d The kinetic constants of NAD+-GDH of T. novellus are different depending on the presence of AMP 
Table 1. Some characteristics of selected prokaryotic GDHs  
The distribution of gdh genes does not show any strong pattern that correlate with the 
phylogeny [56]. It was believed for some time that NAD- and NADP-GDHs were originated 
via single gene duplication [57], but as genomes are sequenced and more gdh genes are 
identified this hypothesis has been ruled out. The analysis of phylogenetic distribution 
patterns of the gdh gene families provides strong support for numerous horizontal gene 
transfer events involving prokaryotes, as well as microbial eukaryotes. Differential gene 
loss, on the other hand, does not seem to have played an important role in the evolution of 
gdh genes in any of the three domains of life. Sequence comparisons for GDHs from a 
diverse range of sources show that the hexameric enzymes are similar whatever their 
coenzyme specificity [58, 59]. On the other hand, the tetrameric enzymes are less well 
understood because of a lower number of characterized tetrameric GDHs. Organisms 
bearing a tetrameric GDH, which have catabolic roles, also possesses a genetically distinct 
hexameric NADP-linked enzyme with a biosynthetic role. Mammalian GDHs represent a 
clear deviation from its ancestral forms, since they have the so-called antenna, a 48 amino 
acid insertion near the carboxy terminus, although it is not clear when this feature evolved. 
Sequenced genomes from Ciliates show that their GDHs present a smaller antenna from that 
of mammalians, although other members of the Protista, such as trypanosomes, have GDH 
almost identical to the bacterial forms. Ciliates are an evolutionary missing link in the GDH 
evolution [60] 
The structure of GDH of many eukaryotic and prokaryotic organisms has been considerably 
studied and characterized since the beginning of the 50s. As mentioned above, Most GDHs 
studied so far are homopolymers consisting of two to six subunits of molecular weight 
40,000 to 60,000 (fungal NAD-specific GDHs and bacterial large GDH are exceptions). Most 
of the characterized GDHs are hexameric and the most common structure found is two 
trimers of subunits stacked directly on top of each other [61-63]. Some GDHs such as that 
from bovine liver, which is the best-characterized enzyme [1], may have higher order 
multimeric structures. This enzyme, which is a hexamer in solution, aggregates to form a 
high molecular weight species and this polymerization is promoted by a high concentration 
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of enzyme, by high ionic strength and also by allosteric ligands or cofactors [64]. Since the 
local concentration of GDH in some tissues is very high, aggregation might be a regulatory 
mechanism of the activity in vivo. 
Eukaryotic and prokaryotic GDHs share relatively high conservation in their primary and 
secondary structures [61] and the crystal structures of the bacterial [59, 65, 66] and 
mammalian forms [61, 63] of GDH confirm that the general architecture and the locations of 
the catalytically important residues have remained unchanged throughout evolution. Each 
subunit in this multimeric enzyme is organised into two domains separated by a deep cleft. 
One domain directs the self-assembly of the molecule into a hexameric oligomer with 32 
symmetry. The other domain is structurally similar to the classical pyridine nucleotide-
binding domain but with the direction of one of the β-strands reversed. Upon glutamate 
binding, the enzyme can adopt different conformations by flexing about the cleft between its 
two domains. NAD+ binds in an extended conformation with the nicotinamide moiety 
buried deep in the cleft between the two domains [59, 61, 63, 65, 66]. The bottom domains of 
each trimer make wide contacts with each other, while the NAD+-binding domains bearing 
the nucleotide-binding motif are poised at the top of the structure.  
The largest structural difference between mammalian and bacterial GDH is the antenna, 
which has a helix-loop-helix conformation. The antenna ascends from the NAD+-binding 
domain surface via a long, 23-residue helix and then descends back with a random coil 
structure. The helices of the "antenna" domains in each subunit of the trimer wrap around 
each other with a right-handed twist to form the core of the antenna protrusion. Extensive 
contacts between “antennae” may represent hexamer interactions in solution and, perhaps, 
with other enzymes within the mitochondrial matrix [61]. The fact that antennae are only 
found in the forms of GDH that are allosterically regulated by numerous ligands leads to the 
interpretation that it plays a major part in this regulation. In contrast to the extensive 
allosteric homotropic and heterotropic regulation observed in mammalian GDH (see below), 
bacterial forms of GDH are relatively unregulated. 
3. GDH enzymology and physiological role 
As a reversible enzyme, GDH has the potential for catalysing the reaction in the 
biosynthetic, aminating direction, or in the catabolic, deaminating direction. The actual 
physiological reaction of each GDH depends on several factors, as the kinetic constants of 
the enzyme for its different substrates or the environment where the cell is developed 
may widely vary. In general, NADP+-GDHs usually operate in the biosynthetic direction, 
that is, synthesizing glutamate by the assimilation of ammonia into 2-OG [6, 31, 39, 40, 45, 
67, 68], whereas NAD+-GDHs have primarily a catabolic function, yielding ammonia and 
2-oxoglutarate from the oxidative catabolism of glutamate [23, 24, 39, 68] (Table 1). 
Sometimes, both enzymes are present in the same organism, and play a different 
physiological role due to their different kinetic properties or their different time or place 
of expression [27, 51, 69, 70]. Pseudomonas aeruginosa and presumably other members of 
the genus Pseudomonas have a NADP+-specific and a NAD+-specific GDH, and it has been 
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hypothesized than the latter acts specifically in arginine catabolism by converting 
glutamate, a product of the ammonia-producing arginine succinyl transferase (AST) 
pathway, into 2-OG, since it is allosterically modulated by arginine (positively) and citrate 
(negatively) [25]. Similarly, the only active GDH from Bacillus subtilis (RocG, NAD+-
dependent) appears to be involved in arginine and proline catabolism [46]. On the other 
hand, despite the catabolic function assigned to NAD+-GDHs, the existence of an NAD+-
specific GDH with an unusual biosynthetic role has been reported in the oral bacterium 
Capnocytophaga ochraea [35]. In this case, it was found that only the NAD+-GDH 
ammonium assimilating activity could be detected in cell free extracts, probably due to 
the high concentration of ammonium and ammonium precursors that can be found in the 
gingival crevicular fluid. Interestingly, GDHs have been shown to play a substantial and 
even predominant role in nitrogen assimilation in conditions of N2 fixation in the Gram 
positive bacteria Bacillus macerans and Bacillus polymyxa [44, 45]. Nitrogen fixation only 
occurs under extreme nitrogen-limiting conditions, when nitrogen from other sources is 
very scarce. In these conditions nitrogen is always assimilated using the GS/GOGAT 
pathway, since the Km of GS for ammonium is much lower than that of GDH. This is not 
the case in B. macerans and B. polymyxa, as in these organisms the GOGAT activity is much 
lower than GDH activity in nitrogen-fixing cells. A NAD+-GDH involved in glutamate 
fermentation has also been described in the anaerobic Gram-positive bacteria 
Peptostreptococcus asaccharolyticus [54]. In this organism, GDH is the first enzyme of the 
glutamate fermentation via the hydroxyglutarate pathway, and can represent as much as 
10% of total protein when grown on glutamate. Very high levels of GDH production has 
also been reported in some hyperthermophilic archaea like Pyrococcus furiosus or some 
Thermococcus strains [5, 6, 71]. These preferentially biosynthetic enzymes represent an 
exceptionally high percentage of total soluble protein of the cell, in some cases up to 20%, 
which suggests an important role of these enzymes in these organisms at an extremely 
high temperature for life. 
Determination of the GDH enzymatic structure has allowed the elucidation of the 
mechanisms for allosteric regulation and negative cooperativity. The activity of glutamate 
dehydrogenase in animals is allosterically regulated by purine nucleoside phosphates and 
other metabolic intermediates. In brief, GTP and ATP are allosteric inhibitors whereas GDP 
and ADP are allosteric activators. Hence, a lowering of the energy charge accelerates the 
oxidation of amino acids. Their in vivo regulation may be dependent on the metabolic status 
of the cell, or in the tissue they are located. The intracellular compartmentalization of the 
cofactors, and the GDH itself, may also drive the reaction in one or the other direction. In 
vertebrate cells, GDH appears to be localized primarily in the mitochondrial matrix [1]. The 
effects of nucleosides on mammalian GDH are complex. For the bovine liver GDH, four 
binding sites per subunit have been described, being the active site (site I), the adenine 
nucleotide regulatory site (site II), the guanine nucleotide regulatory site (site III) and the 
reduced coenzyme regulatory site (site IV). Some substrate and effectors bind just the active 
site (glutamate, oxoglutarate, ammonia, NADP+) while others are able to bind two different 
sites (NAD+, ADP, NAD(P)H) [19] 
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One characteristic of microbial GDHs is the absence of the antenna structure that functions as 
a heterotropic allosteric site. In agreement with this, the vast majority of microbial GDHs do 
not appear to have this level of complexity in GDH modulation by purine nucleoside 
phosphates. However, some microbial GDHs also show homotropic and even heterotropic 
allosteric control, especially those from the GDH180 family. GDHs from Psychrobacter sp. 
TAD1, Streptomyces clavuligerus or Pseudomonas aeruginosa show positive cooperativity of 
substrate binding, a common feature associated with the complex regulation in vertebrate 
GDHs, but unusual in bacteria [23, 25, 37]. Furthermore, the Gram-positive bacterium 
Clostridium symbiosum displays an apparent negative cooperativity and inhibitory effect of 
the enzyme cofactor in certain conditions of pH and concentration [49]. On the other hand, 
heterotropic control, either positive or negative, has been found in an increasingly number 
of microorganisms. Accordingly, some aminoacids such as L-aspartate or L-arginine are 
positive allosteric effectors of NAD+-GDH from the psychrophilic bacterium 
Janthinobacterium lividum and P.aeruginosa [24, 25], while nucleotides such as ATP or AMP 
modulate NADP+-GDH from Salmonella enterica sv. Typhimurium and NAD+-GDH from S. 
clavuligerus and Thiobacillus novellus [23, 40, 43]. In the latter case, AMP has been found to be 
actually an essential activator for S. clavuligerus GDH activity. Conversely, some microbial 
GDHs have allosteric inhibitors, such as TCA cycle intermediates in the archaeon 
Halobacterium halobium, in Salmonella enterica sv Typhimurium, and in P. aeruginosa [25, 40, 
72], or nucleotides such as ADP in the NAD+-GDH of Capnocytophaga ochraea [35]. Finally, 
the NAD+-GDH from the actinomycete Mycobacterium smegmatis is modulated by the small 
protein kinase GarA [26]. 
4. Regulation of bacterial GDH gene expression 
The diverse roles of bacterial GDH in different organisms provide for a variety of regulatory 
mechanisms. Here we show a few examples for selected bacteria in which transcriptional 
regulation of GDH genes has been characterized. 
4.1. Regulation of GDH synthesis in the enterobacteria 
Transcriptional regulation of the gdhA gene, encoding NADP-GDH, was first described in 
the diazotrophic enterobacterium Klebsiella pneumoniae, and then in Escherichia coli [73]. 
Transcription of gdhA is repressed in both enteric bacteria under nitrogen limitation by the 
general nitrogen control system (Figure 3,A). This is consistent with the fact that low affinity 
for ammonium limits the use of GDH for glutamate synthesis at ammonium concentrations 
below 1 mM. The enterobacterial general nitrogen control (Ntr) system is a very well 
characterized signal transduction and regulatory network encompassing seven elements: the 
alternative σ factor σ54, encoded by rpoN, the uridylyl transferase-uridylyl removing enzyme 
GlnD, two PII signal transduction proteins, GlnB and GlnK, the two-component system 
NtrB-NtrC and the LysR-type transcriptional regulator Nac. Nitrogen status is signalled by 
the intracellular pools of glutamine (indicative of nitrogen sufficiency), and 2-OG (indicative 
of nitrogen limitation). These signals are perceived by the PII proteins by means of their 
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reversible GlnD-dependent uridylylation in response to decreased glutamine levels and by 
allosteric modulation via 2-oxoglutarate binding. Interaction with PII proteins in either their 
uridylylated or deuridylylated states is responsible for posttranslational regulation of the 
activities of a variety of proteins involved in nitrogen metabolism, including glutamine 
synthetase, nitrogenase and the sensor kinase/phosphatase NtrB. Deuridylylated GlnB 
promotes NtrB-dependent dephosphorylation of NtrC under nitrogen excess [2, 74]. In 
nitrogen-limiting conditions, phosphorylated NtrC (NtrC-P) activates multiple σ54-
dependent promoters, controlling the expression of over one hundred genes related in E. coli 
[75]. NtrC-regulated genes encode multiple functions related to nitrogen metabolism, 
including transport and utilization pathways for diverse nitrogen sources, the nitrogen 
fixation sensor-regulator pair NifL-NifA (in the diazotrophic Klebsiella pneumoniae), and the 
nitrogen regulator Nac. Transcription of Nac is initiated from an NtrC-activated σ54-
dependent promoter and autorepressed [76, 77]. Nac in turn activates and represses a set of 
genes whose products are mostly related to nitrogen metabolism. Nac-activated genes 
include those involved in the catabolism of histidine, proline, urea and alanine, among 
others [78-80]. Notably, Nac represses the genes coding for the two enzymes that synthesize 
glutamate, gdhA, encoding GDH, and gltAB, encoding GOGAT [81]. Unlike most LysR-type 
transcriptional regulators, the activity of Nac is not modulated by the presence of a small 
ligand, and the protein is synthesized in its active form [79]. Thus, the nitrogen limitation 
dependency of Nac regulation exclusively reflects the increase in concentration under 
nitrogen limitation due to its transcriptional regulation. Nac is not present in many bacteria 
containing the Ntr system, and is conspicuously absent in the closely related and well-
characterized S. enterica [82]. As the need for two different regulators (NtrC and Nac) has 
been questioned, Nac has been proposed to act as an "adaptor" that integrates genes 
transcribed from σ70-dependent promoters (which cannot be directly regulated by the 
activator of σ54-dependent promoters NtrC) into the general nitrogen control network [83]. 
Transcription of the gdhA gene is repressed by Nac under nitrogen limitation in both E. coli 
and K. pneumoniae (in contrast, gdhA expression is not nitrogen-regulated in S. enterica). Nac 
exhibits two modes of transcriptional repression of the gdhAp promoter. "Weak" repression 
involves Nac binding as a dimer to the promoter region in a single site located at -100 to -75 
relative to the transcriptional start site [84]. "Strong" repression is observed when a Nac 
tetramer is simultaneously bound to the aforementioned site, centered at -89, and a 
downstream site centered at +47. The proposed regulatory mechanism for "strong" 
repression involves Nac bending DNA, looping out the intervening region, and forming a 
repressor loop reminiscent of those formed by LacI and GalR at the lac and gal promoters, 
respectively [79]. 
In addition to Nac-mediated repression, gdhA is subjected to positive regulation by a second 
LysR-type transcriptional regulator, ArgP. ArgP is an activator whose activity is 
antagonized by lysine. ArgP interacts with the gdhA promoter region at a single site between 
-100 and -50. Lysine inhibits interaction of ArgP with this site, thus preventing activation 
[85]. Activation is also prevented by Nac interaction with the overlapping binding site 
centered at -89, as both regulatory proteins bind in a mutually exclusive fashion. Thus 
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"weak" repression is in fact the result of the antagonist action of Nac on ArgP-mediated 
activation [82, 85]. The role of lysine as a signal can be rationalized if one considers that 
glutamate must serve two roles in the cell, as both an amino group donor for over 80% of 
the nitrogenous compounds in the cell, and as a counterion to K+ in osmotic pressure 
homeostasis. In order to sense the amount of glutamate being used for biosynthesis, the 
pools of one or more amino group acceptor may be used instead of glutamate itself. Lysine 
is likely one of those nitrogenous compounds that serve as surrogates for glutamate in 
signaling the extent of glutamate overflow from osmotic pressure homeostasis into the 
biosynthetic pathways for other nitrogenous compounds [85]. Consistently, gdhAp activity 
is decreased in rich media containing amino acids [81], and lysine levels may be one of 
several signals that mediate the feedback regulation of gdhAp. However, the identity of 
other compounds that may fulfill this role is as of yet unknown. 
 
Figure 3. Regulatory circuits for bacterial glutamate dehydrogenase genes. The cartoons represent the 
known regulatory circuits for K. pneumoniae (A), P. putida (B), P. aeruginosa (C), B. subtilis (D), S. coelicolor 
(E) and C. glutamicum (E). Sigma 54- or SigL-dependent promoters are displayed as white arrows. Other 
promoter types are displayed as black arrows. Question marks represent aspects that are not well 
characterized. CCR: carbon catabolite repression. 
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4.2. Regulation of GDH synthesis in pseudomonads 
Little is known about the transcriptional regulation of GDH synthesis in most Gram-
negative bacteria. However, the regulatory mechanisms behind gdhA regulation were 
recently revealed in the soil bacterium Pseudomonas putida [86]. Similarly to its enteric 
counterparts, P. putida represses gdhA expression during nitrogen-limited growth in a Ntr 
system-dependent fashion (Figure 3,B). P. putida harbors a simplified general nitrogen 
control system that lacks the major PII protein, GlnB, and the transcriptional regulator Nac. 
In this scheme, the only PII protein, GlnK, controls the phosphorylation/dephosphorylation 
balance of NtrC in response to nitrogen availability using mechanisms likely similar to those 
found in the enterics [87]. In the absence of Nac, NtrC has been shown to directly regulate 
some of the functions that are controlled by Nac in the enterics, including activation of codB 
and ureD, encoding cytosine deaminase and urease respectively [88], and repression of the 
GDH gene gdhA [86]. NtrC binds the σ70-dependent gdhAp promoter region cooperatively at 
four different sites, centered at positions -118, -95, -21 and +12 relative to the transcriptional 
start. While simultaneous occupancy of all four sites yields the maximal levels of repression, 
only the promoter-proximal I and II sites were found to be absolutely required for 
repression. A mechanism based on a repressor loop involving four NtrC dimers has been 
proposed for negative regulation of the gdhAp promoter in P. putida. Although repression is 
partially sensitive to the phosphorylation state of NtrC in vitro, in vivo evidence indicated 
that phosphorylation of NtrC is not required for efficient repression of the gdhAp promoter. 
Since NtrC synthesis is itself nitrogen regulated via the glnAp promoter, the increase in 
repressor concentration under nitrogen limitation appears to be the major determinant of 
nitrogen-regulated expression of gdhA in P. putida [86]. 
Pseudomonas aeruginosa encodes two GDH enzymes, a NAD-dependent GDH encoded by 
gdhB, primarily involved in glutamate deamination to 2-oxoglutarate, and a NADP-dependent 
GDH, encoded by gdhA, primarily involved in ammonium assimilation. The catabolic enzyme 
is linked to the AST pathway for aerobic utilization of arginine as a carbon source. Glutamate 
is the end product of the AST pathway, and NAD-GDH serves the purpose of connecting 
arginine catabolism to the central metabolism via 2-oxoglutarate. Transcription of gdhB is 
activated by the arginine regulatory protein ArgR in response to the presence of arginine, 
which is also an allosteric modulator of the enzyme activity (Figure 3,C). An ArgR binding site 
is found immediately upstream from the -35 box of the gdhB promoter. Induction of the 
expression of gdhB and activation of the encoded dehydrogenase by arginine serve to direct 
the flow of glutamate into the TCA cycle [25]. Conversely, transcription of gdhA is repressed 
by ArgR in the presence of arginine. Such repression could serve to minimize the operation of 
an energy-consuming futile cycle involving the simultaneous function of gdhA and gdhB when 
P. aeruginosa uses arginine as a carbon source. Repression of gdhA expression is exerted from a 
single ArgR binding site centered at position -41, and a simple steric hindrance mechanism has 
been proposed at this promoter [89]. Downregulation of gdhA expression by the Ntr system 
under nitrogen limitation has also been reported [90], but the factors and mechanisms 
involved are uncharacterized. Since P. aeruginosa also lacks Nac, direct repression by NtrC 
similar to that observed in P. putida [86], may also occur in this organism.  
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4.3. Regulation of GDH synthesis in Bacillus subtilis 
The Bacillus subtilis genome contains two genes encoding GDHs, rocG and gudB. While RocG 
is an enzymatically active GDH, GudB is inactive, due to a duplication of three amino acid 
residues at its active center. Decryptification of gudB in a rocG background is achieved by 
high-frequency acquisition of a suppressor mutation consisting of the precise deletion of 
part of the 9-bp direct repeat that prevents activity [46, 47]. Both RocG and decryptified 
GudB are primarily catabolic dehydrogenases, and de novo glutamate synthesis in B. subtilis 
is performed exclusively by GOGAT.  
Similarly to P. aeruginosa GdhB, RocG is not nitrogen-regulated and is linked to arginine and 
proline catabolism, as its expression is induced by arginine, ornithine and, to a lesser extent, 
proline. Transcription from the rocG promoter depends on the product of the Bacillus subtilis 
sigL gene, an ortholog of the alternative σ factor σ54 [91], and is activated by the UAS 
binding protein RocR in response to the presence of arginine, ornithine, or proline with the 
assistance of the arginine-dependent activator AhrC (Figure 3,D). SigL, RocR and AhrC also 
control transcription of the two operons, rocABC and rocDEF, involved in arginine 
conversion into glutamate. In that regard, RocG-dependent deamination of glutamate to 2-
oxoglutarate can be viewed as the final step in the use of arginine, ornithine, and proline as 
carbon or nitrogen, providing rapidly metabolizable carbon- or nitrogen-containing 
compounds for biosynthesis [92]. Interestingly, inducibility of RocG synthesis by arginine 
precludes growth on glutamate as the sole carbon source.  
The most salient feature of the rocGp SigL-dependent promoter is the absence of an 
upstream activator sequence (UAS) for RocR. Instead, the UAS present at the rocAp 
promoter, located immediately downstream from the rocG coding sequence, is the cis-acting 
element essential for RocR-dependent activation of rocGp. This sequence has been shown to 
be active when placed upstream or downstream and as far as 15 kb away from the target 
promoter [93]. According to the general model of σ54-dependent promoter activation, RocR 
bound to its target sequence activates transcription by interacting with promoter-bound σ54-
RNA polymerase by a mechanism that involves looping out of the intervening DNA 
sequences. The AhrC protein is also required for activation of rocG (as well as rocABC and 
rocDEF), and it apparently modulates the activity of RocR by means of protein-protein 
contacts [94]. 
Unlike the arginine utilization operons rocABC and rocDEF, rocG transcription is subjected to 
carbon catabolite repression in the presence of glucose. Such repression is mediated by the 
regulatory protein CcpA. A cre (catabolite responsive element) site is located at positions +39 
and +51, and is required for CcpA binding and rocGp repression. CcpA binding at this 
location prevents transcription from the rocGp promoter, but also acts as a roadblock for 
low-level readthrough transcription from an upstream promoter, which is relevant in the 
absence of both glucose and the cognate inducers [92]. As in other CcpA-regulated genes, 
CcpA-mediated repression requires the assistance of the accessory proteins HPr and Crh. 
A final feature of the B. subtilis GDH RocG worth mentioning is its role in the regulation of 
the assimilatory glutamate synthase operon, gltAB. RocG belongs to a group of proteins 
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designated "trigger enzymes", which have catalytic as well as regulatory functions. RocG 
interacts with the LysR-type transcriptional regulator GltC, which is the cognate activator of 
the gltAB operon. RocG-GltC interaction results in inactivation of the latter, which in turn 
prevents activation of the assimilatory glutamate synthase in conditions in which glutamate 
is already being synthesized from arginine-related amino acids or proline. This mechanism 
allows tight control of glutamate metabolism by the availability of carbon and nitrogen 
sources [95-97]. 
4.4. Regulation of GDH synthesis in other Gram-positives 
The Streptomyces coelicolor gene gdhA, encoding a NADPH-dependent GDH, is negatively 
regulated under ammonium limitation by GlnR (Figure 3,E). GlnR is an OmpR-like 
transcriptional factor, which is the master regulator of nitrogen metabolism in S. coelicolor. 
This response includes activation of glnA, glnII genes, encoding two glutamine synthetases, 
and repression of gdhA, among others [98]. The GlnR regulon appears to be conserved in 
Mycobacterium and other actinomycetes. The nitrogen signal is transduced by a variation of 
the enterobacterial Ntr signal transduction system, including the PII protein GlnK and 
GlnD, which catalyzes adenylylation and deadenylylation of GlnK in response to the 
nitrogen status. GlnR activity is presumably regulated by phosphorylation, as it displays the 
conserved phosphorylatable aspartate residue present in many response regulators, but the 
identity of its sensor kinase is currently unknown [99]. GlnR exerts repression of the gdhA 
promoter region by binding at a conserved site centered at position -73, but the underlying 
mechanisms of repression are not yet understood [98]. Interestingly, synthesis of the 
regulator GlnR is repressed by the response regulator PhoP under phosphate limitation, 
thus providing a link between phosphorus and nitrogen metabolism in S. coelicolor [100]. 
AmtR is a repressor of the TetR family, which acts as the global nitrogen regulator in the 
industrially relevant Corynebacterium glutamicum [Burkowsky, 2003]. Because of the high 
basal intracellular concentrations of glutamate and glutamine (up to 200 mM and up to 50 
mM, respectively), C. glutamicum does not use these amino acid pools to sense nitrogen 
availability. Instead, ammonium is probably used to modulate the activity of the adenylyl 
transferase GlnD [101]. Adenylylated GlnK interacts with AmtR to release the repressor 
from its target promoters under nitrogen limitation. AmtR represses the expression of at 
least 35 genes, including glnA, encoding glutamine synthetase, gltBD, encoding glutamate 
synthase and the amtB-glnK-glnD operon, encoding a high-affinity ammonium transporter 
and the signal transduction proteins, GlnK and GlnD. GDH activity is high and relatively 
constant in different growth conditions [50]. Transcription from the gdhAp promoter is 
repressed 2-fold by AmtR (Figure 3,F) under nitrogen excess and interaction of AmtR with 
the gdhAp promoter region has been detected [102]. Intriguing as it may be, upregulation of 
GDH under nitrogen limitation does not appear to be physiologically relevant, as sufficient 
activity is present under the high ammonium concentration conditions in which GDH 
contributes to ammonium assimilation. Other transcription factors (FarR, WhiH and OxyR) 
have been documented to bind the gdhAp promoter region, but the relevance of these 
interactions is so far unknown [102].  
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5. Involvement of GDH in biotechnological processes 
In addition to the different physiological roles of GDHs from different bacteria in nitrogen 
assimilation, amino acid catabolism, osmotic balance or tolerance to high temperatures, 
GDH catalysis is crucial for a number of biotechnological processes. These include industrial 
production of glutamate by C. glutamicum and related species, which involves catalysis in 
the aminating direction, and production of aromas by lactic acid bacteria during cheeses 
ripening, which involves catalysis in the opposite direction. 
5.1. Production of L-Glutamate by Corynebacterium glutamicum 
C. glutamicum is a facultatively anaerobic, nonpathogenic, non-motile, biotin-auxotrophic, 
Gram-positive soil bacterium that was isolated more than 50 years ago in a screen for 
bacteria that excrete glutamate. Since then, derivative strains of this bacterium and related 
species have been isolated as glutamate producers, and industrial processes for biological 
glutamate production have been developed. Annual L-glutamate production is estimated to 
be over 2 million tons, with a continuously increasing demand (3% per year), above all in 
developing countries. L-glutamate is mainly used in food as a flavour enhancer. 
In addition to its importance in industrial biotechnology, C. glutamicum has gained interest 
as a model organism for the Corynebacterineae, an industrially relevant suborder of the 
actinomycetes. Because of the academic and industrial interest, its physiology and 
metabolism have been deeply characterised, three research groups have independently 
determined the genomic sequence of C. glutamicum strains [103-105], and global analysis 
techniques such as proteomics, transcriptomics, metabolomics and metabolic flux analysis 
have been used to obtain a holistic view of the glutamate production process. 
C. glutamicum exponentially growing cells do not accumulate glutamate. However, 
glutamate production and excretion can be easily induced by an astonishing variety of 
treatments, which allow accumulation of glutamate in the culture medium to a 
concentration as high as 80 g L-1. These include biotin limitation [106], which was the first 
identified condition for glutamate overproduction, addition of fatty acid ester surfactants 
such as Tween 40 (polyoxyethylene sorbitan monopalmitate) or Tween 60 
(polyoxyethylene sorbitan monoestearate) [107], addition of certain β-lactam antibiotics 
such as penicillin [108], use of glycerol-auxotrophic or fatty acid-auxotrophic strains [109], 
use of temperature-sensitive strains cultured at higher temperature [110], or addition of 
ethambutol, an inhibitor of cell wall arabinogalactan synthesis [111]. In spite of the 
apparent diversity of treatments to induce glutamate production and secretion, all of 
them have features in common and there is a unified view that glutamate production is 
triggered by environmental conditions that produce damage of the cell surface structures 
[112-114]. 
Since C. glutamicum is a biotin auxotroph, supplementation of a defined medium with a 
limiting concentration of biotin in batch cultures results in reduced total biomass and 
concomitant glutamate production. Biotin is a co-factor of acetyl-CoA carboxylase, the first 
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enzyme for fatty acid biosynthesis, and a reduction of this enzyme activity leads to changes 
in the fatty acid composition of the membrane. In support of this view, a mutation in dtsR1, 
which codes for the beta subunit of acetyl/propionyl-CoA carboxylase, requires fatty acids 
for growth and, when limited, overproduces glutamate even when grown with an excess of 
biotin [109]. On the contrary, amplification of its gene dosage resulted in reduction of 
glutamate production induced by biotin limitation, detergents or penicillin [115]. Glycerol 
limitation in mutants unable to produce it provokes similar membrane alterations due to the 
limitation of membrane lipid precursors. Besides the ubiquitous cell membrane, members of 
the genus Corynebacterium, together with Mycobacteria and Nocardia, have a special cell 
envelope structure, which consists of a second lipid layer containing mycolic acids, which 
has a highly ordered structure and plays an important role in determining solute fluxes 
[116]. Interestingly, mycolic acids of the outer lipid layer are covalently linked to an 
arabinogalactan layer, which in turn is covalently linked to the underlying peptidoglycan of 
the cell wall. This structure may thus be envisioned as one large macromolecule, the 
mycolyl-arabinogalactan-peptidoglycan complex. Treatments with ethambutol or penicillin 
clearly affect the structure of the cell envelope. The triggering effect of Tween 40 or Tween 
60 (but not Tween 20 or Tween 80) may be due to alterations of the mycolic layer structure 
[112] although it may also affect the activity of acetyl-CoA carboxylase [113], thus leading to 
cell envelope alterations. 
It was thought for some time that all these treatments affecting cell envelope structure 
increased the membrane permeability, which would in turn allow leakage of glutamate. 
However, it is obvious that a specific carrier-mediated export is required, as the increase in 
the membrane permeability is specific for glutamate, not for other solutes, and glutamate is 
still exported against a concentration gradient. The glutamate transporter was identified by 
characterising mutants that produced and accumulated glutamate. All these mutants had 
substitution mutations or even an insertion mutation in the NCgl1221 gene, which codes for 
a product showing homology to mechanosensitive channels such as the E. coli yggB gene 
product [113]. The mutant alleles appear to code for a constitutively opened glutamate 
channel. Exchange of the wild-type allele for these mutant alleles led to glutamate 
overproduction and excretion without any inducing treatment, and rendered cells resistant 
to the L-glutamate analog 4-fluoroglutamate. Overexpressing wild type NCgl1221 did not 
result in constitutive glutamate excretion but led to increased glutamate production and 
excretion after the induction treatments. On the contrary, a deletion mutant lacking 
NCgl1221 could not excrete glutamate [113]. Therefore, opening the glutamate channel 
appears to be essential for glutamate production and export. In addition, this is the first 
response of C. glutamicum to membrane tension alterations, which triggers all other 
metabolic adaptations leading to efficient glutamate production. The NCgl1221 (yggB) 
product has 4 transmembrane segments, is located in the cytoplasmic membrane [117] and 
has been recently shown to work as a mechanosensitive channel able to increase the cell 
survival rate of Bacillus subtilis after osmotic down-shock [118]. 
Although C. glutamicum has other potential ammonium assimilating enzymes such as 
alanine dehydrogenase or diaminopimelate dehydrogenase, their contribution to 
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ammonium assimilation is very limited, according to the in vivo flux analyses [119]. C. 
glutamicum and related glutamate-producing species have GDH, GS and GOGAT. Thus, C. 
glutamicum assimilates ammonium, the preferred carbon source of most bacteria, either via 
GS/GOGAT or via GDH. As in many other bacteria, GS/GOGAT is the main ammonium 
assimilation pathway when its concentration is limiting, whilst GDH assimilate most of the 
ammonium when it is present in concentrations above 5 mM [120]. Under glutamate 
production conditions, which implies high ammonium concentration, the gltB and gltD 
genes encoding the GOGAT subunits, are fully repressed by ammonium and no GOGAT 
activity is detected [119, 121]. Therefore, the main glutamate producing enzyme in these 
conditions is GDH. 
Production and excretion of large quantities of glutamate require glutamate export to the 
culture medium but also modification of metabolic fluxes to produce high amounts of 
glutamate. Metabolic flux analysis under exponential growth vs. glutamate producing 
conditions [119, 122-125], indicated significant changes in catabolic pathways (Figure 4). 
Under non-growing, glutamate-producing conditions, glucose catabolism either via 
glycolysis or the pentose phosphate pathway was clearly reduced. Additionally, there was a 
significant redistribution of the fluxes at the 2-OG branch point between the TCA cycle and 
the glutamate biosynthetic pathway, that reduced the flux towards succinyl CoA formation 
about 2/3, with a concomitant increase in the reductive aminating reaction catalysed by 
GDH. The increase of the metabolic flux towards glutamate is not due to an increase in the 
2-OG-producing isocitrate dehydrogenase (ICDH) or GDH activities because they remain 
constant [125]. In fact, increasing either ICDH or GDH activity by overexpressing their 
coding genes, did not affect glutamate production [123].  
The factor with greatest impact on glutamate production is a reduction of the 2-oxoglutarate 
dehydrogenase complex (ODHC) activity [123, 125]. During exponential growth, although 
sufficient GDH specific activity was observed, the flux catalyzed by GDH was very small 
because the Km value of GDH for 2-OG is much higher (approximately 50-fold higher) than 
that of ODHC. Once the ODHC specific activity was decreased after the triggering signals, 
2-OG accumulated, and consequently, glutamate was overproduced by GDH. In spite of the 
initial report claiming that an odhA deletion mutant, which has no ODCH activity, 
overproduced and excreted glutamate [126], there are a number of reports on odhA mutants 
with contradictory results. It appears that those OdhA mutants that overproduced 
glutamate had an additional mutation in Ncgl1221 (yggB) [113], which clearly indicates that 
reduction or elimination of ODHC activity is necessary but not sufficient for glutamate 
overproduction. 
Obviously, GDH activity requires the presence of sufficient concentration of its substrates. 
Paradoxically, most of the NADPH required for anabolic reactions is generated at the 
pentose phosphate pathway, which is reduced under these conditions. However, it appears 
that the reaction catalysed by ICDH provides sufficient NADPH to fulfill the demands of 
the GDH reaction. Similarly, glutamate production and excretion requires a continuous 
supply of carbon. This is achieved by an increase in the anaplerotic reactions that produce 
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oxaloacetate. In C. glutamicum two reactions can yield oxaloacetate. One is the standard 
anaplerotic reaction catalysed by the phosphoenol pyruvate carboxylase (PEPc). The other is 
pyruvate carboxylase (Pc), which catalyses oxaloacetate production from pyruvate. 
Metabolic flux of PEPc remains constant in both conditions whilst the Pc flux, undetectable 
during exponential growth, is clearly increased in the glutamate-producing conditions upon 
addition of Tween-40 [124]. This suggests a relevant role of Pc in providing sufficient 
oxaloacetate for glutamate production. Despite this evidence, pyruvate carboxylase cannot 
be relevant for glutamate production when induced by biotin limitation, as biotin is also a 
prosthetic group of Pc. As expected, pyc disruptants lacking Pc can produce and excrete 
glutamate as the wild type strain [127], indicating that PEPc may be sufficient to provide the 
required carbon under this particular inducing regime.  
 
Figure 4. Metabolic fluxes from glucose to glutamate under vegetative growth or non-growing 
glutamate-producing conditions. Red arrows show metabolic fluxes reduced during glutamate 
production. Green arrows show those reactions that appear or are increased under the same condition. 
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How is ODHC activity decreased during glutamate production? ODHC is a complex 
composed of three different subunits: OdhA (E1), SucB (E2) and LpdA (E3). Many TCA 
cycle enzymes are regulated at transcriptional or posttranscriptional levels [128]. Activity of 
this complex is controlled by OdhI, a small protein (15,4 KDa) that binds OdhA (the E1 
subunit). Induced glutamate excretion is virtually abolished in a OdhI deletion mutant, thus 
indicating that inhibition of ODHC activity through OdhI is critical for glutamate 
overproduction [129]. The OdhI function is regulated by phosphorylation by PknG, which 
phosphorylates and inactivates OdhI [130], and dephosphorylation by Ppp. PknG deletion 
mutants showed higher glutamate production when induced by some treatments [129], 
which is consistent with its role in controlling ODHC activity. 
The main question is why do C. glutamicum cells excrete large amounts of L-glutamate when 
exposed to the mentioned induction treatments? Certainly, it does not appear that it is a 
response to metabolic changes since the inducing treatments do not imply changes in 
nutritional status. Since these treatments all affect cell surface structures and may therefore 
alter membrane tension, L-glutamate production may be the response to this membrane 
stress, as glutamate might function as a compatible solute to prevent cells from bursting. 
Thus, L-glutamate production by C. glutamicum may be a mechanism of adaptation to 
environmental changes affecting cell surface structures that starts by opening a glutamate 
export mechanosensitive channel, which in turn somehow triggers the metabolic 
adaptations (reduction of pentose phosphate pathway, reduction of ODHC activity, increase 
of the anaplerotic reactions) required to produce and excrete high amounts of glutamate. A 
similar role of L-glutamate in osmoprotection was also described for E. coli [131], and 
confirmed by the osmosensitive phenotype provoked by mutations unable to activate gdhA 
in a GOGAT deficient background during osmotic upshift [4]. However, there are no reports 
on metabolic adaptations leading to glutamate production and excretion upon osmotic 
shock in this bacterium. 
5.2. Aroma and flavour production by Lactic Acid Bacteria (LAB) 
Accelerating or diversifying flavour development in cheese is of major economical interest 
since final flavour of cheeses partly determines the consumer's choice. Flavour formation 
occurs during cheese ripening, and is associated to non-starter lactic acid bacteria (NSLAB), 
adventitious microflora that occur in the milk or appear later during cheese manufacturing. 
After characterisation, some strains have been selected as flavour-producing adjunts and 
shown that cheeses with these adjunts are richer in free amino acids and have enhanced 
flavour intensity [132]. However, flavour development is a time consuming and expensive 
process that is still not well mastered, and selection of strains for cheese ripening is still an 
empirical process based on cheese trials with different strains and sensory analyses, that has 
had varying success [133]. 
Amino acid catabolism, particularly that of aromatic amino acids, branched chain amino 
acids, and methionine, is a major player in flavour formation in cheese, especially in cheeses 
containing only LAB. Amino acid conversion to aroma compounds proceeds by two 
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different pathways: (i) elimination reactions catalysed by amino acid lyases that produce 
different alcohols, and (ii) transamination reactions leading to different 2-oxoacids. The 
latter is the major pathway in LAB. The resulting 2-oxoacids are not responsible for flavour 
production but are then transformed to aldehydes, alcohols, carboxylic acids, hydroxy acids 
or methanethiol by additional steps that may be catalysed by the 2-oxoacid-producing LAB 
or by the inoculated starter LABs [134, 135]. Figure 5 shows the transaminations and further 
reactions leading to aroma compounds. It appears that the different flavours produced by 
different LAB strains depend on the proportion of the different 2-oxoacid produced and, 
therefore, on the relative aminotransferases activities [136]. 
 
Figure 5. Main amino acid catabolic pathways in LAB leading to aroma compounds (boxed). Doted 
arrows represent chemical reactions. 
Although lactococci have high aminotransferase activity, only very low and slow amino acid 
degradation occurs. Cheeses are rich in amino acids and peptides but the concentration of 2-
OG is low. Supplementation of several types of cheeses with 2-OG led to a decrease in the 
levels of amino acids important for aroma development, which indicated that catabolism of 
these amino acids had been enhanced [137, 138], and sensory analyses indicated that 
addition of 2-OG resulted in changes in creamy character, aroma intensity and fruity notes. 
These results clearly established that 2-OG availability is the limiting factor for the 
transamination reactions that convert aminoacids to aroma compounds and prompted 
scientist to look for sources of 2-OG. 
Ocurrence of GDH in starter and non-starter LAB is heterogeneous, as just a few LAB strains 
show GDH activity. Some strains of the starter Lactococcus lactis have GDH activity but it is 
coded in a plasmid (pGDH442) rather than in its chromosome [139]. However, these GDH+ 
strains are glutamate auxotrophs and cannot synthesize glutamate because of 2-OG 
limitation. The oxidative TCA cycle in these strains is interrupted at the isocitrate 
dehydrogenase step [140], thus blocking the major source of 2-OG for most bacteria. Because 
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of this, GDH can only be used for glutamate catabolism, and this reaction constitutes the 
major source of 2-OG in these strains. As shown in Fig. 5, the GDH role in aroma 
development by LAB in cheeses is to catalyse the oxidative deamination of glutamate in 
order to replenish the 2-OG consumed by the transamination reactions. The importance of 
GDH in aroma production was initially shown by cloning and heterologous expression of 
the GDH gene from Peptostreptococcus asaccharolyticus into a GDH- strain of L. lactis, which 
resulted in an increase of amino acids degradation and, more importantly, an increase in the 
proportion of carboxylic acids, which are important aroma compounds [141]. This result is 
the proof of concept that GDH can substitute the exogenous 2-OG. Other reports describing 
the effect of GDH on aroma production have followed, including the natural transfer by 
conjugation of the gdh gene coded in the pGDH442 plasmid among LAB strains [142]. The 
relevance of this is that the resulting transconjugants are not considered genetically 
modified organisms and can be used in the food industry as starters or adjuncts. 
An evident correlation between GDH activity and aroma production has been established 
for both mesophilic and thermophilic LAB [143, 144]. Because of this, the presence of GDH 
activity has been proposed as a criterion to select flavour-producing LAB strains for cheese 
ripening. The use of different LAB strains with different aminotransferases especificities 
together with the use of GDH to enhance the transamination reactions may represent an 
effective way of intensifying and diversifying cheese aromas. 
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1. Introduction 
Differentiation of the male phenotype including the outward development of secondary sex 
characteristics as well as the initiation and maintenance of spermatogenesis is stimulated by 
androgens (O'Shaughnessy et al., 2009; Verhoeven et al., 2010). There are two major 
androgens secreted by the testes: testosterone (T) and dihydrotestosterone (DHT). Weaker 
androgens: dehydroepiandrosterone (DHEA) and androstenedione are secreted in smaller 
amounts and converted metabolically to T and other androgens. Testosterone is the most 
abundant androgen. However, DHT is the most potent one.  
As the result of intensive research over the last 20 years it has been confirmed that estrogens, 
produced by androgen aromatization, are also important in the regulation of male 
reproductive function (Carreau et al., 2003). In mice deficient for the estrogen receptor α 
gene (αERKO) infertility, increased steroid acute regulatory protein (StAR) and 17β-
hydroxysteroid dehydrogenase (17β-HSD) mRNA levels together with elevated T level have 
been found (Akingbemi et al., 2003; Eddy et al., 1996). 
Specific receptors for androgens and estrogens have been found in both somatic and germ 
cells of the testis (Bilinska et al., 2000; Bilinska & Schmalz-Fraczek, 1999; Sierens et al., 2005; 
Wang et al., 2009). It has been confirmed that these receptors act as transcription factors 
regulating steroidogenesis at the transcription level. Furthermore, steroidogenesis requires 
the coordinated expression of related proteins and steroidogenic enzymes in response to 
hormonal stimulation. In Leydig cells luteinising hormone (LH) induce steroidogenesis by 
elaborating accumulation of intracellular cyclic adenosine monophosphate (cAMP), 
activation of protein kinase A (PKA) and expression of StAR resulting in subsequent T 
biosynthesis and secretion. Intratesticular T is maintained at constantly high levels. In the 
rat, endogenous T concentrations are the highest at stage VIII of the spermatogenic cycle 
(Parvinen, 1982). In addition, this stage together with stage VII have been found to be 
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particularly sensitive to androgen action, especially in four steps of germ cell development: 
spermatid adhesion and development, spermiation, progression through meiosis and 
spermatogonial differentiation (Verhoeven et al., 2010). Thus spermatogenesis is closely 
related and absolutely dependent on steroid hormone biosynthesis, action and control. 
2. Steroidogenesis in the testis  
In the male, Leydig cells which are present in the interstitium of the testis express all of the 
enzymes essential for the conversion of cholesterol to androgens and estrogens. The major 
pathways of steroid hormone synthesis are well established, and the sequence of the 
responsible steroidogenic enzymes has been elucidated (Payne & Hales, 2004). There are 
two major classes of steroidogenic enzymes: the cytochrome P450 heme-containing proteins 
and the hydroxysteroid dehydrogenases (HSDs). The first class contains: cytochrome P450 
side chain cleavage (P450scc), cytochrome P450 17α-hydroxylase C17-C20 lyase (P450c17) 
and cytochrome P450 aromatase (P450arom), whereas the second includes both 3β-
hydroxysteroid dehydrogenase/Δ5-Δ4-isomerase (3β-HSD) and 17β-hydroxysteroid 
dehydrogenase/ketosteroid reductase (17β-HSD/KSR), (Payne, 2007). 
The initial step of T biosynthesis is the conversion of the C27 cholesterol to the C21 
pregnenolone (Figure 1). This reaction is catalyzed by the cytochrome P450scc, which is 
located in the inner mitochondrial membrane. Pregnenolone diffuses across the 
mitochondrial membrane and is further metabolized by enzymes associated with the smooth  
 
Figure 1. Steroid biosynthesis pathways in Leydig cell. 
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endoplasmic reticulum. P450c17 catalyzes the conversion of C21 pregnenolone or progesterone 
(P4) to the C19 dehydroepiandrosterone or androstenedione, respectively, while 3β-HSD 
catalyzes the conversion of Δ5-3β-hydroxysteroids (pregnenolone or dehydroxypregnenolone, 
and DHEA, respectively) to the Δ4-3-ketosteroids (P4, or 17α-hydroxyprogesterone, and 
androstenedione, respectively). Depending on the animal species, biosynthesis of sex hormones 
proceeds down either one or both of the Δ4 and Δ5 pathways. In rodents, the Δ4 pathway is 
primary whereas in primates, pigs and rabbits Δ5 pathway is dominant (Fluck et al., 2003; 
Mathieu et al., 2002). In the final step of sex hormones biosynthesis, conversion of 
androstenedione into T, 17β-HSD is involved. It was reported that the balance between these 
androgens depends on the type and activity of 17β-HSD present (Simard et al., 2005). 
3β-HSDs are membrane-bound enzymes that are distributed in both mitochondrial and 
microsomal membranes (Payne & Hales, 2004; Pelletier et al., 2001). The relevance of dual 
localization of these HSDs is related to substrate accessibility (Simard et al., 2005). 
Coprecipitation studies have shown that, in the inner mitochondrial membrane, 3β-HSD 
comprises a functional steroidogenic complex with P450scc, which immediately provides 
substrates converted from cholesterol to the 3β-HSD (Cherradi et al., 1995). 
During the past decade, multiple isoforms of 3β-HSDs have been isolated and characterized 
in human, mouse and rat tissues. Six, highly homologous in their amino acid sequence 
isoforms have been identified in the mouse, but only two of them: 3β-HSD type I (3β-HSD 
I), and 3β-HSD type VI (17β–HSD VI) are expressed in the testis. In human testis only 3β-
HSD I has been found (Payne & Hales, 2004). 
Similarly to 3β-HSDs, 17β-HSDs are membrane-bound enzymes, and their soluble forms 
have also been reported. To date, 14 different types of 17β–HSDs have been identified 
(Blanchard & Luu-The, 2007). Unlike 3β-HSDs there is very little homology among the 
different 17β-HSD enzymes. Only three types, 17β–HSD type 3 (17β–HSD 3), 17β–HSD type 
5 and 17β–HSD type 12 (17β–HSD 12), have been detected to be exclusively expressed in the 
testis. 17β-HSD 3 converts androstenedione to T as well as it is an important partner of 
P450arom involved in conversion of C18 steroid, estrone to E2 (Andersson et al., 1995). 
Recently, it has been confirmed for mice, humans and primates that 17β-HSD 12 shares high 
homology and function with 17β-HSD 3 (Blanchard & Luu-The, 2007; Liu et al., 2007).  
The hydroxysteroid dehydrogenases belong to the same phylogenetic protein family, 
namely the short-chain alcohol dehydrogenase reductase superfamily. These enzymes are 
involved in the reduction and oxidation of steroid hormones requiring NAD+/NADP+ as 
acceptors and their reduced forms as donors of reducing equivalents. Studies have shown 
that mouse 3β-HSD has different cofactor preference: 3β-HSD I requires NAD+ while 3β-
HSD type IV and V requires NADP+ as cofactors. Interestingly, 17β-HSD 3 prefers NADPH 
as a cofactor, and its primary activity is reductive. Studies have shown that a mutation in 
HSD3B3 gene leads to decreased NADPH binding to tyrosine that has been identified as a 
critical residue for binding. Substitution of tyrosine with different amino acids resulted in 
alterations in cofactor preference switching from NADPH to NADH (Andersson et al., 1995; 
McKeever et al., 2002). In addition, Schäfers et al. (2001) have reported different cofactor 
preference for 17β-HSD 3 on different days of postnatal development in rat. 
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Both 3β-HSD and 17β-HSD are well known Leydig cell-specific markers in different 
mammals, at different times of development and under different perturbation regimes 
(Bilinska, 1994; Hejmej et al., 2011b; Mendis–Handagama & Ariyaratne, 2001; Teerds et al., 
2007). In previous studies, activity of HSDs in testis of various mammals was mostly 
detected using histochemical techniques (Badrinarayanan et al., 2006; Bilinska 1979, 1983, 
1994; Hutson, 1989), (Figure 2). Nowadays the resolution of their localization increased with 
applying specific antibodies (Kotula-Balak et al., 2011; Pelletier et al., 1999; Pinto et al., 2010). 
It has been reported that 3β-HSD type III (3β-HSD III) as well as 17β-HSD 3 and 17β-HSD 
type 10 are useful markers also for germ cells in rat, mouse, equine and black bear testis 
(Almeida et al., 2011; Ivell et al., 2003; O’Shaugnessy et al., 2000). Recently Scott et al. (2009) 
have indicated 17β-HSD 3 as a good marker for Sertoli cells in fetal mouse testis. 
 
Figure 2. (A-B) Histochemical localization of 3β-HSD (A) and 17β-HSD (B) in cultured mouse Leydig 
cells. Note various intensity of the staining in the individual cells (arrows-strong staining, arrowheads-
weak to moderate staining). Magnifications, x 320. 
3. Age-dependent activity of HSDs 
In testis of mammals two morphologically and functionally different Leydig cell populations 
have been identified. One develops prenatally (fetal Leydig cells, FLCs) and the second arises 
postnatally (adult Leydig cells, ALCs), (Mendis-Handagama & Aryiaratne, 2001; Pinto et al., 
2010). These two generations have different gene expression profiles, which indicate that they 
originate from separate types of stem cell (Dong et al., 2007; O’Shaugnessy et al., 2002b). 
Differentiation of FLCs is initiated by human chorionic gonadotropin (hCG), whereas 
development of ALCs is critically dependent on LH (O’Shaughnessy et al., 1998). After birth 
the population of FLCs decreases in size, although some fetal-type cells persist even in the 
adult testis. In the rat, FLCs that are arranged in large compact clusters and contain 
numerous lipid droplets. In ALCs the nuclei are large and cytoplasmic content is sparse with 
a few lipid droplets. The cytoplasm of Leydig cells of both populations contains abundant 
smooth endoplasmic reticulum (SER) and tubulovascular mitochondria, which are important 
organelles in biosynthesis of steroid hormones.  
The FLCs are fully competent steroidogenically. It has been demonstrated that in rat, FLCs 
start to express LH receptors (LHR) and 3β-HSD I from fetal day (fd) 15.5 (Payne & Hales, 
2004). However in mouse, 3β-HSD I expression has been detected shortly before fd 11 
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(Baker et al., 1999). Recently with the use both histochemical and immunohistochemical 
methods the presence of 3α-hydroxysteroid dehydrogenase (3α-HSD) and 17β-HSD has also 
been confirmed in FLCs of rat (Haider, 2004).  
From fd 15.5 FLCs start actively producing T and its synthesis increases gradually (Habert & 
Picon, 1984). Expression of hormone receptors and enzymes in FLCs arise continuously 
during existence of this population in the testis. Interestingly, Ivell et al. (2003) have 
demonstrated that 17β-HSD type 10 (17β-HSD 10) starts to be expressed at the time when 
FLCs begin to involute. However, the pick of oxidative activity of these enzyme has been 
determined on postnatal day (pd) 16 (Schäfers et al., 2001).  
Fetal population of Leydig cells is the primary source of T, androstenedione and DHT in 
both fetal and early postnatal testis (Ariyaratne & Mendis-Handagama, 2000; Huhtaniemi & 
Pelliniemi, 1992). Multiple studies have shown that T-producing capacity of FLC is 
significantly greater than that of ALC and is calculated to be even 87 pg per cell (Aryaratne 
& Mendis-Handagama 2000; Huhtaniemi et al., 1982; Tapanainen et al., 1984).  
During the neonatal-prepubertal period T is required for differentiation and morphogenesis 
of the male genital tract, activation of the hypothalamo-hypophyseal-testicular axis, 
completion of the testicular descent, masculinization of the brain, control of Sertoli cell 
number, initiation of spermatogenesis and formation of ALC precursors (Ariyaratne & 
Mendis-Handagama, 2000; Haider, 2004).  
Steroidogenic capacity of FLCs is still high through the first postnatal week, although 
concentrations of circulating T are much lower due to decrease in number of these cells. 
Moreover, the inhibitory effects of Müllerian Inhibiting Substance (MIS) and transforming 
growth factor-bs (TGF-bs) on FLCs steroidogenic activity in postnatal testis have been 
described (Wu et al., 2007). 
Testosterone production gradually increases to high levels with the development of ALCs 
(Benton, 1995; Chen et al., 2010; Hardy et al., 1989). The proliferation and differentiation of 
the adult population is regulated by an interplay of multiple regulatory factors, that can 
simulate, as well as inhibit, Leydig cells at each developmental stage. The development of 
ALCs is initiated around day 14 after birth and finishes around day 60. This process consists 
of multiple steps of proliferation and differentiation such as: proliferation of precursor cells; 
differentiation of precursor cells to Leydig cell progenitors, progenitors into newly formed 
adult Leydig cells, newly formed adult Leydig cells into immature adult Leydig cells; and 
finally, maturation of the immature adult Leydig cells to mature adult Leydig cells. In the 
rat, it has been reported that stem cells and mesenchymal precursor cells do not express 
steroidogenic enzymes however precursor cells acquire 3β–HSD III and other setroidogenic 
enzymes like cytochromes: P450scc and P450c17 prior to gain LHR (Hardy et al., 1989; 
Teerds et al., 2007; Zirkin, 2010). These cells have negligible amounts of 17β-HSD 3 while 
expression of steroid metabolizing enzymes 5α-reductase and 3α-HSD is high. Thus 
precursor cells produce androsterone as their main androgen product (O'Shaughnessy et al., 
2000). Also expression of AR by early developmental stages of ALCs lineage is required for 
further transformations of these cells under androgen control (Ge & Hardy, 1997).  
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Differentiation of progenitors to newly formed adult Leydig cell is associated with the cell 
cytoplasm shape change from spindle shaped to polygonal. Newly formed Leydig cells 
move toward the central interstitium and locate near blood capillaries although they do not 
exclusively arrange in clusters. These cells express LHR and the levels of 3β–HSD VI, 
P450scc and P450c17 increase with the further steps of Leydig cell differentiation 
(Ariyaratne & Mendis-Handagama, 2000; Shan et al., 1993). It has been demonstrated that in 
mice Hsd3b3 and Hsd3b6, remain fairly stable after birth but show a pubertal rise in 
expression around pd 20 (O'Shaughnessy et al., 2002) 
5α-androstane-3α and 17β-diol is synthesized as the predominant androgen with the 
emergent increase in activity of 17β–HSD 3 and in a continuous presence of 5α-reductase 
and 3α-HSD (Hardy et al., 1990). It is worth noting, that in immature ALCs 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD 1) and 11β-hydroxysteroid dehydrogenase 
type 2 start to be expressed. In the rat testis, the presence of 11β-HSD 1 is in coincidence with 
the first appearance of elongated spermatids in the seminiferous tubules (Haider, 2004).  
Adult Leydig cells are the dominant cell type of the Leydig cell lineage from pd 56 (Benton 
et al., 1995). Transformation of immature adult Leydig cells into mature adult Leydig cells is 
characterized by a significant increase in the average cell size and disappearance of 
cytoplasmic lipid droplets. The capacity to secrete T increases significantly in mature adult 
Leydig cells because of their enhanced responsiveness to circulatory LH due to the 
acquisition of higher numbers of LHR. During this time in the mouse testis, 3β-HSD VI 
becomes the predominant isoform of HSDs (Payne & Hales, 2004).  
Additionally, the sharp decline in 5α-reductase activity overlaps. Shan et al. (1993) have 
reported that the mature Leydig cells by pd 90 produce 150 times more T than progenitors, 
and five times more than immature Leydig cells. Such high T levels are required for 
initiation, maintenance and regulation of the spermatogenesis. By day 90 the secretory 
capacity per ALC in rat has been estimated as 1.43 pg.  
During puberty ALCs are particularly sensitive to androgens and expression of AR mRNA 
in this time is significant. Studies have shown that in the absence of AR, there is 
developmental failure of ALC maturation (O'Shaughnessy et al., 2010). However, there is 
well known phenomenon when ALCs destroyed by ethane dimethane sulphonate (EDS) 
administration can proliferate to regenerate the original population of Leydig cells (Teerds 
& Rijnities, 2007). 
In aging human testis, both serum and intratesticular T concentrations progressively decline 
being in correlation to decreased LH level. In rat, these changes have been reported to be 
strain-dependent (Harman et al., 2001). In Brown Norway rats, the decrease in T level 
concomitantly with an increase in FSH level and unchanged LH level have been detected 
(Chen et al., 2002). Several studies have demonstrated that in men decrease in T level is 
associated with alterations in body composition, diminished energy, muscle strength and 
physical function, depressed mood and decreased cognitive function (Matsumoto, 2002). 
These age related changes result from the loss of steroidogenic capacity of the Leydig cells 
and/or reduction in their number (Chen et al., 2001, 2009). It has also been found that in 
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aging Leydig cells adenyl cyclase is maintained that results in the defect of the cAMP-LH 
signaling cascade. In addition, protein and mRNA levels of StAR have been significantly 
reduced, suggesting deficits in the transport of cholesterol to the inner mitochondrial 
membrane of aged Leydig cells. Moreover, the activity, protein level, and mRNA level of 
P450scc, P450c17, 3β–HSD and 17β–HSD have been found markedly reduced in old Leydig 
cells (Ivell et al., 2003; Luo et al., 1996; Midzak et al., 2009; Zirkin & Chen, 2000). 
Interestingly, these authors have demonstrated that long-term suppression of 
steroidogenesis by administration of T prevents or delays the reduced steroidogenesis that 
accompanies Leydig cell aging due to suppressing the production of the reactive oxygen 
species that are a by-product of steroidogenesis itself. 
4. Regulation of HSDs function 
4.1. Pituitary hormones and other peptides 
Primary control of 3β-HSD expression occurs through the activation by LH its receptor and 
the induction of the cAMP second messenger system (Simard et al., 2005). Recent findings 
from our own laboratory have revealed that bank vole Leydig cells treated with LH have 
increased steroidogenic capacity and T secretion (Gancarczyk et al., 2003). A profound 
hypogonadal effect and suppression of T production has been demonstrated in boars treated 
with deslorelin, an agonist of gonadotropin-releasing hormone (GnRH), (Kopera et al., 
2008). In Leydig cells of treated boars very weak or lack of LHR and 3β-HSD expression has 
been detected. In contrast, Lin et al. (2008) who treated mouse Leydig cells with GnRH 
agonists (I and II) have demonstrated that 3β-HSD has been stimulated directly resulting in 
increase of T production. On the contrary, 17β-HSD was not induced in treated cells. 
Formation of cAMP activates steroidogenesis by temporally distinct manners either, acutely 
(minutes) due to StAR action or chronically (hours) related on P450scc, P450c17, 3β-HSD 
and 17β-HSD activities. The delivery of cholesterol into the inner mitochondrial membrane 
is the rate-determining step in steroidogenesis. Also the differences in the way that cultured 
Leydig cells respond to cAMP have been reported. In mouse Leydig cells, cAMP has 
stimulated T production which then suppressed 3β-HSD at the mRNA level, whereas 
addition of cAMP to cultured rat Leydig cells increases 3β-HSD activity and expression at 
both the mRNA and protein level after 24–72 h (Keeney & Mason 1992; Payne & Sha 1991). 
Interestingly, expression of 3β-HSD has been reported to be dependent upon steroidogenesis 
factor 1 (SF1). SF1 response element has been detected in the proximal promoter region of the 
human 3β-HSD type II gene. Recently Scott et al. (2009) have confirmed that the mouse 3β-
HSD I gene promoter has three potential SF1 consensus binding sites. However, it is 
currently unknown whether SF1 regulates the expression of 17β–HSD. 
A series of studies show that pituitary hormone-prolactin (PRL) and thyroid hormones 
regulate activity of HSDs. In Leydig cells of hypophysectomized rats treated with PRL, a 
significant increase in number of 3β-HSD immunopositive cells together with an increase in 
T and E2 concentrations was found (Dombrowicz et al., 1992; Manna et al., 2001). Also our 
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own studies have revealed that in bank voles treated with PRL, the levels of androgens and 
estrogens have increased markedly within the testis (Gancarczyk et al., 2006). These results 
point the role of PRL in promoting multiplication, differentiation and regulation of 
steroidogenic function of Leydig cells. Similar functions have been confirmed for thyroid 
hormones. In physiological levels these hormones have profoundly increased the number of 
mesenchymal precursors of ALCs and supported their further differentiation (Maran, 2003; 
Mendis-Handagama et al., 1998; Teerds et al., 1998).  
4.2. Steroids 
In Leydig cells, the action of P4, has been reported to be mediated only by non-classical 
receptors while the classical nuclear progesterone receptor has not been found in these cells 
(Oettel & Mucopadhay 2004). The direct stimulatory or inhibitory effect of P4 on 
steroidogenesis in Leydig cells has been demonstrated, although its mode of action remains 
obscure (El-Hefnawy et al., 2000; Schwarzenbach et al., 2003). In rats, exposure in utero to 
subnormal levels of hydroxyprogesterone suppresses testicular steroidogenesis by 
decreasing the HSDs levels, which in turn suppresses the reproductive activity of the male 
(Pushpalatha et al., 2003). Studies have shown that in elderly men P4 levels increase within 
the testis and the spermatic vein, having a detrimental effect on Leydig cell steroidogenic 
function (El-Hefnawy & Huhtaniemi, 1998). It is interesting but still not resolved if and how 
P4 influences HSDs.  
It has been reported that both endogenous and exogenous sex hormones are able to modify 
steroidogenesis at the level of 3β-HSD. In rats treated with an androgen antagonist, 
increased induction of hCG and 3β-HSD activity has been observed, whereas treatment with 
an androgen agonist decreased hCG induction and 3β-HSD activity, respectively (Ruiz de 
Galarreta et al., 1983). Similarly, T and DHT have inhibited 3β-HSD activity in adult rat and 
mouse Leydig cells (Simard et al., 2005). Recent findings by Kostic at al. (2011) have 
demonstrated that in andorgenized rats, T upregulated P4 synthesis. In these animals 
prolonged treatment with high T doses caused significant increase of 3β-HSD mRNA and 
protein levels whereas no effect has been observed on 17β-HSD expression. Freeman (1985) 
has demonstrated that E2 inhibited P4 biosynthesis in a dose-dependent manner in Leydig 
cells via inhibition of the activity of 3β-HSD. Also studies in vivo on rats and bank voles 
treated with E2 have shown disturbances in sex hormones balance within the testis. Low T 
and high E2 levels in treated animals have been reported to affect spermatogenesis 
(Gancarczyk et al., 2004; Rao & Chinoy, 1986). 
4.3. Testicular paracrine factors 
It has already been accepted that the function and activity of the testis is regulated by many 
locally produced factors and by cell-cell interactions. The effects of cytokines and growth 
factors on HSDs expression has been reported to be diverse (for review see Herrmann et al., 
2002). Tumor necrosis factor (TNF) and interleukin 1 (IL-1) inhibited 3β-HSD activity in 
mouse and rat Leydig cells. However, IL-1 only inhibited cAMP stimulated enzyme 
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synthesis, whereas TNF also reduced basal enzyme expression. In contrast, epidermal 
growth factor (EGF) increased activity and expression of 3β-HSD, which has also been 
demonstrated for transforming growth factor (TGF). Acidic fibroblast growth factor (aFGF) 
and basic fibroblast growth factor (bFGF) inhibited 3β-HSD. In pig Leydig cells, bFGH has 
been reported to increase 17β-HSD expression (Sordoillet et al., 1992). Our own studies in 
bank voles have revealed that insulin like growth factor I (IGF-I) stimulates whereas IL-1 
and interleukin 1α (IL-1α) inhibit testis steroidogenic and spermatogenic function in 
sexually active males (Gancarczyk et al., 2006; Kmicikiewicz & Bilinska, 1997; Kmicikiewicz 
et al., 1999). Interesting results have been recently reported by Ivell et al. (2011) who 
demonstrated that 17β-HSD 10 mRNA expression in mice testis is regulated by locally 
produced relaxin (RLN) dependently of animal age. 
4.4. Photopheriod 
In seasonal breeders the function of the pituitary-testicular axis undergoes annual cyclic 
variations. Multiple studies including our own have shown that photoperiod is an 
important factor regulating steroidogenesis. Changes in LH and FSH secretion depending 
on the light length are responsible for seasonal variations in size, structure and function of 
the testis (Bartke & Steger, 1992). Under laboratory conditions, bank voles kept in long light 
regime show higher testis weight and increased steroidogenic activity than animals exposed 
to short one (Bilinska et al., 2000, 2001; Tähkä et al., 1982). In several seasonal breeders, the 
serum and testicular concentrations of steroid hormones have exhibited seasonal 
fluctuations and are always lower in regressed animals (Frungieri et al., 1999; Hance et al., 
2009; Kotula-Balak et al., 2003). 
In addition, the Leydig cell morphology as well as localization and expression of HSDs have 
been found to change seasonally in the sika deer, black bear and northern fur seal 
(Hayakawa et al., 2010; Ibluchi et al., 2010; Tsubota et al., 1997, 2001). In black bears during 
their mating season, 17β-HSD 3 has been detected both in Leydig cells and in Sertoli cells. 
Moreover, in these animals expression of 3β-HSD was the highest in June. In Syrian 
hamster, specific melatonin receptors (mel1a) have been reported in Leydig cells via which 
melatonin down-regulated the gene expression of both 3β-HSD, and 17β-HSD (Frungieri et 
al., 2005). 
4.5. Endocrine disrupting chemicals 
A large body of information concerning the effects of endocrine disrupting compounds 
(EDCs) on Leydig cells steroidogenesis during fetal development and in adult mammals has 
been accumulated in the past decades. EDCs can disturb morphology and normal endocrine 
functions of the Leydig cells or oppose the actions of androgen through their estrogenic or 
anti-androgenic properties (Hejmej et al., 2011a). A number of compounds act directly on 
Leydig cells to diminish T production by interfering with the expression of steroidogenic 
enzymes, at the protein and/or mRNA level (Skakkebaek, et al., 2001). 
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Our recent results have shown that administration of the estrogenic compound, 4-tert-
octylphenol (OP), to adult bank voles has caused the significant decrease of 3β-HSD and 
increase of P450arom expression concominantly with the alteration of the androgen/estrogen 
balance within the tesis of sexually active animals (Hejmej et al,. 2011b). Similar results have 
been reported by Victor-Costa et al. (2010) on rats treated with atriazine. These authors 
concluded that inhibition of 3β-HSD function is one of the possible mechanism through 
which xenoestrogens disturb spermatogenesis. In vitro studies on Leydig cells obtained from 
various mammals have revealed decrease in the activity and expression of 3β-HSD after OP, 
bisphenol A (BPA) and genistein administration (Hu et al., 2010; Kotula-Balak et al., 2011; Ye 
et al., 2011). Our study demonstrated that OP markedly disturbes morphology and 
steroidogenic function of the Leydig cells through direct effect on 3β-HSD expression and 
localization (Kotula-Balak et al., 2011). In detail, treatment with high doses of OP (10-4–10-6 
M) resulted in a reduced staining intensity and the staining was usually located near the 
nucleus, whereas in the low OP doses (10-7 and 10-8 M) it was manly dispersed throughout 
the cytoplasm (Figure 3). 
 
Figure 3. (A-C) Immunostaining for 3β-HSD. Positive staining of various intensity is confined to the 
cytoplasm of Leydig cells (arrows). Note, clearly reduced staining for 3β-HSD in Leydig cells treated 
with high OP dose (B). In many cells weak to moderate staining in the perinuclear region is visible 
(arrowheads). In Leydig cells treated with low OP dose (C) the intensity of immunostaining is similar to 
that of the control (A), (arrows). Only in a few cells staining in the perinuclear region is visible 
(arrowhead). Bars 20 µm. 
It is worth noting that the effect of EDCs on HSDs function can be diverse depending on the 
choice of animal species, age, routes of administration and dose levels. Studies of Pogrmic-
Majkic et al. (2010) have shown that in rat Leydig cells atriazine stimulated 17β-HSD, 
whereas other authors reported inhibition of these enzyme in rat and human microsomes 
treated with various xenoestrogens (Hu et al., 2010; Vaithinathan et al., 2008; Ye et al., 2011). 
Recently, it has also been found that antiandrogens such as tributylin, triclosan and flutamide 
modified HSDs expression in Leydig cells and microsomes of various mammals (Kim et al., 
2008; Kumar et al., 2009; McVey & Cooke, 2003; Ohno et al., 2005; Ohsako et al., 2003). 
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5. HSDs in pathological conditions 
5.1. Temperature and 3β-HSD activity 
In recent years, disorders of human male reproductive development increased in incidence 
(Sharpe & Skakkebaek, 1993; Toppariet al., 1996). Cryptorchidism and hypospadias are the 
two most common congenital malformations that comprise a testicular dysgenesis 
syndrome (TDS), which arises during fetal development and manifests in adulthood 
(Skakkebaek et al., 2001).  
Several studies have shown that increased intratesticular temperature in cryptorchid testes 
affects spermatogenesis, resulting in either reduced fertility or infertility. Other evidences 
collected over the years have indicated that increased testicular temperature negatively 
influences the development and differentiation of Leydig cells causing impairments in sex 
hormones biosynthesis (Huff et al., 2001; Kotula-Balak et al., 2001; Pinart et al., 2000).  
Our recent studies have shown that in cryptorchid horses disturbances in differentiation 
and/or maturation of Leydig cells may be related to altered intracellular communication. In 
these animals decreased immunoexpression of gap junction protein, connexin 43, in 
testicular cells were accompanied with reduced expression of LHR, 3β-HSD and disturbed 
androgen/estrogen balance (Hejmej et al., 2005, 2007; Hejmej & Bilinska, 2008), (Figure 4). 
Altered expression of these proteins and imbalance in sex hormones level detected in 
cryptorchid horses suggested their additional influence on morphology and function of 
undescended testis. Markedly reduced expression of 3β-HSD has been also reported in rats 
with experimentally induced cryptorchidism (Wisner & Gomes, 1978). No significant 
changes in T levels have been detected in patients with cryptorchidism as well as other 
mammalian species (Bilinska et al., 2003; Farrer et al., 1985; Illera et al., 2003; Kawakami et 
al., 1999; Ren et al., 2006; Ryan et al., 1986). 
 
Figure 4. Immunohistochemical localization of 3β-HSD in testis of normal (A) and cryptorchid stallion 
(B). Counterstaining with Mayer’s haematoxylin. The presence of 3β-HSD is confined to Leydig cells 
(arrows). Note a clearly weaker staining in the cryptorchid horse (A) than in the healthy stallion (B). LC-
Leydig cells, ST-seminiferous tubules. Bars 20 µm. 
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5.2. 3β-HSD and 17β-HSD deficiency 
The development of the male internal and external genitalia in an XY fetus requires a 
complex interplay of many critical genes, enzymes and cofactors. In early fetal life, in the 
bipotential embryo, both Wolffian ducts and Müllerian ducts are present. Testosterone 
produced by FLCs acts on AR to stabilize the Wolffian ducts whereas MIS causes regression 
of Müllerian ducts (George et al., 2010). The formation of male external genitalia is induced 
by T and DHT.  
Disruption in androgen production and/or action leads to disorder of sex development 
(DSD) also known as male pseudohermaphroditism. DSD is defined as a congenital 
condition in which development of chromosomal, gonadal or anatomical sex is atypical in 
such individuals (Hughes et al., 2006). 46, XY DSD is an autosomal recessive form of DSD 
which was first described in 1971 (Saez et al., 1971). Disturbances of androgen production 
can occur in all steps of T biosynthesis and its conversion into DHT. 
Around 40 various mutations have already been described in HSD3B2 gene. Mutation in 
this gene results in 3β-HSD II deficiency and decreased T biosynthesis (Payne & Hales, 
2004). Severe form of 3β-HSD deficiency named congenital adrenal hyperplasia (CAH) 
impairs also steroidogenesis in adrenals (Moisan et al., 1999). In male patients, either 
perineal hypospadias or perineoscrotal hypospadias and ambiguous external genitalia or 
microphallus have been reported (Simard et al., 2005). Also, in these individuals 
gynecomastia has been observed as common at puberty. Serum levels of Δ5 steroids are 
elevated whereas levels of Δ4 steroids are slightly increased. In adulthood, males with 3β-
HSD II deficiency can reach normal levels of T due to the peripheral conversion of elevated 
Δ5 steroids by 3β-HSD I and/or due to testicular stimulation by high LH levels. Most of the 
patients with mutation in HSD3B2 gene are raised as males and display male social sex but 
there are some cases described where such individuals are castrated in childhood and 
treated as female (Mendonca et al., 2008). Males with 3β-HSD II deficiency share common 
clinical features with patients deficient for 17β-HSD 3 and 5α-reductase 2.  
Deficiency of the 17β-HSD 3 can be caused by either homozygous or compound 
heterozygous mutations in the HSD17B3 gene (Geissler et al., 1994). This autosomal 
recessive disorder manifests in males as undermasculinization characterized by hypoplastic-
to-normal internal genitalia (epididymis, vas deferens, seminal vesicles, and ejaculatory 
ducts), but female external genitalia and the absence of a prostate (Boehmer et al., 1999; 
Lindqvist et al., 2001; Sinnecker et al., 1996; Ulloa-Aguirre et al., 1985). 
At the time of puberty, there is a marked increase in plasma LH and, consequently, in 
testicular secretion of androstenedione. Mendonca et al. (2010) have found that significant 
amounts of the circulating androstenedione are converted to T in peripheral tissues by an 
unidentified member of the 17β-HSD family, thereby causing virilization in many of these 
individuals. To date, 19 mutations in the HSD17B3 gene have been found. Most of these 
patients are raised as girls during childhood but starts to display masculine behavior at 
puberty (Mendonca et al., 2008). 
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6. Conclusion  
In Leydig cells, multiple factors regulate 3β-HSD and 17β-HSD function exerting very 
diverse effect. Nowadays further characterization of physiological and pathological 
conditions as well as endogenous and exogenous agents that can modify HSDs expression is 
becoming increasingly necessary. Especially, in light of recent reports indicating an increase 
in the incidences of developmental and functional disorders of the male reproductive tract. 
Exploration of the site and possible mechanisms of action of these agents in steroid 
biosynthesis is becoming important future research direction. 
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1. Introduction 
In the fields of biochemistry and medicine there is growing interest to the crucial role of 
mitochondria in changing of physiological states and disease development. This interest is 
fueled by rapid progress in the modern branches of mitochondriology: Mitochondrial 
Physiology (MiP) and Mitochondrial Medicine [1-8]. Numerous investigations 
demonstrated mitochondrial dysfunctions in different experimental models of stress or 
disease. These results were obtained under clearly pronounced functional disorders induced 
by strong external stimuli or pathogenic mutations. These observations increased interest in 
the detection of mitochondrial dysfunctions in the organism as early biomarkers of 
pathogenic processes. The detection of mitochondrial dysfunction is crucial at subclinical 
stages of disease because it can lead to more effective prevention and earlier intervention. In 
spite of this benefit to date the available testing methods cannot properly measure the state 
of mitochondria in the organism in ex vivo observations. Past successes of respiration 
measurements in isolated mitochondria distracted attention from obvious, methodological 
shortcoming of the existing method of mitochondria isolation: intentional destroy of their 
native structure organization into entire network. It is known nowadays that the responses 
of mitochondria to various physiological challenges are based on the reversible dissociation 
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of such subtle network structure. In the network state mitochondrial respiration proceeds at 
a low rate while excitation leads to the dissociation of the network and an increase in 
respiration. We demonstrated this shortcoming in simultaneous polarographic and 
microscopic studies of network fragments in KCl rat liver homogenate that contains a higher 
density of tissue than is usual (1:1 tissue:solution) [9-11].  
Since the first step of isolation of mitochondria is network destruction, this method 
artificially mimics the physiological signal of the activation of respiration. Thus, 
mitochondria isolated from non-active tissues using the standard methodology do not 
maintain low levels of respiration typical of the quiescent state and show rapid respiration. 
A matter of great concern of biochemists is primarily not to inhibit the enzyme activity; 
therefore, rapid respiration of isolated mitochondria did not cause apprehension. However, 
the hyperactivation of functions as an initial step of their alteration preceding inhibition is 
well known in physiology. That is why artificially accelerated respiration of isolated 
mitochondria means in essence the LOSS of data for norm in biochemical investigations. The 
importance of preservation of the native mitochondrial network in ex vivo observations was 
recently highlighted in a special issue of IJBCB assembled under the editorial guidance of R. 
Rossignol [12]. 
The modern investigations clearly demonstrate strong correspondence in functional state of 
mitochondria and their native organization in the network. This is formulated by the 
impressive motto: “To be in good shape - to survive” [13]. At the beginning of mitochondria 
isolation coryphaei of mitochondriology considered possible loss of native properties caused 
by preparation. H. Krebs attracted the attention to the acceleration of respiration of 
mitochondria by dilution. He preferred to study mitochondria in homogenate as more 
native. A. Lehninger mentioned that effects observed in mitochondria in vitro can often 
reflect their “preparative story” but not native properties. N. Kaplan and collaborators 
carried out the study just of the SDH activity by the most sensitive function: the reversed 
electron transfer, which was at that time recently discovered by B. Chance [14]. They 
explained discrepancies between data of some leading laboratories by the dependence of the 
effects on the common experimental additions and conditions. Chance participated in 
discussion of results and all his life developed technics to measure mitochondria inside the 
organism. 
However, the convenient method to study mitochondria ex vivo was not found. Meanwhile 
the advantages of work with isolated mitochondria by rapid recording technics stimulated 
biochemists to wide studies and doubts on properties of preparations were neglected. 
In order to overcome the crucial methodological shortcoming of traditional procedures, we 
have created a novel, CytoBioChemical (CBCh) method which preserves mitochondrial 
network ex vivo using glass-adhered blood lymphocytes. Studies of various physiological 
and pathological states using the novel CBCh method have shown greater responses of the 
mitochondria to functional changes in the organism compared with mitochondria isolated in 
the form of single granules. 
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An additional, clinical benefit of the CBCh method is the ability to measure mitochondrial 
function from a drop of blood, substantially reducing the invasiveness of muscle biopsy that 
is currently required for mitochondrial disease diagnosis. Besides, CBCh method abolishes 
problem of liquid blood sample changing during work with a group of patients. The state of 
glass-adhered cells is stable for several hours and after that all samples can be activated 
simultaneously by insertion into media for measurement of enzyme activity.  
In this review we briefly summarize our previous results on elaboration the method, 
focusing on recent data on its application in physiological and clinical studies. A special 
attention is paid to interpretation of the data because some unknown phenomena were 
revealed. Perspectives of further development of our method will be also considered.  
2. A brief description of the cytobiochemical method.  
Succinate dehydrogenase and α-ketoglutarate dehydrogenase  
as markers of adrenaline or acetylcholine regulation in the organism 
The CBCh method for the study of mitochondrial dehydrogenases was developed to avoid 
the loss of native mitochondrial network structure in ex vivo experiments. The CBCh method 
was based on the combination of cytochemical techniques of blood smear fixation on the 
glass with the use of modern biochemical media for incubation of mitochondria. The 
composition of the used medium was modified to resemble more closely the intracellular 
medium to better preserve ex vivo the quiescent state of mitochondria inside lymphocytes. 
We measure dehydrogenase activity by reduction of nitroblue tetrazolium (NBT) to blue 
formazan. The image of lymphocytes after succinate (SUC) oxidation is shown in Figure 1. 
Blue mitochondria are located by periphery. The bulk of the cell is occupied by large nuclei 
stained with neutral red after SDH measurement for identification of lymphocytes in the 
smear. 
 
Figure 1. Images of human glass-adhered lymphocytes after SUC oxidation.  
Images were collected using an oil immersion lens (100x/1.25) under a light microscope (Leica, DM 
2000) equipped with a camera (Leica, DFC-425) connected to a computer.  
SDH activity is registered by blue staining with formazan in mitochondria. Red staining is used for 
nuclei visualization. 
In the search for the best conditions for network preservation, we have shown that common 
substances and conditions obligatory for the investigation of oxidative phosphorylation, 
such as inorganic phosphate, ADP, Ca2+, pH 7.4, evidently sucrose, as well as dilution of 
tissue are not only biochemical activators but they also dissipate assemblies of mitochondria 
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[9-11]. Because the test of NBT reduction is more sensitive to electrons than oxygen 
consumption, the CBCh method first allowed us to measure low-rate respiration without 
artificial high concentrations of stimulators. This characteristic corresponds to a real 
Quiescent State of mitochondria in the cell. It is of great importance because additions 
distort the physiological regulation. For instance, ADP results in a shift of the ADP/GDP 
ratio in mitochondria and inhibits SDH. At the dawn of the polarography era, some leading 
mitochondriologists believed this extreme stimulation to be artificial, and the measurement 
of respiration without any external additions to be more physiological and desirable. 
However, the advantages of rapid-recording polarography were so attractive, compared 
with the previous monumental and slow manometric epoch that the polarographic method 
spread quickly over the world. Considering the aforesaid, the possibility to measure the real 
Quiescent State respiration is one more crucial advantage of the CBCh method. Therefore, 
besides the preservation of network by fixation, the quiescent state is protected by exclusion 
of the artificial addition of exogenous activators. Due to the combination of cytological and 
biochemical advantages, the novel method was called Cytobiochemical.  
The measurements of the dehydrogenase (DH) activity are carried out using the 
cytochemical technique of glass-adhered cells by nitroblue tetrazolium reduction after 1-h 
incubation at 37 oC. The basal medium contains: 125 mM KCl, 10 mM НEPES, 1.22 mM NBT, 
рН 7.2 ± 0.05.  
As distinct from the cytochemical method according to which only one sample with 
substrate is usually studied for DH activity measurement, the several selected samples 
with different additions are investigated according to CBCh procedure. The additions will 
be mentioned and explained further. These additions allow one to analyze the 
biochemical mechanisms of DH activity regulation. The regulation of the SDH activity by 
isocitric acid (ISC) and its combination with KGL activity were found to be most 
informative. A set of separate samples forms a CBCh pattern of DH activity and serves as 
a sensitive marker of the state of the DHs in the organism and, therefore, of the state of 
the organism itself. Examples of patterns and their interpretation will be described 
further. 
The special interest to SDH is due to a great domination of SUC over other substrates in the 
rate of oxidation, known more than a century, and crown by the brilliant Chance’s discovery 
of even greater domination in energy-dependent NAD+ reduction [15, 16].  
As cited below, our group demonstrated numerous effects of stimulation of mitochondrial 
and physiological functions by SUC. The crucial role of SDH in tumor resistance and 
cardioprotection and disease development is recently reported [17-20]. The special 
properties of KDH are less known and will be considered further. 
It was shown in previous studies by our group that the oxidation of SUC and selective 
activation of SDH are involved in adrenergic (ADR) regulation, while the oxidation of α-
ketoglutarate (KGL) and selective activation of KDH is involved in cholinergic (ACH) 
regulation (see also for more details [10], section 3.2.).  
Study of Succinate Dehydrogenase and α-Ketoglutarate Dehydrogenase in Mitochondria Inside  
Glass-Adhered Lymphocytes Under Physiological Conditions – The Two Dehydrogenases as Counterparts of … 239 
 
Figure 2. Substrate - hormonal system. Participation of mitochondria in physiological regulation.  
Reciprocal adrenergic - cholinergic regulation as a whole with oxidation of succinate - α-ketoglutarate. 
Link between sympathetic and parasympathetic nervous system and mitochondria, or link between non 
- neuronal intracellular hormones and substrates.  
Therefore, the measurement of the activity of the chosen DHs, SDH and KDH, provides also 
information on the level of reciprocal ADR/ACH regulation in the organism. Substrates of 
the two DHs, SUC and KGL, were shown to influence the ADR and ACH level as well as 
support physiological functions under load and in recovery. It is of importance that the 
regulatory effects of SUC and KGL in the organism are well pronounced in concentrations 
far below than necessary for substrate supply. To differentiate these two activities of 
substrates, the low concentrations manifesting general regulatory action in the organism 
were called “signal” suggesting that it is realized via specific receptors [21-34]. It was an 
exciting event for our group when later on such receptors were found indeed, and also for 
only the two of many mitochondrial substrates. As the authors of the first paper stated, the 
cause of this selectivity was not clear [35-40]. However, it is well explained from the 
standpoint that just a pair of substrates is needed as a counterpart of also the paired 
ADR/ACH regulatory system. The novel mechanism of physiological regulation was named 
by our group Substrate-Hormonal System. It is presented in Figure 2. It serves as a link 
between the vegetative nervous system and mitochondria. This system may exist also inside 
cells with no innervation: in embryos, yeasts, plants, and as was shown recently, in 
lymphocytes [41-45]. 
As was mentioned above, the SDH/KDH ratio reflects in mitochondria the balance of ADR 
and ACH regulation in the organism.  
3. Methodological meaning of statistical analysis in modern biomedical 
investigations 
Usual desire of physician to find unique for a certain patient individual diagnosis and 
treatment become to be an advanced direction of the modern probative medicine. Some 
statistical algorithms appeared which substantiate individual conclusions made earlier 
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intuitively. The latter usually expelled these conclusions from the area of science, although 
this does not correspond to the truth. Misunderstanding between practical physicians and 
experts in statistics is based on the mistakes in applications of statistical methods in 
biomedical investigations. 
Very interesting and useful monograph by Thomas A. Lang and Mishelle Secic: “How to 
report Statistics in Medicine. Annotated Guidelines for Authors, Editors, and Reviewers” [46] 
has the purpose to fill the gap between mathematicians and physicians. The chapter: “The 
difference between clinical and statistical significance” substantiates the importance of a single 
observation, for example, life-saving of one person, in spite of its statistical unreliability. 
In this respect the statistical validity of CBCh method for individual measurement is of 
importance and will be briefly considered below. We share also the idea of the authors that 
statistical analysis in biomedical investigations should be actively used for design of 
experiment but not only for evaluation of the results. We can illustrate this by our experience. 
1. Statistical treatment 
Besides its crucial advantage in preservation of native structure organization of 
mitochondria CBCh method possesses one more important property. This is high statistical 
validity of a single result because it is obtained by computer quantitation of a multitude of 
microscopic images, which measure enzyme activity. This kind of calculation finds an ever 
increasing application in biomedical studies. In the case of dehydrogenase activity 
determination by CBCh method, both in rats and in people, even in a small part of 
experimental samples with minimal enzyme activity, the number of objects measured was 
about a hundred.  In most cases it was 300 - 500 images, while in a considerable part of 
samples with maximal activity, the number of images was more than 700. According to the 
standard determination of statistical significance, it is practically maximal, as judged by 
measurements even a hundred of images. Therefore all the data obtained in our work by 
computer quantitation are statistically significant at the level of 0.001 (99.99%). 
We did statistical analysis for our data and illustrate this result in Fig. 3 by putting in the 
bars presenting ± S.D. As seen, S.D. is negligible in contrast to non-computer treatment 
which deals with a considerably smaller number of measurements. Therefore, we believe it 
possible do not overload all the figures by designation of minor bars after preliminary 
explanation in Methods for the presented data sampling. Such description may be 
convenient for presentation of other data obtained by computer quantitation. 
In case of more than single individual measurement, such as data presented in Fig.8, we 
indicate ± S.D. in diagrams. 
2. Design of experiment for the purpose to diminish “uncontrolled” statistical variations 
of data. 
The preliminary design directed to diminishing of “uncontrolled” statistical variations of 
data was considered in the Guidance cited and in the valuable monograph by Glanz [47]. In 
these handbooks, protocols of comparison of results of the action of different substances are 
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described, convenient even in examination of people for which the selection of conditions is 
limited compared with animals. We can add to them examples from our experience. A pair 
comparison of results in one person in contrast to group comparison belongs to these 
protocols. This list is continued by: performance of measurements at maximal possible 
identical time. Comparison with healthy control, taken on the same day and at the same 
hour, or at least for four seasons separately, for which the difference of reactions is known. 
Performance of a comparison with controls, taken in the same laboratory simultaneously 
with examined group instead of using averaged data for norm, which increases variations. 
 
 
Figure 3. Changes in the activity of SDH and KDH and ROS formation in glass-adhered blood 
lymphocytes in rats during short-term painless psychoemotional stress (PES) in a box.  
Data are presented as a total area (S) of formazan granules in 30 cells.  
Owing to a great amount of objects (200-800) the presented values are statistically significant at the level 
of 0.001 (99.99%). 
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In connection with data in animal models, described in this paper, we shall consider in more 
detail the protocol of the selection of really statistical homogenous groups of animals, which 
was elaborated in our laboratory. The necessity to form statistically homogenous groups of 
animals for application of statistical analysis for treatment of results is well known, although 
often it is practically ignored. We found that, in the selection of animals assumed to be 
similar many factors still exist, that cause uncontrolled variations of the state of animals and 
preparations obtained. We select animals bred in the vivarium of our Institute within 1-3 
days after birth. We do not use for one group animals from only one brood because it is 
known from physiological data and found by the CBCh method that at least three 
subgroups can be differentiated in the one brood according to physiological activity [48]. 
These subgroups correspond to weight distribution. For standard investigations we take 
animals with greater weight, close to each other on the day of selection - 4 weeks, the time of 
transfer of young rats to dry feed and taking off from mother milk suckling (100-110 g). It 
was shown in the special experiments that the prolongation of suckling to 6 weeks 
considerably improves CBCh data and weight increase as compared with 160-180 g, when 
suckling was stopped at 4 weeks. The differences are found also in animals at the age of 6 
week, before maturation and at the age of 8 week, just after maturation (190-210 g). 
According to physiological data the differences between these ages are due not only to 
maturation but also to domination of adrenergic regulation before maturation and 
cholinergic regulation after maturation. We found manifestation of these physiological 
phenomena by the ratio of SDH and KDH activities. For standard investigations we have 
chosen the age of 8 weeks, however other ages can be used but in separate groups. Usually 
these details are not considered in experiments, which lead to the increase in variations of 
the results. 
Besides careful choice of animals, maintenance of conditions of treatment of isolated tissue 
preparation is of importance. Usual measurement of data in so called “parallel” samples for 
analysis taken from liquid preparation: suspension of mitochondria, tissue homogenate or 
liquid blood is indeed not simultaneous but subsequent in time. It is carried out 
subsequently, often during prolonged time of storage, while preparation is changed, which 
gives variations of results. These variations reflect not only changes in the state of the 
preparation itself but also its response to the pronounced changes in time of cosmophysical 
environment. This problem is fundamentally investigated in many year studies of S. Shnoll 
[49]. Many investigators confess that they meet such variations when make repeated 
measurements. However, observed deviations seem to be obscure and are neglected. Our 
method of preparation of fixed smears, which are more stable in time, allows one to carry 
out analysis much more close to simultaneous. Elimination of the considered sources of 
variations affords the possibility to observe practically completely identical results for 
different animals in the same physiological state within the selected group of 6-8 species. 
Such example is given at the upper panel of Figure 3. As shown under 120 min PES CBCh 
data for two animals are identical. Statistical probability of data for individual organism, 
considered in paragraph 1, allows one to compare the influence of investigated factors on 
individual animals in the same group. Comparison the results obtained in one group of 
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animals (upper panel) completely agree with results in the other group (lower panel), 
selected in different time. In both cases we observe maximal activation of dehydrogenases in 
the initial stage of stress - alarm reaction at 30 and 60 min, their further decline approaching 
the initial level to 120 min, however in the both cases with a small excess, which is 
considered in the description. Prolongation of stress to 180 min, presented at lower panel, 
shows increase in inhibition in time. On the reasons considered for upper panel we did not 
show minor bars in the lower panel as well as in the further similar figures in the text. 
However the number of images measured and statistical significance are given in legend. 
The attention to the creative search of causes of result variations and to the real possibilities 
of their diminishing will improve efficiency of studies. This affords making smaller number 
of experiments with more definite results. Such approach presents more deep penetration of 
statistical analysis into biomedical investigations. 
4. Demonstration of high physiological sensitivity of the CBCh method 
in models of increased adrenergic regulation. SDH/KDH ratio as a 
distinct borderline between intensive functioning and early dysfunction  
Over a long initial period, the biochemical mechanisms of stress were studied under action 
of strong chemical or physical stressors, which are beyond the range of physiological 
adaptation. In spite of this, the responses of isolated mitochondria studied under pain 
immobilization stress for a long time, 24 h, were not pronounced, accounting for no more 
than 20% inhibition of succinate oxidation measured by the polarographic method [11, 50, 
51]. The considerably higher sensitivity of the CBCh assay to changes in the physiological 
state is evident, as it reveals a great-range difference of SDH activity, 2-3 times and more, 
under the influence of much milder stressors compatible with life, such as the 
administration of ADR in submaximal dose or painless short-time restraint of rat in a 
narrow box for 30-120 min, psychoemotional stress (PES). A comparison of mitochondrial 
responses observed in isolated mitochondria and in mitochondria inside lymphocytes is 
convincing, considering that the state of animals after strong or physiological stress differed 
greatly. After strong stress, animals were exhausted and could not move, while animals 
after short-term stress looked like intact.  
The changes in the SDH and KDH activities after the administration of ADR are presented 
in the upper panel of Figure 4. As shown, these activities are moderate and nearly equal in 
the initial quiescent state. Under the action of ADR, the initial acute phase of stress, an alarm 
reaction arises. It is clearly manifested by a pronounced (more than twofold!) increase in the 
SDH activity, and by a fall (about twentyfold!) in the KDH activity. Under 24-h restraint in a 
box, a stress phase of exhaustion develops. It is also clearly pronounced by a decrease in the 
SDH activity approximately to the initial level. It is very important that this decline does not 
mean a restoration of the initial state because the KDH activity nearly disappears. Therefore, 
the dynamics of SDH activity develops according to a bell-shaped curve with a maximum at 
early stages of stress. This corresponds to the classic stress dynamics followed by 
physiological data.  
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As mentioned, the SDH activity serves as a marker of ADR regulation, which supports the 
external work of tissues, while the KDH activity is a marker of ACH regulation which is 
responsible for restoration of expenditures for work and underlies the general immune 
resistance of the organism, including the participation of lymphocytes. Therefore, we 
consider the critical fall in the KDH activity as a manifestation of stress that exceeds the 
range of physiological adaptation. It is worth mentioning that the 24- h PES when so 
dramatic changes in the DH activity were observed by the CBCh method is not as severe as 
the widely investigated rough form of immobilization when only small changes in 
respiration were found in isolated mitochondria. 
An extremely interesting, quite novel area of real adaptive changes in the DH activity opens 
during even milder PES of shorter duration: 30, 60, 120 min. As seen in the lower panel of 
Figure 4, during 30 and 60 min a gradual hyperactivation of the both SDH and KDH activity 
are observed without the critical fall of the latter. Changes in the KDH activity are only of 
somewhat less extent than that of SDH. By 120 min hyperactivation of the both DHs is 
followed by the return to the quiescent state.  
The status of DHs at 120-min PES is of crucial importance. 
Let us remind that in the initial completely quiescent state, the activity of both DHs is low 
and nearly equal. This is time to note that the KDH activity is somewhat higher than SDH, 
which is well reproduced in the independent observations. This small excess of KDH 
activity over SDH is of great importance because it corresponds to the domination of ACH 
regulation over ADR regulation in the quiescent state. As shown in the lower panel of 
Figure 4, by 120 min both DHs return nearly to the initial level. Two wonderful details of 
this state should be noticed. The first is that a slight prevalence of KDH activity over SDH 
appears which is typical of the quiescent state. The second is that the level of both is 
somewhat higher than in the initial state before stress. 
These specific features evidence a real return to the well balanced quiescent state in spite of 
continuation of stress. In essence this decrease in DH activity is a real adaptation to the load 
during training. 
Such phenomenon is well known in physiological observations and only after repeated 
training.  
But it has been never observed in a single short-term experiment, the more so for 
mitochondrial processes. A search for biochemical markers of such a desirable state was 
only a dream of physicians and trainers. The CBCh method revealed such changes in a 
short-term experiment and in a wide range. 
A finding these two types of early changes in responses of mitochondria to the pathogenic 
influence detected for the first time a distinct borderline between stimulating, adaptive 
action of load and the transition to its adverse action, which increases the risk of pathology. 
The reliable detection of this border is particularly important for the prevention of disease or 
a more effective intervention.  
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Figure 4. Changes in SDH and KDH activity and their ratio in rats. 
Upper panel. Administration of moderately increased dose of adrenaline (50 μg/100 g) for 30 min and 
long-term (24-hour) psychoemotional stress in a box. SDH activity is expressed as a mean area (S) of 
formazan granules in 30 cells. 
Low panel. Short-term psychoemotional stress in a box. SDH activity is expressed as a total area (S) of 
formazan granules in 30 cells. 
Owing to a great number of objects calculated (200-800) the presented data are statistically significant at 
the level of 0.001 (99.99%) 
As shown in the last example in the lower panel of Figure 4, the prolongation of PES to 180 
min exceeds adaptive reserves as it leads to a fall in the activity of both DHs. This inhibition 
corresponds to the stage of exhaustion of stress. Thus the dynamics of SDH and KDH 
activity changes presented in both panels of Figure 4 for the first time clearly reveals 
mitochondrial mechanisms that underlie the physiological development of stress. 
In contrast to the results obtained on isolated mitochondria, the CBCh method allows one to 
observe a broad range of mitochondrial states from deep quiescence up to strong excitation 
followed by pathological exhaustion in the model of wholly physiological stress. This area 
of states of mitochondria is not available under the conditions of standard biochemical 
investigations and is Terra Incognita for mitochondriologists.  
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Further we shall describe some other unknown phenomena in this unexplored area.  
5. Other CBCh characteristics of mitochondria besides SDH and KDH  
5.1. Endogenous substrates (ES), SDH true and SDH latent 
As mentioned in Methods, for the CBCh characteristic of SDH we used additional samples 
besides the basal with the addition of millimolar substrate concentrations of SUC. The main 
of them are shown in Figure 5 and 7, which present more completely the experiments 
demonstrated in Figure 4. Some additional samples are also given in Figure 6. 
The first column from the left shows the reduction of NBT by only ES oxidation without 
addition of exogenous substrates. This indicator is ignored in most cytochemical 
investigations. Meanwhile its consideration provides additional valuable information. 
The first important characteristic which is determined with the help of ES is a more precise 
measurement of SDH activity with subtraction of the contribution of substrates other than SUC. 
As shown in Figure 5, in intact animal the value of reduction in sample SDH is close to that 
in the sample ES. When subtracting the data for ES from the data for SDH, as it is 
accustomed in biochemistry, it turned out that the addition of 5 mM SUC absolutely does 
not increase the reduction in the least. This means that the reduction in the sample with SUC 
is not caused by SDH activity but is due to other processes. These data show that SDH in 
physiological quiescence of the organism is not active, keeping a latent state. In contrast, 
after ADR administration reduction due to ES is lower, the SDH activity is considerably 
higher, and the difference SDH-ES is great. We call this calculated value true SDH activity 
(SDHtru) because the subtraction eliminates the contribution of other substrates. To 
distinguish this corrected value from the common SDH activity measured without 
subtraction we term the latter the total SDH (SDHtot). The loss of SDH activity in the 
quiescent state of the organism is well explained from the standpoint of physiology. In the 
quiescent state, the ADR regulation is switched off reciprocally to ACH regulation. 
Apparently, SDH as a target of ADR in mitochondria follows hormone signal, switching 
activity off. As shown in the last example under prolonged -24 h stress corresponding to the 
exhaustion stage, the activity of both DHs declined. 
The state of non-active SDH can also be termed latent or “sleeping” because it does not 
function in spite of SUC addition. The finding of this state of SDH is one of the most 
important attainments of the CBCh method. Such a state is not known in biochemical 
investigations of mitochondria because they lose the quiescent state during preparation and 
measurements. Biochemists are familiar only with initially activated SDH. The wide range 
of states from quiescent state to activation is lost for current observation. The loss of the 
initial basal level of respiration, i.e. the quiescent state, is in essence the absence of data for 
norm in current biochemical investigations. 
We have found that the crucial difference in SDH activity between healthy and sick people 
or between calm and anxious animals is just the loss of the quiescent state. This means that, 
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in the state of relative physiological quiescence, sick people has no quiescent state in 
mitochondria. This will be demonstrated further. 
 
Figure 5. CBCh patterns of mitochondria measured in glass - adhered lymphocytes from intact and 
stressed rats. Adrenaline administration, 30 min,  and PES 24 h. NBT reduction is expressed as a mean 
area of formazan granules in 30 lymphocytes 
Owing to a great number of objects calculated (200-800) the presented data are statistically significant at 
the level of 0.001 (99.99%) 
5.2. KDH activity measurement. Addition of malonate (MAL) 
The pair of columns in Figure 5 next to SDH presents the KDH activity measurements 
without and with the addition of MAL. These samples contained also NAD+ as a soluble 
cofactor of KDH. It is worth reminding that MAL should be obligatory added for correct 
determination of KDH activity. It was well known but undeservedly forgotten in many 
polarographic measurements that SUC generated in mitochondria during KGL oxidation 
may amount to a considerable part of respiration in the presence of KGL added. The SUC-
dependent portion of respiration should be subtracted from total respiration with KGL. The 
data presented show that the SUC-dependent portion of KDH activity is absent in the intact 
state, when SDH is non- active. In contrast, this portion rises in excited animals. It is evident 
from this example that the own KGL oxidation is negligible under strong excitation. The 
elimination of the SUC-dependent portion of NBT reduction by MAL allows one to measure 
KDH activity more precisely. Reciprocal changes in KDH and SDH activities in the presence 
of MAL become also more evident. 
5.3. Signal action of SUC and ADR 
The last pairs of columns in Figure 5 presents the data on NBT reduction with the addition 
of 5 μM, “Signal” concentration of SUC or 5 μM of ADR with substrate concentration of 
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SUC - 5 mM. The effects of signal concentrations were negligible or absent when measured 
with subtraction of sample with MAL in the intact animal. However, both effects rise similar 
to the SDH activity in ADR-activated animal. Under prolonged stress, they both decline also 
in accordance with SDH activity. These data are the first evidence of a great SDH activity in 
the presence of low, signal concentration of SUC, far below the substrate ones, under the 
influence of ADR. 
Signal concentrations of ADR act synergetically to SUC. These data serve as a further 
evidence for synergism between SUC and ADR. 
5.4. Addition of MAL: Endogenous SUC (ESUC = ES - MAL), reactive oxygen 
species (ROS) formation 
MAL is commonly used to exclude the contribution to oxidation of SUC, either added or 
endogenous (ESUC), formed in mitochondria from other substrates, particularly from KGL. 
Although the amount of ESUC is very low compared with that of added KGL, SUC 
dominates in competition for the respiratory chain due to the dominating reducing power of 
SDH. ESUC has additional advantage over added SUC, because it forms inside 
mitochondria and is better available to SDH [16]. In CBCh measurements, a decrease in 
formazan formation corresponds to the inhibition of respiration. The difference in reduction 
between sample ES and (ES+MAL) gives a measure of ESUC.  
We observed an increase in ESUC content in animals excited by endogenous ADR (stress) or 
ADR administration. ESUC also increases in a spontaneously anxious individuals, animals 
or people. 12 examples of typical patterns of MAL effects on NBT reduction with ES are 
presented in Figure 6. They were selected from more than 20 volunteers examined. Among 
them we have found four types of repeating patterns and no more variations. Each type is 
presented by three examples. The form of pattern is well reproduced for each type. 
Therefore we believe the pattern to be a regular relationship but not random combination of 
characteristics. All volunteers were in the relatively calm state. Blood samples were taken in 
the laboratory between 9-10 a.m. after a very weak breakfast at about 8 at home. All of them 
were practically healthy, however, the level of health and the state on the day of 
examination varied. Probably, in accordance with these differences, we found four types of 
repeating patterns. 
Ranging the patterns according to the increase in the SDH activity from low to high, we 
differentiated the following States: Deep Quiescence, Operative Quiescence, Activity, and 
Activation with Inhibition. 
The decrease in NBT reduction, caused by MAL, is particularly pronounced in the subgroup 
Activation, in which the SDH activity is the highest. The members of this subgroup have 
personal reasons for anxiety and activity. The same type of pattern but with a lower amount 
of ESUC was found in the subgroup named Operative Quiescence, because the SDH activity 
was considerably lower than in the subgroup Activity. The decrease in NBT reduction 
caused by MAL evidences the contribution of ESUC to respiration when SDH is active. 
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Figure 6. Four (and no more) types of specific CBCh patterns of SDH found in healthy volunteers and 
presented by three examples. Owing to a great number of objects calculated (200-800) the presented 
data are statistically significant at the level of 0.001 (99.99%) 
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Together with this traditional effect of MAL, we revealed the opposite action of MAL, 
namely, an increase in NBT reduction. It was most pronounced in the subgroup Activation 
with Inhibition, which was distinguished according to a decreased SDH activity relative to 
the Activation subgroup. One cause of the inhibition (example 20) could be an elder age and 
initial hypertension demanding the intake small doses of adrenoblockers, which also 
inhibits SDH. In this case, an increase in NBT reduction by MAL is the highest. This effect is 
also well pronounced relatively to ES in two other examples in this subgroup. This 
unknown effect of MAL on NBT reduction is also observed in Deep Quiescence, in which all 
activities are at the lowest level. 
Thus, MAL manifests the ability to increase NBT reduction in case of low SDH activity, in 
contrast to its traditional inhibition of respiration is great when SDH activity is high. 
In our opinion, the increase in NBT reduction by MAL is a marker of ROS formation in 
mitochondria. As shown in Figure 7, ROS formation sharply rises at the beginning of stress. 
During stress, the rise of ROS formation declines as evidenced by our measurements with 
MAL. This agrees with other results [52]. As shown in the last example in Figure 7, ROS rise 
again by the exhausting stage. The biochemical mechanism of this effect of MAL is in deep 
inhibition of SDH, which leads to a fall of coenzyme Q reduction from full reduction to free 
radical form. Free radical form of Q produces superoxide in interaction with surrounding 
oxygen [53]. 
5.5. Dual regulatory effect of ISC on SDH activity in the area of physiological 
regulation. GTP-recoupling but not oxaloacetate (OAA)-inhibition regulates 
SUC oxidation under physiological conditions 
ISC is a natural efficient intramitochondrial antioxidant [54]. Reducing equivalents 
produced by ISC NAD(P)-dependent dehydrogenases protect the most sensitive enzymes 
aconitase and KDH from oxidation and increase the stability of mitochondria to oxidative 
stress, which accompanies any stress. It was shown long ago that ISC abolishes OAA 
inhibition of SDH in aged mitochondria or under severe stress [50, 55]. This effect is due to 
OAA elimination by reduction into malate because of increase in the reduction of the 
respiratory chain. A similar effect is usually attained by the addition of glutamate, which 
eliminates OAA via transamination. As distinct from glutamate, the application of ISC for 
the elimination of SDH inhibition was nearly forgotten. This may be due to the fact that its 
fully active natural isomer is commercially hardly available, while the available chemical 
racemate is less active. Fortunately, due to the collaboration with microbiologists 
manufacturing natural ISC, we had an opportunity to investigate this substance [56].  
Our investigation of the influence of natural ISC on SDH activity during PES under more 
physiological conditions of the CBCh method discovered an unknown effect of this 
substrate. In spite of acceleration of inhibited SUC oxidation, ISC strongly suppresses 
hyperactivated SDH. This effect is shown in Figure 7. It is clearly seen that ISC addition 
suppresses greatly SDH activity in the hyperactivated state, 30, 60, 120 min of PES. 
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However, ISC preserves the ability to stimulate inhibited SDH under 180- min PES. Besides, 
we have found that ISC does not influence the SDH activity in the Quiescent State. The two 
opposite effects of ISL: an increase and a decrease in SDH activity are easily explained by 
the single antioxidant mechanism. The increase in NBT reduction by MAL at the beginning 
of PES shows the development of oxidative stress. This agrees with other observations. The 
level of oxidative stress is regulated by well-balanced interactions of several processes 
occurring in mitochondria. Among them are initial uncoupling and its secondary recoupling 
by GTP [52].  
Recoupling effect of GTP can explain our observation that preserving the KDH, which is a 
real source of GTP-formed in substrate-level phosphorylation, protects SDH from 
hyperactivation followed by inhibition. 
 
Figure 7. CBCh patterns of mitochondria measured in glass -adhered lymphocytes from intact and 
stressed rats under mild PES of different duration. 
NBT reduction is expressed as a total area of formazan granules in 30 lymphocytes. 
Owing to a great number of objects calculated (200-800) the presented data are statistically significant at 
the level of 0.001 (99.99%) 
In this metabolic environment, protection of KDH from oxidation by ISC allows one to 
support GTP generation and to diminish the uncoupling that was a cause of initial SDH 
hyperactivation. This explanation agrees well with our repeated observations that the 
preservation of high KDH activity simultaneously with activation of SDH is typical of 
activity within physiological adaptation area. The “scissors” between SDH rise and KDH 
fall are observed in severe stress or pathology. Therefore, three different effects of ISL on 
SDH activity: suppression of hyperactivation, activation of inhibition, and absence of 
influence in norm, allow one to differentiate clearly functional states of SDH. The area of 
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SDH regulation involving KDH-dependent GTP – recoupling - is not known in biochemical 
investigations because SDH is initially hyperactivated under the experimental conditions. 
The hyperactivation of SDH elevates the risk of inhibition by OAA due to the increase in its 
formation. Indeed, OAA inhibition is often observed, when SUC oxidation is accelerated, for 
example, by uncoupling. Therefore, OAA inhibition is considered to be the only mechanism 
of SDH control. However, this is true for in vitro conditions in biochemical experiments in 
isolated mitochondria. The preservation of the area more close to physiological conditions in 
the CBCh method opens Terra Incognita of unknown regulation of the SDH activity by 
GTP-recoupling instead of usual OAA inhibition.  
The last but not least, it is worth mentioning that the mutual reciprocal regulation of SDH 
and KDH activity is further evidence of ADR and ACH regulation in mitochondria. In 
essence, it corresponds to the reciprocal influence of ADR and ACH on physiological 
functions: stimulation, and restriction with restoration, respectively. 
Before continuation, let us put in a brief insertion to memorize the better approach of CBCh 
determination of SDH activity to mitochondrial processes compared to pure enzymatic 
measurements.  
Interlude: СBCh activity of SDH is not so much a characteristic of abstract DH, as a 
measure of the rate of SUC oxidation in mitochondria 
What is the interest of physiologists and physicians in measurement of enzyme activities? 
Evidently they need to learn how the enzymes work in the organism in different states. 
Many purely enzymatic methods give exact information, although rather abstract in respect 
of the conditions in vivo. Preservation of the native state and native surrounding of SDH 
and KDH under CBCh conditions permit measurement of SUC oxidation, that approaches 
the real rate of respiration in mitochondria in vivo rather than an abstract activity of SDH. 
This is one more crucial advantage of CBCh measurements of DHs activity. 
6. Revealing fine physiological differences in the state of the organism in 
norm by the activity of dehydrogenases as measured with the CBCh 
method. Differences in the activity and responses of SDH in rabbits with 
opposite behaviour  
The CBCh method clearly detects some fine physiological differences in the state of the 
organism that were earlier not observed in mitochondria. Among them are some age-
related differences in rats at different stages of ontogenesis, namely, in newborn animals, 
depending on the time of feeding with mother milk, prior to or immediately after 
maturation, as well as individual differences of pattern types between healthy humans 
that are related to the current condition or temperament [48, 57]. Both age-dependent 
changes and differences of temperaments reflect different ratios of ADR/ACH regulation. 
In the earlier age, ADR regulation dominates; after maturation, it is more balanced by 
ACH.  
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Figure 8. Responses of ES and SDH to activation by administration of adrenaline or succinate measured 
in lymphocytes of rabbits with different behavior. 
A - calm rabbit, B - restless rabbit. SDH activity is expressed as a mean area of formazan granules in 30 
cells. The mean of three measurements in different days for each rabbit are presented, M ± SEM. * - р< 
0.05, ** - p<0.01, comparing to the respective initial state, # - p<0.05, comparing to the calm rabbit. 
As one of the models of domination of these regulation types we studied individual 
differences of CBCh patterns in rabbits with different behaviour.  
One rabbit was calm during the experiment; another rabbit escaped and was anxious and 
restless even when it was not exposed to treatment. They represented characteristic types of 
a cholinergic and adrenergic, respectively. Figure 8 demonstrates significant differences 
between the calm and restless rabbits in the level of ES and in the SDH activity. 
The reserve of ES in the calm rabbit is much greater than in the restless. After the injection of 
ADR, the level of ES in the calm rabbit decreases; however, this level is higher than in the 
restless animal under the influence of ADR. In the intact restless animal, the level of ES is 15 
times lower than that of the intact calm rabbit and 5 times lower than in the calm animal 
after the injection of ADR. This indicates an enhanced expenditure of substrates in the 
restless animal. 
The SDH activity in the calm rabbit is low, and the injections of ADR or SUC strongly 
stimulates it. The stimulation of SUC is somewhat stronger, which increases the risk of the 
transition from hyperactivation to inhibition. By contrast to ADR, the injection of SUC also 
increases the level of ES. 
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SDH in the intact restless rabbit is hyperactivated nearly up to the level of calm under ADR 
influence. Thus, as judged by ES level and the SDH activity, the restless rabbit has no 
quiescence in the quiet state without external excitations. The same state of continuous 
internal metabolic excitation is inherent in all patients examined in our laboratory in 
contrast to healthy volunteers. The data will be considered in the next sections. 
At the background of the initially high SDH activity in restless rabbit ADR administration 
leads to only small stimulation, which only somewhat exceeds the level under the influence 
of ADR in calm rabbit. The influence of SUC, which was somewhat stronger activator when 
injected to the calm rabbit, leads to realization of risk of transition to inhibition in restless 
animal. 
The difference in ADR and SUC effects on ES can be explained by different mechanisms of 
their influence on SDH activity. ADR only activates SDH through protein kinase. The 
influence of SUC is more complicated. SUC is an allosteric activator of SDH [58]. 
Simultaneously the rise of SUC level increases OAA formation, which inhibits SDH 
according to the mechanism of the negative feedback. 
These effects are better pronounced in a sample without SUC addition, namely ES, because 
SUC excess partially abolish OAA inhibition. Therefore in sample ES SDH inhibition is 
better observed than in sample for SDH measurement, containing 5 mM SUC, because it is 
not masked by the addition of substrate. Probably, the main part of ES under SUC injection 
is ESUC, which is accumulated due to OAA inhibition. It should be considered that 
measurements are made for an hour. Insight into dynamics of the processes can be achieved 
by a comparison of data for calm rabbit, in which oxidation is slower with those for restless 
one, in which oxidation is accelerated. As shown for calm rabbit, at the beginning rapid 
oxidation of SUC occurred, resulted in an increase in OAA, which is evidenced by the initial 
accumulation of ESUC. The next stage is presented by data for restless rabbit in which 
stronger inhibition of SDH by OAA is already developed, which is not completely abolished 
by SUC addition and therefore ESUC accumulation is higher than in calm animal. 
The data presented show great difference of the two CBCh properties of the state of 
mitochondria in animals with opposite behaviour, which corresponds in magnitude to the 
pronounced individual peculiarities in behaviour. 
We have also found the pronounced difference in the SDH and KDH activity in rats before 
maturation, 6 week old with domination of ADR regulation, and just after maturation, 8 
week old with increase in ACH regulation. These changes are close to differences between 
calm and restless rabbits. 
It was shown also that complicated menopause in rats and women, which is manifested 
under the decrease in ADR regulation in the organism, is related to the increase in the SDH 
activity and can be corrected by metabolic regulators, containing SUC - “Amberen” [59]. 
The data considered support the view of existence of the link between activity of studied 
DHs and the level of ADR and ACH regulation. 
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7. The changes in SDH and KDH activity in patients with metabolic 
syndrome and arterial hypertension 
The stages of the SDH and KDH activity changes found under stress were observed in 
patients with metabolic syndrome and arterial hypertension. 
Disturbance of normal metabolic flexibility between oxidation of glucose and fatty acids is 
the basis of many diseases. High dietary fat intake and low physical activity provoke this 
disorder. Complex of accompanied biochemical changes is called metabolic syndrome. 
Metabolic syndrome underlies various pathological symptoms, such as obesity, insulin 
resistance, type 2 diabetes, risk of hypertension, heart diseases and others [1, 60-65].  
Metabolic syndrome is caused by increased intensity of life accompanied with persistent 
sympathetic hyperactivation and deficit of physical activity that leads to PES. That is why 
we have studied the participation of mitochondria in development of PES. The importance 
of mitochondria in development of metabolic syndrome is caused by their crucial role in 
intracellular oxidation. Aerobic fibers of skeletal muscle mitochondria make a major 
contribution to regulation of metabolic syndrome and support metabolic health of the whole 
organism.  
 
Figure 9. True SDH without and with ISC in not severe patients suffering from food allergy 
accompanied by arterial hypertension. 
Data are expressed in mean area (S) of formazan granules in 30 cells. Owing to a great number of 
objects calculated (200-800) the presented data are statistically significant at the level of 0.001 (99.99%) 
Inscription above - types of patterns. 
SDHtru is calculated as the difference between samples SUC 5 mM - MAL 5mM.  
The changes of SDH and SDHisc activity are presented in per cents respective to conditional norm of 
patient 1 (100%). The low row for SUC 5mM, the upper row for SUC 5 mM + ISC 5 mM.  
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The changes in the SDH activity in non-severe, non-hospitalized and workable patients with 
allergy to some food products are given in Figure 9. In this case for more precise 
determination of the SDH activity we subtracted ES contribution from the data for the 
sample with SUC addition. This value was termed as a true SDH (SDHtru). It was 
determined under addition of SUC and also SUC+ISL, modulator of the SDH activity. This 
provides determination of the functional state of SDH as considered in section 5.5. 
Calculation of SDHtrue help to find clearly pronounced similarity between some patients, 
which is masked by ES contribution. According to SDHtru the patients can be joined in 
subgroups with nearly identical data for members inside one subgroup and clearly different 
from the other. 
The first example from the left is for healthy person. The next one, 1, is taken as reference 
control to other patients. He used diet containing no allergenic products for more than 7 
years and for this period his body weight, AD and other physiological characteristics were 
greatly normalized. Other patients have some pathological symptoms and used 
recommended diet for only several months. Among them we have found increase in SDH 
activity. 
For healthy people full absence of SDHtrue - complete quiescence state is observed. Low 
SDHtrue was determined for patient with normalization of the state. In all others patients 
different levels of activation or hyperactivation of SDH were found. In the state of 
hyperactivation without inhibition, ISL addition results in only the tendency to stimulation. 
Progressive hyperactivation is masked by internal inhibition of OAA. This is revealed by the 
increase in activity with ISL. For the patients with greater symptoms, presented in the right 
part of the Figure 9, the increase in the internal inhibition is typical, which is manifested in 
both, the SDH activity decrease and strong increase in activation by ISL. 
Hyperactivation of the SDH activity without inhibition is more typical of patients 
hospitalized with hypertension. In Figure 10 data are presented on the total SDH activity 
(SDH tot) without subtraction of ES contribution. It is seen also, as in Figure 9, that for the 
healthy control very low activity of SDH is typical. The rise in the activity can be considered 
as hyperactivation without inhibition by both, their greater value and because ISL does not 
stimulate it but, in contrast, decreases. ISL addition serves as unique test of the functional 
state of SDH developed by our group. Additionally to the explanations of ISL influence in 
section 5.5 it should be mentioned that effect of ISL is dose-dependent. It can be seen from 
the example of patient N2. Addition of 5mM of ISL decreases hyperactivation of SDH per 
2/3, while 50μM only per 1/3. 
The extent of the deflection of the SDH activity from norm should be quantitatively 
determined using different concentrations of ISL. In Figure 10 (as in Figures 5 and 7) the 
KDH activity is also given, as well as the response of mitochondria to the signal 
concentration of SUC - 5μM. In norm the KDH activity is low and nearly equal to the SDH 
activity. At hyperactivation of SDH in patients N2 and N3, KDH is also greatly increased, 
however less than SDH. Such coupled changes in the two DH activities in patients are 
similar to those, which were found in rats under PES within the range of physiological 
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adaptation. However, the changes in more severe patient, N4 are already beyond the 
physiological range and are analogous to that for damaging stress in Figure 4. It is also seen 
that the response to signal concentration of SUC corresponds to the SDH activity, measured 
with substrate concentration of SUC, as shown in Figure 5. 
The presented examples show that the loss of full value quiescence, which is manifested in 
the complete switching SDH off, is a general difference of all examined patients from 
healthy people. Therefore mitochondria of patients in the relatively quiet state of the 
organism have no metabolic quiescence. 
According to the influence of ISL functional state of SDH in patients with hypertension 
differs from that of patients with allergy. Hidden inhibition of SDH is typical of allergy, 
while hyperactivation of SDH is more typical of hypertension. This coincides with more 
pronounced sympathetic hyperactivation in hypertensive patients, demanding intake of 
adrenoblockers. 
 
 
 
 
Figure 10. CBCh patterns of patients hospitalized with hypertonic disease. 
The data are expressed as the total area of formazan granules in 30 lymphocytes. 
AP, upper line - the data just before blood taking, low line - more stable data from History of the 
disease. The gender and age are indicated between. 
Owing to a great number of objects calculated (200-800) the presented data are statistically  
significant at the level of 0.001 (99.99%) 
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8. Conclusion  
The experience of the reviewed study evidences reliability to approach ex vivo more closely 
to the state of investigated tissue in the organism. In order to maintain native state of 
isolated tissue it is necessary to join the both, care of biochemical processes and physical 
structure. Only combined biochemical and biophysical approaches will provide attaining 
the desirable goal to study biochemical mechanisms of physiological processes ex vivo.  
This approach opens unknown areas in biochemical regulation in the organism, as shown 
for instance, by SDH and KDH regulation. One of the mostly known phenomenons, OAA 
inhibition of SDH, is considered as the main regulator of the SDH activity. However, 
according to investigations under more physiological conditions, it seems to be in many 
cases rather artifact of “preparative story” of mitochondria. The wide range of SDH states 
under the physiological and pathological conditions in the organism, compatible with life, 
are DH hyperactivation, which is far from the inhibition. This state is probably controlled by 
GTP, produced due to KDH activity in substrate-level phosphorylation during KGL 
oxidation. This restriction of SDH by KDH is in essence identical to reciprocal 
interrelationship between parasympathetic a sympathetic nervous regulation of 
physiological functions. 
A very convincing observation of this substrate-hormonal interaction, as judged by the 
CBCh method, which cannot be achieved in investigation of isolated mitochondria, can be 
also mentioned as the crucial result of preservation of the native structure of mitochondria 
under study.  
9. Perspectives of the CBCh method development  
The wide application in clinical practice of the proposed very sensitive method to penetrate 
the state of human mitochondria is the most near, reliable and useful perspective. This 
penetration is even deeper than in the current biochemical studies. The procedure of the 
measurement is not the main difficulty on this way. It is within the range of the commonly 
used clinical tests and may be advanced for the convenience. 
In order to the CBCh analysis will bring benefit to patients, physicians should acquire deep 
knowledge of the investigated biochemical processes. Fundamental data from handbooks 
are not sufficient for this purpose. It is necessary to learn more special area, which is 
developed in current studies by the CBCh method. This area is advanced even in modern 
mitochondriology, because it is created during novel experiments. The authors are 
preparing the special guidance to facilitate the entrance in the new area. We are also glad to 
help to overcome individual difficulties in the procedure and analysis of data. 
Radical approach to the state in the organism through to the preservation of the native 
structural state of the tissue, found in the study oh DHs, encourages widening the 
developed conditions on the great variety of the cyto- and histochemical determinations.  
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Earlier we have stated that the main advantage of the CBCh method lies in the use of 
lymphocytes as indicators of the overall metabolic status of the entire organism, which is 
especially useful as an early diagnostic tool of various mitochondrial dysfunctions. This method 
can be also used for individual selection of drugs in sample of blood of a certain person. 
However, the CBCh method may also be used as a tool for the study of lymphocytes as an 
independent object of study, which carries important functions in the immune response. The 
use of the CBCh method for the study of dehydrogenase activity, as well as other indicators, 
is likely to lead to a better understanding of the dependence of the immune response on 
mitochondrial functions. 
The novel area of CBCh investigations of lymphocytes can be related with their use as cells 
possessing recently discovered pronounced ACH regulation, both - vagus -dependent and, 
particularly interesting, self-dependent, intracellular, which is based on the internal pool of 
non-neuronal ACH. The simultaneous study of ACH level and dehydrogenase activity in 
lymphocytes can provide further penetration into substrate-hormonal regulatory system 
that was pioneered in our laboratory. 
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1. Introduction 
Glycolysis is an anabolic pathway common in both aerobic and anaerobic organisms. Sugars 
and polysaccharides have to be transformed into glucose or one of its phosphorylated 
derivatives before being processed any further. In the course of degradation, ATP is 
produced. Pyruvate may be regarded as the preliminary final product of the degradation - 
in a strictly formal sense - because it is here that the pathway ramifies: pyruvate is hydrated 
under anaerobic conditions resulting in either lactate (in lactic-acid bacteria) or ethanol (in 
yeast). If glycolysis results in these final products, it is spoken of fermentation. In the 
presence of oxygen pyruvate is converted to acetyl-coenzyme A and oxidized to CO2 in the 
tricarboxylic acid (TCA) cycle (Figure 1). In yeasts, as well in most non-photosynthetic cells, 
mitochondrial oxidative phosphorylation is the main process of ATP synthesis in aerobic 
conditions. Aerobic pathways permit the production of 30 to 38 molecules of ATP per one 
molecule of glucose. Although two molecules of ATP come from glycolysis and two more 
directly out of the TCA cycle, most of the ATP arises from oxidative phosphorylation. 
The main catalytic function of the TCA cycle is to provide reducing equivalents to the 
respiratory chain through the oxidative decarboxylation of acetyl–CoA (8), but every TCA 
cycle intermediate is commonly used by other metabolic reactions. The eight enzymes from 
the TCA cycle are encoded by 15 nuclear genes in S. cerevisiae [1]. The first reaction of TCA is 
catalyzed by citrate synthase (1) and it is the condensation of acetyl–CoA and oxaloacetate 
resulting in the formation of citrate. The second reaction of the TCA is catalyzed by 
aconitase (2), leading to the conversion of citrate into isocitrate. Aconitase is located both in 
mitochondria and in cytosol. The next step of the TCA is the oxidative decarboxylation  
of isocitrate to -ketoglutarate (3). There are three known isoenzymes of isocitrate  
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Figure 1. TCA cycle. 
dehydrogenase, a mitochondrial NAD+-specific one and two NADP+-dependent ones (one 
mitochondrial and the other cytosolic). A number of pieces of evidence point to the role of 
mitochondrial NAD+-specific isocitrate dehydrogenase in the regulation of the rate of 
mitochondrial assembly besides its specific role in the TCA cycle [2]. The formation of 
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succinate is catalyzed by -ketoglutarate dehydrogenase (4), which promotes the oxidative 
decarboxylation of -ketoglutarate via succinil–CoA to succinate, which is then converted to 
fumarate by succinate dehydrogenase (5). The next step of the TCA cycle is the conversion 
of fumarate to malate by the enzyme fumarase (6), which exists as separate cytosolic and 
mitochondrial forms. There is not yet a clear explanation for the existence of these two 
forms; however, the localization and distribution of fumarase appears to be unique because 
there is only one translation product, which is targeted to mitochondria [3]. Malate 
dehydrogenase (7) catalyzes the last step of the TCA and leads to the oxidation of malate to 
oxaloacetate. There are three isoenzymes of malate dehydrogenase: a cytosolic, a 
mitochondrial and a peroxissomal one; however, the mitochondrial one accounts for 90% of 
malate dehydrogenase activity when glucose is being metabolized [4]. 
TCA cycle flux appears to be constricted at two steps on the basis of the limited availability 
of the substrates oxaloacetate and -ketoglutarate. The genes encoding TCA proteins might 
also be regulated by glucose levels. In S. cerevisiae the depletion of glucose increases 3–10 
times the TCA messenger RNAs [5]. Oxygen limitation could also induce a shift in the TCA 
cycle, which operates as a cycle during aerobic growth [6]. 
All reactions of glycolysis take place in the cell  cytosol. The citric acid cycle and the 
respiratory chain are located within mitochondrial matrix. In contrast with all of the other 
enzymes of the TCA cycle, which are soluble proteins found in the mitochondrial matrix, 
succinate dehydrogenase (SDH) is an integral membrane protein tightly associated with the 
inner mitochondrial membrane [7]. Membrane-bound succinate dehydrogenase (EC 
1.3.99.1) or succinate-coenzyme Q reductase or Complex II, is present in all aerobic cells. It 
was discovered by Thunberg in 1909. Now we know that  SDH has several particularly 
interesting properties: (1) it is a membrane-bound dehydrogenase linked to the respiratory 
chain and a member of the tricarboxylic acid (TCA) cycle; (2) its activity is modulated by 
several activators and inhibitors; and (3) it is a complex enzyme, and covalently bound 
flavin adenine dinucleotide (FAD) [8]. 
2. SDH structure 
SDH is a heterotetramer composed of flavoprotein (Fp) of about 70 kDa, an iron-sulfur 
protein (Ip) of about 30 kDa, and two hydrophobic anchoring subunits of 7-17 kDa. The Fp 
contains the active site and the unusual cofactor, an 8α-N(3)-histidyl-FAD linked at a 
conserved histidine residue (Figure 2).  
FAD attachment is stimulated by, but not dependent upon, the presence of the iron-sulfur 
subunit and citric acid cycle intermediates such as succinate, malate, or fumarate [9].  
The Ip subunit contains three different iron-sulfur clusters: [2Fe-2S], [3Fe-4S], and [4Fe-4S] 
(Figure 3).  
These clusters are coordinated by conserved cysteine residues: [2Fe-2S] (Cys-67, Cys-72, 
Cys-75, Cys-87); [4Fe-4S] (Cys-159, Cys-162, Cys-165, Cys-226) and [3Fe-4S] (Cys-169, Cys-
216, Cys-222) [10]. 
 
Dehydrogenases 214 
 
Figure 2. The covalent bond between FAD and succinate dehydrogenase. 
 
Figure 3. The 2Fe-2S cluster of succinate dehydrogenase [9]. 
The hydrophobic anchoring subunits are integral membrane proteins and interact with 
quinone substrates. The yeast and mammalian SDH also contains a b-type heme. Oyedotun 
et al. [11] demonstrated the presence of an amount of cytochrome b562 steichiometric to 
covalent FAD. Together, the Fp and Ip form a catalytic dimer that is attached to the 
membrane by the anchoring subunits, thereby composing the holoenzyme. In yeast, the 
SDH Fp, Ip, and two anchoring subunits are encoded by the nuclear genes, SDH1, SDH2, 
SDH3, and SDH4, respectively, which have all been cloned and sequenced. The SDH 
subunits are translated in the cytoplasm, targeted to mitochondria by cleavable amino-
terminal presequences, translocated across both mitochondrial membranes, and finally 
assembled with each other and their respective co-factors into a functional complex [10].  
The quaternary structure model of the SDH for different cells, e.g. S. cerevisiae and 
mammalian, was described in study conducted by Oyedotun and Lemire [10] and 
Yankovskaya et al. [12]. First subunit of SDH provides the binding site for the oxidation of 
succinate. The side chains Thr254, His354, and Arg399 stabilize the molecule while FAD 
oxidizes and carries the electrons to the first of the iron-sulfur [2Fe-2S] clusters. Whereas, 
ubiquinone binding site is located is in a gap composed of three SDH subunits. Ubiquinone 
is stabilized by the side chains of His207 of second subunit, Ser27 and Arg31 of third subunit 
C, and Tyr83 of fourth subunit. The quinine ring is surrounded by Ile28 of third subunit and 
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Pro160 of second subunit B. These residues, along with Il209, Trp163, and Trp164 of second 
subunit B, and Ser27 (C atom) of third subunit, form the hydrophobic environment of the 
quinine binding pocket. The succinate binding site and ubiquinone binding site are 
connected by a chain of redox centres including FAD and the iron-sulfur clusters. This chain 
extends over 40 Å through the enzyme monomer with an edge-to-edge distance between the 
centres is less that 14 Å limit for physiological electron transfer [8, 11].  
In the place for heme b, the N 2 atom of Sdh3p His106 and the S  atom of Sdh4p Cys78 are 
correctly oriented to form coordinating bonds with the central iron atom of the heme. The 
distance between the iron atom and the N 2 atom is 2.21 Å, but  the S  atom of Cys78, the 
putative second heme axial ligand, is 2.96 Å away from the heme Fe. UQ can be docked into 
two spatially separated sites with an edge-to-edge distance of 25.4 Å. The new amino acid 
residues that may determine the structural or catalytic properties of each of the two quinone 
binding sites were identified. The model also provided insight into the unusual use of a 
cysteine (Sdh4p Cys78) as the second heme ligand instead of the histidine residues [10].  
3. SDH function and regulation 
Succinate dehydrogenase is a key enzyme in intermediary metabolism and aerobic energy 
production in living cells. This enzymes catalyses the oxidation of succinate into fumarate in 
the Krebs cycle (1), derived electrons being fed to the respiratory chain complex III to reduce 
oxygen and form water (2). This builds up an electrochemical gradient across the 
mitochondrial inner membrane allowing for the synthesis of ATP. Alternatively, electrons 
can be diverted to reduce the ubiquinone pool (UQ pool) and provide reducing equivalents 
necessary to reduce superoxide anions originating either from an exogenous source or from 
the respiratory chain itself (3) [13] (Figure 4). 
 
Figure 4. The functions of the succinate dehydrogenase in the mitochondria [13]. 
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In the reaction of oxidation of succinate to fumarate, two hydrogen atoms are removed from 
substrate by flavin adenine dinucleotide (FAD), a prosthetic group that is tightly attached to 
succinate dehydrogenase (Figure 5).  
 
Figure 5. The succinate dehydrogenase reaction. 
Two electrons from the reduced SDH-FADH2 complex are then transferred to ubiquinone 
(Q), a soluble component of the electron transport system complex II. Ubiquinone is then 
reduced to ubiquinol ( QH2). 
Flavin adenine dinucleotide (FAD) is an essential cofactor for SDH enzyme. The generation 
of adenosine triphosphate (ATP) in mitochondria is coupled to the oxidation of 
nicotinamide adenine dinucleotide (NADH) and FADH2 and reduction of oxygen to water 
within the respiratory chain and a three-dimensional structure of the mitochondrial 
respiratory membrane protein complex II. FAD attachment is stimulated by, but not 
dependent upon, the presence of the iron-sulfur subunit and citric acid cycle intermediates 
such as succinate, malate, or fumarate [9]. The substrate analog malonate is a competitive 
inhibitor of the succinate dehydrogenase complex. Malonate, like succinate, is a 
dicarboxylate that binds to cationic amino acid residues in the active site of the succinate 
dehydrogenase complex. However, malonate cannot undergo oxidation because it lacks the 
-CH2 - CH2- group necessary for dehydration. To study the effects of a competitive 
inhibitior on the activity of succinate dehydrogenase, malonate will be added to a reaction 
mixture; malonate is sufficiently different from succinate that it cannot de dehydrogenated, 
i.e. malonate is not metabolized [8, 14]. 
SDH is a difficult enzyme to extract from respiratory membrane whilst still retaining its in 
vivo properties. Most of the extraction procedures used in early work were rather drastic 
and yielded soluble preparations of rather dubious integrity. However, the recent 
introduction of a more gentle method, involving disruption of the membrane with 
chemotropic agents, has yielded an active and nearly homogeneous enzyme of relatively 
low molecular weight (97,000). This enzyme can be separated by freezing and thawing into 
two inactive subunits. One of these, an iron sulphur flavoprotein of molecular weight 
70,000, contains one mole of FAD and four moles each of iron and labile sulphide per mole 
of protein; The other, an iron-sulphur protein of molecular weight 27,000, also contains four 
moles each of iron and labile sulphide.  It was determined that the large subunit of SDH is 
essential for catalytic activity, but the function of the small subunit, be it catalytic or 
regulatory [8].  
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Electronic paramagnetic resonance measurements of SDH components indicated that at 
least three separate centres are present. The S-3 centre (E'o = +60 mV) is a high potential Fe-S 
protein and is probably identical with the 4Fe-rS centre of low molecular weight subunit. 
Centres S-1 and S-2 (E'o = +15 mV and -260 mV respectively), are of the 2Fe-2S ferredoxin 
type and are probably associated with a larger, flavin containing subunit. Thus, electron 
transfer from succinate to ubiquinone probably occurs in the sequence: FAD, S-1, S-3. The 
redox potential of S-2 is rather too low to allow this centre to be catalytically active in the 
forward direction [8,15]. 
The catalytic activity of succinate dehydrogenase is modulated both by post translational 
phosphorylation/acetylation and active site inhibition. For example, phosphorylation of the 
Sdh1 subunit leads to attenuate activity of SDH. The activity of this enzyme may be also 
modulated by Krebs cycle intermediates including oxaloacetate or malonate which are 
strong inhibitors. Mechanisms of inhibition by these compounds differ significantly because 
oxaloacetate, a competitive inhibitor of succinate dehydrogenase, bounds with a sulfhydryl 
group of the enzyme to abolish the enzyme activity [16]. It is known that SDH is sensitive to 
different thiol-binding reagents. Inhibition of the enzyme by these kinds of reagents resulted 
from the modification of a sulfhydryl group located at the active site. This thiol, although 
not essential for substrate binding or catalysis, could influence the binding of 
dicarboxylates, probably by steric hindrance when a larger group or a charged group were 
attached to it. The inhibition of SDH by histidine specific reagents was also reported, and 
the participation of an imidazole ring in the initial step of succinate oxidation was 
suggested. The inactivation of SDH by phenylglyoxal and 2,3 –butanedione showed the 
presence of an arginine-residues  that interacts with dicarboxylate to form the primary 
enzyme-substrate complex [17].  
SDH is not only known to catalyse a unique reaction, which requires the participation of its 
four subunits, but deleterious mutations in any of the SDH genes should invariably result in 
a decreased SDH activity. Therefore, the striking phenotypic differences associated with 
mutations in the four subunits raise puzzling questions. SDH also plays a specific role in the 
maintenance of the mitochondrial UQ pool reduction. Ubiquinone, beside its function as an 
electron carrier mediating electron transfer, is admittedly working as a powerful antioxidant 
in biological membranes. Then, only a portion of the UQ pool may be actually involved in 
electron transfer depending on dehydrogenases involved. Accordingly, the measurable 
redox status of the UQ pool should result from the reducing activity of the different 
dehydrogenases, the oxidising activity of complex III and the kinetic equilibrium in the 
pool. The UQ pool therefore represents an electron sink and, when reduced, an antioxidant 
reservoir in the mitochondrial inner membrane. However, UQ is a double-faced compound, 
possibly working as either an antioxidant when fully reduced to ubiquinol, or a pro-oxidant 
when semi-reduced to the unstable ubisemiquinone form. Possibly together with reduced 
cytochrome b, semi-reduced quinones constitute the prominent source of superoxides. 
Finally, when defective, the abnormal amount of superoxides can be produced, e.g.  flavin 
radicals of complex I. Delivering electrons for the full reduction of UQ to UQH2 might then 
be of a tremendous importance for the control of oxygen toxicity in the mitochondria. 
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Therefore, the SDH, thanks to its unique redox properties, may be a key enzyme to control 
UQ pool redox poise under these conditions [13]. 
Also mutations in genes encoding SDH subunits lead to reduced activity of SDH enzyme. 
The yeast cells disrupted in SDH2 (sdh2Δ) showed dramatically accumulate succinate 
resulting in inhibition of at least two α-ketoglutarate dependent enzymes that generate 
succinate as a by-product. Disruption of complex II activity should alter TCA cycle 
metabolite levels in the mitochondrial matrix. It was found that neither sdh1Δ, nor sdh2Δ 
cells have measurable SDH activity. The succinate accumulates to 8-fold higher levels in 
sdh2Δ cells relative to wild-type cells. Furthermore, complex II + III activity was completely 
abolished in both SDH mutants without a corresponding compensation in NADH 
dehydrogenase activity. As a result, complex IV activity was decreased in the SDH mutants 
[18] (Figure 6). 
 
Figure 6. Relative concentration of main metabolities of TCA cycle for sdh1Δ, nor sdh2Δ yeast cells [18]. 
4. SDH activity assay 
The succinate is the most efficient energy source, so the SDH activity assay can be an 
important method for measurement of the yeast vitality in scope to control, e.g. different 
fermentation processes [19].  SDH activities can be measured in vitro in cell lysates or in 
mitochondrial fraction as well as in situ in individual cells. Since SDH is bound to the inner 
membrane, it is easily isolated along with the mitochondria by different techniques: sucrose 
density gradient ultracentrifugation, free-flow electrophoresis or a commercially available 
kit-based method [20]. The mitochondrial fraction is the source of the enzyme. Since none of 
the key components can be measured directly, the reaction succinate → fumarate is 
measured by monitoring the reduction of an artificial electron acceptor. To use an artificial 
electron acceptor, the normal path of electrons through the mitochondrial electron transport 
system must be blocked. This is accomplished by adding either sodium azide or potassium 
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cyanide to the reaction mixture. These poisons inhibit the transfer of electrons from 
cytochrome a3 to the final electron acceptor, oxygen, thus electrons cannot be passed along 
by the preceding cytochromes and coenzyme Q. Instead, the electrons from SDH-FADH2 
can be picked up by an artificial electron acceptor, such as the dye 
2,6dichlorophenolindophenol (DCIP). The reduction of DCIP can be followed 
spectrophotometrically since the oxidized form of the dye is blue and the reduced form is 
colorless. This reaction can be summarized as 
SDH-FADH2 + DCIPoxid.  →  SDH-FAD + DCIPred. + 2H+  
The change in absorbance, measured at 600 nm, can be used to follow the reaction over time 
[21]. To use an artificial electron acceptor, the normal path of electrons in the electron 
transport chain must be blocked. This is accomplished by adding either potassium cyanide 
or sodium azide to the reaction mixture. The rate of the disappearance of the blue color is 
proportional to the concentration of enzyme. The change in absorbance of the mixture is 
measured as a function of time and the enzyme concentration is determined from these data. 
Enzymatic reactions in yeasts are usually studied in cell-free extracts which requires 
disruption of cells and as consequence, inactivation of particular enzymes often can be 
observed. Generally we can conclud that determination of SDH enzyme activity has proved 
to be a difficult enzyme to extract from respiratory membrane whilst still retaining its in vivo 
properties. Most of the described extraction procedures were rather drastic and yielded 
soluble preparations of rather dubious integrity [8].  
In recent years quantitative histochemical procedures has been proved to be a powerful 
research tool, especially in microphotometric assessment in situ of the specific activity of 
dehydrogenases in individual cells. These assays are simple and valid alternative to 
conventional biochemical techniques. Methods in situ can provide the cellular resolution 
necessary to determine enzyme-specific activities not only in whole cell preparations but 
also in distinct subcellular compartments [19].  
Reduction of various tetrazolium salts by dehydrogenases of metabolically active cells leads 
to production of highly colored end products – formazans (Figure 7). The history of the 
tetrazolium salts and formazans goes back 100 years, to when Friese (1875) reacted benzene 
diazonium nitrate with nitromethane, to produce a cherry-red "Neue Verbindung". This was 
the first formazan. Nineteen years later, Von Pechmann and Runge (1894) oxidised a 
formazan to produce the first tetrazolium salt [21].  
 
Figure 7. Tetrazolium salt and its coloured formazan. 
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Many hundreds of tetrazolium salts and formazans were prepared in the following years, 
but only a handful have found applications in biological research.There is a wide range of 
tetrazolium salts commonly used in the field of microbiology from the classical ones to the 
new generation of its derivatives. Among them are: blue tetrazolium chloride (BT),  2,3,5-
triphenyl tetrazolium chloride (TTC), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), 5-cyano-2,3-ditolyl tetrazolium chloride (CTC), 2,3-bis(2-methoxy-4-nitro-5-
sulphophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT),  4-[3-(4-
idophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST1), 2-(p-
iodophenyl)-3(p-nitrophenyl)-5-phenyltetrazolium chloride (INT) or 2,2'-dibenzothiazolyl-
5,5'-[4-di(2-sulfoethyl)carbamoylphenyl]-3,3'-(3,3'-dimethoxy-4,4' biphenyl) ditetrazolium, 
disodium salt (WST-5) [19, 22, 23].  
In the case of enzymatic reaction conducted in situ the plasma membrane forms a barrier 
with low degree of penetration. Therefore, cell permeabilization, e.g. by digitonin, is 
recommended as an alternative method for the study of intracellular enzyme activities. 
According to the results obtained by Berlowska et al. [23] digitonin was effective in 
membrane permeabilization without negative influence on cell morphology. After digitonin 
treatment, the visible formazan crystals were observed inside the yeast cells, but not outside 
them (Figures 8-10 A, B).  
The formazan products are water-insoluble, but readily diffuses out of yeast cells after 
solubilization in DMSO. Good correlation (R2=0,97) between BTf absorbance intensity after 
DMSO extraction and number of yeast cells was seen. Linear correlation was observed in the 
concentration range of yeast cells from 9107 to5108 per sample. For yeast cell 
concentrations below 1107 per sample the formazan color intensity signals were too low to 
detect with good precision. The results obtained for SDH activity were in good agreement  
 
Figure 8. Yeast cells after reaction with blue tetrazolium chloride (BT). A – without permeabilization; B 
– with permeabilization by 0.05% digitonin. Images of light microscopy. 
(A) (B)
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Figure 9. Yeast cells after reaction with 2,3,5-triphenyl tetrazolium chloride (TTC). A – without 
permeabilization; B – with permeabilization by 0.05% digitonin. Images of fluorescence microscopy. 
 
Figure 10. Yeast cell after reaction with 2,3,5-triphenyl tetrazolium chloride (TTC). A – without 
permeabilization; B – with permeabilization by 0.05% digitonin. Images of scanning microscopy. 
with that of ATP content in yeast cells. Significant decreasing of succinate dehydrogenase 
activity and ATP content were observed during aging of tested yeast strains [19, 23]. 
5. The role of SDH in human disease 
Saccharomyces cerevisiae is a simple eukaryotic organism, with a complete genome sequence. 
Many genetic tools that have been created during these years, including the complete 
(A) (B)
(A) (B)
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collection of gene deletions and a considerable number of mechanisms and pathways 
existing in higher eukaryotes was first studied and described in yeast. Moreover, about 40% 
of human genes whose mutations lead to diseases have an orthologue in yeast and genomic 
screens have been extended to mitochondrial diseases. The study of mitochondrial functions 
and dysfunction is of special interest in yeast because it is in this organism that 
mitochondrial genetics and recombination have been discovered and that 
nucleomitochondrial interactions have been studied in-depth. There are also specific reasons 
for choosing S. cerevisiae for mitochondrial studies. This organism is petite-positive, which 
can successfully grow in the absence of oxygen. Therefore it can lose its mitochondrial 
genome provided it is supplied with a substrate for fermentation. Consequently, all 
mutations of the mitochondrial genome can be studied without cell lethality. The frequency 
of homologous recombination is very high (1% recombination is considered to correspond 
to about 100 bp in the mitochondrial genome). It is genetically easy to transfer mitochondria 
from one nuclear genetic background to another via karyogamy. Additionally, mitochondria 
can be transformed making in vitro mutation analysis possible. The richness and ease of 
yeast molecular genetics opens big opportunities, and even the major difference existing 
between human and yeast mitochondrial genomes, i.e. the predominant heteroplasmy of 
human and the homoplasmy of yeast, can result in the easier definition of the pathogenic 
mutations. To review mitochondrial diseases may be a very difficult task because the 
definition might include different kinds of metabolic disorders or degenerative syndromes 
[24]. Moreover, some important aspects have been extensively reviewed and the reader 
might refer to very good recent articles by DiMauro and Garone [25] for historical aspects, 
by Wallace et al. [26, 27] for bioenergetics, by Spinazzola and Zeviani [28] for nucleo–
mitochondrial intergenomic cross-talk. The previous review by Schwimmer et al. [29] was 
given an important outline of yeast models of mitochondrial diseases. SDH in yeast and 
human are very similar. They are composed of four subunits (SDHA-D, like SDH1-4 in 
yeast), all encoded by nuclear genes.  
In the last ten years, deficiencies in TCA cycle enzymes have been shown to cause a wide 
spectrum of human diseases. For instance, mutation in the gene encoding fumarase is a rare 
cause of encephalomyopathy and a far more common cause of leiomyomas of the skin and 
uterus and of renal cancer (Table 1). 
The TCA path dysfunction may also result from concurrent impairments in several steps of 
the cycle. The combined deficiencies in SDH and aconitase was observed in Friedreich’s 
ataxia [22, 39]. Measures in autopsied brains from Alzheimer’s Disease (AD) patients reveal 
a decrease in the activity of α-ketoglutarate dehydrogenase complex (KGDHC) and an 
increase in malate dehydrogenase (MDH) activity [33]. The ratios between TCA enzymes are 
consistent for each mammalian tissues presumably reflecting their metabolic demand. 
Consequently, in addition to the determination of residual absolute activities, estimation of 
ratios between enzyme activities is an effective means of detecting partial but potentially 
harmful deficiencies. When used to assess respiratory chain activities, this approach enabled 
the identification of several gene mutations, even in patients with partial respiratory chain 
deficiencies. At present, TCA enzyme activities are measured using a series of independent  
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Enzyme Clinical presentation References 
Fumarase 
Progressive encephalopathy 
Hereditary leiomyomatosis and renal cell 
cancer 
[30] 
[31] 
Malate dehydrogenase Alzheimer’s disease  [32, 33] 
Citrate synthase No disease identified so far  
Aconitase No disease identified so far  
Isocitrate dehydrogenase Low-grade gliomas [34] 
-Ketoglutarate 
dehydrogenase 
Congenital lactic acidosis [35] 
Succinyl-CoA ligase 
Encephalomyopathy with mtDNA 
depletion 
[36] 
Succinate 
dehydrogenase 
Encephalopathy (Leigh syndrome) 
Pheochromocytoma and paraganglioma 
[37] 
[38] 
Table 1. Primary deficiencies in TCA cycle enzymes in humans [22]. 
assays that are both laborious and time-consuming. The limited set of assays allowing both 
measurement of all TCA enzyme activities and detection of abnormalities in enzyme activity 
ratios were developed. These assays were used successfully to detect severe and partial 
isolated deficiencies in several TCA enzymes. The first assay measures succinyl-CoA ligase, 
SDH, glutamate dehydrogenase (GDH), fumarase, and malate dehydrogenase. This assay 
was performed in medium containing 50 mM KH2PO4 (pH 7.2) and 1 mg/ml BSA. The 
reduction of DCPIP was measured using two wavelengths (600 nm and 750 nm) with 
various substrates and the electron acceptors decylubiquinone and phenazine methosulfate. 
The second assay measured -ketoglutarate dehydrogenase, aconitase, and isocitrate 
dehydrogenase activities. The pyridine nucleotide (NAD+/NADP+) reduction is measured 
with various substrates using wavelengths of 340 nm and 380 nm. In the third assay, citrate 
synthase was measured by monitoring dithionitrobenzene (DTNB; Ellman’s reagent) 
reduction at wavelengths of 412 nm and 600 nm [22].  
The deleterious mutations in any of the SDH genes should invariably result in a decreased 
SDH activity [13]. Hence, SDH 'inactivation' induces abnormal stimulation of the hypoxia-
angiogenesis pathway. Therefore, the striking phenotypic differences associated with 
mutations in the four subunits raise puzzling questions. It has been reported that inherited 
deficiencies of SDH associated with presence of mutant protein Fp are always associated 
with relatively high residual activities, ranging from 25-50% of control mean values. As a 
comparison, less than 5% residual activity is frequently measured in patients with severe 
defect of complex IV or complex I. The mutations in any of the SDH cause the complex II to 
fully disassemble. When complex II is absent, it can be disregarded as a source of additional 
superoxide production. Thus, the superoxide overproduction would lead to tumour 
formation that should be ascribed to the decreased ability of the SDH to adequately reduce 
the Q pool, a necessary condition to resist oxidative stress [8].  
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Ubiquinone, beside its function in the respiratory chain as an electron carrier mediating 
electron transfer between the various dehydrogenases and the cytochrome path, is working 
as a powerful antioxidant in biological membranes [13]. It is possibly for this exact reason in 
much larger amounts compared to other electron carriers of the respiratory chain, including 
the sum of the dehydrogenases. When it is defective, the respiratory chain can produce an 
abnormal amount of superoxides involving additional respiratory chain components such 
as flavin radicals of complex I. Delivering electrons for the full reduction of Q to QH2 might 
then be of a tremendous importance for the control of oxygen toxicity in the mitochondria. 
Therefore, the SDH is a key enzyme to control Q pool redox poise under these conditions, 
due to its unique redox properties [8]. 
Iron-sulfur (Fe-S) proteins facilitate multiple functions, including redox activity, enzymatic 
function, and maintenance of structural integrity. More than 20 proteins are involved in the 
biosynthesis of iron-sulfur clusters in eukaryotes. Defective Fe-S cluster synthesis not only 
affects activities of many iron-sulfur enzymes, such as aconitase and succinate 
dehydrogenase, but also alters the regulation of cellular iron homeostasis, causing both 
mitochondrial iron overload and cytosolic iron deficiency. Fe-S cluster biogenesis takes 
place essentially in every tissue of humans, and products of human disease genes have 
important roles in the process [40]. 
Succinate is an oxygen sensor in the cell and can help turn on specific pathways that 
stimulate cells to grow in a low-oxygen environment (hypoxia). In particular, succinate 
stabilizes a protein called hypoxia-inducible factor (HIF) by preventing a reaction that 
would allow HIF to be broken down. HIF controls several important genes involved in cell 
division and the formation of new blood vessels in a hypoxic environment. Mutations in 
genes encoding SDH subunits have been linked to severe encephalopathy and, more 
recently, to familial paraganglioma (PGL) and pheochromocytoma (PHEO) (PHEO: adrenal 
gland PGL). Isolated complex II deficiency is a very rare condition, occurring in 
approximately 2–4% of all respiratory chain enzyme deficiencies. At least three mutations in 
the SDH genes have been identified in people with PGL or PHEO, which are noncancerous 
(benign) tumors associated with the nervous system. SDHB-D gene mutations are seen most 
commonly in people with PGL, but they were found in people with PHEO. However, a 
single mutation in the SDHA gene increases the risk that an individual will develop the 
condition, and additional mutation that deletes the normal copy of the gene is needed to 
cause tumor formation. This second mutation, called a somatic mutation, is acquired during 
a person's lifetime and is present only in tumor cells. The SDH genes mutations associated 
with nonsyndromic PGL or PHEO change single protein building blocks (amino acids) in 
the SDH protein sequence or result in a shortened protein. As a result, there is little or no 
SDH enzyme activity. Because the mutated SDH enzyme cannot convert succinate to 
fumarate, succinate accumulates in the cell. The excess succinate abnormally stabilizes HIF, 
which also builds up in cells. Excess HIF stimulates cells to divide and triggers the 
production of blood vessels when they are not needed. Rapid and uncontrolled cell division, 
along with the formation of new blood vessels, can lead to the development of tumors. 
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Mutations in the SDHA gene were identified in a small number of people with Leigh 
syndrome, a progressive brain disorder that typically appears in infancy or early childhood. 
Affected children may experience vomiting, seizures, delayed development, muscle 
weakness, and problems with movement. Heart disease, kidney problems, and difficulty 
breathing can also occur in people with this disorder. The one child died suddenly at the age 
of five months from a severe deterioration of neuromuscular, cardiac, and hepatic 
symptoms after an intermittent infection. The SDHA gene mutations responsible for Leigh 
syndrome change single amino acids in the SDHA protein or result in an abnormally short 
protein. These genetic changes disrupt the activity of the SDH enzyme, impairing the ability 
of mitochondria to produce energy. Further studies showed that several patients with 
complex II deficiency do not have mutations of SDHA. This suggested a role of additional 
nuclear genes involved in synthesis, assembly, or maintenance of SDH.  It is not known, 
however, how mutations in the SDHA gene are related to the specific features of Leigh 
syndrome [41, 42]. 
Two plausible hypotheses have been proposed to explain the peculiar linkage between 
disruption of electron flow through mitochondrial complex II and tumorigenesis in 
neuroendocrine cells. In the reactive oxygen species (ROS) hypothesis, it is proposed that an 
intact, catalytically active SDHA subunit generates genotoxic ROS by uncoupled electron 
flow from succinate to oxygen or water in cells where one of the electron-carrying subunits 
(SDHB, SDHC or SDHD) is missing or inactive. The ROS model implies that genotoxic ROS 
mutagenize nuclear proto-oncogenes or tumor suppressors (Figure 11). This model predicts 
that ROS should be increased in cells lacking SDHB, SDHC or SDHD, but not when SDHA 
is missing. Although certain mutations in these genes result in ROS production in 
Saccharomyces cerevisiae and mammalian cell lines, it is not clear that ROS accumulate to 
levels that are mutagenic. 
 
Figure 11. ROS model [18]. 
In the succinate accumulation hypothesis, the loss of SDHB results in loss of SDH activity 
and causes succinate accumulation (Figure 12). 
 
Dehydrogenases 226 
 
Figure 12. Succinate accumulation model [18]. 
Excess succinate is shuttled from the mitochondrial matrix to the cytoplasm, where it 
inhibits any of several aKG-dependent enzymes (E) that regulate levels or activities of 
important regulatory proteins (black box). The loss or inactivation of SDHB, C or D proteins 
yields a catalytically inactive SDHA subunit, resulting in blockade of the TCA cycle and 
diffusion of accumulated succinate to the cytoplasm. Succinate can then act as an inhibitor 
of a-ketoglutarate-dependent enzymes that use ferrous iron and molecular oxygen as 
cofactors to hydroxylate their substrates and generate succinate as a product. It has been 
demonstrated that two a-ketoglutarate -dependent enzymes, the prolyl hydroxylases, are 
inhibited by succinate accumulation in cells that have lost SDHD function. Smith et al [18] 
reported that yeast cells disrupted in SDH2 (sdh2Δ) show increased in ROS production and 
protein oxidation without detectable increase in DNA damage. More strikingly, sdh2Δ cells 
dramatically accumulate succinate resulting in inhibition of at least two aKG-dependent 
enzymes that generate succinate as a by-product [18]. 
6. Metabolic engineering of yeast SDH for the biotechnological processes 
Metabolic engineering, i.e., the intentional redirection of metabolic fluxes, plays an 
exceptional role in improving yeast strains for all industrial applications. In contrast to 
classical methods of genetic strain improvement such as selection, mutagenesis, mating, and 
hybridization, metabolic engineering confers two major advantages: (1) the directed 
modification of strains without the accumulation of unfavorable mutations and (2) the 
introduction of genes from foreign organisms to equip S. cerevisiae with novel traits. The 
latter is particularly crucial for industrial biotechnology to provide pathways that extend the 
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spectrum of usable industrial media (e.g., lignocellulosic biomass) and/or to produce 
compounds not naturally formed by S. cerevisiae. Since the first introduction of metabolic 
engineering, there have been tremendous enhancements of its toolbox, and several related 
disciplines have emerged, such as inverse metabolic engineering and evolutionary 
engineering. These developments have strongly influenced yeast strain improvement 
programs in the past few years and have greatly enhanced the potential for using yeast in 
biotechnological production processes [43].  
The main goals of metabolic engineering can be summarized in the following four 
categories: (1) improvement of yield, productivity and overall cellular physiology, (2) 
extension of the substrate range, (3) deletion or reduction of by-product formation and (4) 
introduction of pathways leading to new products. Commonly these goals can be achieved 
by a three-step procedure. Firstly, a genetic modification is proposed, based on metabolic 
models. After genetic modification, the recombinant strain is analysed and the results are 
then used to identify the next target for genetic manipulation, if necessary. Thus, the 
construction of an optimal strain involves a close interaction between synthesis and analysis, 
usually for several consecutive rounds. The rapid development and frequent success in this 
field is demonstrated by the large number of reviews about the theoretical and practical 
aspects of metabolic engineering. Knowledge of cellular and microbial physiology, as well 
as the underlying metabolic networks or enzymes, is an important prerequisite for 
successful engineering. A new term, ‘inverse metabolic engineering’ (IME) coins to 
encompass the construction of strains with a particularly desirable physiological phenotype, 
e.g. enhanced production of heterologous protein [44].  
Recently, a computational approach for the identification of every possible biochemical 
reaction from a given set of enzyme reaction rules was reported. This analysis suggested 
that the native pathways are thermodynamically more favorable than the alternative 
possible pathways. The pathways generated involve compounds that exist in biological 
databases, as well as compounds that exist in chemical databases and novel compounds, 
suggesting novel biochemical routes for these compounds and the existence of biochemical 
compounds that remain to be discovered or synthesized through enzyme and pathway 
engineering [45]. 
Due to its importance in traditional biotechnology such as baking, brewing, and wine 
making, research activities historically have focused on the yeast Saccharomyces cerevisiae. It 
is relatively tolerant to low pH values and high sugar and ethanol concentrations, i.e., 
properties which lower the risk of contamination in industrial fermentation. These features 
are the major reasons for increasing S. cerevisiae exploration in industrial (“white”) 
biotechnology, focusing on the fermentative production of industrially relevant 
biochemicals, e.g., glycerol, propanediol, sugar alcohols, organic acids, etc. Among these 
compounds, several organic acids may fulfill a role as platform molecules using their 
(multiple) functional groups as a target for enzymic or chemical catalysis [43].  
In the United States were identified 10 organic acids as key chemical building blocks [44]. 
Similarly, the European focus group BREW identified 21 key compounds that can be 
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produced from different, including renewable sources, a number of which were organic 
acids [45]. One example of such a chemical is succinic acid. Succinic acid is used as a 
surfactant, detergent or foaming agent, as an ion chelator, and also in the food industry as 
an acidulant, flavoring agent or anti-microbial agent, as well as in health-related products 
(such pharmaceuticals and antibiotics). Currently, it is produced from petrol and is too 
expensive to be used as a general building-block chemical. However, provided that its price 
becomes competitive, succinic acid could replace petrol-derived maleic anhydride in 
chemical synthesis processes in the future [46-47]. Similar chemical derivatizations can be 
applied to malic and fumaric acid, so that they can also be considered interesting C4 
building blocks [48-53]. 
The chemical behavior of the dicarboxylic acid – succinic acid is determined principally by 
its two carboxyl groups. This substance is either directly utilized in the pharmaceutical or 
chemical industry or represent building block or precursor for further chemical or 
enzymatic syntheses. The following reactions and derivatives are considered interesting: (1) 
reductions of succinic acid to 1,4-butanediol, -butyrolactone, tetrahydrofuran and its 
derivatives; (2) reductive amination of succinic acid or -butyrolactone to pyrrolidiones; (3) 
polymerization of succinic acid with diols (building block of polyesters); (4) polymerisation 
of succinic acid with diamines to form polyamides, etc. The examples of the substances that 
can be derived from succinic acid are shown in table 2.  
Butanediol, tetrahydrofuran and -butyrolactone, are standard substances for the chemical 
industry. These are used as solvents, as well as for fiber and polymer production. 
Dimethylsuccinate is one of the so-called dibasic esters that have great potential as solvents 
with environmentally benign characteristics. Thus, the potential market volume for succinic 
acid is high, fuelling substantial efforts to establish a microbial process for succinic acid 
production [47]. 
The chemical synthesis of succinic acid is predominantly based on maleic anhydride and 
requires heavy metal catalysts, organic solvents, high temperatures and high pressures. It 
makes the conversion of maleic anhydride to succinic acid costly and ecologically 
questionable [49]. On the other hand, succinate is produced naturally by many 
microorganisms as an intermediate of the central metabolism or as a fermentation end 
product.  
The succinate producers include bacterial strains, e.g. Mannheimia succiniproducens [54]. 
However, none of these microorganisms are currently used in industry. Some prokaryotes  
 
No Name Chemical structure Examples of uses 
1 1,4 -Diaminobutane  
Used for polyamide 
production 
2 Succindiamide 
 
Used as anticonvulsant 
drugs and to form covalent 
bonds between proteins or 
peptides and plastics 
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No Name Chemical structure Examples of uses 
3 1,4 – Butanediol (BDO)  
Replacement of fossil-
derived BDO by bio-based 
BDO in polybutylene 
tereftalate (PBT) 
Replacement of fossil-
derived BDO by bio-based 
BDO in polybutylene 
succinate (PBS) 
4 Succinonitrile  
Precurser for industrial 
production of polyamides 
5 Dimethylsuccinate 
Used as fuel oxygenates and 
as green solvents 
6 
N-methyl-pyrolidone 
(NMP) 
 
Replacement of fossil-
derived NMP by bio-based 
NMP; NMP is an important, 
versatile solvent for  the 
chemical industry 
8 2-Pyrolidone As above 
7 -Butyrolactone (GBL) 
 
Replacement of fossil-
derived BGL by bio-based 
BGL ; BGL is important as 
an intermediate in the 
manufacture of pyrrolidone 
derivatives and as a solvent 
for polymers and 
agrochemicals 
9 Tetrahydrofuran (THF) 
 
Replacement of fossil-
derived THF by bio-based 
THF ; THF is mainly used as 
a solvent and as an 
intermediate in the 
production of thermoplastic 
polyurethanes, elastic fibers 
etc. 
Table 2. Examples of various substances that can be derived from succinic acid by chemical conversion 
[47]. 
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have complex medium requirements and they are generally unable to grow and produce 
organic acids at the low pH values.  These restrictions provide strong incentives to integrate 
and optimize succinate production pathways in other microorganisms via metabolic 
engineering approaches. 
The popularity of S. cerevisiae in basic and applied research is undoubtedly influenced by its 
classification as GRAS (generally regarded as safe) by the U.S. Food and Drug 
Administration (FDA). Baker’s yeast S. cerevisiae was the first eukaryotic organism in which 
complete genomic sequence was determined. Several databases such as the Saccharomyces 
Genome Database (http://www.yeastgenome.org/) and the Comprehensive Yeast Genome 
Database (http://mips.gsf.de/genre/proj/yeast/) contain an enormous amount of information 
concerning S. cerevisiae genes, open reading frames, and gene products. The yeast S. 
cerevisiae became a well established eukaryotic model organism to study fundamental 
biological processes such as aging, mRNA transport, the cell cycle, and many more. 
Saccharomyces cerevisiae grows well in a simple chemically defined medium, under acidic 
conditions, even at pH values equal 3. At such low pH values, many weak acids, including 
succinate, occur predominantly in their undissociated form. This is advantageous for 
industrial production, as it reduces the need for titration with alkali and allows for direct 
recovery of undissociated acids. Consequently, there is no need for large quantities of 
acidifying agents, and the formation of salt byproducts (e.g. gypsum) is strongly reduced.  
In addition, S. cerevisiae robust tolerance in acidic conditions represents a major advantage 
in that it lowers the risk of contamination in industrial fermentation [44, 49].  
The yeast-based fermentation process, which operates at a much lower pH than competing 
processes, allows succinic acid to be produced with a significantly higher energy efficiency 
compared to the traditional method. This compound is not accumulated intracellularly. It is 
also one of the first bio-based processes that sequesters carbon dioxide in the production 
process [47, 53]. This makes the yeast Saccharomyces cerevisiae a suitable and promising 
candidate for the biotechnological production of succinic acid on an industrial scale. 
The metabolic engineering strategy was used for the oxidative production of succinic acid 
by deletion SDH1, SDH2 genes in the genome. Arikawa et al. [55] reported an increased 
succinic acid productivity in sake yeast strains with deletions of TCA cycle genes. In 
comparison to the wild-type, succinate levels were increased up to2.7 fold in a strain with 
simultaneous disruption of a subunit of succinate dehydrogenase (SDH1) and fumarase 
(FUM1) under aerobic conditions. The single deletion of gene SDH1 led to a1.6-fold increase 
of succinic acid production. In another study on sake yeast strains, the deletion of genes 
encoding for succinate dehydrogenase subunits (SDH1, SDH2, SDH3, and SDH4) also 
resulted inincreased succinate productivity in aerobic conditions. Raab et al. [48] reported 
the construction of yeast strains for the biotechnological production of succinic acid. The 
genes SDH1, SDH2, IDH1 and IDP1, which encode mitochondrial enzymes were deleted 
with the aim to disrupt succinate and isocitrate dehydrogenase activity to redirect the 
carbon flux and to allow succinate to accumulate as an end-product. This study showed that 
the yeast S. cerevisiae is capable of synthesizing significant amounts of succinic acid, which is 
exported quantitatively into the culture broth and not being accumulated intracellularly. 
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The constructed yeast strains with disruptions in the TCA cycle produced succinic acid up 
to 3.62 g/L at a yield of 0.11 mol /mol glucose in shake flask cultures.  
Saccharomyces cerevisiae is one of the most highly researched model organisms in different 
biological studies. Using this yeast we can effectively re-examine long-standing and 
fundamental questions regarding regulation of metabolism and prediction of dynamic 
models in various cells, including mammalian tissues. This is a considerable knowledge 
about the composition, enzymology and membrane binding of the enzyme and relatively 
new discoveries about its genetics and biosynthesis. Through such efforts, we are able to 
identify key features of cellular metabolic pathways which can be use both in medicine and 
in different biotechnological processes. 
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1. Introduction 
The main purpose of the chapter is clarify description of the role of intracellular enzyme-
dehydrogenase in the soil environment, as well as presentation of soil factors, influencing 
an enzymatic activity, by either stimulation or inhibition effect on soil dehydrogenase 
activity (DHA).  
The most common laboratory procedure used for DHA determination is the method 
developed by Casida et al. (1964). According this method, specific dyes such as the 
triphenyltetrazolium chloride (TTC), that can specify the flow of electrons are useful 
indicators of electron transport system (ETS) activity. By the reduction of colorless, water 
soluble substrate (TTC) by dehydrogenases present in the soil environment, an insoluble 
product with red color (triphenylformazan-TPF) is formed. TPF can be easily quantified 
calorimetrically at the range of visible light (485 nm). This test however, reflected positive 
answer only at neutral range of pH and in presence of calcium carbonate for buffering soil 
system. Briefly, if the red colors of soil samples prepared for spectrophotometer analyses are 
more intensive, the measured level of DHA is higher. Consequently, soil samples without 
red colors or those with light red colors are characterized by lower DHA values. 
Determination of DHA in the soil samples gives us large amount of information about 
biological characteristic of the soil. It was confirmed that although oxygen and other 
electron acceptors can be utilized by dehydrogenases, most of the enzyme is produced by 
anaerobic microorganisms. In other words, soil DHA strongly increases under anaerobic 
conditions.  
Several environmental factors, including soil moisture, oxygen availability, oxidation-
reduction potential, pH, organic matter content, depth of the soil profile, temperature, 
season of the year, heavy metal contamination and soil fertilization or pesticide use can 
affect significantly DHA in the soil environment. In the current chapter we would like to 
concentrate on precise description of mentioned factors effect on soil DHA level. Presented 
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results of laboratory experiments were conducted on different soil types, representing 
dominant types of arable soils in Poland, in order to demonstrate changeability and 
variability of DHA at diverse soil environment. 
2. Role of dehydrogenase activity in the soil environment 
There are lots of enzymes in soil the environment, such as Oxidoreductases, Hydrolases, 
Isomerases, Lyases and Ligases. Each of them play key biochemical functions in the overall 
process of material and energy conversion (Gu et al., 2009). 
Soil dehydrogenases (EC 1.1.1.) are the major representatives of the Oxidoreductase 
enzymes class (Gu et al., 2009). Among all enzymes in the soil environment, dehydrogenases 
are one of the most important, and are used as an indicator of overall soil microbial activity 
(Quilchano & Marañon, 2002; Gu et al., 2009; Salazar et al., 2011), because they occur 
intracellular in all living microbial cells (Moeskops et al., 2010; Zhao et al., 2010; Yuan & 
Yue, 2012). Moreover, they are tightly linked with microbial oxidoreduction processes 
(Moeskops et al., 2010). What is important dehydrogenases do not accumulate extracellular 
in the soil.  
Dehydrogenases play a significant role in the biological oxidation of soil organic matter 
(OM) by transferring hydrogen from organic substrates to inorganic acceptors (Zhang et al., 
2010). Many specific dehydrogenases transfer hydrogen to either nicotinamide adenine 
dinucleotide or nicotinamide adenine dinucleotide phosphate (Subhani et al., 2001). 
Throughout mentioned co-enzymes hydrogen atoms are involved in the reductive processes 
of biosynthesis. Due to this fact, the overall DHA of a soil depends on the activities of 
various dehydrogenases, which are fundamental part of the enzyme system of all living 
microorganisms, like enzymes of the respiratory metabolism, the citrate cycle, and N 
metabolism (Subhani et al., 2011). Thus, DHA serves as an indicator of the microbiological 
redox-systems and could be considered a good and adequate measure of microbial oxidative 
activities in soil.  
Brzezińska et al. (2001) found that active dehydrogenases can utilize both O2 and other 
compounds as terminal electron acceptors, although anaerobic microorganisms produce 
most dehydrogenases. Therefore, DHA reflects metabolic ability of the soil and its activity is 
considered to be proportional to the biomass of the microorganisms in soil. However, the 
relationships between an individual biochemical property of soil DHA and the total 
microbial activity is not always obvious, especially in the case of complex systems like soils, 
where the microorganisms and processes involved in the degradation of the organic 
compounds are highly diverse (Salazar et al., 2011). 
3. Soil factors stimulating dehydrogenase activity 
Among different environmental factors with special emphasis on enzymatic activities in the 
soil environment it is possible to screen some, which have positive impact on DHA. The 
most important soil factors stimulating soil DHA are described below.  
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3.1. Soil moisture 
Life in the soil environment, as well as land use is related to alternate cycles of 
humidification and drainage (Wolińska & Bennicelli, 2010). Water availability strongly 
affects on soil microbial activity, community composition (Geisseler et al., 2011), and 
consequently on soil enzymatic activities. As soils dry, the water potential increases, and as 
well microbial activity as intracellular enzyme activity slows down (Geisseler et al., 2011). In 
the case of wet soils, increased moisture could bring into soil solution soluble OM, what 
might be responsible for increase of bacterial population number (Subhani et al., 2001). 
What is important, we should have consciousness that any compound, which alters the 
number or activity of microorganisms, could on the other hand affect on soil biochemical 
properties, and ultimately also on soil fertility and plant growth (Subhani et al., 2001).  
A basic hydrophysical characteristic of soil is water retention, that can be described as a 
dependence between soil water content and soil water potential.  Soil water content in the 
function of the soil water tension is described by pF curve, which provides information about 
the ability for water retaining by the soil pores at any given water tension, or conversely, how 
tightly a water is held between soil aggregates (Wolińska & Bennicelli, 2010).  
The Figure 1 demonstrates diminishing trend for DHA behaviour at different soil moisture, 
described as water potential values. During this experiment gig set of soils (n=315), 
including all representatives among the most typical Polish mineral soils (Eutric Cambisol, 
Eutric Histosol, Eutric Fluvisol, Mollic Gleysol, Orthic Podzol, Rendzina Leptosol, Haplic 
Phaeozem) were investigated. However, each of soil unites displayed DHA reducing trend 
with increase of soil pF value, what means that maximum values of DHA in the soil profiles 
are indirectly connected with maximum soil moisture (pF 0). 
 
Figure 1. DHA (µgTPFg-1min-1) dependence from water potential (pF) at different mineral Polish soil 
types, during reoxidation (n=315), according to Wolińska (2010) 
Statistical relationships between DHA and soil water content, described as pF value in the 
range of pF0 – pF3.2, determined by Wolińska & Bennicelli (2010) are presented in Table 1. 
Founded significant negative relationships between DHA and pF are confirmed by our 
above mentioned observations, that DHA is strongly affected by soil moisture. These strong 
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correlations are undoubtedly connected with the fact that the metabolism and the survival 
of soil microorganisms are also strongly impacted by the availability of water (Uhlirova et 
al., 2005), what is essential for microbial survival and activity. Consequently, low water 
availability can inhibit microbial activity by lowering intracellular water potential, and thus 
by reducing of hydration and enzymes activity (Wall & Heiskanen, 2003). Periods of 
moisture limitation may affect microbial communities through starvation. Thus, the most 
common environmental stress for soil microorganisms is perhaps drought (Wolińska & 
Stępniewska, 2011). 
It was shown in many studies that DHA is significantly influenced by water content and 
dropped with the decrease of soil humidity. For example, Gu et al. (2009) observed higher 
DHA level (even by 90%) in flooded soil, rather than in non-flooded conditions. The higher 
DHA values in flooded conditions agreed also with results presented by Zhao et al. (2010) 
and Weaver et al (2012).  
 
DHA
response 
Depth
(cm) pF 
Rendzina Leptosols 
0-20 
50-60 
-0.98*** 
-0.95** 
Eutric Fluvisol 
0-20 
50-60 
-0.97*** 
-0.22 n.s. 
*, **, *** - indicate significance at the 5, 1 and 0.1% level, respectively, n.s. – not significant differences 
Table 1. Statistical significance of differences between DHA and pF described by correlation coefficient 
(R) (95% LSD method, n=15), according to Wolińska & Bennicelli, 2010 
The decline of DHA with an increase of pF value, could be also explained by the fact, that 
flooding of soil with water significantly increased the electron transport system (Wolińska & 
Stępniewska, 2011). Dehydrogenases however, are responsible for electron transport in the 
soil environment. It was also reported that DHA is higher in flooded, anaerobically soils, 
than aerobically incubated soils (Trevors, 1984; Subhani et al., 2001). 
3.2. Soil aeration state (redox potential and oxygen diffusion rate) 
Oxygen diffusion rate (ODR) is usually considered to be the most critical proximal regulator of 
microbial activities (Hutchinson, 1995). Moreover, it is often assumed that a decrease of soil 
water content (higher value of pF), cause a significant (P<0.001) increase of ODR and redox 
potential (Stępniewski et al., 2000; Wolińska & Bennicelli, 2010). The available literature shows 
that low ODR level, ranged below its critical values (35 µg O2 m-2s-1), is favorable and optimal 
for DHA (Stępniewski et al., 2000; Brzezińska et al., 2001; Wolińska & Bennicelli, 2010).  
We confirmed that dehydrogenases are sensitive enzymes, indirectly depended on the soil 
aeration status (Wolińska & Bennicelli, 2010). Based on performed measurements we found, 
that pF constitutes a significant factor, determining ODR in the soil environment, as well as 
its DHA level (P<0.01). The reoxidation processes, occurring in the direction from pF 0 to pF 
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3.2, were the reason of DHA inhibition and stimulation of ODR level in the Rendzina 
Leptosols and Eutric Fluvisol soil samples (Fig. 2). We also stated that soil DHA at pF 3.2 was 
lower by about 60.86%, in comparison to the activity estimated at pF 0. 
 
Figure 2. The response of soil DHA to varied aeration factors (pF and ODR), at surface layers of 
Rendzina Leptosols and Eutric Fluvisol , during reoxidation process (according to Wolińska & Bennicelli, 
2010). Averaged values of three replicates with standard deviations are presented 
The Figure 3. demonstrates that low oxygen diffusion rate (2.8-25 µg O2 m-2 s-1) was optimal 
for DHA, what was also confirmed by correlation coefficient (Wolińska & Bennicelli, 2010; 
Wolińska, 2010). Our results and founding’s are compatible with work of Stępniewski et al. 
(2000), Brzezińska et al. (2001), and Yang et al. (2005). 
Statistical relationships between DHA and ODR, determined for two soil types (Rendzina 
Leptosols and Eutric Fluvisol) by Wolińska & Bennicelli (2010) are presented in Table 2. At 
every case negative correlations DHA-ODR were determined. 
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DHA
response 
Depth
(cm) ODR 
Rendzina Leptosols 
0-20 
50-60 
-0.90** 
-0.84* 
Eutric Fluvisol 
0-20 
50-60 
-0.96** 
-0.16 n.s. 
*, **, *** - indicate significance at the 5, 1 and 0.1% level, respectively, n.s. – not significant differences 
Table 2. Statistical significance of differences between DHA and ODR described by correlation 
coefficient (R) (95% LSD method, n=15) 
Redox potential (Eh) is the next, important, environmental factor, which expresses the 
tendency of an environment to receive or to supply electrons in solution (Stępniewski et al., 
2005). The well-oxygenated soils are characterized by high values of Eh (600-800 mV), in 
quite well-oxygenated soils Eh ~ 500-600 mV, whereas in anaerobic conditions drop of Eh 
below 300 mV or even lower values were observed (Pett-Ridge & Firestone, 2005; 
Stępniewski et al., 2000).  
It is well known, that Eh play a crucial role in regulating microbial activity as well as 
community structure (Pett-Ridge & Firestone, 2005; Song et al., 2008), and affecting on soil 
enzymatic activity, especially DHA. Brzezińska et al. (1998) indicated that among all 
aeration parameters, Eh plays the most important role in determining soil DHA level. 
Similar conclusions were also reported by Włodarczyk et al. (2001) and Menon et al. (2005).  
We founded significant negative relationships between DHA and Eh (Fig. 4) at surface 
layers of Mollic Gleysols, Eutric Fluvisols, Rendzina Leptosols and Haplic Phaeozems, where 
determined correlation coefficients equaled as follows: r=-0.91*, r=-0.43*, r=-0.47** and r=-
0.48** (Wolińska, 2010).  
 
Figure 4. Relationship between soil DHA level and Eh at Mollic Gleysol (n=9, r=-0.91*), according to 
Wolińska (2010) 
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Negative correlations DHA-Eh were also described by Brzezińska et al. (1998), who 
determined r=-0.75***, r=-0.83*** and r=-0.87*** for temperature 10, 20 and 30ºC, respectively, 
and by Stępniewski et al. (2000), and Nyak et al. (2007). 
Mentioned relationships DHA-Eh have significant negative character, what means that 
increase of soil DHA level is indirectly connected with decrease of Eh values, as most of 
microorganisms, which are responsible for DHA prefer rather anaerobic conditions, and 
belong to obligate anaerobes. What is more, anaerobic conditions are consequence of 
flooding and decrease of oxygen availability in soil environment. Competition for oxygen 
limits aerobic processes and the subsequent oxygen deficiency creates local anaerobic 
microsites, which stimulates growth of anaerobic bacteria (Wolińska & Stępniewska, 2011), 
and finally DHA. Also, in the absence of oxygen in the soil a decline of Eh and the reduction 
of oxidized forms (nitrate, Mn4+, Fe2+ and SO42-) takes place. Bohrerova et al. (2004) reported 
that the most common ions forming the redox couples of soil include NO3-/NO2-, Fe3+/Fe2+, 
and Mn4+/Mn2+. In the literature data, it was also assumed that DHA is strongly affected by 
both Fe as Mn presence in the soil (Brzezińska et al., 1998; Włodarczyk et al., 2002). 
3.3. Organic matter content 
Soil organic matter (OM) has important effects not only on soil enzymes activities but first of 
all on microorganisms activities. Soil OM has been considered as an indicator of soil quality 
(similarly like dehydrogenases,) because of its character of nutrient sink and source that can 
enhance soil physical and chemical properties, and also promote biological activity (Salazar 
et al., 2011). Interestingly, not only amount of OM in the soil is important but most of all its 
quality, as OM affects the supply of energy for microbial growth and enzyme production 
(Fontaine et al., 2003).  
It is evident that soil enzymatic activity is strongly connected with soil OM content. The 
higher OM level can provide enough substrate to support higher microbial biomass, hence 
higher enzyme production (Yuan & Yue, 2012). Several authors reported positive correlation 
between DHA and OM content (Chodak & Niklińska, 2010; Moeskops et al., 2010; Romero 
et al., 2010; Zhao et al., 2010; Yuan & Yue, 2012).  
Zhang et al. (2010) indicated also that as well DHA and CaCO3 correlated with OM content, 
and what is more DHA, OM and CaCO3 were correlated with each other in their spatial 
distribution, suggesting that abundant OM content contributed to the formation of 
pedogenic calcium carbonate. 
Salazar et al. (2011) hypothesized that activities of dehydrogenases in different forest 
ecosystems are involved in the carbon cycling, and they also reported their positive 
relationships. Dehydrogenases, are highly associated with microbial biomass (MB), which in 
turn affects on decomposition of OM and the release of  CaCO3  (Zhang et al., 2010). 
We also investigated effect posed by total organic carbon (TOC) and response of DHA in the 
agricultural used Mollic Gleysol, taken from Kosiorów village (SE part of Poland). We 
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determined significant (P<0.0001) correlation between TOC-DHA (Fig. 5). Mentioned strong 
relationship was also confirmed by high value of correlation coefficient (r=0.99***). In our 
laboratory conditions the optimal value of TOC content for reaching maximal values of soil 
DHA was its level above 25%. 
 
Figure 5. Relationship between DHA and TOC content in the Mollic Gleysol (n=9, r=0.99***), according 
to Wolińska & Stępniewska (unpublished data) 
Analogically to our investigations also Koper et al. (2008) found and reported strong 
significant relationships between DHA and organic carbon content in Haplic Podzol soil 
samples, and they described mentioned correlations by r coefficient ranged between 0.56* 
and 0.98*. 
The study of Kumar et al. (1992) indicated that DHA displayed the close, positive 
correlations not only with OM content but also with fungal population abundance in four 
forest stands (two at low and two at higher attitudes).  
High correlation coefficient reported for enzymatic activities and TOC level suggested an 
important role of these enzymes in transformations of basic components of soil OM 
(Wolińska & Stępniewska, 2011). There is in general agreement with previous results 
indicated by Pascual et al. (2000), who found that soils characterized with low microbial and 
biological activity (e.g. low microbial carbon and low respiration rate), also display the 
lowest values of DHA. 
Summarizing, the higher content of OM, the more active the soil microorganisms. 
Microorganisms accelerate the degradation of OM, which is reflected in soil respiration and 
release of carbon dioxide from the rizosphere (Zhang et al., 2010), thus DHA is positively 
correlated with OM content. Similarly, increase of DHA with higher microorganisms 
number was reported (Fontaine et al., 2003). 
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3.4. pH 
The literature data, currently available, referring to the connections between DHA and soil 
pH are still ambiguous.  
Generally, enzyme activities tend to increase with soil pH (Błońska, 2010; Moeskops et al., 
2010) – please put a space before Moeskops. Błońska (2010) determined significant positive 
correlation (r=0.50***) DHA-pH(water) in the pH range 3.67-5.88.  
Fernandez-Calviño et al. (2010) noted significantly positive correlations among soil DHA 
and pH in the range of 4.1 (pHKCl) and 4.9 (pHwater), suggesting that acidity suppressed 
potential enzyme activity.  
Adequately, a study by Levyk et al. (2007) demonstrated that acidic conditions in the pH 
range between 1.5–4.5 resulted with strong DHA inhibition in relation to alkaline soils, 
whereas Ghaly & Mahmoud (2006) noted that under acidic conditions with pH less than 6.5, 
the rate of TTC - specific substrate for DHA, did not decrease. 
According to Frankenberger & Johanson (1982), the weakening of enzymatic activity in soil 
with the increase of soil acidity is the effect of destroying ion and hydrogen bonds in 
enzyme active centre. 
On the other hand, study performed by Włodarczyk et al. (2002) indicated maximum DHA 
at pH 7.1, similarly to the work of Ros et al. (2003), where optimum for DHA was noted for 
pH 7.6-7.8. Also Brzezińska et al. (2001) reported that the best pH conditions for DHA 
ranged between 6.6-7.2.  
Natywa & Selwet (2011) noted positive correlation between DHA and pH in soils under 
maize growth at pH range from 5.17 to 7.27.  
Trevors (1984) concluded that very little DHA is observed below pH 6.6. and above pH 9.5. 
According to Nagatsuka & Furosaka (1980) the optimum range for DHA is contained 
between 7.4–8.5. However we should realize that many heterogeneous soil types might not 
be included in mentioned above range. 
Our investigations, performed on Mollic Gleysol sample (from Kosiorów village) indicated 
however, that DHA also reached high level at lower pH values–between 5.5-5.73 (Fig. 6). 
Significant inhibition of DHA (even by 95%) we scarcely noted when soil pH was above 
5.75.  
It is often assumed that pH may affects soil enzymes level in three different ways (Shuler & 
Kargi, 2010):  
1. by changing in the ionic form of the active sites of the enzymes, which consequently 
affect the enzyme activity and hence the reaction rate, 
2. by altering the three-dimensional shape of enzyme, and 
3. by affecting the affinity of the substrate to the enzyme. 
Thus, the pH factor is considered to be the best predictor of DHA in the soil environment 
(Quilchano & Marañon, 2002; Moeskops et al., 2010).  
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Figure 6. Relationship between DHA and pH values in the Mollic Gleysol (n=18, r=-0.70**), according to 
Wolińska & Stępniewska (unpublished data) 
3.5. Temperature 
Many researchers have studied effect posed by temperature incubation on soil DHA and/or 
on soil microorganisms abundance (Subhani et al., 2001;  Ghaly & Mahmoud, 2006; Trasar-
Cepeda et al., 2007). Taking into account the important fact that DHA is found inside the 
viable soil microbial cells only, its activity must be the highest at a temperature close to 
optimum temperature for microorganisms growth and their development (Wolińska & 
Stępniewska, 2011).  
It is known that, the rate of enzyme catalysis generally increases with increase in 
temperature until the unfavorable temperature, at which enzyme becomes denaturized and 
hence its activity reduces (Wolińska &  Stępniewska, 2011).  
Our investigations were concentrated on investigations of DHA changeability at 
temperature range 5-30ºC, what reflect natural changes of soil temperature during seasons. 
Surface layer (0-20 cm) of Mollic Gleysol was used for experiment. Soil samples were 
incubated at the following temperatures: 5, 10, 20 and 30ºC. DHA was measured after 30 h 
incubations at proper temperature and after ethanol extractions. Absorbance was tested at 
λ=485 nm (UV-1800 Shimadzu). Received results are presented in Fig. 7. 
We found growing, linear trend for DHA with increase of temperature at the range from 5 
to 30ºC, what we described by R2=0.97. The differences between DHA level estimated at 5 
and 30ºC were significant (P<0.01), analogically like between 5 and 20ºC (P<0.05). The lowest 
values of DHA at 5ºC were found, where DHA equaled 1.259 (µg TPF g-1 min-1*10-6), whereas 
the same soil sample incubated at 30ºC reached DHA level of 3.149 (µg TPF g-1 min-1*10-6), 
what was by c.a. 60% higher in relation to DHA level from 5ºC. Quite high DHA level (2.741 
µg TPF g-1 min-1*10-6) was also estimated at 20ºC, where mentioned value was only by 13% 
lower than maximum DHA, from 30ºC.  
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Figure 7. The dependence between DHA and temperature incubation in the Mollic Gleysol, according to 
Wolińska & Stępniewska (unpublished data). Averaged values of three replicates with standard 
deviations are presented 
Casida et al. (1964) indicated that incubation of soil samples at 37ºC increased of soil DHA 
above the value normally observed at lower temperatures.  
Trevors (1984) described positive significant correlation among DHA and temperature in the 
range from 5 to 70ºC and determined r coefficient on the level of 0.99*. Moreover, study by 
Trasar-Cepeda et al. (2007) reported that increased temperatures up to 57-70ºC enhanced the 
product formation in the reaction catalyzed by soil dehydrogenases increased with, 
explained by the fact that specific substrate (TTC), used for DHA determination, is 
chemically reduced at high temperatures.  
Analogically, Subhani et al. (2001) noted positive correlation in soil samples incubated at 10, 
25 and 40ºC (under constant moisture – flooded conditions), what confirmed by r=0.82*.  
As suggested by Cirilli et al. (2012) optimum temperature for soil DHA is 30ºC, what is in 
agreement with our findings. Similarly, Brzezińska et al. (1998) indicated that under 
laboratory conditions DHA demonstrated the highest activity at 28-30ºC. 
3.6. Season of the year  
Seasonal variations in both microbial biomass and soil enzymatic activities reflect the 
combine effects of temperature, moisture, substrate availability and other environmental 
factors. Dehydrogenases belong to the enzymes displaying strong fluctuations in their 
activities caused by season of the year, as they are in close relationships with dynamic of 
microbial activity. 
 
Dehydrogenases 194 
Yuan & Yue (2012) stated the highest DHA level in autumn season and the lowest value of 
DHA in winter time. The study performed by Piotrowska & Długosz (2012) indicated that 
DHA level in Luvisols revealed significantly higher values in April (by 96%) than in August, 
probably due to intensive winter wheat growth with an increased secretion of substrates 
such as polysaccharides, organic acids, which may have affected the growth and activity of 
microorganisms. 
Similarly, our investigations demonstrated the highest level of DHA in Eutric Fluvisol 
sample taken in May (0.0087 µg TPF g-1 min-1), than in the same soil type taken in October, 
where DHA was reduced by 42.5 % (Fig. 8). Quite high level of DHA (lower by 14.9% from 
its maximum reaching in May) we also noted in July. Moreover, we did not found 
significant differences (P>0.05) in DHA values during autumn season, where DHA 
remained on similar level equaled 0.000598 (µg TPF g-1 min-1) and 0.0005 (µg TPF g-1 min-1), 
for September and October, respectively. 
 
Figure 8. Effect of the season of the year on soil DHA in the Eutric Fluvisol, according to Wolińska & 
Stępniewska (unpublished data). Averaged values of three replicates with standard deviations are 
presented 
Analogical trend like our observations, related to high Oxidoreductases activity at the time 
form spring to autumn was noted by Januszek (1993). A study by Włodarczyk (2000) 
performed on Orthic Luvisol sample, showed that DHA demonstrated seasonal pattern and 
reached the highest values in September, whereas the lowest in winter time. Similarly effect 
noted Tripathi et al. (2007), who indicated maximum DHA in September and its reduction in 
January. 
Spring season is strongly connected with increase in microbial activity, intensification of 
oxido-reduction reactions and temperature change, what is indirectly impacted with DHA, 
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and is the reason of slight DHA increase during this time. Moreover, taking into account 
that DHA is present inside viable microbial cells, its activity must be the highest at 
temperature 20-30ºC (temperature characteristic for summer and early autumn), close to the 
optimum temperature for microbial growth, activity and development (Wolińska & 
Stępniewska, 2011).  
4. Soil factors inhibiting dehydrogenase activity 
Some of environmental factors have ability to affect negatively on DHA, by reducing its 
activity. In the role of enzyme inhibitors usually different molecules are involved, which by 
binding to enzymes activation sites are the reason of prohibition the enzymes from 
catalyzing its reaction, and finally decrease their activity. The most important soil factors 
inhibiting soil DHA are described below. 
4.1. Depth of the soil profile 
Depth of the soil profile is one of the most known and popular environmental factor 
reducing soil DHA level. It is well known that the highest microorganisms abundance is in 
the surface layer of the soil profile (till to the depth of 30 cm), at the deepest part of the soil 
the number of microbial cells is limited, and consequently also DHA level display 
diminishing trend.  
 
Figure 9. DHA (µgTPFg-1min-1) at different depth of the Mollic Gleysol profile (n=18, P<0.001), according 
to Wolińska founding (unpublished data) 
The confirmation of the above statement might be the Fig. 9, where effect of depth on DHA 
in Mollic Gleysol is presented. The highest level of DHA we noted in surface layer (0-20 cm), 
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whereas at the deepest part of the soil profile (40-60 cm) DHA was reduced by 95%, in 
relation to the surface layer. This trend is undoubtedly connected with presented in 
literature data and mentioned above spatial distribution of soil microorganisms (Agnelli et 
al., 2004; Levyk et al., 2007; Wolińska, 2010), and its preference to inhabiting the surface 
layers, where optimum conditions for its growth and development are guaranteed. 
Our results are in agreement and might be supported by the findings of Xiang et al. (2008), 
who observed that DHA was roughly 4-fold higher in surface (till to 5 cm depth), than in 
subsoil (90-100 cm). It was also suggested by study of Gajda (2008), that values of DHA 
noted in the anthropogenic soil, till depth to 4 cm were by c.a. 30% higher in relation to the 
deeper part of the soil profile.  
Brzezińska (2006), reported even 9-fold increase of DHA in the surface layer of the soil, than 
in the subsurface parts and 25-fold higher enzymatic activity in surface than in subsoil.  
Generally it is possible to state, that both diversity, abundance as distribution of 
microorganisms are more even under oxic (surface layers) conditions, relative to anoxic 
(deeper layers) conditions (Fierer et al., 2003; Wolińska & Stępniewska, 2011). 
4.2. Fertilization and pesticide amendment 
Organic and inorganic fertilizers are commonly used to increase nutrient availability (Macci 
et al., 2012). The balanced fertilization of major elements (N, P, K) for plant nutrient could be 
beneficial for the growth of plant aboveground parts and roots (Chu et al., 2007), and also 
for improvement of soil structure (Macci et al., 2012).  
However, fertilization could affect on the population of soil microorganisms and 
consequently soil enzymatic activities. It is often assumed, that inorganic fertilizers had 
relatively less effect on soil enzymes activity than organic fertilizers (Chu et al., 2007; Xie et 
al., 2009; Romero et al., 2010). Macci et al. (2012) noted, that DHA usually reached higher 
level in the organic treatments.  
As was suggested by Chu et al. (2007) and Xie et al. (2009) long-term balanced fertilization 
greatly increased DHA level in the soil environment, rather than nutrient-deficiency 
fertilization. Zhao et al. (2010) indicated, that soils with higher fertility are more capable of 
maintaining the original biological functions (i.e. have a higher functional stability).  
On the other hand, Moeskops et al. (2010) compared the effect of organic and conventional 
farming practices on soil enzymatic activities. On the organic farms, soil fertility was 
maintained mainly with composted OM, in contrast to conventional farmers, who combined 
fresh manure and chemical fertilizers, and typically applied large amounts of pesticides. As 
a consequence, a strong negative impact of intensive fertilizer and also pesticide use on 
DHA was demonstrated (Moeskops et al., 2010). 
Soil DHA is an indicator of soil quality and microbial activity and also is the most frequently 
used to determining the influence of various pollutants (like pesticides or excessive 
fertilization) on the microbiological quality of soils (Xie et al., 2009; Tejada et al., 2010).  
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Despite the fact that pesticides are important tools in agriculture that help to minimize 
economic losses caused by weeds, insects and pathogens, they also are recognized as a 
source of potential adverse environmental impacts (Tejada et al., 2010). It is often assumed 
that less than 0.3% of the pesticide reaches its target pest, the remaining 99.7% is released to 
the environment, representing a potential hazard for non-target organisms (Muñoz-Leoz et 
al., 2011).   
Stepniewska et al. (2007) noted the relationship between soil DHA and Fonofos (Stauffer 
Chemical Co., Westport, USA) concentration in the Mollic Gleysol. In the investigated 
samples influence of pesticide on soil enzymatic activity started to be observed after one 
week of incubation, but since 14th day to the end of experiment this effect was significant 
and noticeable (Fig. 10). Generally, 1µg g-1 dose of Fonofos was responsible for about 26% 
inhibition of soil DHA, whereas ten times higher factor reduced activity for 46.6% at 21st day 
of incubation time, later fall of enzymatic activity ranged from 22.5% to 30% in relation to 
the control samples was considered.  
 
Figure 10. Dynamic of DHA during incubation at 20ºC (0 - control, 1 - 1µg g-1 Fonofos supplement; 10 - 
10 µg g-1 Fonofos supplement), according to Stępniewska et al., 2007. Averaged values of three 
replicates with standard deviations are presented 
Our results suggest a negative effect of Fonofos on soil DHA in the first stage after 
application (1-7 day), later an initial, almost linear growth of DHA was observed and the 
final day of incubation resulted in significant extension of DHA, presumably because the 
process of Fonofos decomposition in the soil environment was almost completely finished. 
Tejada et al. (2010) indicated that MCPA herbicide rate of 1.5 l ha-1 (manufactures rate 
recommended) was the reason of 39.3% soil DHA inhibition, what suggest that the MCPA 
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caused toxic effect on soil enzymatic activity. A field half-life of MCPA ranged from 14 days 
to 1 month, dependently on soil moisture, pH and microorganisms abundance. The most 
important soil factor in predicting MCPA effect on soil enzyme activities is pH, as at acidic 
conditions persistence of pesticide may last even 5 years, whereas at alkaline pH only 6 
days. Moreover, decrease of soil moisture and reduction of microbial abundance influence 
on elongation of MCPA decomposition process. 
We also studied effect posed by MCPA (Organika Sarzyna, Poland) on soil DHA behavior 
(Fig. 11). The following MCPA dosage were introduced into the soil samples: 0.165; 0.30 
and 3.3 mg MCPA per g of soil. Non-amended with pesticide soil sample was marked as 0 
and used as a control. As a result of realized experiment we found linear inhibition of 
DHA by increasing MCPA doses (R2=0.99). Decrease of DHA level at 3.3. mg g-1 MCPA 
dose by c.a. 38.5%, in comparison to the control sample, was noted. However, registered 
inhibition was not significant (P>0.05). Our conclusions are comparable with results 
presented by Tejada et al. (2010). 
 
Figure 11. Effect of MCPA pesticide on DHA level in Eutric Fluvisol, according to Stępniewska 
founding (unpublished data). Averaged values of three replicates with standard deviations are 
presented 
Other pesticide, which we take into account in our investigations was Glyphosate – 
commonly used by Polish farmers (in the form of RUNDUP), a broad spectrum, non-
selective, systemic and post-emergence herbicide, widely popular in soil cultivation, 
forestry, rights-of-way and aquatic systems to prevent grass and weeds competition with 
plant seedlings (Bennicelli et al., 2009). At low doses it is used as a plant growth regulator.  
Glyphosate (Monsanto Co., USA) is a polar substance that is highly soluble in water (12 g l-1 
at 25°C), and insoluble in most organic solvents. In soil is moderately persistent; its half-life 
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is reported between 1 to 174 days (Bennicelli et al., 2009). Glyphosate in soil is transformed 
to aminomethylphosphonic acid (AMPA), which is non-persistent metabolite. As a effect of 
mentioned transformations and in presence of dehydrogenases (microorganisms), 
Glyphosate give CO2 and H2O (Forlani et al., 1999). Glyphosate degradation in soil is mainly 
the reason of microbial activity, while the chemical decomposition and photolysis play a 
minor role (Bennicelli et al., 2009). As was reported by Zabaloy et al. (2008), Glyphosate, as 
an organophosphonate can be used as a source of P, C or N by either gram-positive as gram 
negative bacteria. 
The purpose of our study was to research the influence of Glyphosate on soil DHA in the 
Mollic Gleysol (from Wieprz river valley), Eutric Fluvisol (from Vistula river valley) and Terric 
Histosol (from Bystrzyca river valley), taken from surface layer (0-20 cm). Soil samples were 
enriched with Glyphosate, as follows: with 1 µg (first combination), and 10 µg (next 
version), and 0 µg (control) of pesticide per 1g of soil. Thus prepared samples were 
incubated in thermostatic chamber at 20ºC. Received results are presented in Fig. 12.  
 
Figure 12. Mean DHA in Terric Histosols, Eutric Fluvisols and Mollic Gleysols, in three combinations of 
Glyphosate doses: 0-control; 1-1µg g-1; 10-10µg g-1 (according to Bennicelli et al., 2009) 
We found that both 1 and 10 µg of Glyphosate additions to soils caused a decrease of DHA, 
dependently on the pesticide doses. The strongest effect of Glyphosate was observed in 
Terric Histosols and Eutric Fluvisol (10 µg g-1 of soil),where reduction of DHA by 33-47%, 
relative to control soils (non-amended with Glyphosate), was noted. The most resistant to  
Glyphosate supplement seemed to be Mollic Gleysol, in 10 µg g-1 of soil dose, where DHA 
dropped by c.a. 24%. 
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Suggested by us inhibition effect, may be supported by founding’s of Zabaloy et al. (2008), 
who in typical Ardiudoll from Argentina observed reduction of DHA for about 48%, as an 
effect of Glyphosate contamination, in comparison to control sample. 
Results, suggesting inhibitory pesticide effect on DHA level are also in agreement with 
those obtained by other plaguicides such as: chlorpyrifos (Kadian et al., 2012), or 
vermicompost (Romero et al., 2010). Moreover, Muñoz-Leoz et al. (2011) noted that DHA 
was inhibited by 14%, as a effect of application 5 mg kg-1 tebuconazole fungicide dosage.  
Conversely, others have found also different results. For example, Tejada et al. (2011) noted 
insignificant (by 10%) growth of DHA, when the Prochloraz fungicide applied to the soil 
increased, possibly because the fungicide is commonly used by bacterial communities, as a 
source of energy and nutrients. Also Andreá et al. (2003), noted that DHA was slight higher 
after month from Glyphosate application. In that case authors reported, that Glyphosate 
stimulated DHA, which means that the herbicide might stimulate the soil oxidative 
processes. 
4.3. Heavy metals presence 
Heavy metals, even though they are natural constituents of soil, could have long-term 
hazardous impacts on the health of soil ecosystems, and adverse influences on soil 
biological processes (Pan & Yu, 2011). Generally, it was assumed that heavy metals can 
reduce enzyme activity by interacting with the enzyme-substrate complex, denaturing the 
enzyme protein or interacting with the protein-active groups, they could also affect the 
synthesis of enzyme microbial cells (Pan & Yu, 2011). 
Xie et al. (2009) noted that Cu of 100 mg kg-1 could suppress DHA significantly, while Cd of 
5 mg kg-1 had relative greater influence on soil microbial diversity, what suggest that the 
effect of each soil pollutant on soil microbes and their enzymatic activities was specific.  On 
the contrary, a study by Fernandez-Calviño et al. (2010) indicated adverse effect of Cu on 
DHA (r=-0.24, P<0.01). Threshold Cu concentrations at which changes in the enzyme 
activities became evident were 150-200 mg total Cu kg-1 and 60-80 mg bioavailable Cu kg-1.  
A study by Pan & Yu (2011) undertaken with brown soil, showed that DHA was 
significantly lower by 37.8% and by 51.1% in Cd and Pb treatments, than in control. 
Moreover, mentioned researchers noted that the effect of Cd and Pb combined on DHA 
were higher, than Cd or Pb alone.  
We also investigated effect posed by Cd (2 and 20 mg kg-1) on soil DHA (Fig. 13). Incubation 
of soil material with mentioned Cd doses lasted 42 days. After that DHA was determined 
via Casida et al. (1964) method.  
We observed that Cd presence at concentration of 2 mg kg-1 had stimulating effect on soil 
DHA level, and we noted increase of DHA by 8.8%, in comparison with control sample 
(without Cd contamination). However, 10-fold higher Cd amendment (20 mg kg-1) 
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consequence with strong DHA inhibition, by as follows: 29.4% and 35%, in relation to 
control and 2 mg kg-1 sample, respectively. Observed inhibition effect was probably caused 
by Cd interaction with enzyme-substrate complex, what resulted with strong decrease of 
DHA level.  
 
Figure 13. Effect of Cd on DHA in Eutric Fluvisol (according to Stępniewska & Wolińska, unpublished 
data) from Cd introduction into the soil. Averaged values of three replicates with standard deviations 
are presented 
Our results, may be supported by findings of Moreno et al. (2001), who by investigating the 
influence of Cd on DHA stated, that Cd content strongly affected on DHA, by reducing its 
activity, and this effect is noticeable even after 3 hours.  
Negative effect of heavy metals on DHA was reported also by Kizilkaya et al. (2004), who 
organized the following order of this inhibition: Cu > Cd > Co. Analogically, strong 
reduction of DHA by Cd contamination was indicated by Welp (1999), who tested the effect 
of Co, As, Hg, Cd, Pb and Cu on soil DHA, and demonstrated that the strongest effect was 
displayed by Hg and Cd.  
Stępniewska & Wolińska (2005) found that the application of trivalent and hexavalent 
chromium compounds had a noticeable negative effect on soil DHA (Fig. 14). The soil 
sample (Haplic Luvisol) was amended with Cr (III), as a CrCl3 and with Cr (VI), as a K2Cr2O7 
in the concentration range from 0 to 20 mg kg−1 and 0-100 µg kg-1, for Cr (III) and Cr (VI), 
respectively. The differences in Cr (III) and Cr (VI) doses resulted from the fact that Cr (VI) 
is highly toxic and much mobile form of Cr, and is considered to cause much stronger effect 
on living organisms, than Cr (III). 
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Figure 14. The variations of DHA in Haplic Luvisol at different Cr (III) and Cr (VI) concentrations 
(according to Stępniewska & Wolińska, 2005). Averaged values of three replicates with standard 
deviations are presented 
Non-amended soil samples were used as a control, and their enzymatic activity were 
estimated as 100%. Effect posed by Cr content was calculated as a decrease of its level, in 
relation to the control value. We found that the lowest values of DHA were the effect of 
increasing Cr(III) and Cr(VI) doses. Haplic Luvisol seemed to be very sensitive on Cr 
contamination. DHA was reduced to 18-20% in the samples enriched in Cr (III) forms. 
Surprisingly, the more dangerous form of Cr (VI) was less harmful for DHA in the Haplic 
Luvisol, because enzymatic activity remained on the level of 84%, with a 1µg kg-1 addition 
and decreased to the value of 14% with the highest supplement of Cr (VI). One possible 
explanation for this fact is that. the more dangerous form of Cr (VI) was reduced to the 
less toxic form of Cr (III) by microorganisms, living in the soil (Stępniewska & Wolińska, 
2005). 
In the same way we investigated effect of Cr forms on Eutric Cambisol (Stępniewska & 
Wolińska, 2004). Received results are shown in Fig. 15. We stated that excess of Cr forms in 
soil disturb homeostatic metabolism of microbes, what reflect their enzymatic activity. DHA 
demonstrated a tendency to decrease with increase of Cr concentration. The lowest content 
of both Cr (III) and Cr (VI), at the level of 2 mg kg-1 reduced soil DHA to 51-66%, 
respectively. But at the same time the highest Cr (III) and Cr (VI) supplement at the level of 
20 mg kg-1 limited DHA to 6-15%, in relation to the control.  
Inhibition of DHA by applied Cr compounds was also reported by Wyszkowska et al. 
(2001), who noted that decrease of enzymatic activity in soil should be considered as very 
unfavourable in terms of soil fertility, because soils of good quality and high content of soil 
OM show high enzymatic activity. 
The decrease of soil DHA by several metallic elements (Al, Be, Cu, U) was also discussed by 
Antunes et al. (2011), whereas a study by Nowak et al. (2002) found that DHA decreased by 
up to 85% at 5 mM selenic acid (IV) presence. 
B
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Figure 15. The variations of DHA in Eutric Cambisol at different Cr (III) and Cr (VI) concentrations 
(according to Stępniewska & Wolińska, 2004). Averaged values of three replicates with standard 
deviations are presented 
5. Conclusions 
Soil is a part of the terrestrial compartment, and supports all terrestrial life forms. Thus, 
without proper soil protection policies, numerous problems may arise, like reduction of soil 
fertility, erosion, groundwater contamination, insufficient water holding capacity and loss of 
biodiversity. To asses soil quality, it is essential to measure all potential changes in 
biological soil properties, because they are highly sensitive to any environmental 
perturbations and stresses. A usual approach to diagnose soil quality, is to use a soil 
microbial indicators, which are very sensitive and respond quickly to environmental 
alterations.  
Among different soil indicators, DHA is one of the most adequate, important and one of the 
most sensitive bioindicators, relating to soil quality and fertility. Moreover, their routine 
measurement is simple and low-cost under laboratory condition. However, we should not 
remind about limitations, resulting from laboratory conditions, when we are able to 
measure and estimate only potential DHA, similarly like we are able to cultivate only small 
percentage of soil microorganisms, on artificial media.  
Soil enzymes are strongly associated with microorganisms. Soil enzymatic activity plays an 
important role in catalyzing reactions indispensable in life processes of soil microorganisms, 
decomposition of organic residues, circulation of nutrients, as well as forming organic 
matter and soil structure. Thus, it is possible to say that without proper soil enzymes 
system, soil life processes will be disturbed. 
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DHA is related to quantitative changes in microorganisms populations, as only strictly 
intracellular enzymes can truly reflect microbial activity, because with respect to the 
degradation processes of extracellular soil enzymes, they will be quickly mineralized by 
other enzymes (i.e. proteases), unless they are either adsorbed by clays or immobilized by 
humic molecules. 
It should be also remind, that overall soil DHA level depends most of all from the activities 
of various types of dehydrogenases, which are fundamental part of the enzyme system of all 
living soil microorganisms, i.e. the respiratory metabolism, the citrate cycle, and N 
metabolism.  
Due to this fact, DHA is proposed as the best indicator of the microbiological redox-systems, 
and could be considered as good and adequate parameter of microbial oxidative activities in 
soil. Furthermore, soil DHA is also used as a measure of any soils disruption posed by 
pesticides, heavy metals, or other soils contaminates and improper management practices. 
As DHA is strictly connected with living microbial cells, its activity depends from the same 
environmental factors, which influence on microorganisms abundance, activity and life 
processes. Consequently, when entertaining soil DHA behavior in the soil environment, we 
should be not only limited to DHA, but it is necessity to consider on the most important 
soils factors and conditions, affecting measuring by us DHA level.  
In the presented chapter we described the most important soil parameters, affecting DHA, 
which poses ability either for stimulation or inhibition its activity.  
To sum up the forgoing observations it was demonstrated, that DHA display increasing 
trend under anaerobic conditions, what suggest that the facultative and anaerobic member 
of soil microbial community become more important in soil respiration processes. Thus, soil 
DHA was reported to be negatively correlated with soil water potential, oxygen diffusion 
rate, and redox potential, what means that DHA reached higher values at lower soil water 
potential, lower oxygen diffusion rate and lower redox potential conditions. Analogically, 
negative correlation we also found in the case of soil depth–what was connected with spatial 
stratification of microorganisms abundance and its preference for inhabiting the surface 
layers of the soil profiles. Inhibiting effect on DHA level have also pesticides and soil 
contamination with heavy metals. 
Important parameter affecting soil biological activity is pH. Our investigations 
demonstrated, that optimal pH range for DHA is between 5.5-5.73, what was confirmed by 
correlation coefficient (r=-0.70*).  
Soil DHA depends also from the season of the year, similarly like dynamics of microbial 
activity, and reached the highest level in May, as spring season is strongly connected with 
increase in microbial activity, and intensification of oxido-reduction reactions, what is 
indirectly linked with DHA. 
Positive relationships we noted between DHA and two parameters: TOC and temperature, 
what means that DHA reached higher values at soils with higher TOC content (what is also 
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preferred by soil microorganisms), analogically like increase of temperature to 30°C 
(temperature close to optimum for microorganisms growth and development) resulted in 
DHA stimulation.  
Presented and discussed above results are based on our several years studies, however 
additional investigations are needed and recommended to determine the relative 
contribution of the different environmental effects on soil DHA. However, the discussion 
highlights the strong interactions between the soil environment, soil enzymes 
(dehydrogenases especially) and soil microorganisms.  
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1. Introduction 
Dehydrogenases are a group of biological catalysts (enzymes) that mediate in biochemical 
reactions removing hydrogen atoms [H] instead of oxygen [O] in its oxido-reduction 
reactions. It is a versatile enzyme in the respiratory chain pathway or the electron transfer 
chain. T. Turnberg discovered this group of enzymes between1900-1922. Several 
dehydrogenases are present in tissues of humans, plants and micro-organisms having 
enormous biochemical interests. As a result of the polymorphic nature of this enzyme, it is 
pertinent therefore to limit our interest on the different functions of Lactate dehydrogenase 
in the diagnosis and treatment of malaria. Lactate dehydrogenase, an oxidoreductase [EC 
1.1.1.27] exists in different forms in different tissues possessing different subunits as a multi-
enzyme complex called isoenzyme. It is the last enzyme of the glycolytic sequence or 
pathway essential for ATP generation. The enzyme, 17β-Hydroxysteroid dehydrogenase 
exists in at least fourteen isoforms in tissues involved in the biosynthesis of estrogenic and 
androgenic steroids. Lactate dehydrogenase is a tetrameric enzyme, but only two distinct 
subunits have been found; those designated H for heart (myocardium) and M for muscle. 
These two subunits are combined in five different ways. The lactate dehydrogenase 
isoenzymes, subunit compositions and major locations are shown below. 
Following myocardial infarction (MI), the serum levels of LDH rise within 24-28 hrs, 
reaching a peak by 2-3 days and return to normal in 5-10 days. Especially diagnostic is a 
comparison of the LDH1/LDH2 ratio. Normally, the ratio is less than 1. A reversal of the 
ratio is referred to as “flipped LDH”. Following an acute myocardial infarction, the flipped 
ratio will appear in 12-24 hours and it is definitely present by 48 hours in over 80% of cases. 
Also important, is the fact that, persons suffering from chest pain due to angina only, will 
not likely have LDH altered levels. 
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Type  composition  Location 
LDH1  HHHH  Found in the heart and red blood cells 
and Is 17%-27% of the normal serum 
level.  
LDH2  HHHM  Found in the heart and red blood cells 
and 27%-37% of the normal serum level 
LDH3  HHMM  Found in a variety of organs and is 
18%-25% of the normal serum level. 
LDH4  HMMM  Found in a variety of organs and is 3%-
8% of the normal serum level. 
LDH5  MMMM  Found in liver and skeletal muscles and 
is 0%-5% Of the normal serum level.  
Table 1. Subunit compositions and major locations of Lactate Dehydrogease Isoforms 
2. Measurement of parasite lactate dehydrogenase (pLDH) activity of 
plasmodium falciparum  
Malaria is the most lethal parasitic disease in the world, annually affecting approximately 
500 million people and resulting in 800,000 deaths, mostly in Africa and Sub-Saharan 
countries [1]. Some countries, for example Brazil registered more than 306,000 deaths in 
2009, most of which were in the Amazonian region [2]. In Africa, the figures may be higher 
due to endemic nature of the infection. Transmission occurs through the bite of the female 
anopheles mosquitoes infected with the parasite of which there are five species affecting 
humans. Plasmodium falciparum is the most pathogenic species and may cause severe 
malaria and death in non-immune individuals, especially children under five years [3].Drug 
resistant malaria parasites have emerged and has resulted in treatment failures. This 
resistance might be as a result of mutation at the active sites of drug targets or from 
biochemical changes in the drug receptors [4]. 
Plasmodium falciparum is a significant cause of morbidity and mortality in travelers to 
areas where the parasite is endemic. Non –specific manifestations may equally result in 
failure to recognize malaria until autopsy, when it is often too late to obtain blood for 
microscopic evaluation, which has been in use for years for the diagnosis of malarial 
parasitemia. The Plasmodium falciparum lactate enzyme (pLDH) has been considered, a 
potential molecular target for antimalarials. This is an enzyme assay for the detection of 
Plasmodium falciparum, employed in the assessment of malarial parasitism. The enzyme 
assay is based on the observation that Lactate dehydrogenase(LDH) enzyme of P. falciparum 
has the ability to rapidly use 3-acetylpyridine dinucleotide(APAD) as a co-enzyme instead 
of NAD in the reaction leading to the formation of pyruvate from lactate. Human red blood 
cells’ LDH carries out this reaction at very low rate in the presence of APAD. The measured 
development of APADH leads to the formation of a product that could establish the basis of 
an assay that detects the presence of P. falciparum from in vitro cultures at parasitemic levels 
of 0.02 %. Lactate dehydrogenase is the most abundant enzyme expressed by P. falciparum. 
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A correlation between levels of parasitemia and the activity of parasite LDH from patients 
with malaria is worthwhile. The serum assay for PLDH is followed up to monitor the level of 
PLDH in a patient with cerebral malaria prior to antimalarial therapy and also during recovery 
period. It is evident that measurement of pLDH has a strong correlation with malarial 
parasitemia and can follow a method that can be developed into a simple test for the detection 
of Plasmodium falciparum as an assessment of plasmodium parasitemia. In malarial falciparum 
parasitemia, LDH does not persist in blood, but clears about the time as the parasite, following 
successful treatment. The lack of antigen persistence after treatment makes the pLDH test 
useful in predicting treatment failure. In this respect, pLDH is similar to pGluDH. LDH for 
P.vivax, P.ovale, and P. malariae exhibit 90-92% identity to pLDH from P. falciparum. 
3. Functions of inhibitors of parasite lactate dehydrogenase (pLDH) as 
potential antimalarial agents 
The plasmodium falciparum lactate dehydrogenase enzyme (Pf LDH), has been considered a 
potential molecular target to antimalarials due to this parasite dependence on glycolysis for 
energy production by catalyzing the reduction of pyruvate to lactate. It has been a routine 
activity among drug designers for malarial infestation to embark on the screening of analogs 
to NADH(an essential cofactor) to pLDH.The continued search for new molecular targets for 
drug design is an endless search, since the introduction of the quinolones in malaria therapy. 
Chloroquine interacts specifically with PfLDH in the NADH binding pocket, occupying a 
position similar to that of the adenyl ring cofactor, hence acting as a competitive inhibitor for 
this critical glycolytic enzyme [5,6,7,8]. Analogs of NADH have been identified as new 
potential inhibitors to PfLDH[9].  Computational studies have been undertaken to recognize 
the potential binding of selected compounds to the pLDH active site. This was analyzed using 
Motegro Virtual Docker Software. The researchers selected fifty (50) compounds based on 
their similarity to NADH. The compounds with the best bonding energies included: 
itraconazole, atorvastatin and posaconazole. These were tested against P. falciparum , 
chloroquine resistant blood parasites. All these compounds proved to be active in two 
immunoenzymatic assays performed in parallel using monoclonals specific to pfLDH or a 
histidine rich protein 2 (HRP 2). The IC 50 values for each drug in both tests are similar; values 
were lowest for posaconazole (< 5µM) and were 40-and 100-fold less active than chloroquine. 
The compounds so tested reduced P. berghi parasitemia in treated mice, in comparison to 
untreated control. The drug itraconazole is the least active compound. Posaconazole is an 
inhibitor of ergosterol biosynthesis [10]. In this study, it was the most active drug against P. 
falciparum. It is also, the most effective compound against murine malaria caused by P. berghei 
and was the most promising agent in vitro and in vivo. Itraconazole is normally acquired as a 
tablet, causes a strong inhibition of P. falciparum growth in vitro and is partially active against 
P. berghei. The results of these trials according to the authors proved that molecular docking 
studies are important in the strategy for discovering new antimalarial drugs. This approach is 
more practical and less expensive than discovering novel compounds that require studies on 
human toxicology. The parasite enzyme, lactate dehydrogenase has recently received a great 
deal of attention, since it may constitute a valid therapeutic target for diseases such as malaria 
 
Dehydrogenases 168 
and cancer. Because the LDH enzymes found in P.vivax, P. ovale and P.malariae, all exhibit 90% 
identity to PfLDH; It would be desirable to have new anti-pLDH drugs particularly, ones that 
are effective against P. falciparum, the most virulent species of human malaria. Most invasive 
tumor phenotypes show a metabolic switch (Warburg effect) from oxidative phosporylation to 
an increased anerobic glycolysis by promoting an up-regulation of the human isoform-5 of 
lactate dehydrogenase (hLDH-5 or LDH-A), which is normally present in muscles and liver. 
Hence, inhibition of hLDH-5 may constitute an efficient way to interfere with tumor growth 
and invasiveness.  
4. New enzymatic assay using parasite ldh in diagnosis of malaria in 
Kenya 
The biochemical basis for this assay is on the fact that human red blood cells do not utilize 
APAD in the metabolism of glucose. The study subjects were of three different categories: 
the healthy non-infected individuals staying out of malaria endemic area( controlled GP-
1).The non-symptomatic and parasitemic healthy individuals living in endemic regions 
(both field study –GP 2).The non-parasitemic and parasitemic symptomatic individuals 
living in endemic region (both clinical study Group 3).In the clinical studies, thin smear 
microscopy gave the highest sensitivity as 75.6 % for plasma, while the highest specificity 
was 71.4 %. For red blood cells, the highest sensitivity was 78.4% while specificity was 80 %. 
In field trials, the highest sensitivity was 89 %) using thin smear microscopy, where as the 
specificity was 45% for the plasma cut off, using thick smear. For red blood cells, the highest 
sensitivity was 79% while the specificity was 66.7%. The variations in sensitivity and 
specificity of this assay in comparison to microscopy is a strong indication that pLDH may 
even be measuring sequestered parasites that cannot be visualized by microscopy. The 
results of the study validates the use of pLDH as an alternative objective test for malarial 
diagnosis against microscopy.  
5. Malaria antigen detection tests  
There are currently over twenty (20) such tests commercially available (WHO product 
testing, 2008) and these consist of a group of commercially available tests that allow rapid 
diagnosis of malaria by unskilled laboratory traditional techniques. The first malaria antigen 
suitable as target for Rapid Diagnostic Tests (RDTs) was a soluble glycolytic enzyme, 
Glutamate dehydrogenase. None of the current tests is as sensitive as a thick blood film. A 
major drawback in the use of all dipstick methods is that the result is essentially qualitative. 
In many endemic areas of tropical Africa; however, the quantitative assessment of 
parasitemia is important as a large percentage of the population will test positive. An 
accurate diagnosis of malaria is becoming more and more important in view of the 
increasing resistance of Plasmodium falciparum and the high price of alternatives to 
chloroquine. The enzyme pGluDH (parasite Glutamate Dehydrogenase) does not occur in 
the host red blood cells and was regarded as a marker enzyme for Plasmodium species. The 
malaria marker enzyme test is suitable for routine work and it’s now a standard in most 
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nations afflicted with malaria. The presence of pGluDH is known to represent parasite 
viability, and a rapid diagnostic test using pGluDH as antigen would have the ability to 
differentiate live and dead organisms. It is possible to note that a complete RDT with 
pGluDH as antigen has been developed in China. Glutamate dehydrogenases are 
ubiquitous enzymes that occupy an important branch point between carbon and nitrogen 
metabolisms. Both nicotinamide adenine dinucleotide[ (NAD)EC 1.4.1.2] and nicotinamide 
adenine dinucleotide phosphate (NADP) dependent GluDH [EC1.4.1.4] enzymes are present 
in plasmodia. The NAD-dependent GluDH is relatively unstable and not useful for 
diagnostic purposes. Glutamate dehydrogenase provides an oxidizable carbon source used 
in production of energy as well as a reduced electron carrier, NADH. Glutamate is a 
principal donor to other amino acids in subsequent transamination reactions. The multiple 
roles of glutamate in nitrogen balance, make it a gateway between free ammonia and the 
amino groups of most amino acids. The GluDH activity in P. vivax, P.ovale and P. malariae 
has been tested, but given the importance of GluDH as a branch point enzyme, every cell 
must have a high concentration of GluDH. It is well known that enzymes with high 
molecular weights like GluDH have many isoenzymes which allow strain differentiation 
(given the right monoclonal antibody).The host produces antibodies against the parasite 
enzyme, indicating a low sequence identity.  
6. New therapeutic approaches for treatment of plasmodium falciparum 
The antimalarial treatment so far recommended for P. falciparum consists of drug 
combinations containing Artemisinin derivatives (ACT) known as artemisinin combination 
therapy with other antimalarials, including quinolone compounds such as Amodiaquine 
and Mefloquine. The mechanism of action of the quinolones involve the inhibition of 
hematin polymerization, thus intoxicating the parasite with the ferriprotoporphyrin groups 
generated by hemoglobin degradation. Other antimalarials used in the ACT therapy 
include-Pyrimethamine and proguanil, which inhibit the tetrahydrofolic acid cycle 
(tetrahydropterate reductase, limiting the formation of folic acid, an important cofactor in 
DNA biosynthesis. Despite the arsenal of drugs available for malaria treatment, the disease 
remains a worldwide public health problem. P. falciparum develops resistance under 
selected drug pressure. Plasmodium vivax is the most prevalent human malaria parasite 
world over and has been shown to be resistant to chloroquine, including in Brazil and other 
countries where malaria is endemic. Various efforts have been made to develop new drugs 
(antimalarials), but resistance to drugs has limited the search. The continued search for new 
molecular targets for drug design has broadened the therapeutic arsenal and strategies to 
fight drug resistance in human malarial infestation. 
7. Three new parasite ldh (pan-pLDH) tests for diagnosis of 
uncomplicated malaria 
Since Charles Laveran first visualized the malaria parasite in 1880; the mainstay of malaria 
diagnosis has been the microscopic examination of blood smear. It is the main economic, 
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most preferred and reliable diagnosis using two types of blood films, which is amenable to 
the four species of malaria parasite. These two types of films are (a) the thin blood film 
which is similar to the usual blood films, which allows species to be identified because they 
can be visualized and the appearance of the parasites are much more distorted.(b)the thick 
film from which an experienced microscopist can detect parasite levels or parasitemia down 
to levels as low as 0.0000001% of red blood cells. Diagnosis of species can be difficult 
because, the early trophozoites (“ring form”) of all four species look identical and never 
possible to diagnose the species on the basis of simple ring form. The success of the method 
above requires well trained staff, quality equipment and supervision. The scarcity of these 
facilities within malaria endemic areas becomes limiting. In sub-Saharan Africa and some 
other areas, clinicians often have to rely on clinical signs and symptoms for diagnosis and in 
some areas where increasing emphasis is laid on home based management , malaria diagnosis 
is often equated[11] with fever. It is to be noted that such presumptive treatment without 
laboratory confirmation could contribute to the development of drug resistance[11]. Today, an 
alternative method to the blood film diagnosis approach is the rapid diagnostic test (RDTs), 
recommended by WHO, where reliable microscopy is not reliable or available. Rapid 
diagnostic tests (RDTs) are antigen detection tests, which are simple to use and interpret, 
although the tests also use peripheral blood. The most commonly used RDTs, is the histidine-
rich protein 2 (HRP 2), produced by trophozoites and young gametocytes of plasmodium 
falciparum. HRP 2 test has been the most widely evaluated to date test, and has shown 
consistently high sensitivity. The limitation of this test is that RDTs detect P. falciparum only 
and can remain positive for several weeks after antimalarial treatment. Besides these, a study 
to assess the diagnostic capabilities of three parasite lactate dehydrogenase (pan- LDH)-  
,Vistapan® ,Carestat™ and Parabank® were conducted in Uganda. Similarly, a histidine- rich 
protein 2 (HPR 2) test, Paracheck-Pf® and a Geimsa-stained blood film were performed with 
pfLDH tests for outpatients. A total of 460 patients were recruited for the exercise, 248 had 
positive blood films and 212 with negative blood films. Plasmodium falciparum was present in 
95% of infections. Sensitivity of the tests above 90% was shown by two pLDH tests-Carestart 
(96.5%) and Vistapan (91.9%) and sensitivity above 90% by Parabank (94.3%) and Carestart 
(91.5%). The benefits of these tests when compared with the previous gold standard for 
laboratory confirmation of malaria diagnosis which is a peripheral blood film examined 
microscopically shows the high specificity and validity of the tests.  
An alternative diagnostic method to the rapid diagnostic test (RTD), recommended by 
WHO, where reliable microscopy is not available. RTDs are antigen detection tests, which 
are simple to use and interpret and also use peripheral blood. The most commonly used 
RTD detects histidine -rich protein 2 (HRP2), produced by trophozoites and young 
gametocytes of Plasmodium falciparum. HRP 2 tests have been the most widely evaluated to 
date and show high sensitivity. However, they are limited in that they detect P. falciparum 
only and can remain positive for several weeks after successful treatment[12,13].  
The second type of RTD detects the malaria antigen parasite lactate dehydrogenase (pLDH), 
an enzyme produced in the glycolytic cycle of the asexual stage of all species of 
Plasmodium. Parasite lactate dehydrogenase( pLDH) are produced only by viable parasites, 
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thus being cleared from the blood stream more rapidly after treatment, resulting in test 
becoming negative more quickly. There is no doubt that these characteristics suggest that 
pLDH tests could be used with more confidence for malaria diagnosis at the peripheral 
level. The development of several new pLDH monoclonal antibodies by Flow Inc. has 
enabled the production of a new generation of pLDH tests. These characteristics suggest 
that pLDH tests could be used with more confidence for malaria diagnosis at the peripheral 
level [14]. For confident diagnosis of malaria in routine outpatient department conditions, a 
sensitivity of more than 90% is crucial and this has been achieved by both Carestart and 
Vistapan. The pLDH tests have also demonstrated desirable qualities that could reduce the 
possibility of patients without malaria being given antimalarials, which may therefore 
reduce drug pressure, a major concern at a time when Artemesinin combination therapy 
(ACTs) are being introduced in Africa. The validation of these tests for malaria diagnosis 
involves many stages from the selection of site, enrolment of patients, sample size, study 
procedures, laboratory procedures, study outcomes, analysis and results. The validity of the 
tests after all these procedures must be rated from 90% and above. From the validity tests 
carried out by some researchers, Carestart had estimates for all validity parameters greater 
than 90%. Vistapan and Carestart were also sensitive as Paracheck Pf (p=0.14 and p=0.38) 
respectively. Parabank was less sensitive than all other tests (P<0.001 for each comparison). 
There was no significant difference between the three pLDH tests, but Parabank had a 
higher specificity compared with Paracheck Pf (P=0.02) for P. falciparum detection. In the 
study, the ages of patients were taken into consideration. Sensitivity decreased with older 
age for both Vistapan (97.4%) for the under fives versus 85.7%, P<0.011 and Parabank 
(95.4%) for the under fives versus 73.1%, P<0.001. Three tables were used to summarize the 
results of a study conducted in Mbarara Regional Hospital in Uganda, in a mesoendemic 
area of malaria transmission. These results are shown in tables 2, 3 and 4 respectively. 
7.1. Materials and methods 
The first approach is to select a site, which should be a highly malarial infested zone. 
7.2. Enrolment for the study. 
Patients from the outpatient department were systematically screened for symptoms 
suspected to be malaria and referred to the research clinic. Inclusion criteria were a clinical 
suspicion of malaria; weight≥ 5kg; resident in Mbarara Municipality available for two weeks 
follow up period; and signed informed consent from the study subjects or their legal 
guardians. Exclusion criteria were signs of severe or complicated malaria [15b], signs of 
severe disease; and women with visible pregnancy or suspicion of pregnancy based on the 
assessment of the last normal menstrual period.  
7.3. Sample size 
The required number of patients with positive blood film was calculated using an estimated 
sensitivity of the RDTs of 90%, an alpha error of 0.05 and a precision of 6%. This number (n-
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96) was doubled to permit a stratified analysis by age group (0--4 and ≥5 years. The same 
parameters were used to calculate the required number of patients with a negative blood 
film, thus giving a final minimum sample size of 200 blood-film-positive and 200 blood –
film –negative patients.  
7.4. Study procedures 
On the day of inclusion, demographic and clinical information were recorded, and a 
thick/thin blood film and the four rapid tests (Vistapan, Carestart, Parabank , and 
Paracheck-Pf) were performed. Women with positive pregnancy test and hyperparasitemic 
patients (P. falciparum›250,000 parasites/µl) were given quinine and excluded from further 
follow up. All other patients with positive blood film received an artemether-lumefantrine( 
Coartem®, Norvatis Pharma AG,Bassel,Switzerland), six –dose regimen under directly 
observed therapy. This treatment modality have been shown to be very efficacious with a 
prompt reversion to a negative [16] blood film after treatment. Patients receiving Coartem 
were asked to return to the Clinic on the third, seventh and 14th day after inclusion to repeat 
the blood film and all RDTs 
7.5. Laboratory procedures 
Blood films and rapid tests were performed from the same finger-prick blood. Blood films 
were dried, thin films fixed in methanol, and both films stained with 3% Giemsa for 45 
minutes. Smears were read by experienced technicians, counting parasites against 200 or 500 
white blood cells (WBC) or 200 high power fields before declaring a blood slide negative. 
The parasite density per micro-liter was calculated by multiplying the asexual parasite 
count by 8000 and dividing by the number of WBC counted [17].Plasmodium species were 
confirmed on the thin film and slides with mixed infections had only P.falciparum 
monoinfection, had the asexual density per microliter calculated as for P.falciparum. 
Gametophytes were recorded with species identification where possible. All inclusion slides 
were blinded and double read, with a third reading performed in case of discordance, ie; 
positive/negative discordance for asexual stages; asexualdensity discordance (difference in 
parasitemia≥50%);positive/negative gametocyte discordance. Twenty percent of the follow-
up visit slides were also blinded and double read. External quality control of 290 inclusion 
slides was performed by Shokia Malaria Research Unit, Thailand, giving Mbarara 
laboratory, a sensitivity of 95.5% and a specificity of 100%. All RDTs were performed and 
interpreted according to the manufacture’s instructions. Each test result was interpreted by 
two independent health care providers blind to the result of the blood film and reading 
according to a rota to avoid observer bias. The first reading was performed at the time 
specified by the manufacturer (15 min after preparation for Paracheck Pf and Parabank and 
20 mins for Carestart and Vistapan. The second reading was performed within 15 min of the 
first one. Discordant results were read by the laboratory supervisor for a definitive result. 
Each reader also classified the test as either invalid or doubtful. A doubtful test was defined 
as a test for which the reader was not sure if there was any indication of a line present. At 
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the end of the study, two test readers and two laboratory technicians involved in preparing 
the tests completed a questionnaire concerning the ease of use and interpretation of each 
test. 
Analysis. All data were either recorded directly or transcribed from source data forms to an 
individually numbered case report form (CRF). Data were double entered and validated 
using EpiData version 3.1(EpiData Association,Odense, Denmark)and analysed using Stata 
9.1 (Stata Corp. college station,TX,USA).The study profile and base-line characteristics were 
summarized, including comparative tests between age groups (x 2 test ,Ma-Whitey U test). 
The validity for each test was calculated overall and then stratified by age group, level of 
parasitemia(parasites/µl 1---99,≥100,≥200,≥500), presence/absence of fever, duration of 
illness(0—2vs.3 days and above) and a history of taking antimalarials, using comparative 
tests( x 2 test, Mann-Whitney U test) to compare differences between groups. Kappa 
statistics were calculated for iter-reader reliability for each test on the day of diagnosis. A 
test was considered as reliable if k ≥ 0.8. Univariable and multivariate analyses were 
performed to investigate the association between explanatory factors and the test remaining 
positive at each follow- up visit. 
Results. Demographical and Parasitological characteristics of study subjects. 
Between 26 April and 27th July, 2005, 485 patients from the out-patient department were 
screened. Nine were ineligible (three had severe illness, five were non-residents and one 
was not in the appropriate age group after completion of recruitment in the under fives. 
Sixteen patients did not consent to participate in the study; 239 under fives and 221 aged 5 
years and above. The mean age was 12 years(SD 13years;Table 2). There were 248 positive 
blood films with P. falciparum monoinfections(93.6%), P. malariae monoinfections(2.4%), P. 
falciparum+ P. malariae mixed infections(0.8%) and P. falciparum+ P. vivax mixed 
infections(0.8%). Of the 212 negative films, nine had gametocytes present. Parasitological 
characteristics of positive subjects are given in Table 2. Slides positive with P. falciparum 
had higher parasite densities than those of the other two species. 
Validity of RDTs. 
Only Carestart had estimates for all validity parameters greater than 90% (Table 3). Vistapan 
and Carestart were as sensitive as Paracheck-Pf(P=0.14 and P=0.38 respectively. Parabank 
was less sensitive than all other tests (P‹0.001 for each comparison). There was no significant 
difference in specificity between the three pLDH tests, but Parabank had a higher specificity 
compared with Paracheck.Pf (P= 0.02) for P. falciparum detection. Sensitivity decreased with 
older age for both Vistapan [97.7% (under fives) vs 85.7%, P‹0.01] and Parabank[95.4%( 
under fives)vs73.1%, P‹0.001]. Sensitivity increased with axillary temperature≥ 37.5 0C at 
inclusion for Paracheck.Pf (98.8 vs91.4%, P=0.04), Vistapan(97.6 vs 89.0%, P=0.03) and 
Parabank(91.8vs81.0%, P=0.04) compared with patients with axillary temperature ‹37.5 0C. 
Although, the small number of non-falciparum monoinfections does not permit reliable 
calculations of validity of non-falciparum mutants, all tests detected 100 % (n=6) of the P. 
malariae monoinfections. Plasmodium vivax was detected in 4/6 infections by Carestart, 2/6 
by Vistapan and 1/6 by Parabank. 
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Parameters Group A(<5yrs) 
Group B
(≥5yrs) Overall p-value 
Baseline characteristics n=239 n=221 n=460  
Gender ratio (M:F) 
0.98 
(118:121) 
0.52 
(76:145) 
0.72 
(194:266) 
0.001(X 2) 
Mean age(SD) 
2yrs 
(14 months) 
22yrs 
(12yrs) 
12yrs 
(13 yrs) 
N/A 
Median duration of 
illness in days (range) 
3(1-14) 3(1-30) 3(1-30) 
0.2(Kruskai-
Wallis) 
Previously taken 
antimalarial (n,%) 
81(33.9) 60(27.3) 141(30.7) 0.13( X 2) 
Fever on presentation 
(axillary temp≥ 37.5 0C) 99(41.4) 31(14.0) 130(28.3) <0.001(X 2) 
Parasitological 
characteristic 
n=129 n=119 n=248 ----------- 
Asexual parasitemia 
range (parasites/µl) 
16-703411 16-233241 16-703411 
0.001(Kruskal-
Wallis) 
Geometric mean of 
asexual 
parasitemia(95%Cl) 
7433(4869-
11346) 
1524(975-2384) 3475(2521-4790) 0.001(t test) 
Interquartile range 
(Interquartile value) 
1682-
45748(44066) 
166-
11070(10904) 
641-
23827(23186) 
---------- 
Gametocyte 
carriage(n,%) 
36(27.9) 22(18.5) 58(23.4) 0.11(X 2) 
Table 2. Baseline characteristics of all study subjects and Parasitological characteristics of Slide-positive 
subjects attending Mbarara Regional Referal Hospital, Outpatient department, South -Western Uganda 
Reliability 
The k statistic for the inter-reader reliability for all tests was above 0.90(very good 
agreement) [Carestart,k=0.96(95.0%, Cl 0.94—0.99); Vistapan, k=0.94( 95% Cl 0.91- t 0.97); 
Parabank, k=0.96(95% Cl 0.94-0.99); Paracheck.Pf, k=0.97(95% Cl 0.95-1.0)] 
Time to Negativity of RDTs. 
There were no positive blood films on follow up visits, and therefore, every positive RDT 
result on day 3,7 or 14 was considered a false positive result (Table 4). All three RDTs tested 
had significantly fewer false positive results on every day of follow-up compared with 
Paracheck.Pf(P‹0.001 for all tests on day 3,7 and 14). There was o difference between the 
pLDH tests by day 14, with the percentage of positive tests ranging from 4.6 to 9.5%. 
Younger age group and higher parasite level at inclusion were related to positive Paracheck. 
Pf on all follow-up days (logistic regression, P‹0.01), for all. Age group, fever at diagnosis 
and presence of gametocytes on day 3 were all related to a positive pLDH test on day 3 
(except age group for Parabank)(age group:Vistapan P=0.026, Carestart P‹0.001. 
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Parameters  
Carestart % 
[95 Cl] 
Vistapan% 
[95%Cl) 
Parabank% 
[95% cl) 
Paracheck 
=Pf%(95%cl) 
Sensitivity  
95.6(237/248) 
[90.2-96.6] 
91.9(228/248) 
[87.8-95] 
84.7(210/248) 
[79.6-88.9] 
94(233/248) 
[90.2-96.6] 
Specificity  
91.5(194/212) 
[86.9-94.9] 
89.6(190/212) 
[84.7-93.4] 
94.3(200/212) 
[90.3-97.0] 
87.3(185/212) 
[82.0-91.4] 
PPV  
92.9(237/255) 
[89.1-95.8] 
91.2(228/250) 
[87-94.4] 
94.6(210/222) 
[90.7-97.2] 
89.6(233/260) 
[85.3-93] 
NPV  
94.6(194/205) 
[90.6-97.3] 
90.5(190/210) 
[85.7-94.1] 
84.0(200/238) 
[78.7-88.4] 
92.5(185/200) 
[87.9-95.7] 
PPV: Positive Predictive Value; NPV: Negative Predictive Value 
Table 3. Validity of four rapid diagnostic tests for the detection P. falciiparum species in patients 
attending Mbarara Regional Hospital, out-patient department, southwestern Uganda 
 
RDT  Day 0 na Day 3% [95% Cl] Day 7 %[ 95Cl] Day 14 % [95% Cl] 
Paracheck -
Pf  
226 
86.2(193/224) 
[81.7-90.7] 
80.8(181/224) 
[75.6-86.0] 
69.7(152/218) 
[63.1-75.7] 
Vistapan  221 
36.1(79/219)[29.7-
42.5] 
3.4(51/218)[17.8-
29.0] 
8.9(19/213) 
[5.1-12.7] 
Carestart  230 
42.5(97/228) 
[36.1-48.9] 
27.6( 63/228) 
[21.8-33.4] 
9.5(21/221) 
[5.6-13.4] 
Parabank  204 
17.8(36/202) 
[12.5-23.1] 
8.9(18/202) 
[5.0-12.8] 
4.6(9/196) 
[1.7-7.5] 
 a n is the number of positive tests for each RDT on day 0 in patients who were followed up. 
Table 4. Percentage of positive tests on each follow up visit in patients attending Mbarara Regional 
Hospital, Outpatient department, SouthWestern Uganda. 
In overall, there are not large differences between the tests in terms of ease of use. Some tests 
have small advantages or disadvantages over others. For example, Vistapan has individual 
buffer sachets, considered to be an advantage, where as Carestart has a delay time of over 60 
seconds between blood application and buffer application, considered to be a disadvantage. 
All tests results are stable for a minimum of 24hr.The number of invalid tests was ‹0.5% for 
Parabank and between 0.5 and 2% for Carestart and Vistapan. No test had items requiring 
refrigeration and all tests have undergone temperature stability studies up to 30 0C. 
This study appears to be a pioneer study [17] to evaluate a new generation of pLDH tests for 
malaria diagnosis, performed in a mesoendemic African setting with a predominance of P. 
falciparum infections. The authors showed that several of these tests were validated and 
should be of great use in malaria endemic countries, where microscopy is not available and 
well trained microscopists are lacking. For confident diagnosis of malaria in routine 
outpatient departments, a sensitivity of more than 90% is crucial and this was achieved for 
Carestart and Vistapan. 
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The pLDH tests also demonstrated desirable qualities that could reduce the possibility of 
patients without malaria being treated or given antimalarial drugs, thereby reducing drug 
pressure and resistance, a major concern at a time when artemisinin combination therapy 
(ACTs) are being introduced throughout Africa. Their high specificity would reduce the 
number of patients with false positive results. Secondly, the great reduction in the number 
of tests remaining positive for a long time after treatment had been effected. This is 
reminiscent of the test carried out by HRP 2. Thirdly, the ability to detect both P. falciparum 
and P. vivax, would increase confidence on a negative test result. A variety of factors may 
contribute towards differing sensitivities of the test, such as patients age and level of 
parasitemia, which will vary according to endemic nature of P. falciparum in the locality. 
Lower test sensitivity may be related to low parasitemia in adults in an area of stable 
transmission. This may be a limitation of the tests; although, such patients are less at risk 
from severe clinical episodes to perpetuate parasite transmission. 
8. Comparison of two rapid field immunochromatographic tests to expert 
microscopy in malaria diagnosis. 
The vast majority of malarial tests adopted and used in the past depended on light 
microscopy and expertise in attaining results. Currently, the vast majority of malaria cases 
in the world are diagnosed by the century old standard of light microscopy and stained 
blood smears. Although the technique is sensitive and very inexpensive, there are several 
disadvantages. The disadvantages include practical issues such as electrical requirement, the 
need for experienced staff as well as difficulties in accurate species identification. Efforts 
have been made to develop malaria rapid diagnostic devices (MRDDs) to facilitate field 
diagnosis [18]. While the first generation tests diagnosed only Plasmodium falciparum, 
newer devices were designed to recognize both Plasmodium falciparum and P. falciparum 
specific antigen as well as Plasmodium genus specific antigen. 
The ICT malaria Pf/P.v test is a rapid immunochromatographic assay for the detection of P. 
falciparum-specific Pf HRP 2 and a pan-malarial antigen, manufactures in test card form. 
The name is misleading as the pan malarial antigen may be produced by Plasmodium ovale, 
and Plasmodium malariae as well. The test has been shown to be specific and sensitive. 
Malaria P.f/P.v test has been shown to be 96% sensitive and 90% specific for P. falciparum 
and 75% sensitive and 95% specific for P. vivax [19,20]. 
The OptiMAL dipstick test detects two forms of plasmodium lactate dehydrogenase 
parasites pLDH1; one P. falciparum-specific and one common to the four plasmodium 
species which infect humans. Many researchers reported a 95% sensitivity and 100% 
specificity for P. falciparum, and a 96 % sensitivity and 100% specificity for P.vivax. 
Sensitivity for P. ovale and P.malariae were significantly lower (57% and 47%) respectively. 
Using a batch OptiMAL dipstick procedure in 1999, a large scale field evaluation showed 
the following result: 91% sensitivity and 95% specificity for P.falciparum and 83% sensitivity 
and 100 % specificity for P.vivax [21]. 
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Methodology. The methodology involved the use of patients both symptomatic and 
asymptomatic , who are villagers referred to the study and informed consent obtained. For 
each patient, a finger prick was made and the following were obtained. Fifty microliters of 
blood in a pre-heparinized Eppendorf tube for dipstick assays and two thick/ thin smears, 
one for on –site microscopic diagnosis by Acridine orange(AO) technique (for immediate 
treatment purposes, and the other, for reference Geimsa-microscopist.OptiMAL reader and 
ICT reader, were all blinded to each other’s diagnosis. Patients positive for malaria were 
treated. Thick and thin blood smears were prepared and stained with Geimsa according to 
standard procedures. To declare a sample negative, thick smears were read for 200 
microscopic fields (1000 X) without finding a parasite.If found positive, the number of 
asexual malaria parasites were counted per 500 WBC separately for each species. If there are 
more than 250 parasites/500 WBC, parasites were counted on the corresponding thin film 
per 10,000RBC. Density calculations were based on approximations of7500 WBC/µl and 
5X10 6 RBC/µl. ICT malaria P.f/P.v test kits were used as per manufacturers instructions. 
Ten microliters (10µl) of whol blood was transferred to a sample pad. A buffer reagent was 
added to induce cell lysis and allow PfHRP 2 and pan malarial antigens to bind to colloidal 
gold-labeled antibodies. Additional buffer caused the blood and immune complexes to 
migrate up the test strip and cross monoclonal (mAb) lines. Finally, more buffer was added 
to clear blood from the membrane and facilitate reading. 
Tests are counted as valid, if control lines are observed. They were counted P. falciparum 
positive, if Pf HRP 2 specific and pan-malarial antigen lines were visible or if only PfHRP 2-
specific lines were seen only. If the control and pan-malarial antigen lines were observed, 
the sample was counted as positive for a malaria parasite other than P. falciparum. The test 
result was assigned a value of +0, if no line was seen; +1, if test line intensity was less than 
control line intensity; +2,if it was equal and +3, if it was greater in intensity. Other factors can 
exacerbate drug resistance. The second type of RDT detects the malarial antigen parasite-
lactate dehydrogenase (pLDH), an enzyme produced in the glycolytic pathway or cycle of 
the asexual stage of all species of plasmodium. Parasite lactate dehydrogenase is produced 
only by viable parasites, being cleared from the blood stream more quickly after treatment, 
resulting in the test becoming negative more quickly [22].  
9. Clinical and epidemological findings based on histopathology and 
immunohistochromatographic detection of p.falciparum antigens  
This new technique for determination of P.falciparum is not adopted during autopsy when 
actual diagnosis of P.falciparum infestation is missed mostly during improper diagnosis. 
Many organs and tissues manifest the severity of this type of malaria before death. The 
heart, lung, liver tissues are always available for post mortem analysis. Some other tissues 
used include: spleen, kidney, and brain. The following tissues were equally used in a case of 
five travelers suspected to have died from other chronic diseases not related to malaria. 
These other tissues include: tongue, trachea, thyroid and adrenal glands, gall bladder and 
testis. Viral and or bacterial hemorrhagic fever pathogens were suspected at death [23, 24, 
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25]. In the study, three novel IHC assays targeting HRP 2, aldolase, and pLDH were 
developed and confirmed on severe P. falciparum infection in five travelers whose deaths 
were wrongly suspected. 
Malaria is the most common cause of fever in travelers returning to industrialized cities or 
countries from malaria endemic countries. However, the clinical features of the disease are 
not specific and in some areas where P.falciparum is not endemic, fatal malaria is often not 
suspected. The pathological features of malaria resemble many other viral, rikettsial and 
bacterial infections. An unequivocal diagnosis can be made only by laboratory testing. IHC 
assays and histopathologic review confirmed P. falciparum infections in many study cases 
as being responsible for unsuspected deaths. Abundant hemozoin pigment, a by-product of 
parasite metabolism was distributed diffusely throughout peripheral tissues and in the 
blood vessels in the central nervous system. The findings are consistent with reports of 
hemozoin localization. The density of hemozoin increases in proportion to the duration of 
falciparum infestation and decreases with adequate and appropriate therapy. It has been 
discovered that the hallmark of P.falciparum infection is sequestration, characterized by the 
adherence of mature stage falciparum pRBCs(trophozoites and schizonts) to endothelial 
cells of capillaries and venules.  
Many studies in humans and other animals have described sequestration of trophozoites and 
schizonts in a variety of tissues, including the brain, heart, lung, skeletal muscles and 
subcutaneous tissues. As a result of sequestration, peripheral blood parasitemia, traditionally 
evaluated using Geimsa bood smear, may not give substantive correlative result in the 
pathogenesis of the severity of P. falciparum, hence,the severity of the infection may be under-
estimated. Plasmodium falciparum infection caused respiratory symptoms that resemble 
influenza like-illness in correlation with results from studies. There is pulmonary edema with 
intra-aveolar hyaline membranes and proteinaceous debri, associated with malarial antigens. 
Pulmonary edema is associated with high parasitemias and often leads to respiratory distress 
syndrome. Rust tinged urine described for several patients afflicted with this malaria, is 
associated with hyperbilirubinemia caused by erythrocyte destruction. In many cases of P. 
falciparum, malarial antigens can be detected in tubular epithelial cells in association with 
erythrocyte casts. The HRP 2 antibody used in this study was specific for P.falciparum, 
whereas the aldolase and the pLDH antibodies reacted with both P. falciparum and P. vivax. 
In conclusion, the current approach in the diagnosis and development of new drugs for the 
treatment of Plasmodium falciparum infections is quite novel and holds promise for the 
future. The ubiquitous nature of the enzyme, Lactate dehydrogenase especially, parasite 
lactate dehydrogease (pLDH) as malaria antigen, is indicative of the vital biochemical 
process of metabolism of pyruvate and lactate in microbial cells. The endemic nature of 
malaria in Africa and some Mediterranean countries poses a great challenge to humanity. 
There should be a more radical approach especially in Africa and other countries afflicted to 
tackle this problem which tend to decimate world population. Other frontline drugs which 
are designed to inhibit the enzyme should be developed to add to the success of this 
protocol. In as much as mosquitoes have developed resistance against chloroquine, the drug 
in some places remains the only option for radical cure of malaria.  
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1. Introduction 
Hydroxysteroid dehydrogenases (HSDs) belong to the NADPH/NAD+-dependent 
oxidoreductases, which interconvert ketones and the corresponding secondary alcohols. As 
their names imply, they catalyze the oxidoreduction in different positions of steroidal 
substrates (3α-, 3β-, 11β-, 17β-, 20α- and 20β-position). The steroid-converting HSDs play 
central roles in the biosynthesis and inactivation of steroid hormones, but some of them are 
also involved in the metabolism of diverse non-steroidal compounds [1]. The HSDs are 
integral parts of systemic (endocrine) and local (intracrine) mechanisms. In target tissues 
they convert inactive steroid hormones to their corresponding active forms and viceversa, 
thus modulating the transactivation of steroid hormone receptors or other elements of the 
non-genomic signal transduction pathways. Therefore, HSDs act as molecular switches 
allowing pre-receptor modulation of steroid hormone action [2].  
It is also well recognized that human and certain other primates are unique among animal 
species in having adrenals that secrete large amounts of inactive steroid precursors 
including dehydroepiandrosterone (DHEA). These steroids do not bind to the androgen 
receptor but exert either estrogenic or androgenic action after their conversion into active 
estrogens and/or androgens in target tissues [3]. Imbalanced action of sex steroid hormones, 
i.e. androgens and estrogens, is involved in the pathogenesis of various severe diseases in 
human. Hormone-dependent cancers are commonly lethal both in women and in men, with 
breast cancer being the most prevalent cancer in women and prostate cancer in men in 
several Western countries [4]. In addition, there are various other common hormone-
dependent diseases, such as polycystic ovary syndrome (PCOS) and endometriosis, having 
poorly understood aetiology and lacking efficient pharmacological treatment [5, 6]. 
However, changes in circulating hormone concentrations do not explain all 
pathophysiological processes occured in hormone-dependent tissues. A more inclusive 
explanation is provided by paracrine and intracrine action of sex steroids, namely the 
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regulation of intratissue hormone concentrations by expression of steroidogenic enzymes. 
The modulation of local sex steroid production using pharmaceutical compounds is also a 
valuable treatment option for developing of novel therapies against hormonal diseases [7]. 
In the view of successful practice of inhibiting of non-HSD enzymes (aromatase and 5α-
reductase) [8, 9], recent attempt are made for development of HSD inhibitors as therapeutic 
strategy. Several of HSD enzymes are also considered as promising drug targets and 
inhibitors, for example most of the isoforms of 17β-HSD enzyme [10]. 
In this review, we summarise the data from the literatute and our own data on the main 
HSDs (11β-HSD, 3β-HSD 17β-HSD) focusing our attention on the localization/tissue 
distribution and regulation of the enzyme isoforms and their role in normal and 
pathological processes as revealed by experimental models and clinical observations. The 
review would provide better understanding on multifunctionality of HSDs and their 
relevance to the clinic and that would be helpful for scientists and clinicians, working in a 
new challenging area of development of HSD-inhibitors as new drugs for hormone-related 
deceases.  
2. Steroid hormones and role of hydroxysteroid dehydrogenases in 
steroidogenesis: steroidogenic pathways and general regulatory 
mechanisms 
Steroid hormones are produced by the gonads, adrenal gland and placenta and they play 
vital role in physiological and reproductive processes. Structurally, steroids have a basic or 
common nucleus called the cyclopentanoperhydrophenanthrene, consisting of three, six-
membered fully hydrogenated (perhydro) phenanthrene rings designated A, B and C, and 
one five-membered cyclopentane ring designated D (Fig 1, right top). In 1967, the 
International Union of Pure and Applied Chemistry (IUPAC) established rules for the 
number of carbons in a steroid and thus its biological action can be predicted. For instance, 
21-carbon steroids have progestogenic or corticoid activity, 19-carbon steroids have 
androgenic activity and 18-carbon steroids have estrogenic activity. Cholesterol is a 27-
carbon steroid that gives rise pregnenolone (21-carbon) after cleavage of its side chain. 
Pregnenolone is subsequently converted to progesterone, which in turn give rise androgens 
or corticoids. Androgens are subjected to aromatization of ring A thus giving rise estrogens 
[11]. The pathways of steroidogenesis differ between species, but the pathways of human 
steroidogenesis are shown in the Figure 1. [12]. Cholesterol is the precursor of the steroid 
hormones, providing backbone of the steroid molecule. The enzymes involved in the 
synthesis of steroid hormones can be divided into two major classes of proteins: the 
cytochrome P450 heme-containing proteins (CYP) and the hydroxysteroid dehydrogenases 
(HSD) [13, 14]. These enzymes are primarily expressed in the gonads, adrenal and placenta. 
Interestingly, some of these enzyme activities have been demonstrated in non-endocrine 
tissues, where they may be involved in important paracrine and autocrine actions. This is 
particularly the case in the human fetus where steroid precursors circulates at high levels 
and could be metabolized within tissues to produce active steroid hormones. The first class 
of steroidogenic enzymes, CYP proteins called hydroxylases catalyze reaction of 
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xydroxylation (introduction of hydroxyl group –OH into organic compound) and cleavage 
of the steroid substrate utilizing molecular oxygen and nicotinamide adenine dinucleotide 
phosphate (NADPH, reduced) as the source of reductive potential. Several enzymes are 
included:  cytochrome P450 cholesterol side-chain cleavage enzyme (P450scc, CYP11A1), 
cytochrome P450 17α-hydroxylase (P450c17, 17α-hydroxylase, 17-20 lyase, CYP17A1), P450 
aromatase (aromatase, CYP19A1), 21α-hydroxylase (CYP21A), 11β-hydroxylase (CYP11B1) 
and aldosterone synthase (CYP11B2). The second class of steroidogenic enzymes, HSD 
enzymes called alcohol oxydoreductases catalyze the dehydrogenation of hydroxysteroids. 
Acting as oxydoreductases, HSD enzymes require nicotinamide adenine dinucleotide 
(NAD, oxidized) and/or NADPH as electron acceptor/donor. HSD enzymes include: 3β-
hydroxysteroid dehydrogenase (3β-HSD),11β-hydroxysteroid dehydrogenase (11β-HSD) 
and 17β-hydroxysteroid dehydrogenase (17β-HSD). While each P450 enzyme is the product 
of a single gene, the HSD enzymes have several isoforms that are products of distinct genes 
[15]. There are four types, classified by the number of the carbon acted upon. 
In all species, the first and rate-limiting step in steroidogenesis, in particular androgen 
biosynthesis, is conversion of the C27  cholesterol to the C21 steroid, pregnenolone (Figure 
1). This reaction is catalyzed by cytochrome P450scc enzyme located in the inner 
mitochondrial membrane. Pregnenolone diffuses across the mitochondrial membrane and it 
is further metabolized by enzymes associated with the smooth endoplasmic reticulum. 
These enzymes are: 1) cytochrome P450c17, which catalyzes the conversion of the C21 
steroids pregnenolone or progesterone to the C19 steroids dehydroepiandrosterone or 
androstenedione, respectively; 2) 3β-HSD (∆5-∆4 isomerase), which catalyzes the conversion 
of the ∆5 hydroxysteroids - pregnenolone or dehydroepiandrosterone to the ∆4 ketosteroids 
- progesterone or androstenedione, respectively; 3) 17β-HSD (17-ketosteroid reductase), 
which catalyzes the final step in the biosynthesis of testosterone [16]. 
Corticosteroids (mineralocorticoids and glucocorticoids, C-21 cabons) derive from 
progestagens (progesterone and 17α-OH progesterone) after hydroxylation of carbon-21 by 
the enzyme 21α-hydroxylase. So, aldosterone and corticosterone share the first part of their 
biosynthetic pathway. The last part is mediated either by aldosterone synthase (for 
aldosterone) or by 11β-hydroxylase (for corticosterone). These enzymes are nearly identical 
(they share 11β-hydroxylation and 18-hydroxylation functions). Aldosterone synthase is 
also able to perform 18-oxidation. 11β-hydroxysteroid dehydrogenase (11β-HSD) catalyzes 
the conversion of active cortisol to inert 11 keto-products (cortisone), or vice versa, thus 
regulating the access of glucocorticoids to the steroid receptors.  
The steroidogenic pathays/steroid output are controlled by complex regulatory mechanisms 
that involved wide range of factors like pituitary trophic hormones, growth factors, cytokines 
and steroids. The major factors, expressed since early fetal life, are steroidogenic acute 
regulatory protein (StAR) and Steroidogenic Factor-1 (SF-1). StAR actively transports 
cholesterol from the outer to the inner mitochondrial membrane and allows CYP11A (located 
in the inner membrane) access to cholesterol [17]. Cell specific expression of StAR and P450 
enzymes are regulated by Steroidogenic Factor-1 (SF-1), which binds to promoter region of 
StAR gene and of all CYP genes, activating their expression [18, 19]. The most compelling 
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evidence for the essential requirement for StAR in steroidogenesis is provided by StAR-
specific knockout mice and human mutations that caused the potentially lethal condition 
known as congenital lipoid adrenal hyperplasia.  It is not surprising that 46XY individuals 
with mutated SF1 have XY sex reversal, indicative of disrupted fetal testosterone biosynthesis 
and masculinization. In mice with Leydig cell-specific knockout of SF-1 gene there is lack of 
CYP11A and StAR expression resulting in adrenal and gonadal agenesis [20-23]. The activity of 
P450scc enzyme is regulated by mitochondrial environment [24] and the vital role of this 
enzyme is demonstrated by homozygous mutation of CYP11A gene that is lethal due to 
inability of placenta to produce progesterone [25]. Consequently, 46XY genetic males with 
partial inactivation of CYP11A exhibit major deficiencies in masculinization [26, 27]. 
The combined enzymatic actions of 3β-HSD and P450c17 catalyze the overall conversion of 
pregnenolone to androstenedione, the precursor of testosterone. This conversion can occur 
via one of two main pathways, either via ∆4 or ∆5 pathway and the preferred route is both 
species- and age-dependent. [14] (Figure 2.). 
 
Figure 1. Pathways of human steroidogenesis [12]. 
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Figure 2. Steroid biosynthetic pathways as adapted to Payne, 2007 [16] 
The ∆4 pathway (pregnenolone, progesterone, androstenedione, testosterone) was the first 
indentified route in rat testis and subsequently shown to be preferred one. In the human 
and higher primates, as well as in pig and rabbit the ∆5 pathway predominates in the adult 
and fetal testis because human P450c17 enzyme readily converts 17α-hydroxypregnenolone 
to dehydroepiandrosterone (DHEA), but has little emzyme activity when 17α-
hydroxyprogesterone is the substrate. In the rat, P450c17 readily cleaves both the ∆4 and ∆5 
C21 steroids, but in contrast to the human, it has a preference for the ∆4 pathway. In the 
mouse the ∆4 pathway dominates before puberty but in adult animals the ∆5 pathway may 
also contribute to overall testosterone production. Therefore, differences in preferred 
pathways between species are likely to depend upon relative substrate affinity of P450c17 
enzyme [6, 14].  
The clinical importance of P450c17 enzyme is demonstrated by numerous reports on 
CYP17A gene mutations [28, 29, 30]. Both male and female patients are hypertensive because 
overproduction of mineralocorticoids as well as impaired production of cortisol. Affected 
females exhibit abnormal sexual development resulting in primary amenorrhea. Male 
patients are phenotypic females due to the deficiency of testosterone production. 
3. 3β-HSD gene family – function, tissues distribution, regulation and 
clinical importance 
The 3β-HSD was described in 1951 and later characterized as bifunctional dimeric enzyme 
required for the biosynthesis of all classes of steroid hormones (glucocorticoids, 
mineralocorticoids, progestagens, androgens, and estrogens). Therefore the 3β-HSD controls 
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the critical steroidogenic reactions in the adrenal cortex, gonads, placenta, and peripheral 
target tissues [31]. The 3β-HSD isoforms catalyze the conversion of the ∆5-3β-
hydoxysteroids - pregnenolone, 17α-hydroxypregnenolone, and DHEA, to the ∆4-3-
ketosteroids - progesterone, 17α-hydroxyprogesterone, and androstenedione, respectively. 
Two sequential reactions are involved in the conversion of the ∆5-3β-hydroxysteroid to a 
∆4-3 ketosteroid. The first reaction is the dehydrogenation of the 3β-hydroxysteroid, 
requiring the coenzyme NAD+, yielding the ∆5-3-keto intermediate, and reduced NADH. 
The reduced NADH, activates the isomerization of the ∆5-3- keto steroid to yield the ∆4-3-
ketosteroid (Figure 2.). Stopped-flow spectroscopy studies show that NADH activates the 
isomerase activity by inducing a time-dependant conformational change in the enzyme [15, 
32]. Using histochemical and imunohistochemical techniques 3β-HSD activity was detected 
to the smooth endoplasmic reticulum and mitochondrial cristae and later in the microsomal 
fraction suggesting that 3β-HSD is a membrane-associated enzyme [16]. Submitochondrial 
fractionation studies showed that 3β-HSD is in a functional steroidogenic complex with 
P450scc located in the inner mitochondrial membrane [33, 34], that provides the enzyme 
with immediate substrate metabolized from cholesterol. However, 3β-HSD activity could be 
preferentially distributed to the mitochondria under certain physiological conditions [35, 
36]. 
Isoforms: Structural studies of 3β-HSD family characterized several isoforms, products of 
distint genes. The number of isozymes varies in different species. The isoenzymes differ in 
tissue distribution, catalytic activity (whether they function predominantly as 
dehydrogenases or reductases), in substrate and cofactor specificity, and in subcellular 
distribution [6]. So far, two isoforms were reported in human (h) 3β-HSD, six in mouse, four 
in rat and three in hamster. Multiple 3β-HSD isoenzymes have been cloned from several 
other species, further illustrating that the 3β-HSD gene family is conserved in vertebrate 
species The human type I 3β-HSD gene (HSD3B1) encodes an enzyme of 372 amino acids 
predominantly expressed in the placenta and peripheral tissues (skin, mammary gland, 
prostate, and several other normal and tumor tissues) [37, 38]. In comparison, the type II 
gene (HSD3B2), which encodes a protein of 371 amino acids, shares 93.5% identity with the 
type I and it is almost exclusively expressed in the adrenals ovaries and testes. It is most 
homologous to the type I gene expressed in mice, rats and other species [39, 40]. The 
structure of hHSD3B1 and hHSD3B2 genes consists of four exons which are included within 
a DNA fragment of 7.8 kb and genes are assigned to chromosome 1p13.1 [41]. 
The rat type I and II 3β-HSD proteins are expressed in the adrenals, gonads, kidney, 
placenta, adipose tissue, and uterus and share 93.8% identity. The type III protein shares 
80% identity with the type I and II proteins but, in contrast to other types, it is a specific 3-
ketosteroid reductase (KSR) [42, 43]. The type III gene is exclusively expressed in male liver, 
and there is marked sexual dimorphic expression, which results in pituitary hormone-
induced gene repression in the female rat liver [44]. The rat type IV protein shares 90.9%, 
87.9%, and 78.8% identity with types I, II, and III proteins, respectively. Furthermore, types I 
and IV possess a 17β-HSD activity specific to 5α-androstane-17β-ol steroids, thus suggesting 
a key role in controlling the bioavailibility of the active androgen dihydrotestosterone DHT 
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[45, 46, 47]. Concerning to an enzyme having dual activity, such secondary activity could be 
explained by binding of the steroid in the inverted substrate orientation, in this case C-17 
rather than C-3 possition. [47]. 
To date, six distinct cDNAs encoding murine members of the 3β-HSD family have been cloned 
and all of them are highly homologous and encode a protein of 372 amino acids. Functionally,  
the different forms fall into two distinct classes of enzymes -  3β-HSD types I, II and III 
function as dehydrogenase/isomerases, and are essential for the biosynthesis of active steroid 
hormones whereas 3β-HSD type IV and type V (analogous to rat type III) function as 3-KSRs 
and they are involved in the inactivation of active steroid hormones  [48, 49].  In the adult 
mouse 3β HSD I is expressed in gonads and adrenal gland, whereas 3β-HSD II and III are 
expressed in liver and kidney. The type V isoenzyme is expressed only in the liver of the male 
mouse and the expression starts in late puberty. The type VI isoenzyme is the earliest isoform 
expressed during the first half of pregnancy in cells of embryonic origin and in uterine tissue 
suggesting that this isoenzyme may be involved in the local production of progesterone, 
required for the successful implantation and/or maintenance of pregnancy [50]. In the adult 
mouse, 3β-HSD type VI appears to be the only isoenzyme expressed in skin. The aminoacid 
sequences among the different isoforms and between mouse and human isoforms show a high 
degree of identity. Mouse 3β-HSD I has 84% identity to mouse VI, and 71% identity to human 
II [31, 50]. 
Tissue distribution: As 3β-HSD gene family is widely expressed within the steroidogenic 
organs (adrenal, ovary and testis) as well as in peripheral tissues, the distribution and local 
regulation will be described separately for each organ. 
Adrenal: The onset of 3β-HSD expression in the fetal primate adrenal cortex correlates with 
the ability of the definitive zone to synthesize aldosterone and also allows cortisol 
production by transitional zone cells. Although 3β-HSD is not expressed to a high degree in 
the fetal cortex, P450c17 is expressed, thereby directing the steroidogenic pathway toward  
∆5-hydroxysteroid (i.e., DHEA) production. There is zone-specific steroid secretion pattern 
dependent on the relative expression levels of 3β-HSD, P450c17 and P450 21α-hydroxylase 
(P450c21) that serve as molecular markers of the adrenocortical developmental state [51, 52]. 
After birth, the coexpression of 3β-HSD and P450c21 leads to aldosterone production, 
whereas the coexpression of 3β-HSD and P450c17 results in production of cortisol. The 
expression of P450c17 along with low levels of 3β-HSD expression leads to synthesis of 
DHEA. The differential expression of the enzymes required for zonal-specific steroid 
production in the adrenal is under the control of multiple factors as Adrenocorticotropic 
hormone (ACTH), Epidermal Growth Factor (EGF), Fibroblast Growth Factors (FGFs), 
Insulin-like Growth Factors (IGFs), thyroid hormone (T3), Transforming Growth Factor-β 
(TGFβ) [31, 53, 54]. Therefore, there appears to be a complex interplay of factors controlling 
adrenal development, and combinations of these factors could be involved in the regulation 
of 3β-HSD and other steroidogenic enzymes in vivo. 
Ovary: Ontological studies for 3β-HSD have shown that fetal human ovaries are 
steroidogenically quiescent except for a window late in gestation [55], so most of the 
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estrogens seen by the primate fetus are of placental origin [56]. 3β-HSD is not expressed in 
mouse and rat ovary until first week after birth.This is in contrast to testicular expression 
because androgen production by the male embryo is critical for male sexual development 
[57]. PCOS is an ovarian disorder associated with hyperthecosis of the ovary and elevated 
serum LH, insulin, and androgen levels. Several studies provide evidence of aberrant 3β-
HSD regulation in polycystic thecal cells although the mechanisms are unclear [58]. 
Preantral/antral follicular expression studies show 3β-HSD mRNA and protein expression in 
the human ovary initially in the theca and then in the granulosa layer as folliculogenesis 
continues [59]. In nonprimate species, 3β-HSD has been shown to have different expression 
patterns. In the rat, preantral, antral, and preovulatory rat follicles showed 3β-HSD 
expression in the theca, but no expression was seen in the granulosa layer [60]. In contrast to 
rodents, pigs, and primates, 3β-HSD expression in the cow was seen in all the stages of the 
preovulatory follicle in both theca and granulosa layers [61]. Pituitary hormones are the 
primary means of the regulation of the steroidogenesis in the ovary.The gonadotropins, FSH 
and LH cause an increase in 3β-HSD expression concomitantly with other steroidogenic 
enzymes. The role of prolactin (PRL) on primate 3β-HSD is unclear, although PRL was 
shown to be inhibitory. Interestingly in postmenopausal women 30% of circulating ∆4-
DIONE is of ovarian origin [62]. These studies suggest that ovarian steroid production in 
postmenopausal women continues, but the decline in pituitary control dramatically changes 
the steroid profile. After ovulation, Corpus Luteum (CL) is developed to secrete large amount 
of progesterone that is controlled in part by the amount of 3β-HSD. The enzyme is 
considered as a marker for progesterone production of the CL [63]. In primates, LH/hCG 
action through LH receptor provides a primary mean of luteotropic support [64, 65]. In 
addition, FSH increased 3β-HSD protein and mRNA levels in human granulosa-lutal cells, 
and this effect could be enhanced by insulin [66]. Although the direct control of 3β-HSD by 
PRL in humans has yet to be demonstrated, PRL has been shown to up-regulate 3β-HSD 
transcriptional activity in vitro [67]. During regression of CL (luteolysis) the expression of 
3β-HSD dramatically decreased and there is evidence that LH is mainly involved in 
induction of luteolysis [68]. 
Testis: Testis is the major place for production of androgens, mainly testosterone although 
local conversion/reduction of testosterone to dihydrotestosterone (DHT) by 5α-Reductase 
(5α-Red) occurred in the following part of reproductive system (epididymis and prostate). 
Within the testis, the Leydig cells (LC) are primary place for steroidogenesis as they are only 
cell type in the male that expressed all of the enzymes essential for the conversion of 
cholesterol to testosterone [16]. During development two distinct population of LCs arise 
sequentially, namely fetal and adult LC population, being differentially regulated [20]. 
Immunohistochemical studies have revealed that human Leydig cells express 3β-HSD as 
early as 18 wk of gestation. During gestation in human, 3β-HSD expression is an indicator of 
testicular androgen production. Adult Leydig cells arise postnatally and encompass three 
developmental stages: progenitor, immature and adult Leydig cells [69]. Rat testes of 
postnatal day 15 showed 3β-HSD localization to the smooth ER in precursor Leydig cells 
and that points the beginning of differentiation of adult LC population. At this time point 
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LC expressed P450scc and P450c17, as well. Therefore an antibody against 3β-HSD is 
highly applicable as a marker for visualization both, fetal and adult LC. The expression of 
3β-HSD protein overlapped with expression of other steroidogenic enzymes, P450scc and 
P450c17, clearly demonstrated on Figure 3 and that was confirmed by other authors [70]. 
Development of triple co-localization immunohistochemical technique allows 
distinguishing of presumptive progenitors cells form adult or fetal LC that is very helpful 
to study kinetic and differentiation pattern of LCs (Figure 4) [71]. Application of IHC for 
3β-HSD is widely used by many authors in quantification studies of LC under normal and 
experimental/pathological conditions, especially those of hormonal manipulations [72]. 
3β-HSD immunohistochemistry is also useful tool for validation of EDS (ethane 
dimethanesulfonate) model for selective ablation of adult LC and thus testosterone 
withdrawal. The major regulator of postnatal testicular expression of 3β-HSD in rodents 
and human is the LH, acting via LH receptor located in LCs. That is in contrast to the 
fetal testis where an independent mechanism is suggested [73]. Steroids and growth 
factors (EGF, TGFβ, FGFs, Activin A) are also suggested to control the expression of 3β-
HSD [31]. 
Peripheral tissues; Expression of 3β-HSD in peripheral tissues such breast, prostate, placenta, 
liver, blain and skin will be briefly described in relation to clinical importance. Sex steroids 
are well recognized to play a predominant role in the regulation of cell growth and 
differentiation of normal mammary gland as well as in hormone-sensitive breast 
carcinomas. Estrogens stimulate cell growth of hormonesensitive breast cancer cells, 
whereas androgens exert an antiproliferative action in breast cancer cells [74]. Stage II/III 
infiltrating ductal primary breast tumors demonstrated 3β-HSD activity [75], and 3β-HSD 
protein was seen in 36% of breast carcinoma samples tested [76, 77]. The 3β-HSD expressed 
in human placenta is the peripheral isoform, type I 3β-HSD, and it is under differential 
regulatory control than the adrenal/gonadal isoform, type II 3β-HSD [78, 79]. In the prostate 
epithelium 3β-HSD expression was colocalized with 17β-HSD type V in normal conditions. 
3β-HSD was found in human hyperplastic prostates  suggesting the capacity of the human 
prostate for local androgen production, that increase the hypertrophic potential of the organ 
[80, 81]. Hepatic 3β-HSD expression is presumed to be important in the metabolism and 
inactivation of steroids. 3β-HSD activity in human liver microsomes was shown to be three 
times higher for the reduction of DHT to 3∆-DIOL than the reverse reaction [82]. The 
circulating levels of steroids might affect regulation of 3β-HSD activity in the liver, principally 
through altering Growth Hotmone (GH) and PRL levels, and thereby resulting in feedback on 
steroid degradation [83]. In skin 3β-HSD was confined to keretinocytes, co-expressed with 
17β-HSD. Aberrant expression of these enzymes results in increased scalp DHT levels and 
possibly acceleration of the balding process in genetically predisposed men and women [84, 
85]. 3β-HSD expression was reported in the central nervous system (CNS) and peripheral 
neurons demonstrating the importance of steroid hormones for growth maturation and 
differentiation of nerve tissue. For instance,  3β-HSD together with P450scc are expressed in 
the hippocampus, dentate gyrus, cerebellum, olfactory bulb, and Purkinje cells of the rat brain 
with highest levels in cerebellum [86] as well as in cultured neuronal cells [87] 
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Figure 3. Immunoexpression of steroideogenic ezymes (3β-HSD, cytochrome P450scc and cytochrome 
P450c17 in the Leydig cells (DAB-brown) of postnatal mouse testis after birth to sexual maturity (d2-
neonatal, d12-prepubertal, d20-pubertal, d50-adult) x400. 
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Figure 4. Triple immunostaining for 3β-HSD (blue), α-smooth muscle actin (red) and COUP TFII 
(brown) in fetal (embryonal day 21.5) and postnatal (pubertal-d25 and adult-d75) rat testes. Fetal and 
adult LCs (arrows) are clrearly distinguishable from presumptive ptogenitors cells (arrowheads) x400. 
Regulation: The regulation of 3β-HSD gene family is quite complex process involving 
multiple signal transduction pathways that are activated by growth factors, steroids and 
cytokines and they are differentially dependent on ontogeny and tissue distribution. Initial 
studies investigating the transcriptional regulation of the human HSD3B2 gene are primarily 
focused on the trophic hormones, including ACTH in the adrenal cortex, LH/human 
chorionic gonadotropin (hCG) in theca cells and corpus luteum, as well as LH in testicular 
Leydig cells.  cAMP is well known intracellular mediator of trophic hormone stimulation of 
3β-HSD expression but mechanisms by which cAMP stimulate transcription of the HSD3B2 
gene are not clear yet. [31].  
Gonadal expression of human 3β-HSD II and mouse 3β-HSD I is dependent on SF-1 as 
described for the gonadal-specific expression of the P450 steroidogenic enzymes [88]. 
Studies on mouse Hsd3b1 promoter identified three potential SF-1 consensus binding sites 
[89]. The regulation of HSD3B2 human gene expression involved the transcription factors of 
Stat family (signal transducers and activators of transcription) [90]. Interestingly, the Stat5 
knockout mice displays luteal failure [91]. DAX-1 (dosage-sensitive sex reversal adrenal 
hypoplasia congenita critical region on X chromosome gene-1) was originally isolated by 
positional cloning from patients with DAX-mutation exhibiting adrenal congenita 
hypoplasia associated with hypogonadotropic hypogonadism. The studies examining the 
effects of DAX-1 overexpression on adrenal cell showed suppression of steroidogenesis 
associated with inhibition of the expression of StAR, P450scc, and 3β-HSD [92]. The exact 
mechanisms by which DAX-1 overexpression affects 3β-HSD expression remain unclear. 
Interestingly, transcription factors belonging to the GATA family are emerging as novel 
regulators of steroidogenesis.  In fetal and adult adrenals and gonads several target genes 
for GATA protein were identified such as StAR, CYP11A, CYP17A, CYP19A, HSD17B1, 
human HSD3B1 and HSD3B2 [93]. Moreover, deregulation of GATA expression and/or 
activity might be relevant to pathological processes associated with aberrant HSD3B2 
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expression such as adrenal insufficiency, male pseudohermaphroditism and polycystic 
ovary syndrome (PCOS) [31]. Immune cell populations in the ovary undergo changes 
during the reproductive cycle and cytokines from these immune cells (Interleukin-4, IL-4) 
have been shown to affect steroidogenesis, mediated by Stat [94]. Some growth factors like 
members of the TGFβ family and nerves growth factor have been shown to regulate 
HSD3B2 gene expression [95-97]. There is growing evidence in the literature that steroid 
hormones modulate type II 3β-HSD expression. For example, glucocorticoids stimulate the 
expression of 3β-HSD in adrenal cells [98], whereas androgens inhibit 3β-HSD expression in 
the adrenal cortical cells and in testicular Leydig cells [99, 100]. There are number of 
questions concerning the mechanisms of steroids and the action of their receptors. In 
relation to structure-function aspects the question is what is the influence of known steroid 
agonists and antagonists on the efficacy of activation? What is the effect of other nonsteroid 
factors, which are known to activate other intracellular signaling pathways on steroid-
regulated transcription?  
Clinical importance of 3β-HSD genetic deficiency:  
Homozygous mutations in HSD3B1 are lethal in human due to interruption of pregnancy 
before the end of the first trimester because 3β-HSD I protein is required for progesterone 
synthesis in the placenta (as described above for CYP11A). Many mutations in the HSD3B2 
gene have been identified and are summarized in a review by Simard et al. 2005 [31]. The 
classical 3β-HSD deficiency results from mutations in the HSD3B2 gene (the HSD3B1 gene 
in these patients is normal) and it can be divided, depending upon the severity of the salt-
wasting (salt-wasting or non-salt-wasting forms). The classical 3β-HSD deficiency is a rare 
form of congenital adrenal hyperplasia (CAH) accounting for about 1–10% of cases of CAH. 
The salt-losing forms of CAH are a group of life-threatening diseases that require prompt 
recognition and treatment. Indeed, the autosomal recessive mutations in the CYP21, CYP17, 
CYP11B1, and HSD3B2 genes encoding steroidogenic enzymes can cause CAH, each 
resulting in different biochemical consequences and clinical features. In these cases the 
cortisol secretion is impaired resulting in compensatory hypersecretion of ACTH and 
consequent hyperplasia of the adrenal cortex. However, only deficiencies in 21-hydroxylase 
(CYP21) and 11β-hydroxylase (CYP11B1) predominantly result in virilizing disorders. 
Indeed, in patients with the classical form of these two defects, the most noticeable 
abnormality in the sexual phenotype is the masculinization of the female fetus due to 
oversynthesis of adrenal DHEA. Male individuals suffering from classical 3β-HSD 
deficiency present hypospadias. On the other hand, the complete or partial inhibition of 3β-
HSD activity in the adrenals and ovaries was not accompanied by a noticeable alteration in 
the differentiation of the external genitalia of female patients. The reason for this striking 
difference in phenotype between the male and female individuals is that the deficiency of 
3β-HSD in the fetal testis results in lowering of the T levels below the levels required for the 
normal development of male external genitalia.  
The basal plasma levels of ∆5-3β-hydroxy steroids such as pregnenolone (PREG), 17OH-
PREG, and DHEA are elevated in affected individuals. An elevated ratio of ∆5/∆4-steroids is 
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considered to be the best biological parameter for the diagnosis of 3β- HSD deficiency. The 
best criteria for the correct diagnosis of this disorder now appears to be a plasma level of 
17OH-PREG but 17OH Progesterone (17OH-PROG) also should be measured  for correct 
diagnosis of 3β-HSD deficiency. It is well recognized that plasma levels of 17OH-PROG and 
∆4-DIONE and other ∆4-steroids are frequently elevated in 3β-HSD-deficient patients.  Such 
observations are consistent with a functional type I 3β-HSD enzyme that is expressed in 
peripheral tissues. Moreover, the peripheral type I 3β-HSD activity could explain why 
certain patients were initially misdiagnosed as suffering from 21-hydroxylase deficiency, in 
view of elevated levels of 17OH-PROG and mild virilization seen in girls at birth.  Therefore, 
measurement of the levels of 17OH-PREG should be performed when an elevated level of 
17OH-PROG has been observed in a female neonate without ambiguity of external genitalia 
or if the patient is a male pseudohermaphrodite [31]. 
4. 11-hydroxysteroid dehydrogenase – biological role in the regulation 
of glucocorticoid metabolisms and cortisol levels 
The glucocorticosteroids exert diverse actions throughout the body and many of them have 
important implications in the reproduction and metabolite syndrome. It was recognized that 
within potential target cells, the actions of glucocorticoids are modulated by 11-
hydroxysteroid dehydrogenases (11β-HSD) which catalyse the reversible inactivation of 
cortisol and corticosterone to their inert 11-ketosteroid metabolites, cortisone and 11-
dehydrocorticosterone, respectively [101]. The actions of physiological glucocorticoids 
(cortisol and corticosterone) are modulated by isoforms of the enzyme 11β-HSD (Figure 5, 
[108]). To date, two isoforms of 11β-HSD have been identified: 1) 11β-HSD1 acts 
predominantly as an NADP(H)-dependent reductase that converts inactive circulating 11-
ketosteroids, into active glucocorticoids generating active cortisol or corticosterone; 2) 11β-
HSD2 is a high affinity NAD+-dependent enzyme that catalyses the inactivation of 
glucocorticoids [102-107]. Although the biochemistry of 11β-HSD is well established, the 
physiological significance of glucocorticoid metabolism by these enzymes is still not fully  
 
Figure 5. 11-hydroxysteroid dehydrogenase (11-HSD) (Adopted by Seckl et al., 2004 [108]) 
 
Dehydrogenases 128 
understood. The enzymatic inactivation of cortisol and corticosterone by 11β-HSD enzymes 
appears to be of central importance for protection of gonadal steroidogenesis, prevention of 
intra-uterine growth retardation and metabolite syndrome. 
This review focuses on the importance of 11β-HSD isoenzymes in the developing and aging 
testis, ovary, adrenal gland, placenta and adipose tissue. The current work aims to provide 
recent understanding of the biological roles played by 11β-HSD in different processes and 
diseases including reproduction, adrenal gland function, cystic ovarian disease, and the 
metabolite syndrome. In addition, this review summarizes recent knowledge based on 
human data and genetic models on the clinical importance of 11β-HSD in relation to 
metabolite syndrome.  
5. 11-hydroxysteroid dehydrogenase in developing testis- marker for 
differentiation of the Leydig cells 
The enzyme 11-hydroxysteroid dehydrogenase (11-HSD) is hypothesized to modulate 
LCs steroidogenesis by controlling the intracellular concentration of glucocorticoids. By 
doing so, 11-HSD can protect the LCs against the suppressive effect of glucocorticoids [109-
112]. Glucocorticoids have been found to directly inhibit the transcription of genes encoding 
the key enzymes of testosterone biosynthesis [113,114]. Excessive glucocorticoid exposure 
suppress androgen synthesis and thus decrease serum testosterone (T) levels by inducing 
LC apoptosis and reducing the number of LCs per testis [115,116]. The effects of 
glucocorticoids on LCs are not only associated with the classic glucocorticoid receptor-
mediated mechanism but possibly through the plasma membrane receptor or prereceptor-
mediated action by the glucocorticoid metabolizing enzyme 11β-HSD1 [117]. Both isoforms 
of 11-HSD are localized in testicular LCs [118-121]. Recent studies showed that reductase 
activity predominates in both human and rat type 1 11-HSD [109]. In contrast, the other 
11-HSD isoform, type 2, has been found to be exclusively oxidative [118,110,131]. 
Predominance of oxidative activity results in glucocorticoid inactivation, whereas the 
reductive activity of the enzyme has an opposite effect [109]. Hu et al. [122] postulated that 
inhibition of 11β-HSD1 in rats in vivo, increases intracellular active glucocorticoid 
concentration and thereby affects serum T concentration and steroidogenic enzyme 
expression in the LCs. The above mentioned data suggest an important role of 11β-HSD1 in 
modulating intracellular corticosterone concentrations and, in turn, for a direct effect of 
glucocorticoids on LCs. On the other hand, 11β-HSD type 1 mRNA and its activity was 
decreased corticosterone deficiency, and it seems that LCs need to maintain their 
intracellular concentration of corticosterone for normal function [123].  
Several authors have demonstrated that 11-HSD in LCs is predominantly an oxidase [109-
111] and the enzyme has been suggested as a marker for the functional maturity of rat adult 
LCs [111,112,124,125]. The appearance of 11-HSD correlates with the postnatal increase in 
testicular weight, LCs number, total surface area of the intracellular membranes and T 
production by LCs [112]. Neumann et al. [126] reported a temporal coincidence of the first 
appearance of elongated spermatids in the seminiferous epithelium and the first 
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histochemical demonstration of 11-HSD in the rat LCs on 35 pnd. The developmental 
pathway of ALCs population is accompanied with an increase in the 11-HSD activity and 
thus the enzyme can be used as a marker for steroidogenic differentiation of LCs 
[112,124,126,127]. Examination of 11-HSD in the LCs revealed that both oxidative and 
reductive activities were barely detectable in the progenitors (PLCs), intermediate in 
immature type (ILCs), and highest in ALCs. The ratio of the two activities favored reduction 
in PLCs and ILCs and oxidation in ALCs [109]. Clear recognizable oxidative activity of 11-
HSD is present from 31 pnd onward, first in single ALCs and later in majority of these cells 
[127]. ALCs population expresses high levels of 11-HSD oxidative activity [109,125] and 
enzymatic behavior of 11-HDS in LCs is not consistent with the presence of type 1 alone 
[127,128]. Developmental analysis of 11-HSD in rat LCs revealed that 11-HSD reductive 
activity predominated in LCs precursors, whereas in adult LCs, the enzyme was primarily 
oxidative [118]. This switch, observed in the predominant direction of catalysis of 11-HSD 
from reduction to oxidation in adult LCs, may protect this cell type from glucocorticoid-
mediated inhibition of steroidogenesis. It was demonstrated that the adult LCs expressed 
not only 11-HSD type 1, an oxidoreductase, but also type 2, an unidirectional oxidase [129, 
130]. Due to its high affinity for glucocorticoid substrates and exclusively oxidative activity, 
11-HSD type 2 may also play a protective role in blunting the suppressive effects of 
glucocorticoids on LCs steroidogenesis. The inhibition of 11-HSD1 predominantly lowered 
reductase activity whereas by inhibition of 11-HSD2 alone, the oxidase activity was more 
prominently suppressed [131]. Recently, it has been reported that products such 7α-
hydroxytestosterone significantly switched 11β-HSD1 oxidoreductase activities toward 
reductase in developing rat testis and thus regulates the direction of 11β-HSD1 activity in 
LCs [132]. It seems that the switch of 11-HDS activity from reduction to oxidation during 
the transition from PLCs to ALCs [109] can be associated with the presence of 11-HSD2.  
As mentioned above the main function of glucocorticoids in adult LCs is inhibition of T 
biosynthesis [111]. Glucocorticoids directly regulate T production in LCs through 
glucocorticoid receptor (GR)-mediated repression of the genes that encode T biosynthetic 
enzymes [143,109]. The response of LCs to glucocorticoids depends not only on the number 
of GR and the circulating concentration of glucocorticoids, but also on the ratio of 11-HSD 
oxidative and reductive activities [144]. When oxidation predominates over reduction, 11-
HSD decreases the intracellular availability to active glucocorticoid, attenuating GR-
mediated responses [118]. In this way, T production is maintained in the presence of normal 
serum concentrations of corticosterone and it is inhibited only if 11-HSD oxidative capacity 
in LCs is reduced.  
By using experimental model for treatment with ethane-dimethnesulphonate (EDS) of 
mature rats our studies provided new data about expression pattern of 11-HSD during 
renewal of LCs population [133]. The quantitative immunohistochemical analysis of 11 
HSD2 pattern after EDS treatment revealed progressive increases in the reaction intensity 
during postnatal development (on d 21after EDS) and reached a maximum on d35 and that 
is a turning point in the development from immature to mature LCs [133]. These changes in 
11-HSD2 expression are consistent with previous data about structural and functional 
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maturation of the new population of LCs after EDS [134,135]. Therefore, 11-HSD2 can be a 
useful marker for ALCs differentiation and the reaction intensity might be associated with 
increased 11-HSD oxidative activity that occurred during the transition from PLCs to ALCs 
in postnatal rat testis [109,127]. Moreover, the gene profiling of rat PLCs, immature LCs and 
ALCs showed increased expression of 11-HSD2 gene that is in parallel with enhanced 11-
HSD2 enzyme activity during postnatal development [136]. Together with previous studies 
[126] the data from EDS model suggest the relationship between 11-HSD and kinetics of 
spermatid differentiation and restoration of T production by new LCs population.  
6. 11-hydroxysteroid dehydrogenase in aging testis- role in the response 
of Leydig cells to the glucocorticoids 
It has been established that circulating levels of testosterone decrease with age in both male 
rodents and men [137]. It was demonstrated by analyzing cohorts of healthy men and 
rodents that the decline in androgen levels result from specific age-related changes in the 
male reproductive system and not secondarily from increased disease frequency associated 
with the aging process, [138,139]. Data indicated that the hypothalamic-pituitary axis in the 
aging individuals is still intact [140]. Indeed, it is unlikely that the deficiency in the 
hypothalamic-pituitary axis are primarily responsible for age-related changes in 
steroidogenesis. The reduced ability of aging LCs to produce T might be caused by events 
occurring outside these cells that impinge upon them or by events that occur within LCs 
themselves [141]. It seems that functional changes in LCs themselves rather than their loss 
cause reduced steroidogenesis during aging [142].  
Our data demonstrated that aging affects T production not only through the direct 
suppression of 3-HSD, a key marker for LCs steroidogenic activity but also through the 
inhibition of 11-HSD type 2 and insulin-like 3 (INSL3) factor that are involved in functional 
maturation of the adult LCs [146]. These data suggest that increasing functional 
hypogonadism in aging male rats is likely caused by dedifferentiation of the LCs 
themselves. Our findings for reduced 11-HSD type 2 expression in aging LCs provide new 
evidence for the functional properties of this enzyme in rat testis and bring an additional 
elucidation of the intracellular mechanisms underlying the decrease in T production 
accompanying aging. Significant diminished expression of 11-HSD type 2 in LCs with 
aging implies suppression in 11-HSD oxidative capacity resulting in elevated inhibitory 
potency of corticosterone on T production [136]. The reduced expression of 11-HSD type 2 
in aging rat LCs is also suggestive for decline in LCs protection ability as opposed to 
adverse effect of glucocorticoids on T production [146]. Inhibition of 11-HSD 2 oxidative 
activity by treatment with 11-HSD 2 antisense oligomer results in excess of glucocorticoids 
due to lowering the rate of their inactivation [136]. On the other hand, the elevated levels of 
corticosterone caused decline in oxidative activity of 11-HSD leading to impaired LCs 
steroidogenesis [147]. Therefore, the reduction of 11-HSD type 2 oxidase occurred during 
LC aging [146] appears to be a key event that leads to down-stream deficits in the response 
of LCs to prevent glucocorticoid-mediated suppression of steroidogenesis. (Figure.6) 
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Figure 6. 11-HSD type 2 in developing Leydig cells (LC)- 7, 21 and 35 days after EDS; and aging 
Leydig cells- 3, 18 and 24-months of age. x 400. 
7. 11-hydroxysteroid dehydrogenase in the adrenal gland - expression 
profile under conditions of testosterone withdrawal 
As mentioned above, the enzyme11-HSD catalyzes the interconversion of glucocorticoids 
to inert metabolites in man and rodents and plays a crucial role in regulating the action of 
corticosteroids. Inhibition of 11-HSD allows access of cortisol or corticosterone to the 
mineralcorticoid receptors where they act as mineralcorticoids [148]. Northern blot analyses 
revealed expression of mRNAs encoding both 11-HSD1 and 11-HSD2 in the whole rat 
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adrenal gland. In situ hybridization of rat adrenal cortex and medulla demonstrated specific 
localization of 11 HSD1 mRNA predominantly to the cells at the corticomedullary junction, 
within the inner cortex, suggesting that the oxoreductase enzyme may serve to maintain 
high medullary glucocorticoid concentrations required for catecholamine biosynthesis. In 
contrast, 11-HSD2 mRNA was more uniformly distributed in the cortex and was 
low/absent in the medulla [149, 150]. The expression of 11-HSD2 has been demonstrated in 
rat adrenal gland by immunohistochemical and molecular analyses and the 11-HSD2 
antigen was confined to the zona fasciculata and zona reticularis, but not in the zona 
glomerulosa or medulla [149-151]. The ubiquitous presence of 11-HSD2 in sodium-
transporting epithelia revealed that mineralcorticosteroid action is facilitated by this enzyme 
which metabolizes glucocorticoids and allows aldosterone to bind to the nonselective 
mineralcorticoid receptor [151].  
Using EDS experimental model in adult rats [152] we found that the dynamic of 11-HSD2 
expression correlated with the changes of serum T levels following the exposure after EDS 
[153]. The lowest 11-HSD2 staining intensity was found 7 days after EDS followed by 
progressive increase in the immunoreactivity on day 14 and 21 after EDS [152]. Moreover, 
the restoration of 11-HSD2 activity on day 14 after EDS corresponded with unchanged 
glandular and serum corticosterone levels in treated rats on day 15 reported by Plecas et al. 
[154]. Enzymatic assays on tissue homogenates showed extensive conversion of 
corticosterone to its 11-dehydro product in an NAD+-dependent manner in adrenal gland 
[151]. Using enzymehistochemistry a strong reduction was found in the activity of NADH2- 
cytochrome-C-reductase that is involved in NAD+-synthesis as a cofactor in the adrenal 
gland after EDS treatment of adult rats [155]. Immunohistochemical analysis revealed that 
the 11-HSD2 expression pattern in adrenal gland of EDS treated rats [152] is very similar to 
the enzymehistochemical profile of NADH2- cytochrome-C-reductase [155], supporting the 
view that 11-HSD2 acts as high-affinity NAD+-dependent dehydrogenase in the rat adrenal 
gland [151]. On the other hand, the increase in the expression of 11β-HSD2 in rat adrenal 
gland on day 14 after EDS treatment [152] coincided with the appearance of the 
repopulation of testosterone-producing Leydig cells in the testis [135]. These data suggested 
a possible role of the gonadal steroids, especially of testosterone, as modulators of the 
adrenal gland functional activity and they are consistent with previously reported results 
related to the direct impact of testosterone on the key steps in the adrenal gland 
steroidogenesis [156]. The above mentioned findings characterized 11β-HSD2 (high-affinity 
NAD+- dependent unidirectional dehydrogenase) as a potential target of testosterone action 
in rat adrenal cortex. Our data from EDS experimental model provided new evidence for 
expression of 11-HSD2 in the adrenal gland under conditions of testosterone withdrawal. 
The EDS results bring additional elucidation on the functional significance of 11β-HSD 
system in rat adrenal gland and the regulatory role of testosterone in its activity [152]. 
Together with our previous studies [135,153], these data suggested the relationship between 
11-HSD2 expression in adrenal gland and kinetics of restoration of testosterone production 
during renewal of testicular adult LCs population after EDS treatment. (Figure 7) 
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Figure 7. 11-HSD2 immunoreactivity in rat adrenal gland zones. 35 days after EDS (a, b); 7 days after 
EDS (c, d); 21 days after EDS (e, f). 11-HSD2- immunoreactivity in the zona fasciculata (ZF) and zona 
reticularis (ZR), and the adipocytes of adrenal capsula adipose (A). Less sensitive were the 
adrenocorticocytes of zona glomerulosa (ZG). No positive signals in the medulla (M). x 200. 
8. 11β –hydroxysteroid dehydrogenase in the ovary – cellular 
localization/distribution and relation to Polycistic Ovaries Syndrome and 
obesity in women 
Glucocorticoids exert their effects in all parts of the body and they are involved in a number 
of physiological processes, including female reproduction. The ovary is also affected by the 
glucocorticoids and it is well known that the reproductive function may be impaired in 
cases of adrenal hyperactivity. The ovaries express glucocorticoid receptors and one of the 
prominent glucocorticoids affecting ovarian function is the cortisol [157]. Ovaries lack the 
necessary enzymes for cortisol synthesis and cortisol is not produced de novo [158] but it was 
delivered by the circulation. The 11β-HSD enzymes play a crucial role in controlling the 
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tissue concentration of cortisol. The two types of 11β-HSD (1 and 2) with opposite action 
modifies cortisol exposure by interconversion between active and inactive glucocorticoids 
[159,160].  
In the human ovary expression of 11β-HSD types 1 and 2 is well documented. 11β-HSD type 
2 expression is most prominent during the luteal phase in the corpus luteum and in non-
luteinized granulosa cells from follicles before the mid-cycle surge of gonadotrophins. In 
contrast 11β-HSD type 1 is only seen in granulosa cells from preovulatory follicles [161]). As 
a result, developmentally regulated pattern of 11β-HSD types 1 and 2 promotes high levels 
of cortisol during the mid-cycle surge of gonadotrophins, immediately prior to ovulation, 
whereas reduced levels are maintained throughout the rest of the menstrual cycle [162,163]. 
Therefore the high levels of local free cortisol are suggested to act as anti-inflammatory 
agent that limited the tissue damage occurring in connection with follicular rupture 
[163,164]. This considerations suggest that the regulation of concentration of biologically 
active cortisol in the ovary may be an important physiological mechanism by which 
glucocorticoids affect female reproductive organs. 
The polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder 
among premenopausal women. The symptoms include the consequences of excessive 
androgen production (hyperandrogenemia), anovulation and infertility. The hallmark of 
PCOS is follicular maturation arrest and hyperandrogenemia that is believed to be a critical 
component of the syndrome [165, 66]. Studies regarding the pathophysiology of PCOS focus 
attention to primary defects in the hypothalamic–pituitary axis, ovarian function, insulin 
secretion and action but none of these hypotheses can fully elucidate the multiple clinical 
phenotypes of PCOS [167-169]. Insulin resistance and the associated compensatory 
hyperinsulinemia and centripetal obesity, perhaps reflect an association and linkage of the 
insulin gene with PCOS [170]. PCOS is of unknown etiology, but several lines of evidence 
suggest that there is an underlying genetic cause for PCOS. Ovarian androgen production 
occurs primarily in the theca cells and examination of the metabolism of radiolabeled 
steroid hormone precursors and steady-state levels of mRNAs, encoding steroidogenic 
enzymes, revealed that there are multiple alterations in the steroidogenic machinery of 
PCOS theca cells [171-173]. These observations are consistent with the notion that 
dysregulation of androgen biosynthesis is intrinsic property of PCOS theca cells and that 
PCOS may develop as a consequence of a primary genetic abnormality in ovarian androgen 
production [174]. Elevated adrenal androgen levels are common in PCOS, but the 
underlying pathogenetic mechanisms are poorly understood. One proposed contributing 
mechanism is altered cortisol metabolism. Moreover, PCOS and obesity are independently 
associated with increased expression of 11β-HSD1 mRNA in subcutaneous abdominal tissue 
from lean and obese women with and without PCOS. Decreased peripheral insulin 
sensitivity and central obesity were associated with increased expression of 11β-HSD1 but 
not of 11β-HSD2 mRNA expression [175]. Previous studies have described an increased 
5alpha-reduction of cortisol and impaired regeneration of cortisol from cortisone by 11β-
HSD1 in PCOS, supporting the concept of an altered cortisol metabolism in POCS [176].  
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In the rare syndrome of cortisone reductase deficiency, impaired ability of 11β-HSD1 to 
convert cortisone to cortisol, results in compensatory activation of ACTH secretion and 
adrenal hyperandrogenism [177,178]. This syndrome has been associated with the 
polymorphisms in the HSD11B1 gene, which encodes 11β-HSD1, and female patients 
affected by cortisol reductase deficiency exhibited hyperandrogenism and a phenotype 
resembling PCOS [179,180]. Lower ratios of cortisol/cortisone metabolites in urine in 
patients with PCOS were found compared to controls, suggesting a reduced 11β-HSD1 
activity [179]. Gambineri et al., [180] reported that polymorphism, predicting lower 
peripheral regeneration of cortisol by 11β-HSD1, is related to PCOS status and it is 
associated with increased adrenal hyperandrogenism in lean PCOS. These data strongly 
support a role for the HSD11B1 gene in the pathogenesis of PCOS. According to Gambineri 
et al. [180], the association of the HSD11B1 genotype with PCOS was mainly attributable to 
lean rather than obese PCOS patients, suggesting that in obese PCOS women adrenal 
hyperandrogenism must have a different pathogenetic mechanism as hyperinsulinemia 
[181] or increased cortisol clearance [182]. The above mentioned findings differ from studies 
by San Milla´n et al. [183] and White [184] where no association between HSD11B1 genotype 
and PCOS was found. This fact suggests that HSD11B1 polymorphisms may be relevant 
only in some subgroups of patients and that the pathogenesis of PCOS is different among 
the different phenotypes of the syndrome [180]. Recently, the functional consequences in 
these polymorphisms in HSD11B1 gene were examined and the results confirm previous 
reports that the variant in HSD11B1 confer increased 11β-HSD1 expression and activity, that 
are associated with the metabolic syndrome [183, 185] but are not associated with the 
prevalence of PCOS [186]. These findings are confirmed by study by Mlinar et al. [187], 
reporting that PCOS is not associated with increased HSD11B1 expression. The elevated 
expression of this gene correlates with markers of adiposity and predicts insulin resistance 
and an unfavorable metabolic profile, independently of PCOS. 
9. 11β –hydroxysteroid dehydrogenase in adipose tissue – relation to 
obesity and metabolic syndrome 
The metabolic syndrome describes a cluster of risk factors like insulin resistance, type 2 
diabetes, dyslipidemia, hypertension [188] and co-occurrence of visceral (abdominal, 
central) obesity. There are strong morphological and metabolic similarities between the 
Cushing’s syndrome of endogenous or exogenous glucocorticoid excess and the metabolic 
syndrome [189]. Glucocorticoid excess exerts opposing effects on adipose tissue, with an 
increase in central fat deposition through stimulation of preadipocyte differentiation, 
gluconeogenesis and triglyceride synthesis, while peripheral fat is reduced as a result from 
increased lipolysis and lipoprotein lipase downregulation [108]. Glucocorticoid-induced 
obesity has been investigated in animal models and in humans. It has been shown that 
cortisol levels are modestly elevated in patients with the metabolic syndrome and tend to be 
normal or even reduced in simple obesity [189].  
The preponderance of data suggest that the intracellular glucocorticoid reactivation was 
elevated in adipose tissue of obese rodent models and humans [108, 190]. The enzyme that 
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mediates this activation, locally within tissues, is 11β-HSD1 that converts inactive metabolite 
cortisone to active cortisol, thereby amplifying local glucocorticoid action [104]. 11β-HSD1 
expression in adipose tissue was first reported by Monder and White [144] and it is thought 
to be a dehydrogenase. Studies in leptin-resistant obese rats revealed that obesity was 
associated with an increase in 11β-HSD1 in abdomenal adipose tissue [191]. In human 
subcutaneous abdominal adipose tissue, 11β-HSD1 activity is increased both in vivo and in 
vitro and the enhanced 11β-HSD1 activity in biopsies is accompanied by elevated 11β- HSD1 
mRNA levels [108]). It is interesting to note, that increased subcutaneous adipose 11β-HSD1 
is associated with insulin resistance in obesity, but it is not linked specifically with visceral 
fat accumulation or hypertension [192]. The mechanisms underlying the increase in adipose 
11β-HSD1 activity in obesity and metabolic syndrome are still not fully inderstood. 11β-
HSD1 transcription is regulated by many factors like cytokines, sex steroids, growth 
hormone, insulin and induced weight loss [193-195].  
The key question is whether increased 11β-HSD1 in adipose tissue is a cause or a 
consequence of obesity and it is associated with metabolic syndrome. In order to determine 
this, mice over-expressing 11β-HSD1 selectively in adipose tissue have been generated, 
using the adipocyte fatty acid binding protein (aP2) promoter [196, 197]. The adipose-
selective 11β-HSD1 transgenic mice exhibited elevated intra-adipose, but not systemic 
corticosterone levels, as well as the major features of the metabolic syndrome-abdominal 
obesity, hyperglycaemia, insulin resistance, dyslipidaemia and hypertension. Conversely, 
transgenic mice with overexpression of 11β-HSD1 in liver showed an attenuated metabolic 
syndrome with modest insulin resistance and hypertriglyceridemia, hypertension and fatty 
liver, but with normal body weight [198]. 11β-HSD1-knock-out mice fed on a high-fat diet 
are protected from obesity and metabolic complications [199-201]. Recently, polymorphisms 
in HSD11B1, the gene encoding 11β-HSD1, have been associated with components of the 
metabolic syndrome [186, 202-205]. Moreover, subjects with single nucleotide 
polymorphisms (SNPs) in HSD11B1 gene exhibit increased adipose 11β-HSD1 expression 
and increased whole-body 11β-HSD1 activity, associated with increased prevalence of the 
metabolic syndrome. These findings strengthen the view that variations in 11β-HSD1 
activity influence the metabolic profile and provide a new evidence that HSD11B1 gene 
influence enzyme activity in vivo [186].  
10. 11β-HSD and metabolite syndrome - clinical importance  
Based on human data and genetic models, 11β-HSD1 seems to be cause and promising 
pharmaceutical target for the treatment of metabolic disease. In mice, the increased enzyme 
activity in adipose tissue enhances local glucocorticoid levels and produces a metabolic 
syndrome [196], whereas the decreased enzyme activity protects against obesity and the 
metabolic syndrome [200, 201]. In human, 11β-HSD1 expression is elevated in adipose tissue 
in obesity [206], whereas inhibition of 11β -HSD1 enhances insulin sensitivity and provides 
a new approach to treat type 2 diabetes [207-209]. Polymorphisms in the HSD11B1 gene that 
encodes 11β-HSD1 have been associated with type 2 diabetes [203] and hypertension [204, 
205]. On the other hand, a polymorphism that predicts 11β-HSD1 deficiency may protect 
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against obesity and its metabolic consequences because of impaired regeneration of cortisol 
in adipose tissue [180]. 11β-HSD1 inhibition is a tempting target for treatment of the 
metabolic syndrome and its complications. Selective 11beta-HSD1 inhibitors in rodents 
cause weight loss, improve insulin sensitivity and delay progression of cardiovascular 
disease [210-212]. Pharmacological inhibition of 11b-HSD1 with the anti-ulcer drug 
carbenoxolone has provided evidence that cortisol regeneration influences insulin 
sensitivity, particularly glycogen turnover in healthy human subjects and in patients with 
type 2 diabetes [207, 208]. This corroborated the notion that the enzyme may be an attractive 
option to treat the metabolic disease [108, 190, 202, 212, 213]. Moreover, 11β-HSD1 gene 
knock-out (11β-HSD1-/-) mice exhibited cardioprotective phenotype with improved glucose 
tolerance and lipid profile, reduced weight and visceral fat accumulation in condition of 
chronic high-fat feeding [190, 200, 201, 214]. These data support the beneficial effects of 11β-
HSD1 inhibitors to lower intracellular glucocorticoid levels and to treat both obesity and its 
metabolic complications. 
11. 11β –hydroxysteroid dehydrogenase and pregnancy – role of 11b-HSD 
type 2 as a protective barrier for fetus to overexposure to glucocorticoids; 
implication in intrauterine growth retardation 
In mammals, glucocorticoids are important for fetal growth, tissue development and 
maturation of various organs (surfactant production by the fetal lung, gut enzymes 
activation and development of the brain and liver). However, supraphysiological levels of 
glucocorticoids have been shown to cause fetal growth retardation in mammalian models 
and in human. A number of studies in animal models have examined the effects of prenatal 
exposure to synthetic glucocorticoids on the fetal development and offspring biology. 
Maternal glucocorticosteroid treatment reduces birth weight of the offspring and adults 
exhibit hypertension, hyperinsulinemia, increased hypothalamic–pituitary–adrenal (HPA) 
axis activity and altered affective behavior [215, 216]). Moreover, human intrauterine 
growth retardation is associated with high maternal and fetal concentrations of 
glucocorticoids [217]. Normally, fetal physiological glucocorticoid levels are much lower 
than maternal levels [218]. The physiological fetoplacental barrier to glucocorticoid exposure 
is placental 11β-HSD2 that catalyses the rapid conversation of active cortisol and 
corticosterone to physiologically inert cortisone and corticosterone [219]. 11β-HSD2 acts as a 
protective barrier to glucocorticoids but a small proportion of maternal glucocorticoid 
passes through the placenta [220] thus, maternal stress elevates fetal glucocorticoid levels 
[221]. Different factors are involved in the regulation of placental 11β-HSD2 expression - 
progesterone, estrogen, hypoxia, infection and proinflammatory cytokines reduce placental 
11β-HSD2 activity. Conversely, placental 11β-HSD2 activity is stimulated by glucocorticoids, 
retinoids and leptin [221]. Studies in rats and human indicate that the deficiency in placental 
11β-HSD2 activity results in high fetal exposure to maternal glucocorticoids, with subsequent 
effects on fetal development and birth weight and offspring biology - high plasma cortisol 
levels, permanent hypertension, hyperglycemia and increased HPA axis activity was present 
through the adult life [222-224]. Moreover, individuals homozygous for deleterious mutations 
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of HSD11B2 gene encoding 11β-HSD have low birth weight. Intrauterine growth retardation 
in human is associated with increased fetal cortisol levels and reduced placental 11β-HSD2 
activity [217]. Studies on prenatal exposure to 11β-HSD inhibitors such as glycyrrhetinic acid 
and carbenoxolone have indicated that these agents cause fetal growth retardation and adult 
offspring changes that are very similar to those that are caused by prenatal exposure to 
glucocorticoids such as dexamethasone (readily crosses the placenta) [221]). Mice that are 
homozygous for disrupted alleles of HSD11B2 (i.e. 11β-HSD2–/– mice) also have lower birth 
weight and the offspring display anxiety-related behaviors in adulthood. It seems that the 
conditions of increased fetal glucocorticoid levels, in response to different maternal 
restrictions, sometimes have persistent effects in the offspring - so-called concept of 
developmental physiological programming and that placental 11β-HSD2 is a key player in 
fetal programming [215, 216, 221]. 
12. 17β-HSD dehydrogenase and multifunstional izoforms: localization, 
function and relevance to clinical therapeutic strategies 
17βHydroxysteroid dehydrogenases (17β-HSDs, 17HSD/KSRs) are NAD(H)- and/or 
NADP(H)-dependent enzymes that catalyze the oxidation and reduction of active 17β-
hydroxy- and low active/inactive 17-ketosteroids, respectively. In the presence of substantial 
excess of a suitable cofactor and/or in the absence of a preferred cofactor, 17HSD/ KSRs can 
be compelled to catalyze both oxidative and reductive reactions. Depending on their 
reductive or oxidative activities, they modulate the intracellular concentration of inactive 
and active steroids. Acting as oxidoreductases at the 17-position of the steroid, they play a 
key role in estrogen/androgen steroid metabolism by catalyzing the final steps of steroid 
biosynthesis. Both estrogens and androgens have the highest afnity for their receptors in the 
17β-hydroxy form and hence, 17HSD/KSR enzymes regulate the biological activity of the sex 
hormones.17KSR activities are essential for estradiol and testosterone biosynthesis in the 
gonads, but they are also present in certain extragonadal tissues and can convert low-
activity precursors to their more potent forms in peripheral tissues. Instead, 17HSD 
activities tend to decrease the potency of estrogens and androgens and consequently may 
protect tissues from excessive hormone action [10, 225].  
Up to now, 14 different subtypes have been identified in mammals and they differ in tissue 
distribution, sub-cellular localization, function and catalytic preference (oxidation or 
reduction using the cofactor NAD(H) and NADP(H), respectively) (Table 1). In fact, 17β-
HSDs have diverse substrate specificities in vivo as they also catalyze the conversions of 
other substrates than steroids as for example lipids or retinoids. Until recently, besides 17β-
HSD3 and 17β-HSD14, 17β-HSD1 and 2 were thought to be exclusively converting sex 
steroids. However, the participation of the two latter enzymes (17β-HSD1 and 2) in retinoic 
acid metabolism recently was suggested. Other 17β-HSD types were already known to be 
multifunctional and some of them play important roles in different metabolic pathways. 
17β-HSD7 is mainly involved in cholesterol synthesis, 17β-HSD4 is implicated in β-
oxidation of fatty acids, 17β-HSD5 participates in both prostaglandin and steroid 
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metabolism, and 17β-HSD12 is required in fatty acid elongation. 17β-HSD10 catalyzes the 
oxidation of short chain fatty acids. 17β-HSD6 and 9 play a role in retinoid conversion. For 
some 17β-HSDs, the physiological function is not yet clear. For several types of 17β-HSDs 
participation in the pathophysiology of human diseases has been postulated [225]. The 
specificity of each 17β-HSD subtype for a preferred substrate together with distinct tissue 
localization, suggests that these proteins are promising therapeutic targets for diseases like 
breast cancer, endometriosis, osteoporosis, and prostate cancer. For some of them, their  
 
Type Gene Function Disease-associations References 
1 HSD17B1 Steroid (estrogen) synthesis Breast and prostate 
cancer, endometriosis 
[226, 227] 
2 HSD17B2  Steroid (estrogen, androgen, 
progestin) inactivation 
Breast and prostate 
cancer, endometriosis 
Abnormal eye 
develpment 
[10,226, 227] 
3 HSD17B3 Steroid (androgen) synthesis Pseudohermaphroditism 
in males associated with 
obesity, prostate cancer 
[10,228] 
4 HSD17B4 Fatty acid β-oxidation, 
steroid (estrogen, androgen) 
inactivation 
D-specific bifunctional 
protein-deficiency,  
prostate cancer 
[229] 
5 HSD17B5 Steroid (androgen, estrogen, 
prostaglandin) synthesis 
Breast and prostate cancer  [230,231] 
6 HSD17B6 Retinoid metabolism, 3α-3β-
epimerase, steroid (androgen) 
inactivation? 
 [232] 
7 HSD17B7 Cholesterol biosynthesis, 
steroid(estrogen) synthesis 
Breast cancer   [233, 234] 
8 HSD17B8 Fatty acid elongation, steroid 
inactivation, estrogens, 
androgens 
Polycystic kidney disease [235, 236] 
9 HSD17B9 Retinoid metabolism  [237] 
10 HSD17B10 Isoleucine, fatty acid, bile 
acid metabolism, steroid 
(estrogen, androgen) 
inactivation 
X-linked mental 
retardation MHBD 
deficiency  
Alzheimer’s disease 
[238] 
 
[239] 
11 HSD17B11 Steroid (estrogen, androgen) 
inactivation, lipid 
metabolism? 
 [240] 
12 HSD17B12 Fatty acid elongation, 
steroid(estrogen) synthesis 
 [241, 242] 
13 HSD17B13 Not demonstrated  [243] 
14 HSD17B14 Steroid (estrogen, androgen?) 
inactivation, fatty acid 
metabolism 
Breast cancer, prognostic 
marker 
[244, 245] 
Table 1. Human 17β-Hydroxysteroid dehydrogenases 
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expression level can be used as prognostic marker in breast or prostate cancer. The selective 
inhibition of the concerned enzymes might provide an effective treatment and a good 
alternative for treatment of steroid dependent diseases [246]. Having in mind 
multifunctionaloty 17β-HSD enzymes, the biological and clinical aspects of each isoform 
will be described separately. 
17β-HSD type1: 17β-HSD1 catalyzes the activation of estrone (E1) to the most potent 
estrogen estradiol (E2), predominantly considered as an ezyme of  estradiol biosynthesis. It 
is abundantly expressed in granulosa cells of developing follicles and variable amounts of 
the enzyme are also expressed in human breast epithelial cells. The enzyme is known to 
have a crucial role in the development of estrogen-dependent diseases. Based on the in vitro 
studies, human (h) 17β-HSD1 has been considered as highly estrogen specific, with 
markedly lower catalytic efficacy towards androgenic substrates. There is a clear difference 
in the substrate specificity between human and rodent 17β-HSD1 enzymes; the catalytic 
efficacy of rodent enzyme in vitro is similar for both androgens and estrogens. According a 
recent review by Saloniemi et al. [10], the h17β-HSD1 is not fully estrogenen-specific but it 
possesses significant androgenic sctivity. The enzyme catalyses both oxidative (17-hydroxy 
to 17-keto) and reductive (17-keto to 17-hydroxy) 17b-HSD activity with a proper cofactor 
added in vitro. However, in cultured cells, the h17β-HSD1 has been shown to catalyse 
predominantly the reductive reaction [247]. Although h17β-HSD1 expression in various 
peripheral tissues is low, its catalytic efficacy is markedly higher than those measured for 
17β-HSD7 and 17β-HSD12 [248, 242], suggesting an important role for 17β-HSD1 in 
peripheral E2 formation. Data from animal models further demonstrated the ability of h17β-
HSD1 to enhance estrogen action in target tissues and its decrease after treating the mice 
with 17β-HSD1 inhibitors [10]. These data suggest that 17β-HSD1 plays a major role in 
determining the gradient between the E2 concentrations in serum and peripheral tissues. An 
increased E2/E1 ratio by the 17β-HSD1 point out the pivotal role of 17β-HSD1 in breast 
cancer, ovarian tumor, endometriosis, endometrial hyperplasia and uterine leiomyoma [249, 
250]. Consequently, inhibition of 17β-HSD1 is considered as a valuable therapeutic 
approach for treatment of these deseases. In vivo evaluation of 17β-HSD1 inhibitors is 
complicated by the fact that the rodent enzymes only show moderate homology/identity to 
the human one. Due to these species differences, there is a high probability that inhibitors 
optimized for activity toward rodent 17β-HSD1 do not inhibit the human enzyme. In 
addition, rodents and humans vary considerably in enzyme distribution in the different 
tissues. Attempts to overcome these problems include xenograft models using nude mice.  
Recently generated mouse genetic model for overexpression of17β-HSD1 (HSD17B1-TG 
mice) by Saloniemi et al [10] provided valuable data about common female reproductive 
disorders like Polycystic Ovarian Syndrome (PCOS), ovarian carcinogenesis and 
endometiosis. Overexpression of hHSD17B1 leads to increased androgen exposure during 
embryonic development that caused androgen-dependent phenotypic alterations in female, 
such as increased anogenital distance, lack of vaginal opening and combination of vagina 
with urethra. These alterations observed in the HSD17B1-TG females were effectively 
rescued by prenatal anti-androgen (flutamide) treatment, further confirming the 
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dependence of these phenotypes on androgens. Interestingly, the androgen exposure during 
pregnancy in the HSD17B1-TG mice resulted in benign ovarian serous cystadenomas in 
adulthood. As ovarian serous borderline tumours are positively associated with a history of 
PCOS, thus with a history of (foetal) hyperandrogenism, 17β-HSD1 may promote ovarian 
carcinogenesis via increased estrogen concentration, but also via enhanced androgen 
production. Endometrial hyperplasia in HSD17B1-TG mice closely resembled human 
disease and it was efficiently reversed by 17β-HSD1 inhibitor treatment. The data 
concerning the expression of 17β-HSD1 in normal and diseased human endometrium are 
not fully conclusive. However, in most of the studies, the 17β-HSD1 expression is detected 
in normal endometrium, endometriosis specimens and endometriotic cancer. Other 17β-
HSD enzymes including 17β-HSD2, 17β-HSD5, 17β-HSD7 and 17β-HSD12 have also been 
detected in the endometrium under different pathological conditions like endometriosis and 
PCOS [10]. Collectively, the data suggest that 17β-HSD1 inhibition is one of the several 
possible approaches to reduce estrogen production both in eutopic and in ectopic 
endometrial tissue. 
17β-HSD type-2: 17-HSD/KSR2 converts 17β-hydroxy forms of estrogens and androgens 
(estradiol, testosterone and 5α-dihydrotestosterone) to their less active 17-keto forms 
(estrone,  androstenedione and 5α-androstanedione).The enzyme also possesses 20α-HSD 
activity, thereby activating 20α-hydroxyprogesterone to progesterone. The 17β-HSD2 
enzyme is widely and abundantly expressed in both adult and fetal tissues such as placenta, 
uterus, liver, the gastrointestinal and urinary tracts. Due to its expression pattern and 
enzymatic characteristics, it has been suggested that the 17β-HSD2 enzyme protects tissues 
from excessive steroid action [251]. 17β-HSD2 is localised in the endoplasmic reticulum, and 
it is widely expressed in various estrogen and androgen target tissues both in human and in 
rodents including breast endometrium, placenta and prostate. Furthermore, the 17β-HSD2 
expression in the placenta and in foetal liver and intestine, together with the observed 
oxidative 17β-HSD2activity, are the basis for the hypothesis, suggesting a role for the 
enzyme in lowering the sex steroid exposure of the foetus. 
Phylogenic analyses have indicated that 17β-HSD2 is a close homologue of retinoid-
converting enzymes and has a high sequence similarity to retinol dehydrogenase type 1. In 
addition, studies have shown that retinoic acid (RA) induces expression of 17β-HSD2 in a 
dose- and time-dependent manner in human endometrial epithelial and placental cells  [10]. 
Recent data from transgenic mice (HADS17B2-TG) provide evidence for importance of 17β-
HSD2 for prenatal eye morphogenesis and eye development [10]. These TG mice 
overexpressing human 17β-HSD2 showed growth retardation, disrupted spermayogenesis, 
female masculinization, delayed eye opening, squint appearance of the eyes and some of 
these defects closely resembeled those identified in retinoid receptor mutant mice. The most 
notable changes in the HSD17B1TG mice are well explained by alterations in sex steroid 
action, whereas in the HSD17B2-TG mice the connection to sex steroids is weaker. The 
opposite mouse model of deficiency of 17β-HSD2 provide evidence for the essential role of 
17β-HSD2. Embryonic death in the HSD17B-KO mice is reported, related to lack of action of 
17β-HSD2 enzyme in placenta. Furthermore, the treatment of pregnant female mice with an 
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anti-estrogen or with progesterone did not prevent the foetal loss of the HSD17B2-KO mice, 
thus indicating that embryonic deaths is likely not due to the lack of progesterone or due to 
an increased action of estrogens. 
Osteoporosis is well known to occurs in elderly people when the level of active sex steroids 
decreases. Estrogen replacement therapy is beneficial for the treatment of osteoporosis but it 
is no longer recommended because of adverse effects (breast, endometrial and ovarian 
cancers, stroke, thromboembolism). Since 17β-HSD2 oxidizes E2 into E1, decreasing the 
amount of E2 in bone cells, inhibition of this enzyme is a promising approach for the 
treatment of this disease [225]. Ovariectomized cynomolgus monkeys were used as an 
osteoporosis model to evaluate the efficacy of 17β-HSD2 inhibitors. Decrease in bone 
resorption and maintenance of bone formation was achieved in this experimental model. 
17β-HSD type-3: 17-HSD/KSR3 17β-HSD3 converts ∆4-androstenedione into testosterone 
and it is essential for testosterone biosynthesis. The enzyme is present exclusively in the 
testis and the deficiency of the active enzyme results in male pseudohermaphroditism [252]. 
In addition to the conversion of androstenedione to testosterone, the enzyme is capable of 
catalyzing conversion of 5α-androstanedione to 5α- dihydrotestosterone as well as estrone 
to estradiol [108]. Messender RNA for 17β-HSD3 are over-expressed in prostate cancer 
tissues. As T is known to be responsible for cell proliferation in androgen dependent 
diseases, 17β-HSD3 inhibitors (exerting effects equivalent of chemical castration) could be 
therapeutics for the treatment of such diseases [225].  Day et al. [253] developed the first 
xenograft model in castrated mice to evaluate 17β-HSD3 inhibitors and strong suppression 
of tumor growth by 81% was found, suggesting that 17β-HSD3 inhibition might be an 
efficient strategy for the treatment of hormone dependent prostate cancer. 
There are only few observations in human male deficient in 17β-HSD as rare mutation 
associated with 46XY disorder of sexual development [254]. Patients with 17β-HSD 
deficiency are usually classified as female at birth (although abdominal testes) but 
developed secondary male features at pubery with diminished virilization [255].  
17β-HSD type-4: Among 17-HSD/KSRs, type 4 is an unique multifunctional enzyme 
consisting of 17-HSD/KSR-, hydratase- and sterol carrier 2-like domains. 17β-HSD4 is 
ubiquitously expressed, but in some tissues it shows cell-specific expression. In the brain it 
is present only in Purkinje cells, in the lung only in bronchial epithelium and in the uterus in 
luminal and glandular epithelium. The deficiency of 17β-HSD4 leads to disease known as 
Zellweger syndrome [251]. 
17β-HSD type-5: 17-HSD/KSR5 is also known as type 2 3α-HSD, and diferently from other 
17-HSD/KSRs it belongs to the AKR (aldo-keto reductase) family. With other members of 
the AKR family (type 1 3α-HSD, type 3 3α-HSD and 20α-HSD), 17β-HSD5 shares 84%, 86% 
and 88% identity, respectively. Both human and mouse 17β-HSD5 catalyze the conversion of 
androstenedione to testosterone, and additionally possess 3α-HSD activity. Human 17β-
HSD5 has been previously identified predominantly as 3α-HSD. Human, but not mouse, 
17β-HSD5 also converts progesterone to 20α-dihydroprogesterone effectively. 17β-HSD5 
appears to be involved in the formation of androgens in the testis and several peripheral 
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tissues. Using specific probes and antibodies, human 17β-HSD5 has been localized in liver, 
adrenal, testis, basal cells of the prostate, and in prostatic carcinoma cell lines [251]. 
Recently, up-regulation of 17β-HSD5 was found in breast and prostate cancer [256]. 
17β-HSD type-6: 17-HSD/KSR6 is part of the catabolic cascade of 5α-dihydrotestosterone 
(DHT). The 17β-HSD6 shows low dehydrogenase activity with DHT, testosterone and 
estradiol and possesses a weak oxidative 3α-HSD activity. The 17β-HSD6 enzyme shares 
65% sequence identity with retinol dehydrogenase type 1 and it is most abundantly 
expressed in liver and prostate, at least in rodent tissues [251]. 
17β-HSD type-7: 17β-HSD7 is expressed in the developing follicles and in luteinized cells, 
being the enzyme of ovarian estradiol biosynthesis. Both rodent and human 17β-HSD7 
catalyze exclusively the conversion of estrone to estradiol. The 17β-HSD7 is abundantly 
expressed in corpus luteum during pregnancy and the enzyme is considered to be 
important in E2 production, especially during pregnancy. In addition, 17β-HSD7 mRNA has 
been detected in placental, mammary gland and kidney samples [251]. The 17β-HSD7 
enzyme was first characterised as a prolactin receptor-associated protein in the rat corpus 
luteum, although its role in prolactin signalling has remained unknown. 
A role for mouse 17β-HSD7 in cholesterol biosynthesis was also suggested by the studies, 
showing a similar expression pattern of 17β-HSD7 and cholesterogenic enzymes during 
mouse embryonic development. Data from HSD17B7-KO mouse embryos evidently showed 
the essential role of 17β-HSD7 for cholesterol biosynthesis in vivo. The lack of 17β-HSD7 
resulted in a marked blockage in foetal de novo cholesterol synthesis. Histological analysis 
revealed that the 17β-HSD7 deficiency results in defects in the development of nerve 
system, vasculature, heart, associated with defect in cholesterol synthesis. HSD17B-KO 
deficient mice exhibit embryonic lethal phenotypes Tese data suggest a possible role of 17β-
HSD7 in cholesterol biosynthesis in mice, while its role in E2 production in vivo needs 
further clarification [10]. 
17β-HSD type-8: The Ke 6 gene product has been characterized as a protein whose abnormal 
regulation is linked to the development of recessive polycystic kidney disease in mice and 
later it was discovered to be a 17βHSD8. In in vitro conditions, 17β-HSD8 converts most 
eficiently estradiol to estrone and, to some extent, it also catalyses oxidative reactions of 
androgens and the reduction from estrone to estradiol. The 17β-HSD8 is abundand in 
kidney, liver and gonads. Interestingly, in the ovary, 17β-HSD8 is present in cumulus cells 
and not in granulosa or luteal cells like 17βHSD1 and 7, respectively [251]. 
17β-HSD type-10: The 17β- -HSD10 has a very broad substrate profile. Interestingly, it has 
been proposed that this enzyme plays an important role in the pathological processes of 
Alzheimer’s disease (AD), mainly because 17β-HSD10 binds to amyloid-β peptide and 
appears to be up-regulated in patients suffering from this disease [225]. The mechanism by 
which 17β-HSD10 contributes to the pathology of AD is still not completely understood. The 
protein-protein interaction of 17β-HSD10 with amyloid-β appears to inhibit the enzymatic 
activity of 17β-HSD10.  In vitro studies with a potent 17β-HSD10 inhibitor [257] have shown 
that inhibition of this enzyme can prevent its interaction with the amyloid-β peptide, 
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suggesting 17β HSD10 as a potential target for the treatment of AD.Transgenic mice over-
expressing human 17β-HSD10 suggesting that inhibition of 17β-HSD10 could protect from 
cerebral infarction and ischemia [258].  
17β-HSD type-12: The mammalian 17β-HSD12 was initially characterised as a 3-ketoacyl-
CoA reductase, involved in the long-chain fatty acid synthesis, particularly essential for 
brain arachidonic acid synthesis. Both the human and the mouse 17β-HSD12 share 40% 
sequence similarity with 17β-HSD3, and the data indicate that 17β-HSD12 is an ancestor of 
17β-HSD3. In human and rodents, 17β-HSD12 is expressed universally and the highest 
expression of 17β-HSD12 is detected in tissues involved in the lipid metabolism, including 
the liver, kidney hearth, and skeletal muscle. In mice, the expression has also been detected 
in brown and white adipose tissue. 17β-HSD12 expression is also regulated by sterol 
regulatory element binding proteins, identically to that shown to be involved in fatty acid 
and cholesterol biosynthesis. Interestingly, a reduced expression of 17β-HSD12 in cultured 
breast cancer cells results in significant inhibition of cell proliferation that is fully recovered 
by supplementation of arachidonic acid. In addition to its putative role in fatty acid 
synthesis, human 17β-HSD12 has been shown to catalyse the conversion of E1 to E2 in 
cultured cells, and the enzyme was suggested to be a major enzyme converting E1 to E2 in 
postmenopausal women [10]. Analysis of the HSD17B12-KO embryos indicated that the 
embryos initiated gastrulation but further organogenesis was severely disrupted. The 
mutant embryos exhibited severe defects in the neuronal development (ectoderm-derives), 
they failed to grow several mesoderm-derived structures. Therefore, the embryos at the age 
of E8.5–E9.5 were avoid of all normal embryonic structures that caused their death. 
13. Conclusion 
HSD enzymes are broadly expressed in all steroidogenic organs as different isoforms with 
differential localization and function. HSD are key enzymes involved in growth and 
reproduction and they are considered as suitable targets to modulate the concentration of 
the potent steroids in case of steroid-dependent diseases. As they could act selectively in an 
intracrine manner, inhibitors of these enzymes might be superior to the existing endocrine 
therapies regarding the off-target effects.  Although commont mechanisms operate in 
regulation of steroidogenesis, there are some differences/specificities between rodent and 
human, in particular the susceptibility of fetal testicular stereoidogenesis to environmental 
chemicals with estrogenic/antiandrogenic activity. As the latter appeared to be devoid of 
effect on fetal human testis, this should be taken into account when dial with risk 
assessment of endocrine disruptors for human reproductive health. Species specific 
diffences in steroiodogenesis cause real obstacles in investigation of HSD inhibitors. Some of 
the most active and selective inhibitors were investigated in vivo in animal disease-oriented 
models. They showed efficacy, but none of them reached the clinical trial stage. One reason 
for this might be the difficulty to identify an appropriate species to conduct the functional 
assays, as very potent inhibitors of the human enzyme show little activity toward HSD of 
other species (rodents). In this respect, experiments by using xenograft approach (human 
tissue xenografting in immunocompromised nude mice) would enable us to develop our 
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studies for better understanding of regulatory mechanisms of the expression of HSD 
enzymes. Elucidation of molecular events involved in transcription control of HSD is of 
great importance for molecular desigh of new HSD inhibitors and development of new 
strategies for appropriate treatment of steroid-dependent deceases without use of invasive 
techniques.  
Author details 
Nina Atanassova 
Inst. Experimental Morphology, Pathology and Anthropology with Museum, Bulgarian Academy of 
Sciences, Sofia, Bulgaria 
Yvetta Koeva 
Dept. Anatomy and Histology, Medical University, Plovdiv, Bulgaria 
Acknowledgement 
The authors thank to Professor Richard Sharpe for providing samples from experimental 
models for hormonal manipulations, Chris McKinnel for technical expertise in 
immunohistochemistry. We are also grateful to Professor Michail Davidoff and Assoc. 
Professor Mariana Bakalska for studies on EDS experimental model. Authors’ work was 
supported in part by Grant DEER # 212844 funded by FP7-ENV-CP and Grant # DO 02/113 
funded by NF “Scientific Research” of Ministry of Education Youth and Science in Bulgaria. 
14. References 
[1] Hoffmann F, Maser E.  Carbonyl reductases and pluripotent hydroxysteroid 
dehydrogenases of the short-chain dehydrogenase/reductase superfamily, Drug 
Metabolism Reviews 2007; 39: 87 144. 
[2] Duax WL., Ghosh D, Pletnev V. Steroid dehydrogenase structures, mechanism of 
action, and disease. Vitamines & Hormones 2000; 58: 121–148. 
[3] Labrie F, Luu-The V, Labrie C, Simard J. DHEA and its transformation into androgens 
and estrogens in peripheral target tissues: intracrinology. Frontiers in Neuroendocrinol 
2001; 22: 185–212. 
[4] Cancer Research:http://info.cancerresearchuk.org/cancerstats/ 
[5] Giudice L. Clinical practice. Endometriosis. New England Journal of Medicine 2010; 
362: 2389–2398. 
[6] Goodarzi MO, Dumesic DA, Chazenbalk G & Azziz R. Polycystic ovary syndrome: 
etiology, pathogenesis and diagnosis. Nature Reviews Endocrinology 2010; 7:  219–331. 
[7] Labrie F. Drug insight: breast cancer prevention and tissue-targeted hormone 
replacement therapy. Nature Clinical Practice in Endocrinology & Metabolism 2007; 3: 
584–593.  
 
Dehydrogenases 146 
[8] Schuster D, Laggner C, Steindl TM, Palusczak A, Hartmann RW, Langer T. 
Pharmacophore modeling and in silico screening fornewP450 19 (aromatase) inhibitors, 
Journal of Chemical Information & Modeling 2006; 46: 1301–1311. 
[9] Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar K, An overview on 5alpha-
reductase inhibitors. Steroids 2010; 75: 109–153. 
[10] Saloniemi T, Jokela H, Strauss L, Pakarinen P and Poutanen M. The diversity of sex 
steroid action: novel functions of hydroxysteroid (17b) dehydrogenases as revealed by 
genetically modified mouse models (Thematic Review). Journal of Endocrinology 2012: 
212, 27-40. 
[11] Hafez ESE. Hormones, Growth Factors, and Reproduction. In: Hafez ESE.(ed.) 
Reproduction in Farm Animals. Philadelphia: Lea & Febiger; 1993. p59-93. 
[12] Barrett E. Section VIII The Endocrine System.  In: Boron WF, Boulpaep EL (eds) Medical 
Physiology. A Cellular And Molecular Approach. Philadelphia, PA: Elsevier/Saunders; 
2003 (1st edition) p1009-1110. 
[13] Pezzi V, Mathis JM, Rainey WE, Carr BG. Profiling transcript levels for steroidogenic 
enzymes in fetal tissues. Journal of Steroid Biochemistry and Molecular Biology 2003; 
87: 181-189. 
[14] Scott HM, Mason JI, Sharpe RM. Steroidogenesis in the fetal Testis and its Susceptibility 
to Disruption by Exogenous Compounds. Endocrine Review 2009; 30: 883-925. 
[15] Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from 
cholesterol to active steroid hormones. Endocrine Review 2004; 25: 947-970. 
[16] Payne AH. Steroidogenic Enzymes in Leydig Cells. In: Payne AH. & Hardy MP. (eds) 
The Leydig Cell in Health and Disease. Totowa, NJ: Human Press Inc; 2007, p157-171. 
[17] Arakane F, Kallen CB, Watari H, Foster JA, Sepuri NB, Pain D, Stayrook SE, Lewis M, 
Gerton GL, Strauss 3rd JF. The mechanism of action of steroidogenic acute regulatory 
protein (StAR). StAR acts on the outside of mitochondria to stimulate steroidogenesis. J 
Biological Chemistry 1998; 273: 16339–16345. 
[18] Dube´ C, Bergeron F, Vaillant MJ, Robert NM, Brousseau C, Tremblay JJ.  The nuclear 
receptors SF1 and LRH1 are expressed in endometrial cancer cells and regulate 
steroidogenic gene transcription by cooperating with AP-1 factors. Cancer Letters 2009; 
275: 127–138. 
[19] Parker KL, Schimmer BP. Transcriptional regulation of the genes encoding the 
cytochrome P-450 steroid hydroxylases. Vitamins and  Hormones 1995; 51: p339–370. 
[20] O’Shaughnessy PJ, Johnston H, Baker PJ. Development of Leydig Cell Steroidogenesis. 
In: Payne AH. & Hardy MP. (eds) The Leydig Cell in Health and Disease. Totowa, NJ: 
Human Press Inc; 2007, p173-179. 
[21] Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, Gurakan B, Jameson JL. 
Gonadal determination and adrenal development are regulated by the orphan nuclear 
receptor steroidogenic factor-1, in a dose-dependent manner. Journal of Clinical 
Endocrinology and  Metabolism  2002; 87: 1829–1833. 
[22] Jeyasuria P, Ikeda Y, Jamin SP, Zhao L, De Rooij DG, Themmen AP, Behringer RR, 
Parker KL. Cell-specific knockout of steroidogenic factor 1 reveals its essential roles in 
gonadal function. Molecular Endocrinology 2004;1: 1610–1619. 
 
Hydrohysteroid Dehydrogenases – Biological Role and Clinical Importance – Review 147 
[23] Stocco DM.The Role of StAR in Leydig Cell Steroidogenesis. In: Payne AH. & Hardy 
MP. (eds) The Leydig Cell in Health and Disease. Totowa, NJ: Human Press Inc; 2007, 
p149-155 
[24] Black SM, Harikrishna JA, Szklarz GD, Miller WL. The mitochondrial environment is 
required for activity of the cholesterol side-chain cleavage enzyme, cytochrome P450scc. 
Proceedings of the National Acadamy of Science USA 1994; 91: 7247–7251. 
[25] Miller WL. Why nobody has P450scc(20,22 desmolase deficiency). Journal of Clinical 
Endocrinology and Metabolism 1998;83: 1399–1400. 
[26] Kim CJ, Lin L, Huang N, Quigley CA, AvRuskin TW, Achermann JC, Miller WL. Severe 
combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol 
side chain cleavage enzyme, P450scc. Journal of Clincal Endocrinology and Metabolism 
2008; 93: 696-702. 
[27] Pang S, Yang X, Wang M, Tissot R, Nino M, Manaligod J, Bullock LP, Mason JI. 
Inherited congenital adrenal hyperplasia in the rabbit: absent cholesterol side-chain 
cleavage cytochrome P450 gene expression. Endocrinology 1992;131, 181–186. 
[28] Auchus RJ. The genetics, pathophysiology, and management of human deficiencies of 
P450c17. Endocrinology, Metabolism  Clinics of North America 2001; 30, 101–119. 
[29] Van Den Akker EL, Koper JW, Boehmer AL, Themmen AP, Verhoef-Post M, 
Timmerman MA, Otten BJ, Drop SL, De Jong FH. Differential inhibition of 17 α-
hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations 
identified in patients with P450c17 deficiency. Journal of Clinical Endocrinology & 
Metabolism 2002; 87: 5714–5721. 
[30] Martin RM, Lin CJ, Costa EM, de Oliveira ML, Carrilho A, Villar H, Longui CA, 
Mendonca BB. P450c17 deficiency in Brazilian patients: biochemical diagnosis through 
progesterone levels confirmed by CYP17 genotyping. Journal of Clinical Endocrinology 
& Metabolism 2003; 88: 5739–5746. 
[31] Simard J, Ricketts ML, Gingras S, Soucy P, Feltus FA, Melner MH. Molecular biology of 
the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. 
Endocrine Review 2005;  26: 525-582.  
[32] mas JL, Duax WL, Addlagatta A, Brandt S, Fuller RR, Norris W. Structure/function 
relationships responsible for coenzyme specificity and the isomerase activity of human 
type-1 3β-hydroxysteroid dehydrogenase/isomerase. Journal of Biological Chemistry  
2003; 278: 483–490. 
[33] Cherradi N, Defaye G, Chambaz EM. Dual subcellular localization of the 3β-
hydroxysteroid dehydrogenase isomerase: characterization of the mitochondrial 
enzyme in the bovine adrenal cortex. Journal Steroid Biochemistry & Molecular Biology 
1993; 46, 773–779. 
[34] Cherradi N, Chambaz EM, Defaye G. Organization of 3β-hydroxysteroid 
dehydrogenase/isomerase and cytochrome P450scc into a catalytically active molecular 
complex in bovine adrenocortical mitochondria. Journal Steroid Biochemistry & 
Molecular Biology 1995; 55: 507–514. 
[35] Pelletier G, Li S, Luu-The V, Tremblay Y, Belanger A, Labrie F. Immunoelectron 
microscopic localization of three key steroidogenic enzymes (cytochrome P450(scc), 3β-
 
Dehydrogenases 148 
hydroxysteroid dehydrogenase and cytochrome P450(c17)) in rat adrenal cortex and 
gonads. Journal of Endocrinology 200; 171: 373–383. 
[36] Chapman JC, Waterhouse TB, Michael SD. Changes in mitochondrial and microsomal 
3_-hydroxysteroid dehydrogenase activity in mouse ovary over the course of the 
estrous cycle. Biology of Reproduction 1992; 4: 992–997. 
[37] Luu-The V, Lachance Y, Labrie C, Leblanc G, Thomas JL, Strickler RC, Labrie F. Full 
length cDNA structure and deduced amino acid sequence of human 3β-hydroxy-5-ene 
steroid dehydrogenase. Molecular Endocrinology 1989; 3: 1310–1312. 
[38] Rheaume E, Lachance Y, Zhao HF, Breton N, Dumont M, de Launoit Y, Trudel C, Luu-
The V, Simard J, Labrie F. Structure and expression of a new complementary DNA 
encoding the almost exclusive 3β-hydroxysteroid dehydrogenase/ ∆5-∆4-isomerase in 
human adrenals and gonads. Molecular Endocrinology 1991; 5: 1147–1157. 
[39] Dumont M, Luu-The V, Dupont E, Pelletier G, Labrie F. Characterization, expression, 
and immunohistochemical localization of 3β-hydroxysteroid dehydrogenase/∆5-∆4 
isomerase in human skin. Journal of Investigave Dermatology 1992; 99: 415–421. 
[40] Lachance Y, Luu-The V, Labrie C, Simard J, Dumont M, de Launoit Y, Guerin S, Leblanc 
G, Labrie F. Characterization of human 3β-hydroxysteroid dehydrogenase/∆5-∆4 
isomerase gene and its expression in mammalian cells. Journal of  Biological Chemistry 
1992; 267: 3551 
[41] Morissette J, Rheaume E, Leblanc JF, Luu-The V, Labrie F, Simard J 1995 Genetic linkage 
mapping of HSD3B1 and HSD3B2 encoding human types I and II 3β-hydroxysteroid 
dehydrogenase/∆5-∆4- isomerase close to D1S514 and the centromeric D1Z5 locus. 
Cytogenetics & Cell Genetics 1995; 69: 59–62. 
[42] Zhao HF, Labrie C, Simard J, de Launoit Y, Trudel C, Martel C, Rheaume E, Dupont E, 
Luu-The V, Pelletier G. Characterization of rat 3β-hydroxysteroid dehydrogenase/∆5-∆4 
isomerase cDNAs and differential tissue-specific expression of the corresponding 
mRNAs in steroidogenic and peripheral tissues. Journal of Biological Chemistry 1991; 
266: 583–593. 
[43] Simard J, Couet J, Durocher F, Labrie Y, Sanchez R, Breton N, Turgeon C, Labrie F. 
Structure and tissue-specific expression of a novel member of the rat 3β-hydroxysteroid 
dehydrogenase/ ∆5-∆4 isomerase (3β-HSD) family. The exclusive 3β-HSD gene 
expression in the skin. Journal of Biological Chemistry1993; 268: 19659–19668. 
[44] Couet J, Simard J, Martel C, Trudel C, Labrie Y, Labrie F. Regulation of 3-ketosteroid 
reductase messenger ribonucleic acid levels and 3β-hydroxysteroid dehydrogenase/∆5-
∆4 isomerase activity in rat liver by sex steroids and pituitary hormones. Endocrinology 
1992; 131: 3034–3044. 
[45] Sanchez R, de Launoit Y, Durocher F, Belanger A, Labrie F, Simard J. Formation and 
degradation of dihydrotestosterone by recombinant members of the rat 3β-
hydroxysteroid dehydrogenase/ ∆5-∆4 isomerase family. Molecular & Cellular 
Endocrinolology 1994; 103: 29–38. 
[46] de Launoit Y, Simard J, Durocher F, Labrie F. Androgenic 17β-hydroxysteroid 
dehydrogenase activity of expressed rat type I 3β-hydroxysteroid dehydrogenase/∆5-∆4 
isomerase. Endocrinology 1992; 130: 553–555. 
 
Hydrohysteroid Dehydrogenases – Biological Role and Clinical Importance – Review 149 
[47] Mason JI, Howe BE, Howie AF, Morley SD, Nicol MR, Payne AH. Promiscuous 3β-
hydroxysteroid dehydrogenases: testosterone 17β-hydroxysteroid dehydrogenase 
activities of mouse type I and VI 3β-hydroxysteroid dehydrogenases. Endocrine 
Research 2004; 30: 709–714. 
[48] Payne AH, Clarke TR, Bain PA. The murine 3β-hydroxysteroid dehydrogenase 
multigene family: structure, function and tissue-specific expression. Journal Steroid 
Biochemistry & Molecular Biology 1995; 53: 111–118. 
[49] Payne AH, Abbaszade IG, Clarke TR, Bain PA, Park CH. The multiple murine 3β 
hydroxysteroid dehydrogenase isoforms: structure, function, and tissue- and 
developmentally specific expression. Steroids 1997; 62: 169–175. 
[50] Abbaszade IG, Arensburg J, Park CH, Kasa-Vubu JZ, Orly J, Payne AH 1997 Isolation of 
a new mouse 3β-hydroxysteroid dehydrogenase isoform, 3β-HSD VI, expressed during 
early pregnancy. Endocrinology 1998; 138: 1392–1399. 
[51] Belanger B, Belanger A, Labrie F, Dupont A, Cusan L, Monfette G. 1989 Comparison of 
residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after 
castration: unique importance of extratesticular androgens in men. Journal of Steroid 
Biochemestry 1989; 32: 695–698. 
[52] Dupont E, Luu-The V, Labrie F, Pelletier G. Ontogeny of 3β-hydroxysteroid 
dehydrogenase/∆5-∆4 isomerase (3β-HSD) in human adrenal gland performed by 
immunocytochemistry. Molecular & Cellular Endocrinology 1990; 74: R7–R10. 
[53] Simonian MH. ACTH and thyroid hormone regulation of 3β-hydroxysteroid 
dehydrogenase activity in human fetal adrenocortical cells. Journal Steroid Biochem 
1986; 25: 1001–1006. 
[54] Lo MJ, Kau MM, Chen YH, Tsai SC, Chiao YC, Chen JJ, Liaw C, Lu CC, Lee BP, Chen 
SC, Fang VS, Ho LT, Wang PS. Acute effects of thyroid hormones on the production of 
adrenal cAMP and corticosterone in male rats. American Journal of Physiology 1998; 
274: E238–E245. 
[55] Dupont E, Labrie F, Luu-The V, Pelletier G. Immunocytochemical localization of 3β-
hydroxysteroid dehydrogenase/∆5-∆4 isomerase in human ovary. Journal of Clinical 
Endocrinology & Metabolism 1992; 74: 994–998. 
[56] Kaplan S, Grumach M. Pituitary and placental gonadotropin and sex steroids in the 
human and sub-human primate fetus. Journal of Clinical Endocrinology & Metabolism 
1978; 7: 487–511.  
[57] Grumbach M, Conte F. Disorders of sex differentitiation. In: Wilson JD & Foster EW 
(eds) Williams textbook of endocrinology. Philadelphia: W. B. Saunders; 1999: 1303–
1425 
[58] Nelson VL, Legro RS, Strauss 3rd JF, McAllister JM. Augmented androgen production 
is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. 
Molecular Endocrinology 1999; 13: 946–957. 
[59] Doody KJ, Lorence MC, Mason JI, Simpson ER. Expression of messenger ribonucleic 
acid species encoding steroidogenic enzymes in human follicles and corpora lutea 
throughout the menstrual cycle. Journal of Clinical Endocrinology & Metabolism 1990; 
70: 1041–1045. 
 
Dehydrogenases 150 
[60] Teerds KJ, Dorrington JH. Immunohistochemical localization of 3β-hydroxysteroid 
dehydrogenase in the rat ovary during follicular development and atresia. Biology of 
Reprod 1993; 49: 989–996. 
[61] Voss AK, Fortune JE. Levels of messenger ribonucleic acid for cholesterol side-chain 
cleavage cytochrome P-450 and 3β-hydroxysteroid dehydrogenase in bovine 
preovulatory follicles decrease after the luteinizing hormone surge. Endocrinology 
1993; 132: 888–894. 
[62] Labrie F, Belanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum 
concentrations of adrenal C19 sex steroid precursors and conjugated androgen 
metabolites during aging. Journal of Clinical Endocrinology & Metabolism 1997; 82: 
2396–2402. 
[63] Sasano H, Suzuki T. Localization of steroidogenesis and steroid receptors in human 
corpus luteum. Classification of human corpus luteum (CL) into estrogen- producing 
degenerating CL, and nonsteroid-producing degenerating CL. Seminars of  
Reproductive Endocrinology 1997; 15: 345–351. 
[64] Duncan WC, Cowen GM, Illingworth PJ. Steroidogenic enzyme expression in human 
corpora lutea in the presence and absence of exogenous human chorionic 
gonadotrophin (HCG). Molecular & Human Reproduction 1999; 5: 291–298. 
[65] Benyo DF, Little-Ihrig L, Zeleznik AJ. Noncoordinated expression of luteal cell 
messenger ribonucleic acids during human chorionic gonadotropin stimulation of the 
primate corpus luteum. Endocrinology 1993; 133: 699–704, 
[66] McGee E, Sawetawan C, Bird I, Rainey WE, Carr BR. The effects of insulin on 3β-
hydroxysteroid dehydrogenase expression in human luteinized granulosa cells. Journal 
of the Society for Gynecologic Investigations 1995; 2:535–541. 
[67] Feltus FA, Groner B, Melner MH. Stat5-mediated regulation of the human type II 3β-
hydroxysteroid dehydrogenase/∆5-∆4 isomerase gene: activation by prolactin. 
Molecular  Endocrinology 1999; 13: 1084–1093. 
[68] Stocco CO, Deis RP. Participation of intraluteal progesterone and prostaglandin F2α in 
LH-induced luteolysis in pregnant rat. J Endocrinol 1998; 156: 253–259. 
[69] Mendis-Handagama SMLC, Ariyaratne HBS. Differentiation of adult Leydig cell 
proliferation in the postnatal testis. Biology of Reproduction 2001; 65: 660-671. 
[70] Davidoff MS, Middendorff R, Enikolopov G, Riethmacher D, Holstein AF, Muller D. 
Progenitor cells of the testosterone-producing Leydig cells revealed. Journal of Cell 
Biology 2005; 167: 935-944.  
[71] Kilcoyne K, Sharpe RM, McKinnell C, van den Driesche S, Smith LB, Atanossova N. 
Putative adult Leydig progenitor cells in the rat are reduced in number following DBP- 
induced suppression of fetal intratesticular testosterone. Proceedings of 17th European 
Testis Workshop on Molecilar and Cellular Endocrinology of the Testis. April 20-24 
2012, Stockholm, Sweeden. 
[72] Atanassova N. Morpho-functional aspect of androgen-estrogen regulation of 
mammalian testis and male reproductive tract. DSci Thesis, Bulgarian Academy of 
Sciences, Sofia, 2007. 
[73] Habert R, Lejeune H, Saez JM. Origin, differentiation and regulation of fetal and adult 
Leydig cells. Molecular and  Cellular Endocrinology 2001; 179: 47-74. 
 
Hydrohysteroid Dehydrogenases – Biological Role and Clinical Importance – Review 151 
[74] Bernstein L, Ross RK 1993 Endogenous hormones and breast cancer risk. Epidemiology 
Review 1993; 15 :48–65. 
[75] Gunasegaram R, Peh KL, Loganath A, Ratnam SS. Expression of 3β-hydroxysteroid 
dehydrogenase-5,4-ene isomerase activity by infiltrating ductal human breast 
carcinoma in vitro. Breast Cancer Research & Treatment 1998; 50: 117–123. 
[76] Reed MJ, Purohit A. Breast cancer and the role of cytokines in regulating estrogen 
synthesis: an emerging hypothesis. Endocine Review 1997; 18: 701–715. 
[77] Turgeon C, Gingras S, Carriere MC, Blais Y, Labrie F, Simard J. Regulation of sex 
steroid formation by interleukin-4 and interleukin-6 in breast cancer cells. Journal of 
Steroid Biochemistry & Molecular Biology 1998; 65: 151–162, 
[78] Riley SC, Dupont E, Walton JC, Luu-The V, Labrie F, Pelletier G,Challis JR. 
Immunohistochemical localization of 3β-hydroxy- 5-ene-steroid dehydrogenase/∆5-∆4 
isomerase in human placenta and fetal membranes throughout gestation. Journal of 
Clinical Endocrinology & Metabolism 1992; 75: 956–961. 
[79] Morrish DW, Linetsky E, Bhardwaj D, Li H, Dakour J, Marsh RG, Paterson MC, 
Godbout R. Identification by subtractive hybridization of a spectrum of novel and 
unexpected genes associated with in vitro differentiation of human cytotrophoblast 
cells. Placenta 1996; 17: 431–441 
[80] Amet Y, Simon B, Quemener E, Mangin P, Floch HH, Abalain JH. Partial purification of 
3α- and 3β-hydroxysteroid dehydrogenases from human hyperplastic prostate. 
Comparison between the two enzymes. Journal of Steroid Biochemistry & Molecular 
Biology 1992; 41: 689–692. 
[81] Labrie F, Belanger A, Cusan L, Labrie C, Simard J. History of LHRH agonist and 
combination therapy in prostate cancer. Endocrine Related Cancer 1996; 3, 243–278 
[82] Pirog EC, Collins DC 1999 Metabolism of dihydrotestosterone in human liver: 
importance of 3α- and 3β-hydroxysteroid dehydrogenase. Journal of Clinical 
Endocrinology & Metabolism 1999; 84: 3217–3221. 
[83] Keeney DS, Murry BA, Bartke A, Wagner TE, Mason JI 1993 Growth hormone 
transgenes regulate the expression of sex-specificisoforms of 3β-hydroxysteroid 
dehydrogenase/∆5-∆4 isomerase in mouse liver and gonads. Endocrinology 1993; 133: 
1131–1138. 
[84] Anderson D. Steroidogenic enzymes in skin. Journal of Dermatology 2001; 11, 293-295.  
[85] Asada H, Linton J, Katz SI 1997 Cytokine gene expression during the elicitation phase of 
contact sensitivity: regulation by endogenous IL-4. Journal of Investigarive 
Dermatology 1997; 108: 406–411. 
[86] Mensah-Nyagan AG, Do-Rego JL, Beaujean D, Luu-The V, Pelletier G, Vaudry H 1999 
Neurosteroids: expression of steroidogenic enzymes and regulation of steroid 
biosynthesis in the central nervous system. Pharmacology Review 1999; 51: 63–81. 
[87] Zwain IH, Yen SS 1999 Neurosteroidogenesis in astrocytes, oligodendrocytes, and 
neurons of cerebral cortex of rat brain. Endocrinology 1999; 140: 3843–3852. 
[88] Baker PJ, Johnston H, Abel M, HM C, O’Shaughnessy PJ. Differentiation of adult-type 
Leydig cells occurs in gonadotropin-deficient mice. Reproductive Biology & 
Endocrinology 2003; 1: 1–9. 
 
Dehydrogenases 152 
[89] Martin LJ, Taniguchi H, Robert NM, Simard J, Tremblay JJ, Viger RS. GATA Factors and 
the Nuclear Receptors, Steroidogenic Factor 1/Liver Receptor Homolog 1, Are Key 
Mutual Partners in the Regulation of the Human 3β-Hydroxysteroid Dehydrogenase 
Type 2 Promoter. Molecular Endocrinology 2005; 19: 2358–2370. 
[90] Darnell Jr JE. STATs and gene regulation. Science1997; 277: 1630–1635. 
[91] und S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, 
Bodner S, Grosveld G, Ihle JN. Stat5a and Stat5b proteins have essential and 
nonessential, or redundant, roles in cytokine responses. Cell 1998; 93: 841–850. 
[92] Lalli E, Bardoni B, Zazopoulos E, Wurtz JM, Strom TM, Moras D, Sassone-Corsi P. A 
transcriptional silencing domain in DAX-1 whose mutation causes adrenal hypoplasia 
congenita. Molecular  Endocrinology 1997; 11: 1950–1960. 
[93] Tremblay JJ, Viger RS. Novel roles for GATA transcription factors in the regulation of 
steroidogenesis. Journal of Steroid Biochemestry & Molecular Biology 2003; 85: 291–298. 
[94] Cote S, Feltus AF, Gingras S, Freeman M, Melner MH, Simard J 2000 IL-4 stimulation of 
ovarian 3β-hydroxysteroid dehydrogenase/ ∆5-∆4-isomerase type II gene expression: 
mechanisms of activation. Proceedings of the 82nd Annual Meeting of The Endocrine 
Society, 2000, Toronto, Ontario, p 313 (Abstract 1295). 
[95] Rainey WE, Naville D, Mason JI. Regulation of 3β-hydroxysteroid dehydrogenase in 
adrenocortical cells: effects of angiotensin- II and transforming growth factor β. 
Endocrine Research 1991; 17: 281–296 
[96] Havelock JC, Smith AL, Seely JB, Dooley CA, Rodgers RJ, Rainey WE, Carr BR. The 
NGFI-B family of transcription factors regulates expression of 3β-hydroxysteroid 
dehydrogenase type 2 in the human ovary. Molecular & Human Reproduction 2005; 11: 
79–85 
[97] Martin LJ, Tremblay J. The human 3β-hydroxysteroid dehydrogenase/∆5-∆4 isomerase 
type 2 promoter is a novel target for the immediate early orphan nuclear receptor 
Nur77 in steroidogenic cells. Endocrinology 2005;146: 861–869 
[98] Feltus FA, Cote S, Simard J, Gingras S, Kovacs WJ, Nicholson WE, Clark BJ, Melner MH. 
Glucocorticoids enhance activation of the human type II 3β-hydroxysteroid 
dehydrogenase/∆5-∆4 isomerase gene. Journal of Steroid Biochemistry & Molecular 
Biology 2002; 82: 55–63. 
[99] Perry JE, Stalvey JR. Gonadal steroids modulate adrenal fasciculata 3β-hydroxysteroid 
dehydrogenase isomerase activity in mice. Biology of Reproduction 1992; 46: 73–82. 
[100] Stalvey JR, Clavey SM. Evidence that testosterone regulates Leydig cell 3β-
hydroxysteroid dehydrogenase-isomerase activity by a trans-acting factor distal to the 
androgen receptor. Journal of Andrology 1992; 13: 93–99. 
[101] Bush IE, Hunter SA and Meigs RA. Metabolism of 11-oxygenated steroids Biochemical 
Journal 1968; 107: 239–258. 
[102] Lakshmi V and Monder C. Purification and characterization of the corticosteroid 11β-
dehydrogenase component of the rat liver 11β- hydroxysteroid dehydrogenase complex 
Endocrinology 1988; 123: 2390–2398. 
[103] Jamieson PM, Chapman KE, Walker BR, Seckl JR. 11β -hydroxysteroid dehydrogenase 
type 1 is a predominant 11-reductase in the intact perfused rat liver. Journal of 
Endocrinol 2000; 165: 685–692. 
 
Hydrohysteroid Dehydrogenases – Biological Role and Clinical Importance – Review 153 
[104] Seckl JR, Walker BR. Minireview: 11ß-hydroxysteroid dehydrogenase type 1- a tissue-
specific amplifier of glucocorticoid action. Endocrinology 2001; 142: 1371-1376. 
[105] Albiston AL, Obeyesekere VR, Smith RE and Krozowski ZS. Cloning and tissue 
distribution of the human 11β -hydroxysteroid dehydrogenase type 2 enzyme 
Molecular and Cellular Endocrinology 1994; 105: R11–R17. 
[106] MercerWR and Krozowski ZS. Localization of an 11_-hydroxysteroid dehydrogenase 
activity to the distal nephron. Evidence for the existence of two species of 
dehydrogenase in the rat kidney.Endocrinology1992; 130: 540–543. 
[107] Brown RW, Chapman KE, Edwards CRW and Seckl JR. Human placental 11β-
hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD-
dependent iosform. Endocrinology 1993; 132: 2614–2621. 
[108] Seckl JR, Morton NM, Chapman KE, Walker BR. Glucocorticoids and 11beta-
hydroxysteroid dehydrogenase in adipose tissue. Recent Progess in Hormone Research 
2004; 59: 359-93. 
[109] Ge RS, Hardy DO, Catterall JE, Hardy MP. Developmental changes in glucocorticoid 
receptor and 11ß–hydroxysteroid dehydrogenase oxidative and reductive activities in 
rat Leydig cells. Endocrinology. 1997;138: 5089-95. 
[110] Ge RS, Hardy MP. Initial predominance of the oxidative activity of type 11ß-
hydroxysteroid dehydrogenase in primary rat Leydig cells and transfected cell lines. 
Journal of Andrology 2000; 21: 303-310. 
[111] Monder C, Miroff Y, Marandici A, Hardy MP. 11ß–dehydrogenase alleviates 
glucocorticoid-mediated inhibition of steroidogenesis in rat Leydig cells. Endocrinology 
1994; 134: 1199-1204. 
[112] Phillips DM, Lakshmi V, Moder C. Corticosteroid 11ß–hydroxysteroid dehydrogenase 
in rat testis. Endocrinology 1989;125: 209-216.  
[113] Hales DB, Payne AH. Glucocorticoid-mediated repression of P450scc mRNA and de 
novo synthesis in cultured Leydig cells. Endocrinology 1989; 124: 2099–2104. 
[114] Payne AH, Sha LL. Multiple mechanisms for regulation of 3b-hydroxysteroid 
dehydrogenase/D5-D4-isomerase, 17a-hydroxylase/C17-20 lyase cytochrome P450, and 
cholesterol side-chain cleavage cytochrome P450 messenger ribonucleic acid levels in 
primary cultures of mouse Leydig cells. Endocrinology 1991; 129: 1429–1435. 
[115] Gao HB, Tong MH, Hu YQ, Guo QS, Ge R, Hardy MP. Glucocorticoid induces 
apoptosis in rat Leydig cells. Endocrinology 2002; 143: 130–138.  
[116] Gao HB, Tong MH, Hu YQ, You HY, Guo QS, Ge RS, Hardy MP. Mechanisms of 
glucocorticoidinduced Leydig cell apoptosis. Molecular & Cellular Endocrinology 2003; 
199: 153–163. 
[117] Guo-Xin Hu, Qing-Quan Lian, Han Lin, Syed A. Latif, David J. Morris, Matthew P. 
Hardy, and Ren-Shan Ge. Rapid mechanisms of glucocorticoid signaling in the Leydig 
cell. Steroids 2008; 73: 1018–1024. 
[118] Gao HB, Ge RS, Lakshmi A, Hardy MP. Hormonal regulation of oxidative and 
reductive activities of 11ß–hydroxysteroid dehydrogenase in rat Leydig cells. 
Endocrinology 1997; 138: 156-161. 
 
Dehydrogenases 154 
[119] Jamieson PM, Walker BR, Hapman KE, Andrew R, Rossiter S, Seckl JR. 11 beta-
hydroxysteroid dehydrogenase type 1 is a predominant 11 beta-reductase in the 
perfused rat liver. Journal of Endocrinology 2000; 165: 685-692. 
[120] Seckl JR, Walker BR. Minireview: 11ß-hydroxysteroid dehydrogenase type 1- a tissue-
specific amplifier of glucocorticoid action. Endocrinology 2001; 142: 1371-1376. 
[121] Latif SA, Shen M, Ge RS, Sottas CM, Hardy MP, Morris DJ. Role of 11β-OH-C(19) and 
C(21) steroids in the coupling of 11β-HSD1 and 17β-HSD3 in regulation of testosterone 
biosynthesis in rat Leydig cells. Steroids 2011; 76: 682-689. 
[122] Hu GX, Lin H, Sottas CM, Morris DJ, Hardy MP, Ge RS. Inhibition of 11beta-
hydroxysteroid dehydrogenase enzymatic activities by glycyrrhetinic acid in vivo 
supports direct glucocorticoid-mediated suppression of steroidogenesis in Leydig cells. 
Journal of Andrology 2008; 29: 345-51.  
[123] Parthasarathy C, Yuvaraj S, Ilangovan R, Janani P, Kanagaraj P, Balaganesh M, 
Natarajan B, Sittadjody S, Balasubramanian K. Differential response of Leydig cells in 
expressing 11beta-HSD type I and cytochrome P450 aromatase in male rats subjected to 
corticosterone deficiency. Molecular & Cellular Endocrinology 2009; 311:18-23.  
[124] Haider SG, Passia D, Rommert FFG. Histochemical demonstration of 11ß–
hydroxysteroid dehydrogenase as a marker for Leydig cell maturation in rat. Acta 
Histochemica (Suppl) 1990; 38: 203-207. 
[125] Monder C, Hardy MP, Blanchard RJ, Blanchard DC. Comparative aspects of 11ß-
hydroxysteroid dehydrogenase: development of a model for the mediation of Leydig 
cell function by corticosteroids. Steroids 1994; 59: 69-73.  
[126] Neumann A, Haider SG, Hilscher B. Temporal coincidence of the appearance of 
elongated spermatids and of histochemical reaction of 11ß–hydroxysteroid 
dehydrogenase in rat Leydig cells. Andrologia 1993; 25: 263-269. 
[127] Schafers BA, Schlutius BG, Haider SG. Ontogenesis of oxidative reaction of 17β-
hydroxysteroid dehydrogenese and 11ß–hydroxysteroid dehydrogenase in rat Leydig 
cells, a histochemical study. The Histochemical Journal 2001; 33: 585-595. 
[128] Ge RS, Gao HB, Nacharaju VL, Gunsalus GL, Hardy MP. Identification of a kinetically 
distinct activity of 11ß–hydroxysteroid dehydrogenase in rat Leydig cells. 
Endocrinology 1997;138: 2435-2442. 
[129] Brereton PS, Van Driel RR, Suhaimi FB, Koyama K, Dilley R, Krozowski Z. Light and 
electron microscopy localization of the 11ß-hydroxysteroid dehydrogenase type I 
enzyme in the rat. Endocrinology 2001; 142: 1644-1651. 
[130] Hardy MP, Gao HB, Dong Q, Ge R, Wang Q, Chai WR, Feng X, Sottas C. Stress 
hormone and male reproductive function.Cell & Tissue Research 2005; 322:147-53. 
[131] Ge RS, Dong Q, Sottas CM, Chen H, Zirkin BR, Hardy MP. Gene expression in rat 
Leydig cells during development from the progenitor to adult stage: a cluster analysis. 
Biology of Reproduction 2005; 72: 1405-1415. 
[132] Hu GX, Lian QQ, Chen BB, Prasad PV, Kumar N, Zheng ZQ, Ge RS. 7alpha-
hydroxytestosterone affects 1 beta-hydroxysteroid dehydrogenase 1 direction in rat 
Leydig cells. Endocrinology 2010; 151: 748-54.  
[133] Koeva Y, Bakalska M, Atanassova N, Georgieva K, Davidoff M. 11 hydroxysteroid 
dehydrogenase type 2 expression in the newly formed Leydig cells after ethane 
 
Hydrohysteroid Dehydrogenases – Biological Role and Clinical Importance – Review 155 
dimethanesulphonate treatment of adult rats. Folia Histochemica & Cytobiologica 2007; 
45: 381-6. 
[134] Bakalska M, Atanassova N, Angelova P, Koeva I, Nikolov B, Davidoff M. 
Degeneration and restoration of spermatogenesis in relation to the changes in Leydig 
cell population following ethane dimethanesulfonate treatment in adult rats. Endocrine 
Regulations 2001; 35: 211-217. 
[135] Bakalska M, Koeva I, Atanassova N, Angelova P, Nikolov B, Davidoff M. 
Steroidogenic and structural differentiation of new Leydig cell population following 
exposure of adult rats to ethane dimethanesulphonate. Folia Biologica (Praha) 2002; 48: 
205-209. 
[136] Ge RS, Dong Q, Niu EM, Sottas CM, Hardy DO, Catterall JF, Latif SA, Morris DJ, 
Hardy MP. 11 beta-hydroxysteroid dehydrogenase 2 in rat Leydig cells: its role in 
blunting glucocorticoid action at physiological levels of substrate. Endocrinology 2005; 
146: 2657-2664. 
[137] Hardy M and Schlegel P. Testosterone production in the aging male: Where does the 
slowdown occur? Endocrinology 2004; 145: 4439-40. 
[138] Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of 
aging on serum total and free testosterone levels in healthy men. Baltimore 
Longitudinal Study of Aging. Journal of Clinical Endocrinology & Metabolism 2001; 86: 
724-31. 
[139] Wang C, Hikim AS, Ferrini M, Bonavera JJ, Vemet D, Leung A, Lue YH, Gonzalez-
Cadavid NF, Schwerdloff RS. Male reproductive ageing: using the brown Norway rat as 
a model for man. Novartis Found Symposium. 2002; 242: 82-95. 
[140] Chen H, Huhtaniemi I, Zirkin BR. Depletion and repopulation of Leydig cells in the 
testes in aging Brown Norway rats. Endocrinology 1996; 137: 3447-52. 
[141] Zirkin BR and Chen H. Regulation of Leydig cell steroidogenic function during aging. 
Biology of Reproduction 2000;63: 977-81. 
[142] Chen H, Luo L, Zirkin BR. Leydig cell structure and function during aging. In: Payne 
AH, Hardy MP, Russell LD, eds. The Leydig cell. Cache River Press, Vienna, IL; 1996: 
p221-30. 
[143] Schultz R, Isola J, Parvinen M, Honkaniemi J, Wikstrom AC, Gustafsson JA, Pelto-
Huikko M. Localization of the glucocorticoid receptor in testis and accessory sexual 
organs of male rat. Molecular & Cellular Endocrinology 1993; 95:115-20. 
[144] Monder C, White PC. 11 hydroxysteroid dehydrogenase. Vitamines & Hormones 
1993; 47: 187-271. 
[145] Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR. Carbenoxolone 
increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in 
enhancing glucocorticoid receptor activation. Journal of Clinical Endocrinology & 
Metabolism 1995; 80 :3155-59. 
[146] Koeva Y, Bakalska M, Atanassova N, Georgieva K, Davidoff M. Age-related changes 
in the expression of 11beta-hydroxysteroid dehydrogenase type 2 in rat Leydig cells. 
Folia Histochemica & Cytobiologica 2009; 47: 281-287. 
[147] Sankar BR, Maran RR, Sudha S, Govindarajulu P, Balasubramanian K. Chronic 
corticosterone treatment impairs Leydig cell 11beta-hydroxysteroid dehydrogenase 
 
Dehydrogenases 156 
activity and LH-stimulated testosterone production. Hormone & Metabolism Research 
2000; 32: 142-146. 
[148] Morita H, Cozza EN, Zhou MY, Gomez-Sanchez EP, Romero DG, Gomez-Sanchez CE. 
Regulation of the 11 beta-hydroxysteroid dehydrogenase in the rat adrenal. Decrease 
enzymatic activity induced by ACTH.Endocrine 1997; 7: 331-5. 
[149] Shimojo M, Condon J, Whorwood CB, Stewart PM. Adrenal 11 beta-hydroxysteroid 
dehydrogenase. Endocrine Research 1996; 22:771-80. 
[150] Shimojo M, Whorwood CB, Stewart PM. 11 beta-hydroxysteroid dehydrogenase in the 
rat adrenal. Journal of Molecular Endocrinology 1996; 17: 121-30. 
[151] Smith RE, Li KX, Andrews RK, Krozowski Z. Immunohistochemical and molecular 
characterization of the rat 11 beta-hydroxysteroid dehydrogenase type II enzyme. 
Endocrinology 1997; 138: 540-547. 
[152] Koeva YA, Bakalska MV, Petrova EI, Atanassova NN. 11beta hydroxysteroid 
dehydrogenase type 2 in the adrenal gland by testosterone withdrawal of adult rats. 
Folia Medica (Plovdiv) 2010; 52: 38-42. 
[153] Atanassova N, Koeva Y, Bakalska M, Pavlova E, Nikolov B, Davidoff M. Loss and 
recovery of androgen receptor protein expression in the adult rat testis following 
androgen withdrawal by ethane dimethanesulfonate. Folia Histochemica et 
Cytobiologica 2006; 44: 81-86. 
[154] Plecas B, Pesic VP, Mirkovic D, Majkic-Singh N, hristic M, Solarovic T. Opposite 
effects of dexamethasone and ACTH on the adrenal cortex response to ethane 
dimethanesulphonate (EDS). Experimenatal Toxicology & Pathology 2001; 53: 31-34. 
[155] Petrova E, Koeva Y, Bakalska M, Atanassova N, Davidoff M. Morphofunctional 
characteristics of rat adrenocorticocytes after treatment with ethane 
dimethanesulphonate. Jubilee Scientific Session of Medical University, Plovdiv, 2005, 
abstract book; 164. 
[156] Stalvey JR. Inhibition of 3 beta-hydroxysteroid dehydrogenase- isomerase in mouse 
adrenal cells: a different effect of testosterone. Steroids 2002; 67: 721-31. 
[157] Michael AE & Cooke BA. A working hypothesis for the regulation of steroidogenesis 
and germ cell development in the gonads by glucocorticoids and 11β-hydroxysteroid 
dehydrogenase (11β-HSD). Molecular and Cellular Endocrinology 1994; 100: 55–63. 
[158] Omura T & Morohashi K. Gene regulation of steroidogenesis. Journal of Steroid 
Biochemistry and Molecular Biology 1995; 53: 19–25. 
[159] Monder C & Lakshmi V. Evidence for kinetically distinct forms of corticosteroid 11β-
hydroxysteroid dehydrogenase in rat liver microsomes. Journal of Steroid Biochemistry 
1989; 32: 77–83. 
[160] Mercer W, Obeyeskere V, Smith R & Krozowski Z. Characterization of 11βHSD1B 
gene expression and enzyme activity. Molecular and Cellular Endocrinology 1993; 92: 
247–251.  
[161] Yding Andersen C. Possible new mechanism of cortisol action in female reproductive 
organs: physiological implications of the free hormone hypothesis. Journal of 
Endocrinology 2002; 173: 211–217. 
 
Hydrohysteroid Dehydrogenases – Biological Role and Clinical Importance – Review 157 
[162] Yding Andersen C, Morineau G, Fukuda M, Westergaard LG, Ingerslev HJ, Fiet J & 
Byskov AG. Assessment of the follicular cortisol:cortisone ratio. Human Reproduction 
1999; 14: 1563–1568. 
[163] Yong PYK, Thong KJ, Andrew R, Walker BR & Hillier SG. Development-related 
increase in cortisol biosynthesis by human granulosa cells. Journal of Clinical 
Endocrinology and Metabolism 2000; 85: 4728–4733. 
[164] Hillier SG & Tetsuka M. An anti-inflammatory role for glucocorticoids in the ovaries? 
Journal of Reproductive Immunology 1998; 39: 21–27. 
[165] Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of 
the polycystic ovary syndrome in unselected black and white women of the 
Southeastern United States: a prospective study. Jornal of Clinical Endocrinology & 
Metabolism 1998; 83: 3078–3082. 
[166] Legro, R.S. & J.F. Strauss III. Molecular progress in infertility: polycystic ovary 
syndrome. Fertility & Sterility 2002; 78: 569–576. 
[167] Milutinović DV, Macut D, Božić I, Nestorov J, Damjanović S, Matić G. Hypothalamic-
pituitary-adrenocortical axis hypersensitivity and glucocorticoid receptor expression 
and function in women with polycystic ovary syndrome. Experimental Clinical 
Endocrinology & Diabetes. 2011; 119: 636-43. 
[168] Diamanti-Kandarakis E, Xyrafis X, Boutzios G, Christakou C. Pancreatic beta-cells 
dysfunction in polycystic ovary syndrome. Panminerva Medicine 2008; 50: 315-25. 
[169] Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: 
etiology, pathogenesis and diagnosis. Nature Reviews of Endocrinology 2011;7 :219-31.  
[170] Waterworth DM, Bennett ST, Gharani N, McCarthy MI, Hague S, Batty S, Conway GS, White 
D, Todd JA, Franks S, Williamson R. Linkage and association of insulin gene VNTR 
regulatory polymorphism with polycystic ovary syndrome. Lancet 1997; 349: 986–990. 
[171] Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM.. Augmented androgen production is 
a stable phenotype of propagated theca cells from polycystic ovaries. Molecular 
Endocrinology 1999; 13: 946–957. 
[172] Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS, Strauss JF 3rd, 
McAllister JM.The biochemical basis for increased testosterone production in theca cells 
propagated from patients with polycystic ovary syndrome. Journal of Clinical 
Endocrinology and Metabolism 2001; 86: 5925–5933. 
[173] Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. 
Differential activity of the cytochrome P450 17α-hydroxylase and steroidogenic acute 
regulatory protein gene promoters in normal and polycystic ovary syndrome theca 
cells. Journal of Clinical Endocrinology and Metabolism 2000; 85: 2304–2311. 
[174] J.F.Strauss III. Some New Thoughts on the Pathophysiology and Genetics of Polycystic 
Ovary Syndrome. Annals of New York Academy of Sciences 2003; 997: 42–48. 
[175] Svendsen PF, Madsbad S, Nilas L, Paulsen SK, Pedersen SB. Expression of 11beta-
hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and 
obese women with and without polycystic ovary syndrome. International Journal of 
Obesity (Lond) 2009; 33:1249-56. 
[176] Tsilchorozidou T, Honour JW, Conway GS. Altered cortisol metabolism in polycystic 
ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal 
 
Dehydrogenases 158 
steroid production rates. Journal of Clinical Endocrinology and Metabolism 2003; 88: 
5907-13. 
[177] Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, 
Bedendo O, Ray DW, Laing I, Malunowicz E, White PC, Hewison M, Mason PJ, Connell 
JM, Shackleton CHL, Stewart PM. Mutations in the gene encoding 11β-hydroxysteroid 
dehydrogenase type 1 and hexose- 6-phosphate dehydrogenase interact to cause 
cortisone reductase deficiency. Nature Genetics 2003; 34: 434–439. 
[178] Phillipov G, Palermo M, Shackleton CH. Apparent cortisone reductase deficiency: a 
unique form of hypercortisolism. J Clin Endocrinol Metab, 1996; 81:3855–3860. 
[179] Rodin A, Thakkar H, Taylor NJ, Clayton R. Hyperandrogenism in polycystic ovary 
syndrome: evidence of dysregulation of 11β-hydroxysteroid dehydrogenase. New 
English Journal of Medicine 1994; 330: 460–465. 
[180] Gambineri A, Vicennati V, Genghini S, Tomassoni F, Pagotto U, Pasquali R, Walker BR. 
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal 
hyperandrogenism among lean women with polycystic ovary syndrome. Journal of 
Clinical Endocrinology and Metabolism 2006; 91: 2295-302. 
[181] Hines GA, Smith ER, Azziz R. Influence of insulin and testosterone on adrenocortical 
steroidogenesis in vitro: preliminary studies. Fertility & Sterilility 2001; 76: 730–735. 
[182] Andrew R, Phillips DIW, Walker BR. Obesity and gender influence cortisol secretion 
and metabolism in man. Journal of Clinical Endocrinology and Metabolism 1998; 83: 
1806–1809. 
[183] San Milla´n JL, Botella-Carretero JI, Alvarez-Blasco F, Luque-Ramı´rez M, Sancho J, 
Moghetti P, Escobar-Morreale HF. A study of the hexose-6-phosphate dehydrogenase 
gene R453Q and 11β-hydroxysteroid dehydrogenase type 1 gene 83557insA 
polymorphisms in the polycystic ovary syndrome. Journal of Clinical Endocrinology 
and Metabolism 2005; 90: 4157–4162. 
[184] White PC. Genotypes at 11β-hydroxysteroid dehydrogenase type 11B1 and hexose-6-
phosphate dehydrogenase loci are not risk factors for apparent cortisone reductase 
deficiency in a large population-based sample. Journal of Clinical Endocrinology and 
Metabolism 2005; 90: 5880–5883. 
[185] Draper N, Powell BL, Franks S, Conway GS, Stewart PM & McCarthy MI. Variants 
implicated in cortisone reductase deficiency do not contribute to susceptibility to 
common forms of polycystic ovary syndrome. Clinical Endocrinology 2006; 65: 64– 70. 
[186] Gambineri A, Tomassoni F, Munarini A, Stimson RH, Mioni R, Pagotto U, Chapman KE, 
Andrew R, Mantovani V, Pasquali R, Walker BR. A combination of polymorphisms in 
HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in 
women with and without polycystic ovary syndrome. European Journal of 
Endocrinology 2011; 165: 283-92. 
[187] Mlinar B, Marc J, Jensterle M, Bokal EV, Jerin A, Pfeifer M. Expression of 
11βhydroxysteroid dehydrogenase type 1 in visceral andsubcutaneous adipose tissues 
of patients with polycystic ovary syndrome is associated with adiposity. Journal of 
Steroid Biochemistry & Molecular Biology 2011; 123: 127-32. 
[188] Reaven G. Metabolic syndrome — pathophysiology and implications for management 
of cardiovascular disease. Circulation 2002; 106: 286–288. 
 
Hydrohysteroid Dehydrogenases – Biological Role and Clinical Importance – Review 159 
[189] Walker B, Seckl J. Cortisol metabolism. In: Bjo¨rntorp P, ed. International Textbook of 
Obesity. 2001, Chichester, UK: John Wiley and Sons; 241–268. 
[190] Morton NM, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. 
Frontiers in Hormone Research 2008; 36: 146-64. 
[191] Livingstone DEW, Jones G, Smith K, Jamieson PM, Andrew R, Kenyon CJ, Walker BR. 
Understanding the role of glucocorticoids in obesity: tissue-specific alterations of 
corticosterone metabolism in obese Zucker rats. Endocrinology 2000; 141: 560–563. 
[192] Westerbacka J, Yki-Ja¨rvinen H, Vehkavaara S, Ha¨kkinen A, Andrew R, Wake D, 
Seckl J, Walker B. Body fat distribution and cortisol metabolism in healthy men: 
enhanced 5-reductase and lower cortisol/cortisone metabolite ratios in men with fatty 
liver. Journal of Clinical Endocrinology and Metabolism 2003; 88: 4924–4931. 
[193] Livingstone DEW, Kenyon CJ, Walker BR. Mechanisms of dysregulation of 11 beta 
hydroxysteroid dehydrogenase type 1 in obese Zucker rats. Journal of Endocrinol 2000; 
167: 533–539. 
[194] Mattsson C, Olsson T. Estrogens and glucocorticoid hormones in adipose tissue 
metabolism. Current Medicinal Chemistry 2007; 14:2918-24. 
[195] Andersson T, Söderström I, Simonyté K, Olsson T. Estrogen reduces 11beta-
hydroxysteroid dehydrogenase type 1 in liver and visceral, but not subcutaneous, 
adipose tissue in rats. Obesity (Silver Spring). 2010; 18: 470-5.  
[196] Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A 
transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 
2166–2170. 
[197] Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, 
Shinyama H, Sharp MGF, Fleming S. Transgenic amplification of glucocorticoid action 
in adipose tissue causes high blood pressure in mice. Journal of Clinical Investigations, 
2003; 112: 83–90. 
[198] Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR & 
Mullins JJ. Metabolic syndrome without obesity: hepatic overexpression of 11b-
hydroxysteroid dehydrogenase type 1 in transgenic mice. Proceedings of the National 
Academy of Sciences USA 2004; 101: 7088–7093. 
[199] Kotelevtsev YV, Holmes MC, Burchell A, Houston PM, Scholl D, Jamieson PM, Best R, 
Brown RW, Edwards CRW, Seckl JR & Mullins. 11b-Hydroxysteroid dehydrogenase 
type 1 knockout mice show attenuated glucocorticoid inducible responses and resist 
hyperglycaemia on obesity and stress. Proceedings of the National Academy of Sciences 
USA,1997; 94: 14924–14929. 
[200] Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ & Seckl JR. 
Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose 
tolerance in 11b hydroxysteroid dehydrogenase type 1 null mice. Journal of Biological 
Chemistry, 2001; 276: 41 293–300.  
[201] Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, 
Flier JS, Mullins JJ & Seckl JR. Novel adipose tissue-mediated resistance to diet-induced 
visceral obesity in 11b-hydroxysteroid dehydrogenase type 1 deficient mice. Diabetes 
2004; 53: 931–938. 
 
Dehydrogenases 160 
[202] Stimson RH, Walker BR. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase 
type 1 in obesity and the metabolic syndrome. Minerva Endocrinology 2007; 32: 141-
159. 
[203] Nair S, Lee YH, Lindsay RS, Walker BR, Tataranni PA, Bogardus C, Baier LJ & 
Permana PA. 11Beta-hydroxysteroid dehydrogenase type 1: genetic polymorphisms are 
associated with type 2 diabetes in Pima Indians independently of obesity and 
expression in adipocyte and muscle. Diabetologia 2004; 47: 1088–1095.  
[204] Franks PW, Knowler WC, Nair S, Koska J, Lee YH, Lindsay RS, Walker BR, Looker 
HC, Permana PA, Tatarani PA, Hanson RL. Interaction between an 11bHSD1 gene 
variant and birth era modifies risk of hypertension in Pima Indians. Hypertension 2004; 
44: 681–688. 
[205] Morales MA, Carvajal CA, Ortiz E, Mosso LM, Artigas RA, Owen GI & Fardella CE. 
Possible pathogenetic role of 11 beta-hydroxysteroid dehydrogenase type 1 (11beta 
HSD1) gene polymorphisms in arterial hypertension. Revista Me´dica de Chile, 2008; 
136: 701–710. 
[206] Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, 
Olsson T. Tissue-specific changes in peripheral cortisol metabolism in obese women: 
increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. Journal of 
Clinical Endocrinology & Metabolism 2002; 87: 3330–3336. 
[207] Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CRW. Carbenoxolone 
increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in 
enhancing glucocorticoid receptor activation. Journal of Clinical Endocrinology & 
Metabolism 1995; 80: 3155–3159. 
[208] Andrews RC, Rooyackers O, Walker BR. Effects of the 11beta-hydroxysteroid 
dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 
diabetes. Journal of Clinical Endocrinology & Metabolism 2003; 88: 285–291. 
[209] Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR. Increased in 
vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 
11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 2005; 
54: 872–879. 
[210] Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingström G, Larsson C, 
Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Björkstrand E, 
Abrahmsen LB. Selective inhibition of 11bhydroxysteroid dehydrogenase type 1 
improves hepatic insulin sensitivity in hyperglycaemic mice strains. Endocrinology 
2003; 144: 4755–4762. 
[211] Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, 
Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis 
B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu 
K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer. 11b-HSD1 inhibition ameliorates 
metabolic syndrome and prevents progression of atherosclerosis in mice. Journal of 
Experimental Medicine 2005; 202: 517–527. 
[212] Wamil M, Seckl JR. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a 
promising therapeutic target. Drug Discovery Today 2007; 12) :504-520.  
 
Hydrohysteroid Dehydrogenases – Biological Role and Clinical Importance – Review 161 
[213] Morton NM. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and 
therapeutic target in metabolic disease. Molecular & Cellular Endocrinology 2010 25; 
316: 154-64.  
[214] Morton NM, Ramage L & Seckl JR. Down-regulation of adipose 11b-hydroxysteroid 
dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism 
counteracting metabolic disease. Endocrinology 2004;145: 2707–2712. 
[215] Harris A, Seckl J. Glucocorticoids, prenatal stress and the programming of disease. 
Hormones & Behavior  201; 59: 279-89.  
[216] Marciniak B, Patro-Małysza J, Poniedziałek-Czajkowska E, Kimber-Trojnar Z, 
Leszczyńska-Gorzelak B, Oleszczuk J. Glucocorticoids in pregnancy. Current 
Pharmacology & Biotechnology 201; 12:750-757. 
[217] McTernan CL, Draper N, Nicholson H, Chalder SM, Driver P, Hewison M, Kilby MD, 
Stewart PM. Reduced placental 1β-hydroxysteroid dehydrogenase type 2 mRNAlevels 
in human pregnancies complicated by intrauterine growth restriction: an analysis of 
possible mechanisms. Journal of Clinical Endocrinology & Metabolism 2001; 86: 4979–
4983. 
[218] Beitens IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ. The metabolic clearance rate, 
blood production, interconversion and transplacental passage of cortisol and cortisone 
in pregnancy near term. Pediatric Research1997; 37: 509–519.  
[219] Brown RW, Diaz R, Robson AC, Kotelevtsev Y, Mullins JJ, Kaufman MH, Seckl JR. 
Isolation and cloning of human placental 11β hydroxysteroid dehydrogenase-2 cDNA. 
Biochemical Journal 1996; 313: 1007–1017. 
[220] Benediktsson R, Calder AA, Edwards CRW, Seckl JR. Placental 11β-hydroxysteroid 
dehydrogenase type 2 is the placental barrier to maternal glucocorticoids: ex vivo 
studies. Clinical Endocrinology 1997; 46: 161–166. 
[221] Seckl JR, Holmes MC. Mechanisms of disease: glucocorticoids, their placental 
metabolism and fetal 'programming' of adult pathophysiology. Nat Clinical Practice of 
Endocrinology and Metabolism 2007; 3:479-488. 
[222] Edwards CRW, Benediktsson R, Lindsay R, Seckl JR. Dysfunction of the placental 
glucocorticoid barrier: a link between the foetal environment and adult hypertension? 
Lancet 1993; 341: 355–357. 
[223] Stewart PM, Rogerson FM, Mason JI. Type 2 11β-hydroxysteroid dehydrogenase 
messenger RNA and activity in human placenta and fetal membranes: its relationship 
to birth weight and putative role in fetal steroidogenesis. Journal of Clinical 
Endocrinology & Metabolism 1995; 80: 885–890. 
[224] Murphy VE, Zakar T, Smith R, Giles WB, Gibson PG, Clifton VL. Reduced 11β-
hydroxysteroid dehydrogenase type 2 activity is associated with decreased birth weight 
centile in pregnancies complicated by asthma. Journal of Clinical Endocrinology & 
Metabolism 2002; 87: 1660–1668. 
[225] Marchais-Oberwinkler S, Henn C, Möller G, Klein T, Negri M, Oster A, Spadaro A, 
Werth R, Wetzel M, Xu K, Frotscher M, Hartmann RW, Adamski J. 17β-Hydroxysteroid 
dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and 
recent progress in inhibitor development. Journal of Steroid Biochemistry & Molecular 
Biology 2011; 125: 66-82.  
 
Dehydrogenases 162 
[226] Vihko P, Herrala A, Harkonen P, Isomaa V, Kaija H, Kurkela R, Pulkka A. Controlof 
cell proliferation by steroids: the role of 17HSDs. Molecular & Cellular Endocrinology 
2006; 248: 141–148. 
[227] Vihko P, Herrala A, Harkonen P, Isomaa V, Kaija H, Kurkela R, Li Y, Patrikainen L, 
Pulkka A, Soronen P, Torn S. Enzymes as modulators in malignant transformation. 
Journal of Steroid Biochemistry & Molecular Biology 2005; 93: 277–283. 
[228] Geissler W, Davis D, Wu L, Bradshaw K, Patel S, Mendonca B, Elliston K, Wilson J, 
Russell D, Andersson S. Male pseudohermaphroditism caused bymutations of testicular 
17β-hydroxysteroid dehydrogenase 3, Nature Genetics 1994, 7: 34–39. 
[229] Rasiah KK, Gardiner-Garden M, Padilla FJ, Moller G, Kench JG, Alles MC, Eggleton 
SA, Stricker PD, Adamski J, Sutherland RL, Henshall SM, Hayes VM. HSD17B4 
overexpression, an independent biomarker of poor patient outcome in prostate cancer. 
Molecular & Cellular Endocrinology 2009; 301: 89–96. 
[230] Jin Y, Penning TM. Aldo–keto reductases and bioactivation/detoxication, Annual 
Review of Pharmacology & Toxicology 2006; 47: 263–292. 
[231] Stanbrough M, Bubley GJ, Ros K, Golub TR, Rubi MA, Penning TM, Febbo PG, Balk. 
SP. Increased expression of genes converting adrenal androgens to testosterone in 
androgen independent prostate cancer. Cancer Research 2006; 66: 2815–2825. 
[232] Biswas MG, Russell DW. Expression cloning and characterization of oxidative 17beta- 
and 3alpha-hydroxysteroid dehydrogenases from rat and human prostate. Journal of 
Bioogical Chemistry 1997; 272: 15959–15966. 
[233] Prehn C, Moller G, Adamski J. Recent advances in 17beta-hydroxysteroid 
Dehydrogenases. Journal of Steroid Biochemistry & Molecular Biology 2009; 114, 72–77. 
[234] Haynes BP, Straume AH, Geisler J, A’Hern R, Helle H, Smith IE, Lønning PE, Dowsett 
M. Intratumoral estrogen disposition in breast cancer, Clinical Cancer Research 2010; 
16: 1790–1801. 
[235] Fomitcheva J, Baker ME, Anderson E, Lee GY, Aziz N. Characterization of Ke 6, a 
new17beta-hydroxysteroid dehydrogenase, and its expression in gonadal tissues. 
Journal of Biological Chemistry 1998; 273: 22664–22671. 
[236] Maxwell MM, Nearing J, Aziz N. Ke 6 gene. Sequence and organization and aberrant 
regulation in murine polycystic kidney disease, Journal of Biological Chemistry 1995; 
270: 25213–25219. 
[237] Su J, Lin M, Napoli JL. Complementary deoxyribonucleic acid cloning and enzymatic 
characterization of a novel 17beta/3alpha-hydroxysteroid/retinoid short chain 
dehydrogenase/reductase. Endocrinology 1999; 140: 5275–5284. 
[238] Froyen G, Corbett M, Vandewalle J, Jarvela I, Lawrence O, Meldrum C, Bauters M, 
Govaerts K, Vandeleur L, Esch H, Chelly J, Sanlaville D, Bokhoven H,  Ropers HH, 
Laumonnier F, Ranieri E, Schwartz CE, Abidi F, Tarpey PS, Futreal PA, Whibley A, 
Raymond FL, Stratton MR, Fryns JP, Scott R, Peippo M, Sipponen M, Partington M, 
Mowat D, Field M, Hackett A, Marynen P, Turner G, Gecz J. Submicroscopic 
duplications of the hydroxysteroid dehydrogenase HSD17B10 and the E3 ubiquitin 
ligase HUWE1 are associated with mental retardation. American Journal of Human 
Genetetics 2008; 82: 432–443. 
 
Hydrohysteroid Dehydrogenases – Biological Role and Clinical Importance – Review 163 
[239] Yang SY, He XY , Miller D. HSD17B10: a gene involved in cognitive function through 
metabolism of isoleucine and neuroactive steroids, Molecular Genetics & Metabolism 
2007; 92: 36–42. 
[240] Brereton P, Suzuki T, Sasano H, Li K,  Duarte C, Obeyesekere V, Haeseleer F, 
Palczewski K, Smith I, Komesaroff P,  Krozowski Z. Pan1b (17betaHSD11)- enzymatic 
activity and distribution in the lung, Molecular & Cellular Endocrinology 2001; 171: 
111–117. 
[241] Day JM, Foster PA, Tutill HJ, Parsons MF, Newman SP, Chander SK, Allan GM, 
Lawrence HR, Vicker N, Potter BV, Reed MJ, Purohit A. 17betahydroxysteroid 
dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-
dependent breast cancer. International Journal of Cancer 2008; 122: 1931–1940. 
[242] Luu-The V, Tremblay P, Labrie F. Characterization of type 12 17betahydroxysteroid 
dehydrogenase (17beta-HSD12), an isoform of type 3 17beta-hydroxysteroid 
dehydrogenase responsible for estradiol formation in women. Molecular Endocrinology 
2006; 20: 437–443. 
[243] Horiguchi Y, Araki M, Motojima K.17beta-hydroxysteroid dehydrogenase type 13 is a 
liver-specific lipid droplet-associated protein. Biochemical Biophysical Research 
Communications 2008; 370: 35–238. 
[244] Lukacik P, Keller B, Bunkoczi G, Kavanagh KL, Lee WK, Adamsk Ji, U. Oppermann. U 
Structural and biochemical characterization of human orphan DHRS10 reveals a novel 
cytosolic enzyme with steroid dehydrogenase activity. Biochemical Journal 2007; 402: 
419–427. 
[245] Jansson AK, Gunnarsson C, Cohen M, Sivik T, Stal O. 17beta-hydroxysteroid 
dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic 
marker in estrogen receptor-positive breast cancer. Cancer Research 2006; 66: 11471–
11477. 
[246] Day JM, Tutill HJ, Purohit A & Reed MJ. Design and validation of specific inhibitors of 
17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and 
prostate cancer, and in endometriosis. Endocrine-Related Cancer 2008; 15: 665–692. 
[247] Day JM, Foster PA, Tutill HJ, Parsons MF, Newman SP, Chander SK, Allan GM, 
Lawrence HR, Vicker N, Potter BV. 7Betahydroxysteroid dehydrogenase type 1, and not 
type 12, is a target for endocrine therapy of hormone-dependent breast cancer. 
International Journal of Cancer; 2008 122: 1931–1940.  
[248] Yang SY, He XY, Schulz H. Multiple functions of type 10 17betahydroxysteroid 
Dehydrogenase. Trends in Endocrinoogy & Metabolism 2005; 6: 167–175. 
[249] Vihko P, Herrala A, Harkonen P, Isomaa V, Kaija H, Kurkela R, Pulkka A. Control of 
cell proliferation by steroids: the role of 17HSDs. Molecular & Celular Endocrinoogy 
2006; 248: 141–148. 
[250] Vihko P, Herrala A, Harkonen P, Isomaa V, Kaija H, Kurkela R, Li Y, Patrikainen L, 
Pulkka A, Soronen P, Torn S. Enzymes as modulators in malignant transformation. 
Journal of Steroid Biochemistry & Molecular Biology 2005; 93: 277–283. 
[251] Peltoket H, Luu-The  V, Simard J, Adamski J. 17β-Hydroxysteroid dehydrogenase 
(HSD)/17-ketosteroidreductase (KSR) family; nomenclature and maincharacteristics of 
the 17HSD/KSR enzymes. Journal of Molecular Endocrinology 1999; 23: 1-11. 
 
Dehydrogenases 164 
[252] Geissler W, Davis D, Wu L, Bradshaw K, Patel S, Mendonca B, Elliston K, Wilson J, 
Russell D. Andersson S. Male pseudohermaphroditism caused by mutations of 
testicular 17β hydroxysteroid dehydrogenase 3. Nature Genetic 1994; 7: 34–39. 
[253] Day MJ, Tutill HJ, Foster PA, Bailey HV, Heaton WB, Sharland CM, Vicker N, Potter 
BV, Purohit A, Reed MJ. Development of hormonedependent prostate cancer models 
for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3, 
Molecular & Cellular Endocrinology 2009; 301: 251–258. 
[254] Neocleous V, Sismani C, Shammas C, Efstathiou E, Alexandrou A, Ioannides M, 
Argyrou M, Patsalis PC, Phylactou LA, Skordis N. Duplication of exons 3-10 of the 
HSD17B3 gene: A novel type of genetic defect underlying 17β-HSD-3 deficiency. Gene  
2012; 499: 250-255.  
[255] Faienza MF, Giordani L, Delvecchio M, Cavallo L. Clinical, endocrine, and molecular 
findings in 17beta-hydroxysteroid dehydrogenase type 3 deficiency. Journal of 
Endocrinological Investigations 2008; 31: 85-91. 
[256] Penning TM, Byrns MC. Steroid hormone transforming aldo-keto reductases and 
cancer. Annals of New York Academy of Sciences 2009; 1155: 33–42. 
[257] Kissinger CR, Rejto PA, Pelletier LA, Thomson JA, Showalter RE, Abreo MA, Agree 
CS, Margosiak S, Meng JJ, Aust RM, Vanderpool D, Li B, Tempczyk-Russell A, 
Villafranca JE. Crystal structure of human ABAD/HSD10 with a bound inhibitor: 
implications for design of Alzheimer’s disease therapeutics. Journal of Molecular 
Biology 2004; 342; 943–952. 
[258] Du Yan S, Zhu Y, Stern ED, Hwang YC, Hori O, Ogawa S, Frosch MP, Connolly ES Jr., 
Taggert RMc, Pinsky DJ, Clarke S, Stern DM, Ramasamy R.  Amyloid beta-peptide-
binding alcohol dehydrogenase is a component of the cellular response to nutritional 
stress. Journal of Biological Chemistry 2000; 275: 27100–27109. 
Chapter 5 
 
 
 
 
© 2012 Naik et al., licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Role and Function  
of Dehydrogenases in CNS  
and Blood-Brain Barrier Pathophysiology 
P. Naik, S. Prasad and L. Cucullo 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/48338 
1. Introduction 
Dehydrogenase (DHO) is one of the most common types of enzyme that is crucial in 
oxidation reactions. This enzyme oxidizes its specific substrate by a redox reaction in 
which one or more hydrides (H−) are transferred to an electron acceptor. Apart from 
energetics and ATP formation, DHOs are associated with both catabolic and anabolic 
pathways linked to normal functioning and homeostasis. In this chapter, we will cover 
different aspects of the major DHOs that play a role in the regulation of brain and blood-
brain barrier (BBB) physiology starting from their role in bioenergetic metabolism. In 
born errors in metabolism (IEM) due to genetic deficiency in a single specific DHO have 
strong neurological implications. We will be covering some examples of such IEMs in 
this chapter. Furthermore, aging processes can impair the function or activity of DHOs. 
Recent studies show convincing evidence associating altered DHO activity with the 
pathogenesis and progression of several neurological disorders such as Alzheimer’s and 
Parkinson’s disease. Whether they are contributors to the etiology of the disease or 
symptomatic manifestation of these complex neurological disorders is still debatable; 
however, this link between DHOs and neurological disorders cannot be overlooked and 
will be further discussed in this chapter. We will also cover neuronal signaling, 
neurotransmitter release and degradation emphasizing localized region-specific 
expression of some brain DHOs in these processes. It is not possible to cover the detailed 
cerebral physiology and function in this chapter; however to summarize we will discuss 
the different types of DHOs in central nervous system (CNS) and BBB physiology, their 
key enzymatic action, their function in crucial metabolic pathways, and thus how their 
altered activity or expression can be linked to the underlying pathogenesis of various 
brain disorders.  
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2. Structural and functional complexity of blood brain barrier (BBB) and 
cerebral physiology – A need for high energy 
The BBB is a dynamic interface between the peripheral blood and the brain which controls 
the influx and efflux of substrates and metabolites necessary for normal neuronal function 
(see Figure 1). The BBB is crucial in protecting the brain from harmful substances both 
endogenous and exogenous in nature. Any alteration in normal BBB functions can play a 
central role in the pathogenesis and progression of broad variety of CNS disorders such as 
multiple sclerosis, Alzheimer's disease, neoplasia, hypertension, dementia, epilepsy, 
infection and trauma (1-4). 
At the cellular level, the BBB consists of microvascular endothelial cells (ECs) lining the 
brain microvessels together with closely associated astrocytic end-feet processes and 
pericytes (5-8). These associated cells play a major role in EC differentiation and acquisition 
of morphological and functional characteristics unique to the BBB. At the cellular level, the 
brain microcapillary endothelium is characterized by the presence of tight junctions (TJ), 
lack of fenestrations, and minimal pinocytotic vesicles (9;10). In particular, TJs between the 
cerebral endothelial cells form a diffusion barrier, which selectively excludes most of the 
blood-borne substances from entering the brain, protecting it from systemic influences 
mediated by substances which are primarily polar in nature (such as electrolytes). Transport 
of nutrients (as well as other biologically important substances) from the peripheral 
circulation into brain parenchyma requires translocation through the capillary endothelium 
by specialized carrier-mediated transport systems. On the other hand, potentially harmful 
substances that are lipid soluble are discharged back into the cerebral circulation. This is 
mediated by specialized active efflux systems belonging to the ATP-binding cassette 
transporters (ABC-transporter) superfamily (such as P-glycoprotein (P-gp) and Multidrug 
resistance Protein (MRP)) (11;12). These efflux pumps rely heavily on adenosine 
triphosphate (ATP) as fuel source. Apart from these ATP dependent pumps, energy 
independent transporters such as organic ion carriers add to the complexity of BBB 
transport functions (13). Simultaneously, intake of essential nutrients such as glucose, amino 
acids, peptides, choline occurs through carrier mediated mechanisms (13-17). Topographic 
membrane localization of these transporters is indicative of the polarity of the endothelial 
functions and differentiation that sets apart the BBB endothelium from other vascular beds. 
The BBB endothelial cytoplasm is richly endowed with enzymes(18) including adenosine tri-
phosphatase, acid and alkaline phosphatases, Na+/K+/ATPase, monoamine oxidase, 
cytochrome p450s and various dehydrogenases (19-22). The BBB ECs are also characterized 
by very high density of mitochondria denoting high metabolic activity (23) to support all the 
specialized cellular activities bestowed upon these highly specialized cells. In addition, 
previous work from our group has shown that blood flow can modulate the bioenergetic 
behavior of the BBB endothelial cells favoring the expression of the key metabolic enzyme 
pyruvate dehydrogenase (switch controller from anaerobic to aerobic pathway) (19). 
Contrarily, the RNA level of lactate dehydrogenase (switch controller from aerobic to 
anaerobic pathway) showed decreased expression. In parallel, TCA dehydrogenases such as 
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acotinase, isocitrate dehydrogenase, succinate dehydrogenase were upregulated. These 
results clearly emphasize how altered rheological conditions (e.g., hypoperfusion and 
ischemia) may impact the BBB bioenergetic metabolism and how the BBB is well equipped 
to respond to such changes (see Figure 2). 
 
Figure 1. Schematic representation of the brain microvasculature in relation to the brain. Note how the 
blood vessels start branching in small capillaries while the pia disappears and the endothelium acquires 
the peculiar characteristics of a tight barrier that regulate the exchange of substances between blood and 
brain. TJ between adjacent endothelial cells form a diffusion barrier that selectively excludes most 
blood-borne and xenobiotic substances from entering the brain. In contrast to lipid soluble substances 
including alcohols, anesthetics and barbiturates, the BBB is highly impermeant to polar molecules or 
water soluble electrolytes. However, the passage of certain water soluble, but biologically important 
substances, such as D-glucose or phenylamine are regulated by a variety of specific carrier-mediated 
transport systems. By contrast, larger vessels (arterioles, small arteries and venous) differ from 
capillaries by the presence of smooth muscle cells in their walls and a less stringent vascular bed.  
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Figure 2. Effect of flow on BBB glucose metabolism. Comparative analysis of the expression level of key 
enzymes regulating the glycolytic and TCA pathways strongly supported the gene array data (Panel A). 
Note that the lactate production/glucose consumption ratio measured in the flow-exposed in vitro BBB 
modules was  1. Complete anaerobic metabolism would produce 2 lactates/glucose (ratio = 2) thus, 
indicating that at least 50% of the glucose consumed underwent aerobic metabolism (Panel B). 
The BBB’s ability in maintaining an optimal bioenergetics level at all time is thus crucial to 
meet the energy demand required by its multiple proprietary functions under normal as 
well as pathological conditions (e.g., cerebral ischemia). Energetic pathways (such as 
glycolysis and the tricarboxylic acid cycle -TCA cycle) work in an integrated yet 
independent manner in the BBB endothelium to respond to physiological (e.g., increased 
CNS demand in response to changes in neuronal activity) or pathological events that require 
a prompt BBB response.  
The brain on the other hand possesses an incredibly more complex physiology than the BBB 
vasculature. It is the control center of neuronal as well as hormonal signaling. It is crucial for 
various functions such as homeostasis, behavior, perception and processing of information, 
motor control and memory formation. From a physiological stand point, brain functions 
depend on the ability of neurons to transmit and respond to electrochemical signals. This 
complex crosstalk is controlled by a wide variety of biochemical and metabolic processes 
which involve interactions between neurotransmitters and receptors that take place at the 
synapses. Crucial to this function is the necessity to sustain the bioenergetic demand 
required to maintain optimal neuronal activity (e.g., generation of action potentials, release 
of neurotransmitters, restoration of the membrane polarization following an action potential 
etc). In this respect, the BBB endothelium and glial cells play a major role in brain 
metabolism, by controlling the influx and distribution of nutrients (e.g., glucose and lactate 
shuttles as described later) as well as the chemical composition of the extracellular fluids 
surrounding the neurons. 
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3. Pathways related to energy metabolism in BBB and brain: Lactate 
shuttle: NALS or ALNS?  
Before we begin describing the role of DHOs in energy metabolism, it is imperative to 
understand the various metabolic pathways in the brain involved in energy production. 
Glucose is one of the primary fuel sources available to the brain.  25% of the total glucose 
intake is utilized by the brain despite accounting for  2% of the total body mass (24).  
Glucose enters the glycolytic pathway to produce pyruvate along with net production of 
2ATP and 2NADH (reduced form of nicotinamide adenine dinucleotide) (see Figure 3). Ten 
intermediate reactions occur until pyruvate is formed in the last step. ATP is first used up in 
the first part of glycolysis (until formation of glyceraldehyde phosphate-GAP) and is 
produced later during the second half. The total net ATP gain for each glycolytic cycle is 2 
ATP molecules. Another important step of glycolysis involving glyceraldehyde phosphate 
dehydrogenase (GAPDH), is the conversion of GAP to 1,3-bisphosphate glycerate (1,3- BPG) 
along with NADH formation. Part of the 1,3-BPG thus formed can be further converted into 
2,3-biphosphate glycerate (2,3-BPG) which can bind to hemoglobin enhancing its 
deoxygenation. The remaining 1,3-BPG undergoes further conversion along the glycolytic 
pathways and is finally converted into pyruvate. 
Pyruvate thus formed can either enter the citric acid chain (or Kreb’s cycle or Tricyclic acid 
cycle-TCA) or get converted to lactate which represents the end product of glycolysis. 
Pyruvate to lactate conversion is the last step of anaerobic form of respiration which occurs 
via lactate dehydrogenase and results in 2 molecules of ATP production.  
Conversely, pyruvate can be further converted into acetyl co-A and then enter the TCA 
cycle. This intermediate reaction is crucial in linking glycolysis to the TCA. In this step, 
pyruvate dehydrogenase (PDH) decarboxylates pyruvate to its acetyl form along with 
addition of co-enzyme A. Acetyl co-A then combines with oxaloacetate (4C) in presence of 
water molecule to form citrate (6C). The citrate thus formed cycles through TCA forming 
oxaloacetate in the last step, which can re-enter the cycle reacting with a new acetyl co-A 
(see Figure 3). The various steps in the TCA cycle involve various oxidation reactions 
involving various dehydrogenases such as isocitrate dehydrogenase, α-ketoglutarate 
dehydrogenase, succinate dehydrogenase and malate dehydrogenase. Each of these 
reactions lead to formation of NADH (except for FADH2 i.e. reduced flavin adenine 
dinucleotide formation during conversion of succinate to fumarate). These reducing 
equivalents can then enter the electron transport chain and result in ATP formation or can 
be used by the cell to counteract the oxidative stress caused by reactive oxygen species 
(ROS) and free radicals. A complete cycling of two molecules of acetyl co-A (from a single 
molecule of glucose) results in the production of approximately 10 NADH and 2 FADH2. 
The complete metabolic conversion of a glucose molecule into water and CO2 (glycolysis 
and TCA cycles combined) results in the approximate production of 38 ATP molecules 
(including ATP formed indirectly through NADH and FADH2 which produce 3 and 2 ATP 
molecules respectively).  
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Figure 3. Enzymatic pathways of glycolysis and Kreb’s cycle. Note the DHOs involved in the different 
metabolic pathways. (glycolysis and citric acid cycles).   
It has been an age old concept that glucose is the major energy source to maintain brain 
functions and that lactate does not provide further metabolic use for the neuronal activities 
(25-28). However, it is now accepted that lactate can be produced in the brain under aerobic 
conditions, this is known as aerobic glycolysis. Aerobic glycolysis under normal conditions 
contributes to about 10% of the total energy production in the brain, which can increase 
under ischemic conditions(29). Lactate thus formed can then be shuttled between the 
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various cell types in the brain, be converted back into pyruvate and be fully reutilized 
through complete aerobic respiration. Although this concept of lactate shuttle was proposed 
long ago, it received lot of resistance from the scientific community especially from those 
who believed that glucose is the sole substrate in the brain (30;31). However now, it is 
getting accepted that lactose is also used as a main substrate for energy production under 
normal conditions (32-34). The direction of lactate flow between various cell types in the 
brain as well as its relative contribution with respect to glucose to the overall energy 
production is still debatable and not yet fully understood. As far as the lactate flow between 
the different cell types in the brain there are two current schools of thoughts. One 
supporting the Astrocyte-lactate-neuron shuttle (ALNS) (33;35-37) and the second 
advocating a Neuron-Lactate-Astrocyte-shuttle (NLAS) (38-40). 
Classically, glucose is transported from the cerebral blood flow into the neurons or 
astrocytes via glucose transporters such as Glut-1 and Glut-3 respectively (see Figure 4). 
This glucose is then metabolized to produce ATP through complete aerobic respiration 
(glycolysis and citric acid pathways). In the astrocytes, part of the glucose also gets 
converted into glycogen, as an energy reserve to be used under critical conditions of low 
oxygen supply.  
Astrocytes can withstand low oxygen tension for a longer period of time than neurons and 
have proven to be more resilient to hypoxic insults (7;41-43). Based on the concept of lactate 
shuttle, at the astrocytic level (under resting conditions), glucose can be converted to lactate. 
Lactate thus produced can shuttle first into the interstitial fluid (through monocarboxylate 
transporter –MCT-1 & 4). From there lactate can be influxed into neurons by the neuronal 
specific MCT-2 transporter and converted back into its pyruvate form ready to undertake 
complete aerobic metabolism (36;44;45). This route is known as the Astrocyte-lactate-neuron 
shuttle (ALNS shuttle).  
Continuous glutamatergic activation of neurons results in a more exhaustive energy 
expenditure. As pyruvate utilization during the TCA cycle increases and its cytoplasmic 
levels decrease correspondingly, the condition becomes favorable for increasing both 
glucose and lactate utilization. By the late phase of activation, glutamate released is taken up 
by the astrocytes for recycling. Aerobic glycolysis is enhanced in the astrocytes with 
increased lactate production. The lactate thus formed helps sustain the energy demands of 
astrocytes as well as replenishing the neurons. During intense and prolonged neuronal 
stimulation which may occur under certain conditions, energy replenishment becomes 
crucially important. This is because the continuous glutamate reuptake by the Na+, 
glutamate co-transporter in astrocytes (GLutamate ASpartate Transporter – GLAST; 
glutamate transporter 1 –GLT1) must be paired with an equivalent intense activity of the 
Na+, K+ATPase to efflux the Na+ back in the extracellular space thus continuing the cycle. 
When the extracellular glucose levels become insufficient to sustain this level of activity then 
glycogen stored in the astrocyte is mobilized to provide the extra glycosyl units necessary to 
support the cellular activity. Thus sustained activation of the neurons results in conversion 
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of the stored energy substrate glycogen to glucose and further lactate production for 
shuttling to the neurons. This concept of ALNS shuttle during activation has received 
opposition and few groups suggest that lactate is primarily produced by the neurons and is 
then transported from the neurons to the astrocytes (38;40). 
 
Figure 4. Schematic of neuroenergetics pathways: The astrocyte – neuron lactate shuttle. 
In summary whether lactate flux moves from astrocytes to neurons or vice-versa the 
important point is that glucose is not the sole substrate utilized in the brain. Lactate plays an 
equally important role especially during activation, neurotransmission and pathological 
conditions such as under ischemic insults. This further emphasizes the still dismissed 
importance of lactate dehydrogenase which represents the key switch in the metabolic 
pathway of glucose in the generation of lactate.  
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In summary at the microcapillary level, the BBB acts as a functional interface which is 
charged with the critical task to fuel the brain with energy sources. Whether this is glucose 
or glucose-derived lactate the BBB is the main fuel distribution system to the brain and a 
safe for energy storage to which the brain can avail when normal fuel supplies are short.  
4. IEM 
Mutation in single gene leads to enzyme deficiency that results in type of genetic disorders 
termed as inborn error in metabolism (IEM) (46-50). IEM related deficiencies are generally 
autosomal recessive or X-linked. IEM linked enzyme deficiencies may be directly related to 
metabolic pathways of energy metabolism, purines/pyrimidine synthesis or degradation, 
amino acid synthesis, fatty acid oxidation, etc. Metabolic errors lead to accumulation of toxic 
or absence of essential products in the brain with neurological implications such as ataxia- 
motor control, encephalopathy, mental deficits, learning disabilities and mental retardation 
with structural anomalies. Some examples of DHOs involved include the pyruvate 
dehydrogenase complex.  
4.1. Pyruvate dehydrogenase (PDH) deficiency 
Pyruvate dehydrogenase is a multi-enzyme complex which catalyzes the conversion of 
pyruvate (the end product of glycolysis) into acetyl-coA- a substrate that can enter citric acid 
cycle (for production of ATP and energy equivalents). PDH is a six subunit complex 
composed of E1-pyruvate dehydrogenase, E2-dihydrolipoyl transacetylase and E3-
dihydrolipoyl dehydrogenase, E3BP- E3 binding protein and two regulatory subunits -
pyruvate dehydrogenase kinase and pyruvate dehydrogenase phosphatase. Although 
several mutations in the PDH complex deficiency (such as point mutations, deletions, 
duplications) have been reported so far; deficiency in PDH E1-alpha subunit (abbreviated as 
PDHA1) is the most common type (51-53). PDH deficiencies due to mutations in other 
subunits of the PDH complex are comparatively rare. All mutations leading to PDH 
deficiency are X linked except, the one in regulatory units, which are autosomally recessive 
(54-57). Since PDH results in acetyl co-A formation, the most common clinical manifestation 
of PDH deficiency is severe lactic acidosis. Defects in energy metabolism can cause 
neurological deficits such as mental retardation, developmental delay as well as 
psychomotor retardation. Hypertonia/hypotonia, ataxia, motor dysfunction like spasticity 
are the more common symptoms observed (58). Structural anomalies (such as microcephaly, 
facial dysmorphism) and epilepsy (focal or generalized seizures- both have been reported) 
may develop in utero. Optic atrophy, nystagmus and strabismus are observed at ocular level 
whereas peripheral neuropathies such as in nerve conduction have also been reported. 
Based on clinical case studies, PDH deficiencies have been classified into four typical 
neurological patterns (58-60): 
i. Neonatal encephalopathic pattern with facial dimorphic features and cerebral 
developmental defects, prenatal brain lesions, affecting the females 
ii. Leigh syndrome like presentation with symmetric necrotic lesions of basal ganglia, 
more common in males 
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iii. A chronic relapsing ataxia with prolonged survival 
iv. Static encephalopathy, cerebral palsy like motor deficits associated with paroxysmal 
dystonia. 
Alkali (such as sodium bicarbonate) administration to neutralize severe lactic acidosis and 
provide immediate temporary relief has been reported to treat acute episodes of severe 
acidosis. Chronic treatment strategies for PDH deficiency on the other hand, include 
incorporation of ketogenic diet consisting of high fat, low carbohydrate and low protein. 
High doses of thiamine can be beneficial in treating thiamine responsive PDH deficiency. 
Dichloroacetate (DCA) can reduce the inhibition of PDHc phosphorylation and thus can be 
used to treat severe lactic acidosis to some extent. 
4.2. Branched Chain Alpha Ketoacid dehydrogenase (BCKDH) complex 
Deficiency – Maple syrup urine disease (MSUD) 
Another important dehydrogenase deficiency leading to an inborn error in metabolism is 
that in the branched chain alpha ketoacid dehydrogenase (BCKDH) complex (61;62). This 
complex is similar to PDH complex, and autosomal recessive mutations in the different 
subunits of the complex have been reported for this disease. In this disorder, accumulation 
of branched chain amino acids (BCAAs like isoleucine, leucine and valine) and branched 
chain alpha ketoacids (BCKAs) (with maple syrup odor to the urine) is observed along with 
neurological deficits and developmental disorders. Based on the characteristic 
manifestations and level of neurological complications, this disease is classified into the 
following five forms:  
i. Classical MSUD: This is the most common type of MSUD with early symptoms in 
neonates. Neonates born normal, within 3-7 days of birth show symptoms such as 
lethargy, weight loss, metabolic dearrangement, encephalopathy with hypotonia and 
hypertonia. It is characterized by seizures, coma and even death if not treated. 
ii. Intermediate MSUD: This type shows mild but persistent ketoacidosis and 
developmental delay with 3-30% less dehydrogenase activity. 
iii. Intermittent MSUD: Episodic ataxia, semicoma, elevated BCAAs and BCKAs occur after 
episodes of infection or acute illness. Cognitive functions may be affected only in case of 
repeated episodes of acute illness. 
iv. Thiamine responsive MSUD: Mutation in E2 protein of the BCKDH complex results in 
reduced affinity of cofactor thiamine pyrophosphate (TPP), thus this form of disorder 
can be treated with thiamine substitution. Reduced activity of the complex results in 
hyperaminoacidemia. 
v. E3-deficient MSUD: Combined deficiency of E3 subunit (common component of all 
three mitochondrial multi enzyme complexes - BCKDH, pyruvate dehydrogenase 
complex and alpha ketoglutarate dehydrogenase) results in elevated lactate, pyruvate 
and alpha ketoglutarate along with BCAAs and BCKAs. 
Thus, all these forms of IEM are caused due to varying degree of deficiency in the enzyme 
activity leading to varying levels of neurological complication. Treatment is initiated by 
high calories leucine free diet rich with BCAA-free formulas and an optimum 
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supplementation of isoleucine and valine. Hemodialysis or hemofiltration may be used to 
remove deposited BCAAs and BCKAs from the body. During acute MSUD, brain edema 
and hyponatremia can also occur but can be immediately treated by administration of 
mannitol or diuretic drugs. In adolescents and adults, it can lead to depression, anxiety. 
However, the burden of these pathologies can be decreased by treatment with appropriate 
standard drugs such as psychostimulants or antianxiety drugs. Although no direct drug is 
used to treat MSUD, recent studies have shown the role of phenylbutyrate in increasing 
BCKDH activity, reducing levels of BCAAs and BCKAs and causing relief in MSUD patients 
(63). However, careful monitoring and routine biochemical testing is key in appropriate 
treatment in MSUD affected patients.  
4.3. Succinic semialdehyde dehydrogenase (SSD) deficiency  
SSD deficiency is an autosomal recessive disorder of γ-hydroxybutyric acid (GABA) 
metabolism. In human brain, GABA is the most important inhibitory neurotransmitter. 
Oxidative conversion of succinate semialdehyde to succinic acid is impaired in this 
deficiency. This leads to production of γ-hydroxybutyrate (GHB) (see Figure 5). ALDH5A1 
is the only gene associated with this deficiency. Mild developmental delay, psychomotor 
retardation, hypotonia, ataxia are observed along with extrapyramidal symptoms such as 
dystonia, choreoathetosis and myoclonus. More than 50% of affected individuals develop 
seizures (64-67). Neuroimaging screening generally reveals hyper intensities in globus 
pallidus, sub cortical white matter, cerebellar dentate nucleus and brain stem (68). 
Accumulation of γ-amino butyric acid (GABA) and GHB are considered positive indicators 
for this disease which can be confirmed by testing of SSD enzyme activity in leucocytes. 
 
Figure 5. SSD deficiency: In the absence of SSD, transamination of γ-aminobutyric acid (GABA) to 
succinic semialdehyde is followed by reduction to 4-hydroxybutyric acid (γ-hydroxybutyrate [GHB]). 
SSADH deficiency leads to significant accumulation of GHB and GABA. 
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Current therapies are mostly symptomatic, directed at seizure treatment and amelioration of 
neurobehavioral symptoms. Antiepileptic drugs such as carbamazepine and anti-anxiety 
drugs may be administered in conjunction with physical and occupational therapy. Early 
attempts to use Vigabtrin (GABA transaminase inhibitor) did not meet the therapeutic 
expectations (69). 
4.4. IEM related to fatty acid oxidation 
Fatty acids are a major source of energy in heart as well as muscle. Fatty acid oxidation 
(FAO) is a series of four reactions occurring in mitochondria. The first step is catalyzed by 
four straight chain acyl coA dehydrogenases such as: 
 Short chain acyl coA dehydrogenase (C4-C6 fatty acyl coAs) 
 Medium Chain acyl coA dehydrogenase (C6-C10 fatty acyl coAs) 
 Long Chain acyl coA dehydrogenase (C10-C14 fatty acyl coAs) 
 Very Long Chain acyl coA dehydrogenase (C14-C20 fatty acyl coAs) 
Medium chain acyl-coA dehydrogenase (MCAD) deficiency is the most common fatty acid 
oxidation-related disorder (1:10000 to 1:30000 in US) which is inherited in an autosomal 
recessive fashion (70-72). MCAD is an enzyme that catalyzes breakdown of fatty acids for 
energy production during long periods of prolonged fasting. Accumulation of 
octanoylcarnitine with Reye-like syndrome is typical clinical manifestation of this disorder 
(73;74). Children can exhibit severe hypoglycemia in mild illnesses. It can also lead to 
sudden infant like death syndrome (75). Symptoms may appear from 2 days to 6.5 years of 
age, however the patient can also remain asymptomatic for long time. When left 
undiagnosed MCAD deficiency has a mortality of 20% and 10-15% are severely 
handicapped. A case study of diagnosis as late as 30 years of age is reported in literature. 
The 30 year old man exhibited rhabdomyolysis, muscle weakness, acute encephalopathy 
after exertion in cold and fasting. Urine detection of carnitine led to the diagnosis of MCAD 
deficiency. Point mutation at position 985 in the coding region of MCAD gene was detected. 
449_452 deletion mutation is also studied. During acute episodes, symptomatic relief to 
overcome hypoglycemia cerebral edema, seizures or metabolic acidosis is the main line of 
treatment. Avoiding long periods of fasting is the best preventive measure that can be 
employed in cases with MCAD deficiency. 
Short chain acyl coenzyme A dehydrogenase deficiency (SCAD) is another autosomal 
recessive disorder in mitochondrial fatty acid oxidation. It is characterized by increased C4-
carnitine in plasma and ethylmalonic acid in urine. Clinical symptoms which appear early in 
life include developmental delay, hypotonia, epilepsy and behavioral disorders along with 
hypoglycemia and myopathy (76;77). Unlike MCAD deficiency, if neonatally screened and 
followed up it is found to remain asymptomatic, thus the clinical disease outcome of SCAD 
deficiency is questionable. Thus, need for treatment is not clear. Avoidance of fasting for 
longer hours with age appropriate diet is the only recommendation for prevention of 
primary manifestation. Annual checkup for growth, development is generally suggested.  
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5. Aging: The role of dehydrogenases in metabolic and mitochondrial 
dysfunction 
Aging or growing old is defined as a time related loss and decline in certain morphological, 
anatomical and functional features of body in comparison to its previous state. Beginning as a 
maturation process from childhood to young adulthood, it assumes the characteristic of 
decline through middle and late ages. Accumulation of molecular, cellular, or organ level 
damage leads to higher vulnerability of disease and eventually death. There have been 
numerous theories and hypothesis for causes of aging but it is still under investigation and 
discussion. "The Free Radical Theory of aging (ROS generation), shortening of telomerase, 
DNA methylation and epigenetics are few main ones. Important to us is the "The Free Radical 
Theory of aging since it is closely associated with mitochondria, and linked DHOs (78-81). 
Broadly, both genetic as well as external environmental factors can be responsible for 
promoting the age associated decline in functionalities (82). Oxidative stress and dietary 
restrictions can influence the genes externally. "Oxygen derived species", "Reactive nitrogen 
species" and "Reactive aldehydic species" can cause changes at cellular level ensuing 
damage to our natural defense mechanisms affecting repair and elimination processes in the 
body. In totality, irregularities in function, oxidative changes and the piled up cellular 
damages can lead to homoeostatic imbalance which finally result in aging as well as age-
related diseases. "The Free Radical Theory of aging" suggests generation of superoxide 
radical, hydrogen peroxide and hydroxyl radical as a side reaction to the electron transport 
chain at mitochondrial membrane (83). These free radicals can cause enzyme inactivation to 
different extent with different mechanisms (see Figure 6). Studies show that mitochondrial 
enzymes are resistant to hydrogen peroxide free radical but are fairly affected by hydroxyl 
free radical. On the other hand oxygen free radical by itself can cause significant oxidative 
damage with respect to inactivation of mitochondrial enzymes like NADH dehydrogenase, 
succinate dehydrogenase, NADH oxidase, succinate oxidase and ATPase 2.  
Link between aging and various dehydrogenase enzymes is based on the energy demand of 
our body which involves the participation of different dehydrogenases for production of 
ATP at cellular level (as elaborated in the earlier section of energy metabolism). Several 
dehydrogenases involved in energy metabolism can exhibit altered activity or complete 
inactivation with aging. This can result in hampering energy production as well as 
accumulation of toxic metabolites in the body.  
6. Metabolic dysfunction and its link to Alzheimer’s disease: The role of 
dehydrogenases 
Alzheimer’s disease is the most common form of dementia characterized by loss of memory, 
cognitive decline and change in perception and behavior. Pathological hallmarks include 
accumulation of amyloid beta protein (Aβ) and resulting plaque formation (a cleavage 
protein of amyloid precursor protein-APP) and formation of neurofibrillary tangles (due to 
hyper phosphorylation of microtubule associated protein of neurons in the brain). Genetic 
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mutations in APP protein or ApoE protein (a protein linked to lipid and cholesterol in the 
body) as well as Down’s syndrome are some examples of genetic predispositions that 
increase the propensity to develop Alzheimer’s disease. However, the etiology of the disease 
is still questionable. Both vascular as well as metabolic dysfunction have been accredited as 
major factors prodromic to the pathogenesis and progression of Alzheimer’s disease (84). 
Vascular dysfunction includes reduction in cerebral blood flow, reduced glucose uptake, 
and reduced amyloid beta clearance with cerebral amyloid angiopathy. The patients with 
atherosclerosis have shown to have an increased risk to develop AD. Vascular structural 
anomalies in cerebral vessels (like increased pinocytic activity as well as swelling) have been 
seen in early AD further signifying the importance of vascular dysfunction in AD 
pathogenesis. Defective glucose utilization has been observed earlier than reduced cerebral 
blood flow (CBF), indicating the role of glucose metabolism in AD development. What is of 
primary interest to us is that it is slowly becoming well accepted that metabolic dysfunction, 
related oxidative stress and mitochondrial deficits can precede AD development (84-86). In 
one such recent study, triple transgenic mice 3xTg-AD were developed (having mutations in 
human APPSWE, TauP301L, PS1M146V genes linked with AD) along with their respective 
controls. Decreased mitochondrial respiration was observed along with reduced PDH 
activity. High levels of oxidative stress (via measurement of hydrogen peroxide production 
and related lipid peroxidation), high Aβ levels with high levels of Aβ binding alcohol 
dehydrogenase (ABAD) was observed. Decreased respiration was also observed in 
embryonic neurons, which continued till senescence leading to AD pathogenesis. Thus these 
studies clearly emphasized how mitochondrial dysfunction and resulting metabolic 
respiration preceded AD development. Defective enzyme function(of dehydrogenases) in 
pathways of energy metabolism such as glycolysis, tricarboxylic acid pathway and electron 
transport chain have been well studied in AD progression. Defective PDH, KGDHC, 
cytochrome oxidase along with reduced activity of hexokinase, phosphofructokinase are the 
major enzymes reported in AD so far (87). In the paragraph below we will be further discuss 
some of these DHOs and their mechanism of metabolic dysfunction in AD. We will also 
look at other DHOs apart from those directly involved in the bioenergetics which have an 
important role in pathogenesis of AD. 
One such DHO as mentioned earlier is Aβ binding alcohol dehydrogenase (ABAD). ABAD 
is a short-chain alcohol dehydrogenase which is also called type II hydroacylcoA 
dehydrogenase, 17β-hydrosteroid dehydrogenase type 10 and 2-methyl-3-
hydroxybutyrylcoA dehydrogenase. ABAD acts on various substrates such as branched 
chain fatty acids, alcohols, amino acid catabolites and steroids. In the brain, it is primarily 
localized in mitochondria of neurons. Previous studies have shown high ABAD expression 
in the temporal lobe and hippocampus of AD affected patients (88;89). 
Animals with transgenic (Tg) APP mice have also demonstrated higher expression of ABAD 
(88). As the name suggests, ABAD directly binds to Aβ protein which is highly expressed in 
Alzheimer’s patients. These links suggest role of ABAD dehydrogenase in the 
pathophysiology of Alzheimer’s disease. Another crucial factor in causing AD as discussed 
earlier is mitochondrial dysfunction, related oxidative stress and hypometabolism. In recent 
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studies, it was hypothesized that ABAD can act as a crucial link between increased Aβ 
production and mitochondrial dysfunction in Alzheimer’s disease progression (90-92).To 
test this hypothesis, double transgenic mice with increased levels of ABAD and Aβ were 
developed (along with Tg mAP, Tg ABAD, and not Tg littermate controls)(93). Neuron 
cultures derived from these Tg mice showed increased ROS, oxidative stress and relative 
decrease in ATP production. Further studies indicated defective activity of mitochondrial 
Complex IV as the source of the ROS species, also such effect was not observed in single 
Tg mice with increased ABAD alone (suggesting Aβ acting as a crucial element linking 
the two). Lactate dehydrogenase (LDH) was higher in the Tg mAP/ABAD mice as 
compared to other groups suggesting the reversal to lactate metabolism. Cell apoptosis 
via caspase 3 activity was observed in in vitro studies. Data from the Tg mice also 
suggested reduced ATP production at 9 months of age along with reduced Complex IV 
activity. Overall, ABAD acts a crucial enzyme that can lead to mitochondrial dysfunction 
and disease progression in AD. 
 
Figure 6. : Correlation between aging free radicals, DHOs and the onset of CNS disorders. 
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In another study, ABAD-decoy peptide (ABAD-DP) was introduced in the Tg mAPP mice, 
which prevented the interaction of ABAD with Aβ. As expected, reduction in ABAD-Aβ 
complex formation accompanied with attenuated oxidative stress, increased oxygen 
consumption, increased activity of enzymes associated with mitochondrial respiratory chain, 
improvement in energy metabolism, and increased spatial memory (89). Thus based on these 
studies, inhibitors of ABAD-Aβ hold promise as potential targets for the treatment of AD. 
Another dehydrogenase that is implicated in AD progression is aldehyde dehydrogenase 
(ALDH) (89;94). Aldehyde dehydrogenase is observed as a key enzyme in the brain 
involved in metabolism and degradation of biogenic aldehydes, monoamine 
neurotransmitters such as norepinephrine, dopamine, diamines and GABA. Recent studies 
have also shown that patients with Down’s syndrome have reduced activity of ALDH 
enzyme (95). Two dimensional analysis of proteins extracted from brain samples of nine 
aged patients with Down’s syndrome and nine controls showed that ALDH was down 
regulated in the patients with Down’s syndrome. This resulted in accumulation of 
aldehydes and further formation of tangles and plaques as observed in aged patients with 
Down’s syndrome. 
Oxidative stress and generation of ROS species has been implicated in Alzheimer’s disease as 
elaborated earlier. These oxygen species modify proteins, nucleic acids as well as lead to lipid 
peroxidation. Lipid peroxidation produces toxic aldehydes such as 4-hydroxy-2-nonenal 
(HNE) in several disorders such as Alzheimer’s as well as Parkinson’s disease. In the brain, 
normally ALDH2- an isoform of aldehyde dehydrogenase oxidizes and degrades end product 
of lipid peroxidation such as HNE. The role of ALDH in oxidative stress and age dependent 
memory loss and decline in cognitive function was studied using a transgenic mouse model 
with defective ALDH2 (96). A dominant negative form of ALDH2 mice was produced and its 
effect on the metabolic pathways as well as accumulation of toxic products was tested. As 
expected HNE accumulation was observed in such transgenic mice compared to controls. 
Further testing of cognitive capability was performed using object recognition and water maze 
test. Decreased cognitive function in the transgenic mice was observed along with 
accumulation of tau phosphorylation (a typical pathological sign of Alzheimer’s disease).  
A dominant negative form of ALDH2 mice was produced and its effect on the metabolic 
pathways as well as accumulation of toxic products was tested. As expected HNE 
accumulation was observed in such transgenic mice compared to controls. Further testing of 
cognitive capability was performed using object recognition and water maze test. Decreased 
cognitive function in the transgenic mice was observed along with accumulation of tau 
phosphorylation (a typical pathological sign of Alzheimer’s disease).  
7. Metabolic dysfunction and its link to Parkinson’s disease (PD): The 
role of dehydrogenases 
PD is a neurological disorder characterized by typical motor features such as tremor 
bradykinesia, rigidity, slowness of movement and postural instability. Reduction in number 
of dopaminergic (DA) neurons located in substantia nigra pars compacta is the pathological 
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cause of PD. It is also characterized by accumulation of α-synuclein into inclusions called 
Lewy bodies. 60% of DA neurons are dead and 70% responsiveness of DA is lost. Mostly PD 
is idiopathic, however specific genetic mutations have shown to increase the risk to develop 
PD. Mutations is genes such as α-synuclein, Parkin, PINK1 have been reported so far. After 
diagnosis of PD based on its classical symptoms and neuroimaging, treatment is usually 
done using levodopa (L-DOPA). L-DOPA is converted to dopamine in the brain and can 
temporarily alleviate the motor symptoms. Dopamine receptor agonists as well as selective 
monoamine oxidase-B (MAO-B) inhibitors are also administered along with L-DOPA 
(97;98). Treatment thus helps to partially reduce the symptoms of PD, since the actual 
underlying cause of this disease is still unknown. Altered enzyme activity and 
mitochondrial dysfunction has been linked to PD as well. 
Aldehyde dehydrogenase plays an important role in detoxifying aldehydes in brain. 
Reduced expression of isoforms of ALDH such as ALDH1A1 and ALDH2 is reported in PD 
patients. In addition impaired Complex I activity is documented in PD which can reduce the 
availability of NAD+ cofactor required by ALDHs to remove toxic biogenic aldehydes. Thus 
decreased ALDH function could be the underlying factor preceding the development of PD. 
Using transgenic mice null for both ALDH1A1 and ALDH2, the risk to develop PD was 
tested (99). Such mice exhibited deficits in motor performance typical of PD. Loss of DA 
with increased accumulation of biogenic aldehydes such as HNE was observed. L-DOPA 
administration alleviated the motor deficits suggesting a role of ALDHs in the 
pathophysiology of PD. 
Another DHO implicated in PD is glutamate dehydrogenase (GDH). GDH is a key enzyme 
involved in interconversion of glutamate to alpha-ketoglutarate and ammonia using 
NADP(H) and NAD(H) as co factors. It plays an important role in homeostasis by 
interconnecting amino acid and carbohydrate metabolism pathways. Present in two 
isoforms in humans, the GDH isoform 2 (hGDH2) is overexpressed in the brain astrocytes 
and the sertoli cells in testis. ADP levels act as positive regulators for this enzyme and unlike 
the other isoform it is not inhibited by GTP. Important in recycling glutamate in the brain 
astrocytes, this enzyme works in concert with glutamine synthetase (GS) providing 
ammonia as well as ATP for GS activity. Two parallel studies have shown that increased 
levels of glutamate prepones the onset of the disease by 6 to 13 years (100). Hemizygous 
individuals with a rare variation in hGDH2 (substitution of Ala for Ser445) was detected in 
these individuals. GDH deficiencies have also been linked to the onset of epilepsy. All 
together these results highlight the role of hGDH2 in the maintenance of brain homeostasis. 
ABAD associated with Alzheimer’s disease has also shown to play some role in PD disease. 
ABAD expression is seen to be downregulated in PD patients (101). In mouse models of PD 
generated by administration of neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) ABAD expression is significantly reduced. By contrast, overexpression of ABAD in 
transgenic mice is shown to attenuate MPTP-induced dopaminergic neurogeneration. This 
strongly suggests that ABAD may contribute to the fate of DA neurons during the onset of 
PD. 
 
Dehydrogenases 108 
8. Conclusion 
The brain as well as the BBB have complex structural and functional physiology which 
demands a continuous supply of high energy. Bioenergetic pathways in the brain utilize 
multiple pathways (such as glycolytic metabolism, TCA cycle etc) to ensure that the energy 
requirements of the different cell types in the brain are fulfilled at all time. The BBB acts as a 
critical interface to buffer and influx energy substrates into the brain. Shuttling of multiple 
substrates such as glucose, lactose as well as glycogen derived lactate/glucose commonly 
occurs between the neurons and the astrocytes. Various DHOs are a critical part of these 
bioenergetic pathways and occurrence of DHO defect can lead to inborn errors in the 
metabolism followed by strong neurological complications. PDH is an imporant IEM which 
is directly linked to bioenergectic pathways such as TCA cycle and aerobic respiration. 
Apart from energy metabolism, BCKDH and SSD are IEMs that correlate to other pathways 
in the brain such as amino acid metabolism and neurotransmitter degradation. DHOs (such 
as ALDHs) also play an important role to further degrade the biogenic aldehydes derived 
from the degradation pathways of neurotransmitters such as for epinephrine, 
norepinephrine and GABA which are commonly synthesized in the brain. Furthermore, 
DHOs play an important role in oxidation of fatty acids as an energy supply. Although this 
does not occur in the brain, IEMs affecting these dehydrogenases have shown to correlate 
with at least one reported neurological complication (such as Reye-like syndrome). 
Aging naturally promotes alterations and/or reduction in DHOs’ activity which can alter 
mitochondrial functions leading to hypometabolism other metabolic dysfunction. This can 
ultimately facilitate the onset and progression of various neurological disorders such as 
Alzheimer’s disease and PD. Specifically, altered expression/function of ABAD and ALDH2 
have been associated with the pathogenesis of Alzheimer’s disease whereas alteration of 
ALDH1A1, ALDH2, GDH2 and ABAD have been linked to PD. 
In summary, DHOs play a critical role in supporting neuronal and BBB functions. They 
constitute an integral part of various metabolic pathways in the brain associated with 
energy metabolism, as well as synthesis and degradation of neurotransmitters. Their 
optimal functioning facilitates neuronal signaling and homeostasis. In born as well as 
acquired defects in DHOs have been shown to correlate with various CNS and BBB 
pathophysiologies.  
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1. Introduction 
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common 
enzymopathological disease in humans. This disease is described as a widespread, heritable, 
X-chromosome linked abnormality (Reclos, et al., 2000). It is estimated that it affects 
approximately 400 million people worldwide (Noori-Daloii, et al., 2004). This disease is seen 
most frequently in approximately all of Africa, Asia, and the countries near the 
Mediterranean Sea (Frank, 2005). G6PD enzyme was demonstrated to play an active role in 
survival of erythrocytes. It is known that in the pentose phosphate pathway of erythrocytes, 
glucose-6 phosphate dehydrogenase (G6PD) enzyme provides the production of NADPH 
and GSH. GSH, produced by pentose phosphate pathway can react with H2O2 and reduce it 
to H2O. This prevents the generation of oxidative stress within red blood cells; oxidative 
stress can be induced in erythrocytes whose G6PD enzymes are deficient. In this situation, 
GSH is not produced and H2O2 is not reduced to H2O, leading to oxidative stress and 
hemolysis. This is the only mechanism available for the erythrocyte in order to generate 
reducing equivalence, therefore making it essential for the survival of erythrocytes. In 
individuals whose G6PD enzyme is deficient, different kinds of hemolysis from mild to 
severe are seen bound to differences in variants of the disease (Beutler, 1983, Luzzatto, 
1989). 
In epidemiological studies, it was shown that the prevalence of G6PD deficiency 
significantly related to malaria. Malaria is known as a parasitic disease that affects 300-500 
million people all over the world. It is widespread in tropical and subtropical regions of 
Asia, Africa and American continents. Five different types of Plasmodium species—P. 
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falciparum, P. vivax, P. ovalae, P. malariae and P.knowlesi—lead to this disease by infecting 
erythrocytes. Malaria can become a life-threatening condition when it is not treated. Each 
year, malaria leads to deaths of millions of people all around the world and a large 
percentage of deaths are seen in Sub-Saharan regions of Africa. As it can be easily seen, 
malaria and G6PD deficiency share the same geographic distribution. It was shown that 
G6PD enzyme has various genetic variants and polymorphic frequencies. Highly 
polymorphic frequencies, which are indicators of G6PD deficiency, are seen in endemic 
regions for malaria such as Asia, Africa, Central and South America, while in non-endemic 
regions, these rates decrease, suggesting the relationship between G6PD deficiency and 
malaria (Haworth, et al., 1988, Organization, 2009, Sutherland, et al., 2010). This relationship 
reveals two important results. One of them is that G6PD deficiency provides great 
protection from malaria infection, especially for falciparum infections (Motulsky, 1961, 
Siniscalco & Bernini, 1961, Ganczakowski, et al., 1995). On the other hand, G6PD deficiency 
has been recently demonstrated to cause serious problems in fighting against malaria. 
Primaquine, which is the only drug currently, used in the treatment of Plasmodium 
infections leads to severe hemolysis in G6PD-deficient patients. This drug may even cause 
death in G6PD-deficient patients. When primaquine is administered to individuals with 
G6PD deficiency, its metabolites lead to more severe hemolysis by inducing oxyhemoglobin 
generation, GSH depletion and stimulation of the hexose monophosphate pathway (Beutler, 
et al., 1955, Bolchoz, et al., 2002, Beutler & Duparc, 2007). 
Therefore, investigations on detection of G6PD deficiency have a vital importance for 
malaria patients before their treatment with primaquine. On the other hand, the methods 
that are used for diagnosing G6PD deficiency are unreliable. Even worse is that it is very 
difficult to distinguish heterozygously-deficient patients from healthy individuals (Peters 
& Noorden, 2009). All these data indicate that there is an urgent need to develop new 
methods for reliable detection of G6PD deficiency in order to prevent hemolysis in 
patients treated with primaquine. Current methods cannot determine primaquine 
sensitivity in patients with G6PD deficiency every time. However, in our previously 
researches, we developed a new method for the determination primaquine induced 
hemolysis in vitro. This method provides the determination of G6PD deficiency patients 
that are susceptible to primaquine independently from the variants of G6PD deficiency. In 
our studies, it was determined that this method demonstrated high sensitivity for 
detection of primaquine-induced hemolysis before treatment of malaria patients with 
primaquine.  This chapter aims to represent the relationship between G6PD deficiency 
and malaria, and to demonstrate the method that has high sensitivity for detection of 
primaquine-induced hemolysis in patients with malaria whose G6PD enzyme is deficient 
before their treatment with primaquine.  
This chapter aims to represent the problems in treatment of malaria patients with G6PD 
deficiency by using primaquine, different methods for determination of G6PD deficiency 
and a new method to determine primaquine induced hemolysis before treatment of patients 
with G6PD deficiency.  
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2. Genetic basis of G6PD 
G6PD deficiency was identified in 1956 by Carson et al. (Alving, et al., 1956), and its X-
chromosomal inheritance was discerned in the 1950s by Childs et al. (Childs, et al., 1958). 
G6PD was cloned and sequenced by Persico et al.(Persico, et al., 1986, Persico, et al., 1986) in 
1986 and independently by Takizawa and Yoshida (Takizawa, et al., 1986) G6PD  (Misumi, et 
al., 1982) is in the hexose monophosphate pathway, the only NADPH-generation process in 
mature erythrocytes, which lack the citric acid cycle. Deficiency of this enzyme in 
erythrocytes causes various forms of illnesses such as favism, anemia, chronic 
nonspherocytic hemolytic anemia, drug-sensitive hemolytic anemia, primaquine sensitivity 
and jaundice in newborns (Beutler, et al., 1968). 
By virtue of fact that G6PD is found in all cells, functional and structural studies have 
revealed properties of this housekeeping gene (Luzzatto, 2006). G6PD expression level is 
regulated by hormonal and nutritional factors in only a few tissues. G6PD expression is 
regulated in liver and adipose tissue, and its activity depends on the rate of fatty acid 
biosynthesis (Greene, 1993). The G6PD gene region is one of the first regions of the human 
genome to be completely sequenced (Chen, et al., 1996). The gene encoding G6PD is located 
near the telomeric region of the distal arm of the X chromosome (Pai, et al., 1980, Szabo, et 
al., 1984, Patterson, et al., 1987) (band Xq28) and a valuable X-linked genetic marker for 
determination of X chromosome inactivations (Migeon, 1983). G6PD has various 
polymorphism sites at the G6PD locus like the colorblindness, Xg blood group and the 
hemophilia A locus and has close linkage at the X chromosome (Boyer & Graham, 1965, 
Adam, et al., 1967). G6PD is one of a group of genes including fragile X, (Oberle, et al., 1987) 
color vision (Motulsky, 1988, Filosa, et al., 1993) hemophilia A (Boyer & Graham, 1965) 
clasped-thumb mental retardation syndrome (MASA), (Macias, et al., 1992) and dyskeratosis 
congenita (Arngrimsson, et al., 1993) existing on the distal long arm of the X chromosome.  
The X-linkage of the G6PD gene has important implications. This linkage is very stable and 
linkage with other group locuses is similar in all mammals (Luzzatto & Battistuzzi, 1985, 
Group, 1989, Luzzatto, 1989, Beutler, 1990). In mice, X-linkage of G6PD was shown by 
Epstein (Epstein, 1969). Epstein concluded that the G6PD gene is X-linked in the mouse; its 
synthesis occurs in the oocyte and is dosage-dependent. G6PD is a sex-linked and very 
polymorphic gene in populations in which males have only one allele (hemizygous) and 
females have two G6PD alleles. Thus, females can be either normal or deficient 
(homozygous), or intermediate (heterozygous) phenotypes, whereas males can be either 
normal or G6PD-deficient phenotype (Luzzatto, 2006). The frequency of the deficient 
phenotype is higher in males than females owing to males being hemizygous, in which one 
allele of the gene expresses the deficient phenotype; to arise in females, G6PD-deficiency 
needs two deficient alleles. However, hemizygous deficient males and homozygous express 
the same degree of enzyme deficiency level. Since deactivation of one X-chromosome in 
embryological development in heterozygous females have two populations of red cells 
(G6PD-normal and G6PD-deficient), with a wide range of total G6PD enzyme activity 
depending on the relative proportions. If one of the alleles contains deficiency, as a result of 
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random deactivation of X-chromosomes, about half of the cells will be normal and the other 
half will be deficient, although there is a wide range of variation around that average 
(Nance, 1964, Rinaldi, et al., 1976). For this reason, total G6PD activity in heterozygous 
females can show variability between near-normal to near-deficient (Luzzatto & Battistuzzi, 
1985, Segel, 2000). Deactivation of X-chromosome actualizes at random. Correspondingly, 
binomial distribution would be expected in deficiency level; the extent of this distribution 
depends on X-inactivation time in embryonic tissue and the number of cells in the embryo. 
Furthermore, random deactivation of one X-chromosome engenders genetic mosaics in 
heterozygous females (Luzzatto, 2006). As a result, G6PD mutations show the typical 
mendelian X-linked inheritance (Adam, 1961), severe G6PD deficiency is much more 
common in males than in females, and X-chromosome inactivation in heterozygous females 
for two different G6PD alleles indicate somatic cell mosaicism (Beutler, et al., 1962, Gall, et 
al., 1965). 
The total length of the gene is about 18.5 kb on the X chromosome (xq28) and contains 13 
exons. Exon 13 is about 800 nucleotides long and contains the translation stop codon (Nagel 
& Roth, 1989, Greene, 1993). The protein-coding region is divided into 12 segments, ranging 
in size from 12 to 236 bp (Martini, et al., 1986). Exon and intron numbers and the exon sizes 
and sequences are conserved in higher eukaryotes (Nagel & Roth, 1989, Greene, 1993). The 
first exon contains no coding sequence and intron 2 between exons 2 and 3 is extraordinarily 
long, extending for 9,857 bp. The function of this long intron is unknown; it may be 
important for transcription or processing because compressed versions of the G6PD gene 
still have this largest intron in some species (Chen, et al., 1991, Mason, et al., 1995). 
The sequence of the whole G6PD gene is known (Chen, et al., 1991). G6PD sequence analogy 
between humans and mice or rats is 87%. The analogy between the mouse and rat cDNA 
sequences is greater than humans with 93% similarity. Most of the sequence dissimilarity is 
in the 3´- UTR region, which has 600 nucleotides on average and contains a single polyA site 
(Nagel & Roth, 1989, Greene, 1993). G6PD gene promoter is embedded in a CpG island that 
starts about 680 nucleotides upstream of the transcription initiation site, extending about 
1,050 nucleotides downstream of the initiation site, and ends at the start of the first intron 
(Chen, et al., 1991). CpG island is conserved between some species (Martini, et al., 1986, 
Toniolo, et al., 1991), and has highly enriched guanine and cytosine residues, like 
characteristically in other housekeeping genes and this island appears to be preserved 
between humans and mice (Toniolo, et al., 1991). 
The promoter of the G6PD gene contains a TATA-like, TTAAAT sequence, and a great 
number of stimulatory protein 1 (Sp1) elements (Philippe, et al., 1994, Rank, et al., 1994, 
Franze, et al., 1998, Hodge, et al., 1998). These Sp1-binding sites are essential for promoter 
activity (Philippe, et al., 1994). Deletion analysis has uncovered that the “essential” segment 
of the promoter is only about 150 bp (Ursini, et al., 1990). 
The transcribed region from the initiation site to the poly(A) addition site covers 15,860 bp. 
(Chen, et al., 1991). The major 5’-end of mature G6PD mRNA in several cell lines is located 
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177 bp upstream of the translation-initiating codon (Martini, et al., 1986). The G6PD activity 
and mRNA quantity differ between tissues (Nagel & Roth, 1989, Greene, 1993). S1 nuclease 
and primer extension analyses of mouse G6PD mRNA indicate that when the transcriptional 
start site regulated with lipogenesis in liver and adipose tissue, in kidney G6PD is expressed 
constitutively (Ho, et al., 1988); this quantity potentially depends on oxidative stress, tissue 
specific differences and reductive biosynthesis reactions (Nagel & Roth, 1989, Greene, 1993). 
Some different mRNA forms of G6PD mRNA have been found, but their functions are 
completely unknown. The alternatively spliced form has been documented (Hirono & 
Beutler, 1988, Hirono & Beutler, 1989, Cappellini, et al., 1993), but this mRNA frame contains 
138 nucleotides (Mason, et al., 1988, Persico, et al., 1989, Bautista, et al., 1992, Tang, et al., 
1994). Some researchers (Kanno, et al., 1989) suggested that in reality, G6PD translation 
product made from two separate mRNAs as a result of study to be based on an artifact 
(Henikoff & Smith, 1989, Beutler, et al., 1990, Mason, et al., 1990, Yoshida & Kan, 1990). 
Up to 450 G6PD variants have been identified depending on the enzyme kinetics, 
physicochemical characteristics, and other parameters (Luzzatto & Battistuzzi, 1985, Chen, et 
al., 1991). Nearly 300 variants of these have been confirmed by the World Health 
Organization (1967). Point mutations and small deletions trigger defects in the enzyme 
structure. These structural defects cause altered activity, instability of the enzyme or 
decreased affinity of G6PD for its substrates (Luzzatto, 2006). 
3. Structure of G6PD and enzymatic properties  
G6PD is a typical cytoplasmic, housekeeping enzyme and has been found in all cells from 
liver to kidney and organisms, from prokaryotes to yeasts, to protozoa, to plants and 
animals (Luzzatto & Battistuzzi, 1985, Antonenkov, 1989, Glader, 1999, Notaro, et al., 2000). 
Inactive form of G6PD is a monomer with 515 amino acids and has a molecular weight of 
over 59 kDa (Rattazzi, 1968). The primary structure of the G6PD enzyme in humans has 
been determined from the sequence of full-length cDNA clones (Persico, et al., 1986). 
Furthermore, the tertiary structure of the enzyme has been determined (Au, et al., 1999). 
Dimer structure of the two subunits in the enzyme are symmetrically located across a 
complex interface of β-sheets (Au, et al., 1999).  
Activation of the enzyme requires NADP+ tightly binding to dimer or tetramer formation of 
enzyme. G6PD catalyses the first step of the oxidative pentose phosphate pathway and controls 
reaction velocity (Wrigley, et al., 1972). In this first step, while G6PD catalyses the conversion of 
glucose 6-phosphate (G6P) to 6-phosphogluconolactone, at the same time it reduces NADP to 
NADPH (Au, et al., 1999, Turner, 2000). Human G6PD has no activity with nicotinamide 
adenine dinucleotide (NAD) as coenzyme. Also, G6P is very specific for its substrate compared 
to other hexose phosphates (e.g., galactose 6-phosphate or mannose 6-phosphate) (Luzzatto & 
Battistuzzi, 1985, Glader, 1999). The G6P binding site is nearby lysine 205 in tertiary structure of 
the enzyme, and this amino acid has a critical role in electron transfer (Bautista, et al., 1995). The 
NADP binding site is located nearby 38 to 43 amino acids; this region constitutes the N-
terminus in tertiary structure encoded in exon 3. This site is important for stability of G6PD (Au, 
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et al., 1999). As an inhibitory effect, one of the products of G6PD reaction NADPH is an effective 
inhibitor (Luzzatto, 1967). Increase in NADP and decrease in NADPH as a result of whichever 
oxidative event in cells effect prepotently to increase G6PD activity (Luzzatto & Testa, 1978). 
Consequently, G6PD is the most important enzyme in biosynthesis reactions owing to enzyme 
property as NADPH reducer in its critical role in the cytoplasm (Koehler & Van Noorden, 2003).  
4. The effect of G6PD on erythrocyte metabolism 
4.1. Erythrocytes 
Erythrocytes, which contain hemoglobin, are blood cells that perform the transfer of oxygen 
and carbon dioxide between tissues. G6PD is an important enzyme that performs vital 
functions within all cells of the body (Greene, 1993). The quantity of active G6PD decreases 
during the life of an erythrocyte and also the older erythrocytes become vulnerable to 
oxidative stress. G6PD, an enzyme in the oxidative pentose phosphate pathway, converts 
the nicotinamide adenine dinucleotide phosphate (NADP+) into its reduced form NADPH. It 
is necessary for the protection against oxidative stress in erythrocytes. The cells cannot 
eliminate this stress, which causes hemolysis of erythrocytes. Because H2O2 and other 
reactive oxygen species cannot be reduced, oxidation of hemoglobin to methemoglobin and 
membrane damage occur (Ruwende & Hill, 1998, Peters & Van Noorden, 2009). 
4.2. The importance of pentose phosphate pathway for erythrocytes 
G6PD is the key enzyme in the oxidative pentose phosphate pathway. The first step of the 
pentose phosphate pathway is catalyzed by G6PD. In this step, NADP+ is reduced to 
NADPH, and ribulose-5-phosphate, a precursor of DNA, RNA, and ATP, emerge from G6P 
(Turner, 2000). The most important reducing agent in the cytoplasm of cells is NADPH 
(Koehler & Van Noorden, 2003). The second enzymatic step in this pathway is NADPH 
production as a consequence of reactions that reduce oxidized glutathione (GSSG) to 
reduced glutathione (GSH). The only defense against oxidant stress in the red blood cell 
(RBC) is GSH production (Friedman, 1979, Group, 1989, Peters & Van Noorden, 2009). In 
unstressed, normal erythrocytes, the G6PD activity is only about 2% of total capacity 
(Group, 1989, Peters & Van Noorden, 2009). The pentose phosphate pathway’s main 
function is the generation of reducing capacity through the production of NADPH and 
ultimately, GSH. This is essential for cell survival and is available in the erythrocyte for 
generating reducing capacity (Greene, 1993). 
4.3. Classification of Glucose-6-Phosphate Dehydrogenase variants 
More than 400 variants of G6PD have been distinguished based on their biochemical 
characteristics, enzyme kinetics, physicochemical characteristics, and other parameters 
(Luzzatto & Battistuzzi, 1985, Chen, et al., 1991, Greene, 1993). G6PD B+ is the most 
commonly found enzyme type and it is used as a standard for normal enzyme activity and 
electrophoretic mobility. For identification of other variants, G6PD B+ is used. The rate at 
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which NADP+ is reduced by glucose-6-phosphate with G6PD B+ as the catalyst is the 
standard for activity. Based on this, enzyme activity relative to G6PD B+ variants are 
classified as fast, normal, and slow in terms of electrophoretic mobility and as Classes I—V 
(Luzzatto, 1989, Beutler, 1990, Greene, 1993, Segel, 2000, Betke K, Brewer GJ, Kirkman HN, 
Luzzatto L,Motulsky AC, Ramot B, and Siniscalco M 1967). There are 5 classes for these 
variants. Class I includes chronic nonspherocytic hemolytic anemia with a severe enzyme 
deficiency (e.g., G6PD Minnesota, G6PD Tokyo, G6PD Campinas). Class II variants have 
severe enzyme deficiency without chronic nonspherocytic hemolytic anemia (e.g., G6PD 
mediterrian, G6PD Canton, G6PD Union, G6PD Kaiping). Class III variants includes 
medium or mild enzyme deficiency, with the activity at 10-60% of G6PD B+ (e.g., G6PD Aˉ). 
Class IV variants have a weak or no enzyme deficiency. The activity is 60-100 % of G6PD B+ 
(e.g., G6PD A+). Class V variants have increased enzyme activity (e.g., G6PD Hektoen) 
(Beutler, 1994, Segel, 2000). 
4.3.1. Some Important G6PD Variants 
4.3.1.1 G6PD A+ is the most widely seen variant worldwide and also the first variant in 
which the nucleotide mutation and amino acid substitution were determined (Beutler, 1990). 
This Class IV variant has 90% of the enzyme activity of G6PD B+ (Luzzatto, 1989). This 
variant also called for the African variant cause widely seen in Africa; 20-40% of African 
men and 20% of African American men have this variant. It is faster than G6PD B+ 
electrophoretically and it does not cause hemolysis (Beutler, 1989). G6PD A+ derives from a 
single amino acid substitution of aspartic acid for asparagine at amino acid number 126, and 
this was the result of an adenine to guanine mutation at nucleotide number 376. 
4.3.1.2 G6PD Aˉ is a Class II variant that has 10 to 20% of the activity of G6PD B+ and the 
same electrophoretically mobility as G6PD A+ (Luzzatto, 1989); 11% of African American 
men have this variant. Its half-life is 13 days. Three types of mutations have arisen with 
molecular studies. The most common mutation being at nucleotide number 202 is a result of 
a guanine to adenine mutation at amino acid number 68 substitution of valine to methionine 
(Beutler, 1989, Luzzatto, 1989, Beutler, 1990). The second one occurs at nucleotide number 
680 as a result of a guanine to thymine mutation at amino acid number 227 substitution of 
arginine to leucine. And the third mutation occurs at the nucleotide number 968, as a result 
of a thymine to cytosine mutation at amino acid number 323 substitution of leucine to 
proline (Beutler, 1989). G6PD A + and G6PD Aˉ variants are defined as unique to Africa, but 
they can also be seen in Caucasian populations from Italy, Spain, Southeast Asia, Middle 
East and South America (Beutler, 1990). 
4.3.1.3 G6PD Mediterranean is a widely seen variant in the Mediterranean region and 
Middle East. In addition, it is seen in the Indian subcontinent and other regions of the 
Americas (Beutler, 1991). This Class II variant has less than 10% of the enzyme activity of 
G6PD B+ and the electrophoretical mobility is similar with G6PD B+ (Luzzatto, 1989). Its half-
life is only 8 days and DNA analysis identified two different point mutations. The first 
mutation is a result of a cytosine to thymine mutation at nucleotide number 563, at amino 
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acid number 188 substitution of serine to phenylalanine (Vulliamy, et al., 1988). Second is a 
silent mutation result of a cytosine to thymine mutation at nucleotide number 1311 (Beutler, 
1990). There are many similar Class II variants in the Mediterranean region (Cagliari, 
Sassari, El Fayoum), South Asia (Hong Kong, Canton, Mahidol), and elsewhere. Most of 
these emerge as a consequence of point mutations resulting in single amino acid mutations 
that have variable effects on activity and electrophoretic mobility (Luzzatto & Battistuzzi, 
1985, Luzzatto, 1989, Beutler, 1990, Beutler, 1991, Beutler, 1992).   
5. Clinical tables on G6PD deficiency 
Depending on G6PD enzyme deficiency are: Hemolytic Anemia (Drug-induced hemolysis), 
Diabetes mellitus-induced hemolysis and Infection-induced hemolysis; chronic 
nonspherocytic anemia, Favism and Neonatal jaundice. 
5.1. Hemolytic anemia 
5.1.1 Mechanism of hemolysis. In some people, for example, the Mediterranean-type, G6PD 
deficiency from drug intake occurs, although not a permanent hemolytic condition. In 
erythrocytes, NADPH cannot form with G6PD deficiency and unformed NADPH creates a 
deficiency in conversion of the oxidized form of glutathione (GSSG), to its reduced form 
(GSH) (Lachant, et al., 1984, Beutler, 1994). There is normally plenty of GSH in erythrocytes 
and it protects the cell from oxidizing agents. If G6PD is deficient, hemoglobin is oxidized 
by oxidative substances to be eliminated and it returns methemoglobin that cannot function 
normally. Also, hemoglobin precipitates with denaturation in the cytoplasm forms Heinz 
bodies. These structures attach to the membrane with disulfide bonds and disrupt its 
normal structure. The erythrocytes that contain Heinz bodies in their cytoplasm are 
sequestered by macrophages in the spleen and removed from the circulation. G6PD 
deficiency hemolysis occurs like that in the extravascular compartment and also occurs 
again as a result of membrane defects (Alving, et al., 1956). Thus, drug-induced hemolysis is 
the first and best-known morbid effect of G6PD deficiency. After a 1- or 2-day delay in such 
drug administration, a fall in the hemoglobin (Hb) concentration occurs.  
The red blood cell (RBC) membrane was adhered to by Heinz bodies, which are particles of 
denatured protein. These appear in the early stages of drug administration and disappear as 
hemolysis progresses. Hemolysis usually occurs in blood vessels and hemoglobinuria 
follows. The increase of reticulocytes emerges in response to this situation and the 
hemoglobin level begins to increase again within 8-10 days (Beutler, 1994). In severe 
hemolysis, the patient may complain of back and stomach pain and the urine turns dark. 
The hemolytic anemia is self-limited when G6PD deficiency is relatively mild because only 
the older RBCs are destroyed and the young RBCs have normal or nearly-normal enzyme 
activity (Beutler, 1994).  
Table 1 lists the drugs and chemicals that cause clinically significant hemolytic anemia. 
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5.2. Diabetes mellitus-induced hemolysis. Hemolysis in G6PD deficiency individuals 
might initiate diabetic ketoacidosis. This situation is not exactly accepted. However, 
hemolysis formation has been reported when blood glucose levels are normal in diabetic 
individuals (Beutler, 1994). It has also has been reported that hypoglycemia might 
precipitate hemolysis in patients with G6PD deficiency (Beutler, 1994). 
5.3. Infection-induced hemolysis. Infections are probably the most common cause of 
hemolysis in people with G6PD deficiency. There are numerous reports about the 
importance of infection in causing hemolytic anemia. A large number of bacterial, viral and 
rickettsial infections have been reported as predisposing factors. Infectious hepatitis 
(hepatitis A), pneumonia and typhoid fever are known to trigger hemolysis. Involving the 
upper respiratory tract and gastrointestinal system, viral infections have been reported to 
cause a more severe hemolysis (Luzzatto, 2001). The mechanism of infection-induced 
hemolysis is not clear, but it is thought to be that during the infection, superoxide anion and 
H2O2 production by macrophages causes the hemolysis (Glader, 1999, Luzzatto, 2001). 
5.4. Chronic nonspherocytic anemia 
Class I G6PD variants, such as the absence of precipitating factors in the occurrence of 
excessive hemolytic anemia, lower still further the remaining enzyme activity. This is 
observed in people with chronic hemolytic anemia and oxidative stress, even if unstable 
conditions occur as a result of insufficient enzyme activity in erythrocytes. Granulocyte 
dysfunction is seen in some cases. In these cases, more severe hemolysis is due to increased 
susceptibility to infection (Beutler, 1994, Luzzatto, 2001). 
5.5. Favism is an illness that occurs in G6PD deficiency individuals with acute hemolysis by 
eating raw beans (Vicia fabu). Wet, dry or frozen fava bean ingestion of grains, even if the 
mother eats fava beans can cause hemolysis in newborn infants through breast milk may 
occur (Luzzatto, 2001). Individuals with G6PD deficiency hemolytic effect caused by the 
beans contained many glycosides that are toxic due to the visin and konvisin (Beutler, 1994, 
Akhter, et al., 2011). In addition, β-glucosides in bean seeds, maturity stage of fava beans 
attain very high amounts causing a severe course of hemolytic crisis (Katz & Schall, 1979, 
Greene, 1993, Beutler, 1994). Often, in the G6PD Mediterranean variant, acute and a very 
severe hemolytic crisis are seen due to fava bean ingestion, even capable of causing death 
(Fairbanks, 1999, Luzzatto, 2001). In favism, damage in erythrocytes is similar to oxidative 
damage of drugs. Fava beans include visin, konvisin, ascorbic acid and L-Dopa, which have 
oxidative properties. The most commonly cited konvisin and visin glycosides during 
digestion fava beans by β-glycosidase or acid hydrolysis demolished to the active agents, 
which are converted to "divisine" and "izouramil." Divisine and izouramilin reduce the level 
of the GSH and NADPH in vitro conditions and damage the cell membrane by the 
formation of cross-connection with Heinz bodies; it also has been shown to inhibit Ca2+-
ATPase and catalase (Arese & De Flora, 1990, Beutler, 1994, Gaetani, et al., 1996, Luzzatto, 
2001). 24-48 hours after ingesting foods like fava beans, characteristic symptoms occur in the 
form of pallor, jaundice and hemoglobinuria (Ninfali, et al., 2000). In addition, jaundice, 
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headache, backache, nausea, fever, and chills are all signs of acute hemolysis (Tyulina, et al., 
2000). Favism is most common seen in children between the ages of 2-5, and is also 2-3 times 
more common in boys than in girls (Luzzatto, 2001). Clinical signs of favism begin earlier 
and are more severe than drug-induced hemolytic crises. Rarely, as a result of pollen of fava 
inhalation, hemolysis may occur within hours (Beutler, 1994). While each favism patient 
must have G6PD deficiency, hemolytic reactions may not occur after ingestion of fava beans 
in each person with G6PD deficiency. Each individual with G6PD deficiency of the same 
family could not be affected in the same way when they eat fava bean. On the other hand, 
changes are observed in the same person at different times. Genetic variations between 
individuals, differences of fava bean active metabolites may be responsible for these 
variable characteristics (Meloni, et al., 1983, Group, 1989, Luzzatto, 2001). 
5.6. Neonatal jaundice 
One of the most threatening consequences of G6PD deficiency is neonatal jaundice (Beutler, 
1994). Jaundice in babies with G6PD enzyme deficiency could be mild or severe enough to 
cause kernicterus, a spastic type of cerebral palsy, and may even cause death (Luzzatto, 
1993). In addition, infants with G6PD deficiency, hyperbilirubinemia is more remarkable 
than anemia. It facilitates this because of the inadequate physiological conjugation in liver in 
the neonatal period (Moskaug, et al., 2004). G6PD Aˉ, G6PD mediterrian, G6PD Canton 
variants are known as types that cause kernicterus and hyperbilirubinemia (Luzzatto, 2001). 
Clinically, the jaundice, the level of G6PD in the normal physiological jaundice in newborns 
occur on the same days, or a little earlier, but it takes as long as 2-3 weeks (Tan, 1981, 
Luzzatto, 2001). There are two major differences between jaundice due to incompatibility of 
blood groups and jaundice due to G6PD deficiency. First, the presence of jaundice in G6PD 
deficiency is very rare during childbirth and usually it begins in the second or third day. 
Second, according to anemia, jaundice is more pronounced and it is encountered with 
severe anemia very rarely in the absence of the enzyme (Luzzatto, 1993, Luzzatto, 2001). 
6. Malaria and glucose-6 phosphate dehydrogenase deficiency 
As we mentioned above, there is a strong relationship between malaria and G6PD 
deficiency diseases. In several epidemiological studies, it was shown that distribution of 
malaria was nearly the same with distribution of G6PD deficiency (Motulsky, 1961, 
Siniscalco & Bernini, 1961, Ganczakowski, et al., 1995). This situation reveals two important 
facts. One of them is that G6PD deficiency provides great protection from malaria, especially 
for falciparum infections. On the other hand, using antimalarial drugs can cause life-
threatening hemolytic anemia in patients with G6PD deficiency. Hence, malaria patients 
should be screened for their tendency to G6PD deficiency before their treatment with 
antimalarial drugs. In this part, we will first summarize the importance of malaria for the 
world. Then, we will explore the relationship between these two diseases in detail.      
As it is known, malaria is a parasitic disease that threatens 300-500 million people all over 
the world. Malaria can be defined as the most deadly vector-borne disease in the world 
Glucose-6-Phosphate Dehydrogenase  
Deficiency and Malaria: A Method to Detect Primaquine-Induced Hemolysis in vitro 75 
(Myrvang & Godal, 2000). It is widespread in tropical and subtropical regions of Asia, Africa 
and the American continents. Each year, malaria leads to deaths of millions of people all 
around the world and a large percentage of deaths are seen in Sub-Saharan regions of 
Africa. The causative agents of malaria are the Plasmodium parasites, which are transmitted 
to humans by the bites of infected mosquitoes. If patients are not treated with antimalarial 
drugs, malaria can easily lead to death. Five different types of Plasmodium species—P. 
falciparum, P. vivax, P. ovalae, P. malariae and P.knowlesi—lead to this disease (Wernsdorfer & 
McGregor, 1988, Sutherland, et al., 2010).  
Plasmodium falciparum (P. falciparum) is the most serious and life-threatening form of the 
disease. 80% of death cases are reported from patients that have been infected with P. 
falciparum. It was also demonstrated that resistance has been developed in this type of 
parasites against current antimalarial drugs. It is generally seen in Africa, specifically in sub-
Saharan regions. Interestingly, falciparum-derived malaria cases have been recently 
reported in various parts of the world where this parasite species was believed to be 
completely eradicated.  
Plasmodium vivax (P. vivax) constitutes a milder form of the disease. Vivax infections generally 
do not cause death. However, individuals that suffer from vivax infection also need to be 
treated. Among all Plasmodium species, P. vivax is the one that shows the broadest geographic 
distribution worldwide. Causative agents for 60% of malaria infections are reported as P. vivax 
infections in India. This parasite has a liver stage and can remain in the body for years without 
causing sickness. If the patient is not treated, the liver stage may re-activate and cause 
relapses—malaria attacks—after months, or even years without symptoms. 
Plasmodium ovale (P. ovale) is known as one of the other milder form of the disease. Like P. 
vivax, it generally does not commonly lead to death. Nevertheless, infected individuals 
require medical therapy. This parasite, similar to P.vivax, can live in the liver for long 
periods without causing symptoms. Therefore, if it is not treated, reactivation of parasites 
can be observed in the liver and this leads to relapse of the disease  
Plasmodium malariae (P. malariae) is also another milder form of the disease. It does not 
commonly lead to death. However, it still requires treatment. This type of Plasmodium 
parasites are reported to stay in the blood of some individuals for several decades. 
Plasmodium knowlesi (P. knowlesi) causes malaria in macaques, but can also infect humans 
(Mendis, et al., 2001, Singh, et al., 2004, Mueller, et al., 2007). 
When life cycles of Plasmodium parasites are investigated, it is seen that the parasites 
multiply in the liver of the human body, and then infect erythrocytes. As we mentioned 
before, Plasmodium parasites enter the human body when bitten by an infective female 
mosquito, which is called Anopheles. These mosquitoes become infected with malaria when 
they take Plasmodium-containing blood from an infected person. Approximately one week 
later, these parasites mix with the mosquito's saliva when the mosquito takes its next blood 
meal from another person and this individual is injected with Plasmodium parasites when 
they are being bitten (Bozdech, et al., 2003).  
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Multiplication of the parasites within erythrocytes enhances the severity of the disease and 
cause symptoms such as anemia, fever, chills, nausea, flu-like illness, and, in severe cases, 
coma, and death. Treatment of this disease can be achieved by using antimalarial drugs. 
Primaquine, which is the most common antimalarial drug, can be used as a primary 
prophylactic because it prevents primary parasitemia of Plasmodium species by destroying 
these parasites in the liver before they reach the bloodstream and cause disease (Yazdani, et 
al., 2006).  
As we pointed out before, according to epidemiological studies, the prevalence of malaria 
deeply relates to glucose-6 phosphate dehydrogenase (G6PD) enzyme deficiency. In these 
studies, it was demonstrated that 66 of 77 genetic variants that have reached polymorphic 
frequencies were seen in populations living in tropical and subtropical areas where malaria 
was endemic. On the other hand, this genetic diversity does not occur in populations living 
in non-endemic regions of the world for malaria, indicating that high polymorphism is the 
indicator of G6PD deficiency.    
When investigated in terms of cellular biology, we can see that Plasmodium parasite that 
causes malaria use erythrocytes as host cells. Erythrocytes are also the most affected cells 
from G6PD deficiency. This situation also suggests the relationship between the two 
diseases. In several studies, it was demonstrated that G6PD deficiency provides a protection 
against malaria infections. In one of the early studies, it was indicated that P. falciparum and 
P. vivax parasites preferred to invade younger erythrocytes, which possessed high levels of 
G6PD enzyme. Since enzyme levels are diminished in older erythrocytes, parasites do not 
prefer to invade these erythrocytes. These studies suggested the protective effect of G6PD 
deficiency from parasitemia (Allison & Clyde, 1961, Kruatrachue, et al., 1962). In the recent 
past, Ruwando et al. also carried out a case-control study on more than 2,000 African 
children and exhibited that risk of contracting malaria in patients that have the African form 
of G6PD deficiency decreased at a rate of 46 to 58%. In this study, it was suggested that the 
selective advantage of resistance to malaria was counterbalanced with selective 
disadvantageous results of G6PD deficiency, and this stopped the rise of malaria frequencies 
in endemic regions (Ruwende, et al., 1995). In another study, Ninokata et al. 
(2006) investigated 345 healthy adults for G6PD deficiency on Phuket Island, which had 
been determined to be a malaria-endemic region and found out that 10% of these 
individuals had G6PD deficiency. Interestingly, it was observed that none of the individuals 
had molecular evidence of malaria infection. According to this study, researchers postulated 
that G6PD deficiency provided an advantageous genetic trait against malaria (Ninokata, et 
al., 2006).  
The exact mechanism of this protection is still unknown. However there are two postulated 
explanations. According to the first suggestion, it was found that parasites that cause 
malaria can only survive in conditions with low oxygen levels (Clark, et al., 1989). This 
demonstrates that these parasites are very susceptible to oxidative stress. It is known that in 
the pentose phosphate pathway of erythrocytes, glucose-6 phosphate dehydrogenase 
(G6PD) enzyme has an important role in production of NADPH and GSH. This is the only 
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mechanism for erythrocytes to survive. GSH that is produced by NADP+ reduction reacts 
with H2O2 and reduce it to H2O. This prevents the generation of oxidative stress within red 
blood cells. Since oxidative stress is the most important factor for the disruption of red blood 
cells, these cells are protected from this effect. However, in G6PD deficient erythrocytes, 
G6PD activity is significantly reduced. In G6PD A (-) variant, enzyme activity level reduces 
to 10 or 20% of normal levels, while enzyme activity completely disappears in G6PD variant. 
Therefore, oxidative stress can be induced in erythrocytes whose G6PD enzymes are 
deficient. In this situation, GSH is not produced and H2O2 is not reduced to H2O and leads 
to oxidative stress. Hence, it is thought that since malaria parasites are susceptible to 
oxidative stress, they do not live within the erythrocytes where their maturation occurs 
(Toncheva & Tzoneva, 1985, Greene, 1993). Additionally, during oxidative stress, the loss of 
potassium from the cell and from the parasite can cause the death of the parasite (Friedman 
& Trager, 1981). 
According to the second suggestion, Plasmodium parasites oxidize NADPH and reduce the 
level of reduced glutathione (GSH) in erythrocytes. In the situation of G6PD deficiency, this 
effect becomes more severe and induces oxidative-induced damage within erythrocytes. 
Moreover, Plasmodium parasites break down hemoglobin and release toxic components like 
iron and these substances lead to hemolysis. Hence, the development rates of Plasmodium 
parasites are diminished. Additionally, red blood cells that are affected by oxidative stress 
and are damaged are eliminated by the immune system via phagocytosis. This elimination 
decreases the growth of parasites much more since it occurs during an early ring-stage of 
parasites’ maturation. Therefore, all of these data indicate that G6PD deficiency can provide 
protection against malaria infections. Considering the relationship between G6PD deficiency 
and plasmodium infections, research has aimed to develop antimalarial drugs that decrease 
the level of GSH within erythrocytes and then produce hydrogen peroxide and the other 
free radical species in order to enhance the inhibition of Plasmodium species (Mehta, et al., 
2000, Fortin, et al., 2002, Kwiatkowski, 2005, Prchal & Gregg, 2005). 
Primaquine is the only effective antimalarial drug that provides inhibition of persistent liver 
stages of P. falciparum, P. vivax, and P. ovalae parasites that lead to relapses of malaria 
(Phompradit, et al., 2011).  
However, as we initially mentioned, using primaquine in order to prevent the relapse of malaria 
can be very dangerous for G6PD deficiency patients since its usage results in very severe 
hemolysis. In all G6PD variants, activity levels of the enzyme have been diminished and this 
partially prevents the defense of erythrocytes against oxidative attack. However, when 
primaquine is administered, its metabolites lead to more severe hemolysis than oxidative 
damage by inducing oxyhemoglobin generation, GSH depletion and stimulation of the hexose 
monophosphate pathway. Moreover, primaquine can also induce the generation of Heinz 
bodies, which are insoluble aggregates that attach to the surfaces of erythrocytes. The most 
probable mechanism of primaquine-induced hemolysis is the generation of oxyhemoglobin, 
which forms hydrogen peroxide. Since G6PD enzyme level is low in G6PD-deficient 
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erythrocytes, these peroxides accumulate and lead to denaturation of hemoglobin. Peroxides also 
generate Heinz bodies that attach to cell membranes of red blood cells. Hemolysis occurs when 
damaged erythrocytes pass through the spleen. In each pass, red blood cells lose a portion of the 
cell membrane. After additional passes, membranes of cells completely lose their competency 
(Beutler, et al., 1955, Bolchoz, et al., 2002, Beutler & Duparc, 2007).       
These conditions reach life-threatening scenarios for all G6PD deficiency patients with 
different genetic variants. Hence, individuals that are required to use antimalarial drugs 
should be screened very carefully for their tendency to have G6PD deficiency. For effective 
control and treatment, either a reliable test for detecting G6PD deficiency or an anti-malarial 
drug that can be safely given to G6PD deficiency patients is required. 
7. Detection methods of G6PD deficiency 
Currently, primaquine, which causes hemolysis in G6PD-deficient patients, is the only 
radical cure of Plasmodium vivax infections (Burgoine, et al., 2010). Therefore, screening to 
detect G6PD deficiency is very important. Various tests can be used for the detection of 
G6PD deficiency, which are based on the assessment of the NADPH production capacity of 
G6PD. The most frequently used tests that measure NADPH production are the fluorescent 
spot test, cytochemical assay and spectrophotometric assay. However, fluorescent spot test 
and the spectrophotometric assay are not reliable for the detection of heterozygous females. 
In addition, DNA analysis can be done to detect G6PD deficiency for the homozygous, 
hemizygous, and heterozygous-deficient patients. However, we have to design primers for 
all mutations (Peters & Van Noorden, 2009). 
7.1. Fluorescent spot test 
Fluorescence is a form of luminescence that uses the physical change of emission of light 
upon excitation of molecules. There are various different types of luminescence, classified 
depending on the style of excitation: chemo-luminescence (ending in a chemical reaction) 
photo-luminescence (fluorescence, phosphorescence and delayed fluorescence), bio-
luminescence (via a living organism) and others (Bernard, 2002).  
Nicotinamide Adenine Dinucleotide Phosphate (NADPH) is the reduced form of NADP, 
with absorption maximum at 340 nm and a maximum emission at 460 nm. NADPH 
concentrations have been studied in great detail using optical methods. A parameter for 
direct measurements of the G6PD activity is the fluorescence of NADPH. When G6PD 
shows enough functional activity in erythrocytes, two molecules of NADP+ are reduced to 
NADPH. After the addition of glucose 6-phosphate and NADP+, blood spot fluoresces at 340 
nm if NADPH is produced (Beutler & Baluda, 1966).  
7.2. Spectrophotometric assay 
Spectrophotometric methods are greatly used in biological sciences for quantitative and 
qualitative measurements due to the fact that these methods do not break down the 
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molecules analyzed and enable us to assay small quantities of matter fundamentally 
(Lehninger, 2000). Spectrophotometric techniques allow detection of the concentration of a 
solution by evaluating its absorbance of a specific wavelength by way of a 
spectrophotometer, which produces light at a chosen wavelength and passes it directly 
through the sample. Because every molecule have a specific absorption spectrum, we can 
recognize and characterize its properties or detect its current concentration in the presence 
of other compounds (Lehninger, 2000). 
In the case of enzyme activity measurements, the assay solution contains some other 
compounds that are required for the reaction to occur. Other compounds in the reaction mix 
may absorb light at the same wavelength with the enzyme being analyzed. To eliminate the 
interference of other compounds, the absorbance of a sample solution is compared with 
blank solution, which is taken as the reference. The blank contains everything found in the 
sample solution except the substance to be assayed. 
In the matter of protein (enzymatic activity or protein concentration) measurements, 
colorimetric methods are used. Colorimetric measurements are performed by way of 
quantitative assessment of a colored complex, which is mostly formed by the reaction of a 
colorless compound and a dye reagent. However, the compound that will be analyzed can 
be naturally colored and can be read directly spectrophotometrically. 
Glucose-6-phosphate dehydrogenase catalyzes the first step in the pentose phosphate shunt, 
oxidizing glucose-6-phosphate (G-6-P) to 6-phosphogluconate (6-PG). The enzyme activity 
can be determined quantitatively by spectrophotometer assay method, which is based on 
the rate of NADPH production from NADP+ in G6PD-deficient patients (Kornberg, et al., 
1955, Lohr & Waller, 1974).  
These reactions are illustrated below: 
 
Nictotinamide adenine dinucleotide phosphate (NADP) is reduced by G6PD in the presence 
of G-6-P. The rate of formation of NADPH is proportional to the G6PD activity and is 
measured spectrophotometrically as in increase in absorbance at 340 nm. Production of a 
second molar equivalent of NADPH by erythrocyte 6-phosphogluconate dehydrogenase (6-
PGDH) occurs according to the reaction: 
 
This is prevented by use of maleimide, an inhibitor of 6-PGDH. 
The Enzyme Commission of the International Union of Biochemistry recommends 
expressing this in international units (IU) and defines 1 IU as the amount of an enzyme that 
catalyzes the transformation of 1 micromole of substrate per minute under standard 
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conditions of temperature, optimal pH, and optimal substrate concentration. Specific 
activity relates activity to total mass of protein to avoid bias through individual differences 
in weight (Bairoch, 1993). Therefore, G6PD activity was expressed as units (micromoles of 
NADP reduced per minute) per miligram of soluble protein at 37°C. 
7.3. Cytochemical staining assay  
The Cytochemical staining assay is based on the intracellular reduction of the tetranitro blue 
tetrazolium (TNBT) by the G6PD via exogenous electron carrier 1-methoxyphenazine 
methosulfate and TNBT is reduced to dark-colored water-insoluble formazan, which can be 
determined by light microscopy (Peters & Van Noorden, 2009).  
7.4. In vitro primaquine-induced hemolysis methods 
3 cc of venous blood anti-coagulated by 2% heparin solution (126 mM NaCl, 14 mM 
Na2HPO4, 1 mM KH2PO4, 13,2 mM glucose, pH 7.4) was collected from healthy and G6PD-
deficient persons. The blood was washed three times with sterile heparin solution at 3000 
rpm for 10 min. Erythrocytes were resuspended in PBS after that hematocrit was adjusted to 
2%. This is the one of the most important steps for detection of in vitro primaquine-ınduced 
hemolysis. Primaquine solution was prepared in 0.1 M Tris buffer (pH 7.4). Primaquine 
concentration was used between 1 and 4 mM in experiments. Different concentrations of 
primaquine were added into tubes containing 2% erythrocytes that were prepared before. 
Tubes were then placed and rotated in a rotator tube for 2 hours at 37°C. The rotation speed 
was less than 2 rpm. This is another important step for detection of in vitro primaquine-
induced hemolysis. After 2 hours, the supernatant was collected for the heme concentration, 
which was then determined spectrophotometrically. Hemoglobin released from erythrocyte 
induction of primaquine-induced hemolysis and compared with complete lysis (100% 
hemolysis, control group) obtained by adding 5 mM Tris-HCl (Fig. 1) (Allakhverdiev & 
Grinberg, 1981).  
The principle of this method is based on conversion of Hemoglobin (Hb) to 
cyanmethemoglobin by the addition of KCN and ferricyanide, whose absorbance is 
measured spectrophotometrically as cyanmethemoglobin at 540 nm versus a standard 
solution. Supernatant of hemolyzed red blood was diluted four-fold (v/v) with distilled 
water. On the other hand, the control group was diluted twenty-fold (v/v) with distilled 
water. After that, 50 μL KCN (10% w/v) and 50 μL potassium ferricyanide (2% w/v) were 
directly mixed and the color was measured at 540 nm. The standard curve was constructed 
using the standard cyanmethemoglobin solutions in different concentrations (Bhaskaram, et 
al., 2003). 
This method demonstrated that the in vitro model of primaquine-induced hemolysis can 
be only maintained by using 2% hematocrit in physiological conditions. Primaquine 
leads to hemolysis at concentrations between 1 and 4 mM. Other factors that induce 
primaquine-derived hemolysis are exposure time, incubation temperature, drug  
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Figure 1. In vitro Primaquine-Induced hemolysis 
concentration and amount of oxygen. Despite the fact that there are several methods in 
order to diagnose G6PD deficiency, these methods do not determine primaquine 
sensitivity in patients with G6PD deficiency every time. Therefore, lack of primaquine-
based treatment by considering only G6PD deficiency can be very dangerous in terms of 
health of patients with malaria and the epidemiology of the disease. On the other hand, 
treatment of primaquine-sensitivive individuals with primaquine can cause death. 
Hence, in the Centers for Disease Control and Prevention (CDC) report (Hill, et al., 
2006), it was highlighted that there was an urgent need to develop new in vitro methods 
for determining hemolysis that indicate primaquine sensitivity before treatment of 
patients with this drug. By considering primaquine-induced hemolysis in patients with 
G6PD deficiency, it can be determined whether these patients may be treated with 
primaquine or not. The advantage of this method is that it can determine primaquine-
induced hemolysis before treatment with primaquine and its capacity to determine 
G6PD deficiency.  
8. Conclusion 
This chapter has aimed to represent the relationship between G6PD deficiency and malaria 
and to suggest a sensitive method for detection of primaquine-induced hemolysis in 
patients with G6PD deficiency. As mentioned above, G6PD deficiency is the most common 
enzymopathologic disorder in humans and it affects 400 million people worldwide. In 
patients with G6PD deficiency, oxidative stress cannot be prevented since G6PD enzyme is 
the initial catalyst of the pentose phosphate pathway in erythrocytes that reduces the 
peroxides to H2O. This situation leads to mild to severe hemolysis, changing depending on 
genetic variants of the disease. As we mentioned before, according to epidemiological 
studies, the prevalence of G6PD deficiency deeply relates to malaria. In these studies, it was 
demonstrated that 66 of 77 genetic variants, which have reached to polymorphic 
frequencies, were seen in populations living in tropical and subtropical places where 
malaria was endemic. On the other hand, this genetic diversity does not occur in 
populations living in non-endemic regions of the world for malaria, indicating that high 
polymorphism is the indicator of G6PD deficiency and distribution of malaria is nearly the 
same with distribution of G6PD deficiency. This situation reveals two important results.  
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One of them is that G6PD deficiency provides partial protection from malaria infections, 
especially for falciparum infections. In several studies, it was demonstrated that risk of 
contracting malaria in patients that have G6PD deficiency decreased at a rate of 46 to 58%. 
On the other hand, using antimalarial drugs can cause life-threatening hemolytic anemia in 
patients with G6PD deficiency. Since G6PD deficiency does not provide exact protection, 
these patients still have a risk of contracting malaria. However, using primaquine, which is 
the only radical cure of Plasmodium infections, can induce more severe hemolysis by 
generating oxyhemoglobin, GSH depletion and Heinz bodies and enhancing oxidative 
attack. This threatens the lives of patients with G6PD deficiency. Hence, patients with 
malaria should be screened for their tendency to G6PD deficiency before their treatment 
with antimalarial drugs. Common methods that are used for diagnosing G6PD deficiency 
are unreliable. Even worse is that it is very difficult to distinguish heterozygously-deficient 
patients from healthy individuals. Additionally, current methods cannot accurately indicate 
hemolysis, even though they give information about activity of the enzyme. Also, these 
methods do not determine primaquine sensitivity in patients with G6PD deficiency every 
time. However, the method that we developed provides the determination of primaquine 
sensitivity in patients with G6PD deficiency in vitro independently from the variants of 
G6PD deficiency. The principle of the method is based on the quantitative detection of 
hemolysis by incubation of erythrocytes obtained from G6PD-deficient patients with 
primaquine in low hematocrit while rotating the culture in a hybridization oven for 2 hours 
at 37°C. By considering primaquine-induced hemolysis in patients with G6PD deficiency, it 
can be determined whether these patients may be treated with primaquine or not. The 
advantages of this method are that it can determine the primaquine-sensitivity in patients 
with G6PD deficiency before treatment with primaquine. Using this method not only on 
G6PD deficiency patients but also on patients that suffer from other diseases that may cause 
primaquine-induced hemolysis constitutes another advantage of the method. 
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1. Introduction 
The problem of finding effective chemotherapies for advanced cancer remains largely unsolved. 
We review here the role of a specific class of central metabolic dehydrogenases whose 
regulatory properties are remodeled significantly in cancer cells. These remodeled properties 
may provide an attractive set of targets for the development of new chemotherapeutic drugs. 
The design features of the first agents to be developed attacking these new targets [1,2] may 
illustrate ways to exploit this potentially valuable therapeutic opportunity. 
2. The central role of the pyruvate dehydrogenase (PDH) and alpha-
ketoglutarate (KDGH) complexes in cell metabolism 
The evolution of the high-energy, oxygen-dependent metabolism of eukaryotes [4,5] has 
produced mitochondrial metabolic pathways whose control is centrally focused on a series 
of dehydrogenases. Two of these pivotal dehydrogenases, the pyruvate dehydrogenase 
(PDH) and alpha-ketoglutarate or 2-oxoglutarate (KDGH) complex will be our central focus 
here. These dehydrogenases control the entry of carbon into the TCA cycle from two major 
sources, carbohydrate and gluconeogenic amino acids (pyruvate; PDH) and glutamine 
(KGDH), the most abundant serum amino acid and a central carbon source for normal and 
pathological tissues (Figure 1). The TCA cycle, in turn, is almost exclusively responsible for 
the capture of reducing potential from nutrients for the purpose of driving the oxygen-
dependent mitochondrial electron transport system for ATP production [6]. 
In the solid, three dimensional structure of animal bodies the availability of nutrients and 
molecular oxygen is locally contingent and dynamically variable. Thus, continuous real-time 
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control of PDH and KGDH activities is essential to proper function. Moreover, in various 
pathological contexts these regulatory processes are substantially altered in ways that are 
essential to that pathology and this may reflect targets for therapeutic intervention (see 
sections 5 and 8 below for detailed references). 
 
Figure 1. The pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (KGDH) 
complexes govern the entry of carbohydrate- and glutamine-derived carbon, respectively, into the TCA 
cycle. Glucose and glutamine are two major carbon sources feeding many mammalian cells, including 
tumor cells. These molecules are metabolized to support ATP generation, through cytosolic glycolysis 
and oxygen-dependent mitochondrial metabolism in which most reducing potential is  derived from 
the TCA cycle. As well, both carbon and reducing potential from glucose and glutamine are delivered 
to anabolic, biosynthetic functions. Among these are provision of citrate and NADPH for lipid 
biosynthesis as illustrated and delivery of carbon skeletons from glycolysis and the TCA cycle for amino 
acid biosynthesis (not illustrated). The entry of glucose derived carbon (either from dietary glucose or 
from amino acids used for gluconeogenesis) is controlled by the PDH complex and the entry of 
glutamine derived carbon is controlled by the KGCH complex. Figure redrawn from several sources, 
including [3]. 
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PDH decarboxylates pyruvate, releasing carbon dioxide, capturing reducing potential and 
transferring the two-carbon acyl unit (acetate) to Co-enzyme A (CoA) (Figure 2). 
Structurally homologous KGDH catalyzes the analogous reaction, decarboxylating alpha-
ketoglutarate and generating succinyl-CoA. Each of these reactions is highly exergonic and 
also generates rapidly dispersed or consumed products (carbon dioxide and acyl-CoA). 
Thus, the initial decarboxylation reaction in each case is effectively irreversible, reflecting a 
forward commitment step.  
The catalytic details of PDH and KGDH are as follows (Figures 2 and 3). Each complex 
contains enzymatic activities conventionally referred to as E1, E2, and E3. E1 catalyzes 
oxidative decarboxylation (of pyruvate or alpha-ketoglutarate, respectively) using a 
thiamine pyrophosphate co-enzyme. The activated acyl unit created by this process is 
transferred to sulfhydryl groups of a lipoic acid (lipoate) residue of an E2 subunit. E2 lipoate 
is in the form of lipoamide, in which the carboxylic acid moiety of lipoate is joined in amide 
linkage to epsilon amino group of an E2 active site lysine. The two sulfurs on the lipoate 
moiety (Figures 3) exist in a disulfide configuration which is reduced and acylated 
(thioesters) to produce activated acetate or succinate residues. The E2 subunit further 
catalyzes the transfer of the lipoate-activated acyl residue to CoA leaving dihydro-
lipoamide. Finally, the E3 subunit catalyzes the transfer of the reducing potential in the 
dihydro-lipoamide residues of E2 to NAD+ (through enzyme disulfide to FAD to NAD 
steps) [7,8] to generate NADH for transfer of the reducing potential to the electron transport 
complex and regenerating oxidized lipoate (Figure 2).  
Both PDH and KGDH are very large complexes containing multiple copies of each of these 
three key enzymatic activities (Figure 3). For example, mammalian PDH consists of 60 
copies of the E2 subunit (48 of E2 itself and 12 of the E2 homolog called the E3 binding 
protein, E3BP; Figure 3) [9].  
This organization allows efficient channeling of the products of the intermediate reactions 
[10]. Flux through these complexes is subject to extensive regulation as expected from 
their central role in governing carbon flow in the face of variable supply and demand. The 
end products of PDH and KGDH activity, NADH and acyl-CoA, inhibit complex activity 
directly, apparently by binding to the E2 and E3 active sites, respectively [11,12]. 
However, PDH is much more extensively regulated through its associated kinases and 
phosphatases [13].  
The four PDKs that regulate the mammalian PDH complex are a novel class of kinases 
apparently unrelated to the large families of serine-threonine and tyrosine kinases so 
prominent in other mammalian regulatory processes as reviewed in [7,8]. These kinases are 
named on the basis of their order of discovery, PDKs1-4. Though the PDKs represent a 
related family of kinases, the sequence divergence between the four different isoforms (61-
69%) is consistent with their significantly divergent regulatory behavior [14,15]. Moreover, 
PDK isoform function is apparently ancient and essential as the corresponding isoforms in 
rodents and humans are at least 94% conserved as reviewed in [15]. 
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Figure 2. The catalytic cycle of the pyruvate dehydrogenase (PDH) complex. This cycle begins with the 
oxidative decarboxylation of pyruvate catalyzed by the E1 subunit, generating carbon dioxide and an 
activated two carbon unit (hydroethyl thiamine pyrophosphate, HE-TPP) as illustrated at the 10 o’clock 
position. E1 then catalyzes the transfer of this two carbon unit to one of the lipoate residues of the E2 
subunits, creating acyl-lipoamide as illustrated at the 12 o’clock position. The E2 catalytic activity 
transfers this two carbon unit to CoA, creating acetyl-CoA and dihydro-lipoamide as illustrated at the 4 
o’clock position. Finally, E3 catalyzes the transfer of the dihydro-lipoamide to NADH (through protein 
sulfhydryl and FAD intermediates) to recreate the oxidize form, lipoamide, as illustrated at the 8 o’clock 
position. Both the E2 catalyzed transfer of the lipoamide acyl group to CoA and the E3 catalyzed 
transfer of dihydro-lipoamide reducing potential to NADH are highly reversible reactions. Figure 
redrawn from several sources, including [8]. 
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Figure 3. Functional organization of the pyruvate dehydrogenase (PDH) complex in mammals. This 
complex catalyzes the oxidative decarboxylation of pyruvate to yield acetyl-CoA to feed carbohydrate 
carbon into the TCA cycle and to capture reducing potential in NADH for transfer to the electron 
transport complex (ETC) to support ATP synthesis during step down transfer to molecular oxygen 
(Figure 2). The mammalian PDH complex is built around a core consisting of the inner domains of ca. 
48 copies of the catalytically active E2 protein and 12 copies of the catalytically inactive E2 homolog, 
E3BP, The E1 subunit binds to E2 and the E3 subunit binds to E3BP. Both E2 and E3BP contain lipoate 
residues joined in amide linkage to the epsilon amino groups of specific lysine residues in the lipoyl 
domains (L1-L3). The lipoamide residues on the two lipoyl domains of E2 and the single domain of 
E3BP are acylated, reduced and re-oxidized during the PDH catalytic cycle (Figure 2). The zig-zag lines 
indicate highly flexible proline-rich domains allowing the E2 subunits high mobility throughout the 
complex and, perhaps, beyond. The regulatory kinases (PDKs) control PDH activity by phosphorylating 
(inactivating) the E1 subunit of the complex. Their activity is antagonized by two phosphatases (PDPs). 
The status of E2 lipoate residues strongly modulates the activity of the PDKs with acylation/reduction 
stimulating PDK activity. Figure redrawn from several sources, including [7].The PDKs normally 
function as dimers [see, for example 16,17]. Of particular potential importance is the observation that at 
least two of the PDK isoforms (PDK1 & 2) readily form heterodimers [18].  This raises the possibility 
that there might be as many as 10 different PDK isoforms (four homodimers and six heterodimers). In 
view of the substantial changes in PDK levels associated with malignancy (below), this potential 
complexity may be very important and is worthy of more investigation. 
The PDKs regulate PDH complex activity by responding to diverse allosteric modulators. 
High ratios of acetyl-CoA to CoASH and NADH to NAD+ represent signals of saturation of 
mitochondrial demand. Elevations of these ratios are strong allosteric activators of PDKs, 
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shutting down PDH activity in response to demand saturation [19, 20, 21]. Though 
saturation of mitochondrial demand is most often produced in response to high fat or 
carbohydrate intake in healthy animals, as reviewed in [8], the altered metabolism of tumor 
cells also creates a very new metabolic environment wherein these regulatory processes may 
be entrained for different purposes (below). 
PDKs are also subject to allosteric regulation by pyruvate [22] . Elevated pyruvate levels 
interact synergistically with ADP to inhibit PDK activity (activating PDH). This PDK 
inhibition apparently results from the binding of pyruvate to PDK-ADP inhibiting exchange 
for ATP and, thus, phosphorylation. Dichloroacetate (DCA) is a pyruvate analog and acts 
very similarly to pyruvate in this allosteric modulation of PDK activity [22] DCA was 
subsequently investigated as an anticancer drug (below) on the basis of this observation. 
The final relevant feature of PDK regulation is the response of these regulatory kinases to 
the lipoyl domains of the E2 subunits of PDH [7, 8, 23]. PDK1-3 bind strongly to the L2 
lipoate domain of E2 and more weakly to the E2 L1 lipoyl domain (Figure 3). PDK4 binds to 
the L1 E2 domain and to the sole lipoyl domain of E3BP (Figure 3). This lipoyl domain 
binding requires the lipoamide component of the domain. Moreover, the well characterized 
binding of PDK3 to the E2 L2 domain defines the binding site in detail including the amino 
acids interacting with the lipoamide residue [16]. These residues are highly conserved in 
PDK structure [17] indicating that this binding mode is likely universal to the PDKs. This 
binding of PDKs to E2 lipoyl domains juxtaposes them to their E1 target (associated with the 
E2 subunit binding domain; Figure 3), producing a large increase in the kinase reaction rate. 
PDK dimers apparently interact simultaneously with two lipoyl domains, producing very 
high binding affinity to the PDH complex and supporting hand-over-hand migration of the 
PDKs through the complex [24]. 
Most importantly for our purposes here, the reduction and acylation state of the E2 lipoates 
strongly modulates associated PDK activity [25, 26]. Specifically, acylation and reduction of 
lipoate enhances PDK2 activity [7,8, 27]. Moreover, acetyl-CoA and NADH can be used as 
substrates to run elements of the PDH reaction (above) in reverse, thereby creating reduced 
and/or acylated lipoate residues in response to elevation in the levels of acetyl-CoA and 
NADH in the mitochondrial matrix [25,26]. In other words, the lipoate residues of PDH 
represent a real-time census of these crucial features of the energy status of the 
mitochondrial matrix. 
Several additional details of lipoate regulation of PDH and KGDH are also relevant for this 
discussion. The lipoates in PDH and KGDH comprise a dense cloud of highly mobile 
residues [28], potentially interacting with crucial regulatory functions. This condition results 
from several features of the structure of these complexes. PDH illustrates the crucial issues. 
Each of the ca. 48 E2 subunits contains 2 lipoate (lipoamide) residues and each of the 12 
E3BP proteins contains 1 such residue, for a total of 108 lipoate residues in each complex. 
The regulatory kinases (PDKs-1-4) interact with these lipoate residues embedded in the 
lipoyl domains (Figure 3). Moreover, these lipoyl domains not only have the boom-like 
structure resulting from their connection to lysine epsilon amino groups in the E3 lipoyl 
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binding domains, but also each of these domains is separated by highly flexible 
(alanine/proline-rich) linker domain.  
These details will be important to us below in considering the possible mechanisms of action 
to pursue in developing new drugs based on lipoate structure. Specifically, each PDK can 
potentially interact simultaneously with two lipoate residues, as well as rapidly migrate 
between residues. This creates an environment in which PDKs may effectively sample the 
lipoate cloud, regulating their activity in response to what is effectively a measurement of 
the aggregate cloud status, especially the acylation/redox status of lipoate as determined by 
both forward flux through the complex and by backward charging of lipoate from NADH 
and acetyl-CoA products (above).  
Such a sampling procedure would yield especially robust assessment of enzyme saturation 
and, thus, allow PDK control of PDH to be more reliably connected to the global 
mitochondrial energy status. In vitro studies demonstrate that free lipoate can interact with 
the PDH (and KGDH) complexes [29]. Thus, we anticipate that exogenous lipoate analogs 
might be effective in modulating the activity of PDK bound to the PDH complex (below). 
3. Clinical implications of the reconfiguration of metabolism in cancer 
cells 
The hypothesis that metabolism may be altered in important ways in cancer is longstanding 
[30]. However, our understanding of cancer metabolism and its relationship to malignancy 
and clinical outcome has only recently begun to receive extensive attention. Though our 
knowledge about cancer metabolism remains quite incomplete, some important global 
insights have emerged. 
First, fluxes of both glucose and glutamine, two major carbon sources, are substantially up-
regulated in many tumors as reviewed in [31-36]. More specifically, mutational changes 
altering signaling through the Akt pathway enhance glucose uptake and glycolytic 
metabolism [37]. Likewise, alterations of Myc expression substantially up-regulate 
glutamine utilization [3, 38, 39]. 
Second, evidence from multiple perspectives supports the view that one of the major 
functions of these tumor-specific changes is the redirection of metabolism toward provision 
of increased levels of anabolic substrates. For example, large fractions of glucose carbon are 
diverted into the pentose phosphate pathway in support of nucleotide synthesis and into 
amino acid biosynthesis. Likewise, a large portion of glutamine carbon is siphoned off of the 
TCA cycle as citrate to support lipid biosynthesis (including fatty acids and sterols) (Figure 
1). We can call this the anabolic shift in tumor cells. 
The therapeutic implications of the alterations in cancer metabolism depend heavily on how 
unique these changes are to tumor cells. There is good evidence that some elements of the 
anabolic shift are not unique to tumors cells, but may also be shared with rapidly dividing 
normal cells. For example, activated lymphocytes show some of these same metabolic 
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properties [40]. However, there is also reason to suspect that other features of the cancer cell 
version of the anabolic shift will not be shared with most normal, rapidly dividing cells. In 
particular, the poor vascularization of solid tumors reflects an environment rather different 
than rapidly dividing normal cells typically experience [41, 42]. Tumor cells are likely to 
have additional metabolic adaptations to this extreme environment. 
Of course, the existence of such metabolic adaptations to the extreme tumor 
microenvironment may still not be helpful therapeutically if these adaptations are 
idiosyncratic to each individual case of cancer. Fortunately, there is both empirical and 
theoretical reason to believe that these special adaptations will, in fact, be generally 
consistent and predictable, as we now discuss. It has long been recognized that solid tumors 
bear a striking resemblance to healing wounds [43-45]. Specifically, solid tumors resemble 
wounds that continue the early steps in wound healing, but never resolve as normal wound 
healing does. Thus, it is plausible to speculate that metabolic modifications in tumor cells 
usually or always involve the pathological, uncontrolled activation of regulatory pathways 
normally accommodating cells to the rigors of the wound environment. On this working 
hypothesis, tumor metabolism is expected to have features not shared with normal cells 
(except potentially in healing wounds) and to be potentially universal to most or all cancers. 
The possibility that tumor metabolism might have unique features is particularly important 
therapeutically. The dramatic increase in our knowledge about the genetic changes in cancer 
and our experience with genetically targeted therapies has produced some sobering 
potential insights as illustrated by the following examples. Specifically, in many or even 
most cancers, the “driver” mutations may represent loss-of-function in tumor suppressors 
rather than gain-of-function mutations [46-48]. Moreover, the fraction of tumor-producing 
changes that are epigenetic may be high. All of these features mean that targeting specific 
oncogene-targeted products, such as small molecules like gleevec, may be viable in only a 
minority of tumors [49]. 
Finally, the levels of redundancy in the regulatory circuits mutated in cancers mean that 
targeting an individual gain-of-function driver, even when it is possible, may be 
incompletely successful and subject to evolved resistance.  
The upshot of these genetic considerations is that chemotherapy might be better focused on 
properties of the transformed state rather than on the genetic drivers producing that state. 
Moreover, non-redundant, indispensable properties of the transformed state are expected to 
represent the most propitious of such targets. Cancer metabolism may represent an 
environment in which such desirable targets exist. Below we will develop the argument that 
the dehydrogenases at key control points in metabolism are especially attractive candidates 
for such targets.  
4. Modification of PDH regulation is vital to malignant transformation 
If cancer metabolism is to be a therapeutic target it is vital to identify likely targets for 
intervention. In this section we will review some of the evidence that the PDKs regulating 
The Pyruvate Dehydrogenase Complex in Cancer:  
Implications for the Transformed State and Cancer Chemotherapy 49 
PDH activity are excellent potential candidates for such targets. Later we will return to the 
question of whether the other major dehydrogenase entry point for mitochondrial 
metabolism, KGDH, might also be an attractive therapeutic target. 
PDKs have long been recognized as key regulators of PDH function (above). Moreover, in 
view of the central role of modification of carbohydrate metabolism in cancer (above), 
alteration of PDK regulation in malignancy is likely. Initially, analysis of clinical samples 
demonstrated that up-regulation of PDK levels was a frequent correlate of advanced 
malignancy [50] a pattern that has persisted in subsequent studies [51]. 
These and other observations stimulated systematic detailed study to great effect. Kim, et 
al., [52] and Papandreou, et al. [53] demonstrated that HIF-1, a global regulator of the 
hypoxic response, up-regulated PDK1, with the expected effect of down-regulating carbon 
flow through PDH. Moreover, PDK up-regulation correlated with increased resistance to 
programmed cell death, a hallmark of cancer as reviewed in [54]. In view of the consistent 
hypoxia in solid tumors as reviewed in [41, 42] and the frequent activation of HIF1 in 
tumors as reviewed in [55] these observations suggested that PDK up-regulation might be a 
central element of the cancer metabolic reconfiguration.  
The next challenge was to ask if more direct evidence for the importance of PDK up-
regulation in cancer metabolism could be found. Was PDK up-regulation required for 
malignancy or marginal, epiphenomenal?  Several observations argue strongly that PDK up-
regulation is essential to the malignant phenotype. 
First, McFate, et al. [56] demonstrated that PDK1 up-regulation was essential for the 
malignant phenotype in head and neck squamous cell carcinoma cells (HNSC). Specifically, 
PDK1 expression contributed to induction of limited flux of carbon through mitochondrial 
metabolism and PKD1 over-expression further reduced this flux (as measured by glucose 
consumption and diversion of carbohydrate carbon to lactate formation). Confirming this 
relationship, PKD1 knockdown increased TCA processing of carbohydrate carbon. PDK1 
knockdown reduced several indicators of malignant potential, including ability to resist cell 
death under hypoxia or to form colonies in soft agar in culture. Most importantly, PDK1 
knockdown dramatically, reduced the rate of tumor growth in xenograft models.  
Earlier work from this group indicated that accumulation of glycolytic intermediates might, 
itself, be sufficient to up-regulate HIF1 [57]. Thus, McFate [56] proposed a positive feedback 
loop central to the malignant state wherein PDK1 up-regulation by HIF1 enhanced 
production of glycolytic intermediates (by blocking pyruvate consumption) further up-
regulating HIF1 and so on. 
Second, Lu, et al. [58] found a similar role for HIF1-dependent up-regulation of PDK3 in 
malignant metabolic state. In this case also, reduction in mitochondrial carbohydrate 
metabolism with the corresponding up-regulation of oxygen-independent cytosolic 
glycolysis was driven by elevated PDK3 expression. Of particular importance here, the 
resistance of tumor cells to killing by chemotherapeutic agents paclitaxel and cisplatin was 
strongly improved by PDK3 up-regulation, while PDK3 knockdown sensitized to these 
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agents. Finally, Lu, et al. [58] observed that both PDK1 and PDK3 collaborated to produce 
this drug resistance. 
Collectively, these results clearly indicate that PDK regulation of PDH activity is central to 
the malignant phenotype. Moreover, there is apparently no metabolic bypass of the 
requirement for properly managed mitochondrial metabolism. Mitochondria are not turned 
off in hypoxic tumor cells. Rather, they are redeployed to provide the limited carbon traffic 
they can sustain to the provision of anabolic intermediates (above). There appears to be no 
other way to provide some of these biosynthetic resources (citrate for lipid biosynthesis, for 
example). Further, mitochondria are central controllers of Ca++ signaling [see 59 and 
references therein] and of cell death control as reviewed in [60,61]. Thus, their continued 
properly controlled function is likely to be essential to cancer cell homeostasis and survival. 
These results and considerations are consistent with the hypothesis that this re-regulation of 
PDH cannot be dispensed with. Without this metabolic pattern cancer cells are likely to be 
unable to survive and prosper in the hypoxic environment crucial to malignant progression. 
Thus, PDK re-regulation is a candidate for the kind of essential, non-redundant therapeutic 
target needed if we are to have fundamentally new clinical options. We will argue below 
that this target can be therapeutically exploited in several different ways. 
Before turning to assessment of how we might attack this potential target it is important to 
emphasize a particular implication of PDK re-regulation in cancer cells. Because of the 
possibility of PDK heterodimer formation (above), tumor-specific quantitative changes in 
individual PDK expression may be substantially amplified in their regulatory effects. For 
example, if PDK1 and PDK3 were both up-regulated 10 fold in the in vivo tumor 
environment, this could represent a 100-fold increase in the levels of the hypothetical 
PDK1/PDK3 heterodimer. Such very large effects might represent targets that are essentially 
qualitatively unique to tumor cells. 
5. DCA, attempting to reverse tumor-specific PDK repression of PDH 
activity 
Dichloroacetate (DCA) is a small molecule with a long history of clinical use for treatment of 
elevated serum lactate levels in some inherited metabolic conditions [62]. Moreover, DCA is 
well characterized as being a non-metabolizable pyruvate analog that can strongly inhibit 
PDK function [17,22, 63] .Thus, DCA is a candidate to reverse PDK repression of PDH 
important to cancer cell tumorigenicity (above). 
These considerations influenced Bonnet [1] to investigate DCA’s potential anti-cancer 
effects. These authors observed that DCA treatment could reverse the mitochondrial 
membrane hyper-polarization characteristic of tumor cells without noticeable effect on the 
lower level of polarization in normal cells. Further, DCA substantially increased glucose 
oxidation while decreasing fatty acid oxidation in A549 tumors cells [1]. These and other 
effects correlate with DCA inhibition of cancer cell growth and induction of a modest 
increase in the rate of cancer cell apoptosis. Finally and most importantly, DCA very 
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significantly inhibits tumor growth in mouse xenograft models. Specifically, DCA 
administered ad libitum in drinking water at 75mg/l produced both inhibition of xenograft 
tumor growth and modest, but significant reduction in tumor volume in larger tumors. 
Subsequent reports from other groups corroborate these preclinical findings [64, 65]. 
The clinical follow up on these preclinical results has been generally weak. This largely 
results from economic factors. DCA is a cheap, generic drug and no corporate actors have an 
incentive to develop the agent. To date clinical data consist of several anecdotal case reports 
[66,67] suggesting possible efficacy, including in a poorly differentiated metastatic 
carcinoma. In addition, in view of its low cost and wide availability, DCA is being 
prescribed off-label or self- administered. Anecdotal reports of efficacy from this use group 
can be found in patient/physician webshops (see, for example, www.thedcasite.com). It will 
be of considerable interest to see if sufficient evidence can be accumulated to assess the 
clinical potential of this agent.  
An apparently common side effect of DCA use is peripheral neuropathy. Though this is 
generally limited and reversible, this may not always be the case. A patient report describes 
relatively severe encephalopathy probably induced by DCA doses within the range 
currently being experimented with by patients and their physicians [68]. These problems 
emphasize the importance for individual patients of using DCA only under professional 
medical supervision.  
Finally, a series of small molecule PDK inhibitors have been developed, initially for the 
treatment of diabetes as reviewed in [8]. These compounds are far more potent than DCA on 
a mole basis and it will be of interest to see if they have significant anti-cancer activity. To 
date, no clinical trial data are available on any possible anti-cancer activities of these agents. 
Moreover, the design strategy for these compounds renders them relatively selective for 
individual PDK homodimers. We do not currently know which homo- or heterodimer(s) 
might be the most propitious anti-cancer target(s) for this class of agents. 
6. Thioctoid lipoate analogs exaggerate cancer-specific, PDK-mediated 
repression of PDH to shut down tumor cell mitochondria and induce cell 
death 
The PDH complex includes a dense cloud of lipoate residues making up the functional 
catalytic co-factor domain of the E2 activity (above). Acyl groups and reducing potential can 
be back-transferred to this lipoate cloud from the surrounding mitochondrial matrix pool as 
well as being generated by the conventional PDH forward reaction (above). Moreover, these 
acyl groups and reducing potential can apparently be rapidly shuttled between these 
residues before ultimately being transferred to CoA and NAD+[28]. Finally, the 
oxidation/acylation state of the elements of the lipoate cloud strongly effect the activity of 
the PDK regulatory kinases, with acylation/reduction stimulating PDK activity (above). 
Thus, each PDK homo- or heterodimer docked at any point on the PDH complex is 
apparently continuously exposed to the result of an ongoing, real-time poll of the 
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mitochondrial matrix energy status. Further, these PDKs are then able to act rapidly on all 
their E1 targets in the PDH complex in response to these polling results as a result of the 
combination of the highly flexible linkers surrounding the lipoyl domains to which they are 
bound (Figure 3) and their ability to move hand-over-hand through the complex.  
In vitro studies demonstrate that free lipoate and lipoate-containing lipoyl domain 
fragments can interact productively with the intact PDH complex (above). This suggests that 
lipoate analogs might be able to perturb PDH regulation in vivo. Moreover, this perturbation 
might show strong selectivity for tumor cells in view of the substantial reconfiguration of 
PDK regulation in cancer (above). Based on the original PDH regulatory biochemistry and 
the presumption, subsequently confirmed (above), that PDH regulation was likely to be 
substantially altered in tumor cells, we began a systematic study of lipoate analogs as anti-
cancer agents in the late 1990s (Patent # 6331559, filed 1999). The concept was that 
appropriately designed lipoate analogs might mimic the effects of specific intermediate 
states of lipoate (Figures 3 and 4) on PDK function and, thereby, misinform the PDH 
regulatory machinery in ways that were selectively toxic to tumor cells. 
These studies initially demonstrated that lipoate analogs, designated thioctoids, had strong 
anti-cancer activity in cell culture [2; our unpublished results]. Many of our initial analyses 
were carried out using our current lead clinical investigational compound, CPI-613 (Figure 
4). Indeed, these agents induce cell death in cancer cells extremely efficiently, with all cells 
dying within 24-48 hours by a mixture of apoptosis and necrosis-like mechanisms. This is in 
contrast to DCA which typically induces cell death in only a small fraction of tumor cells in 
culture [1; our unpublished results]. Each of the many human tumor cell lines we have 
examined is comparably sensitive to thioctoids, with tumor genotype at oncogenes and 
multidrug resistance loci having little or no effect on response [2]. 
Though the precise biochemical mechanism of action of thioctoids remains to be established, 
the in vivo behavior of these compounds demonstrates that they modulate PDK regulation 
of PDH [2; our unpublished results]. Moreover, these tumor effects are diametrically 
opposite to the effects of DCA and of other small molecule PDK inhibitors. Specifically, 
DCA induces de-phosphorylation of PDH E1 in vivo [55] while thioctoids induce hyper-
phosphorylation in vivo [2; our unpublished results]. This thioctoid-induced PDH hyper-
phosphorylation is selective for tumor cells and correlates with inactivation of PDH activity 
as assessed by analysis of the oxidative flux of pyruvate carbon through the complex. 
Coincident with this inhibition of PDH activity, thioctoids induce rapid shut down of 
mitochondrial ATP synthesis, typically reducing mitochondrial ATP production from 
pyruvate and glutamine carbon sources to less that 10% of controls within 15-30 minutes [2]. 
Finally, the capacity of CPI-613 to kill tumor cells is significantly attenuated in cell culture 
systems by RNAi knockdown of regulatory PDKs, supporting a role for PDKs in the 
response to these agents. 
Collectively, these results indicate that thioctoid lipoate analogs kill tumor cells by 
addressing tumor-specific PDK regulation of PDH. Moreover, the consequence of these 
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effects is apparently to exploit tumor-specific PDH regulation, in part or entirely, to shut 
down tumor mitochondrial function. As continued mitochondrial function is required for 
the survival of tumor cells, even in the hypoxic solid tumor environment (above), these 
effects are expected to engender the observed response, rapid commitment to and execution 
of mitochondrially controlled cell death pathways. 
 
Figure 4. Structure of thioctoid CPI-613 compared to biogenic lipoates. The structure of the thioctoid 
CPI-613 is shown at bottom. This molecule is a non-redox active analog of lipoate designed to have 
some resemblance to the acylated form of lipoate as it occurs in the normal catalytic cycle of PDH 
(Figure 2). The corresponding biogenic lipoate intermediates in the PDH catalytic cycle are 
illustrated at top. 
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These properties suggested that thioctoids might be promising anti-cancer agents. This 
possibility is further supported by their behavior in human tumor xenograft mouse models. 
Specifically, CPI-613 produces strong tumor growth inhibition in several tumor types. For 
example, the growth of BxPC-3 human pancreatic tumor xenografts implanted 
subcutaneously on posterior flanks is largely or entirely suppressed by intraperitoneal 
dosing with CPI-613 at 25-75mg/kg. Moreover, ca. 40% of these animals survive for more 
than 9 months (termination of study) without regrowth of tumors after an initial three week 
treatment regime. [A large fraction of the 60% mortality in this study is attributable to 
normal attrition in these genetically immunocompromised nude mice. Thus, cancer-free 
post-treatment survival in these animals is apparently substantially higher than 40%.] 
Titration studies demonstrate that CPI-613 produces very substantial tumor growth 
inhibition in xenograft model systems at doses (0.1-1mg/kg) very substantially lower than 
the maximum tolerated dose (ca. 100mg/kg)[2; our unpublished results]. This indicates a 
very high possible therapeutic index. Large-animal toxicology studies further corroborate 
the very low toxicity of CPI-613 [69]. Moreover, drug metabolism studies indicate that CPI-
613 breakdown products are unlikely to pose a barrier to clinical development [70].  
Based on this favorable mechanistic and pre-clinical animal data, Phase I/II clinical trials are 
currently underway at several locations (see comments at http://clinicaltrials.gov/ 
ct2/show/NCT01520805). These studies indicate that adverse events of CPI-613 in humans 
are low and mostly mild (well tolerated to at least 3,000mg/m2, when infused over one hour) 
and suggest efficacy against several advanced cancers, including refractory/relapsed AML, 
in several patients [71-73]. It will be of interest to continue to pursue the clinical 
investigation of these investigational drugs. 
7. The central role of lipoate as a metabolic regulatory signal, other 
potential thioctoid tumor targets 
In view of the capacity of thioctoids to attack tumor cell PDH it may be of value to consider 
the potential of these agents to address tumor metabolism more generally. Indeed, the 
properties of lipoate suggest that it may act as a global mitochondrial regulatory signaling 
molecule, possibly addressing the entire flow of carbon through this compartment. On this 
view, lipoate analogs may address multiple regulatory pathways, some or all altered in 
tumor cells analogously to the well-understood PDH case. 
Specifically, two other enzyme complexes are recognizably homologous to PDH and 
catalyze analogous reactions. One of these is the branched chain oxoacid dehydrogenase 
complex (BCDH) as reviewed in [74]. The other is the KGDH complex (above). BCDH 
governs the entry of carbon from a series of amino acids into the TCA cycle. KGDH governs 
the entry of glutamine-derived carbon (Figure 1). Together with PDH control of 
carbohydrate derived carbon, these three enzymes directly control initial access of all carbon 
to the TCA cycle, except for that derived from fatty acids. Moreover, even fatty acid-derived 
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carbon flow is implicitly governed by lipoate-dependent dehydrogenases because no fatty 
acid carbon can be oxidatively released without first passing through the KGDH complex 
[6]. Thus, all carbon flow through mitochondria is ultimately controlled by lipoate-
containing enzymes. 
The role of lipoate residues in controlling PDH function and the unique capacity of these 
residues to poll and reflect the mitochondrial energy status strongly suggests that lipoate 
residues will play a role in regulating BCDH and KGDH function. While this possibility 
remains to be investigated, it is noteworthy that the BCDH complex is regulated by kinases 
homologous to PDKs. It is plausible that these regulatory kinases are also responsive to 
lipoate redox/acylation state. Moreover, in view of the rather dramatic reprogramming of 
tumor mitochondrial metabolism, it is also plausible that BCDH regulatory kinases may be 
reprogramed in malignancy.  
KGDH is apparently not regulated by PDK-like kinases and the details of its metabolic 
regulation remain to be investigated. However, the complex shows strong allosteric 
regulation by end products, consistent with important regulatory objectives [75, 76]. Thus, it 
is likely that KGDH lipoates also participate in this regulation in some way that largely 
remains to be determined. 
As reviewed in section 3 above,  the lipoate residues of PDH, BCDH and KGDH exist as a 
cloud polling crucial features of the mitochondrial energy state, including the aggregate 
levels of free reducing potential (NADH) and of their respective acyl-CoA products. 
Moreover, these details of the mitochondrial energy state are likely to be among the state 
variables most informative about the moment-to-moment metabolic needs of the 
mitochondrion. Further, these regulatory goals of mitochondria are so substantially altered 
in tumor cells that we anticipate that all these potential lipoate-sensitive regulatory targets 
might be substantially altered in tumor cells, as they clearly are in the PDH case. Finally, the 
long boom-like structure of the enzyme linked lipoamide moieties (Figures 2) and their 
attachment to highly mobile E2 enzyme subdomains (Figure 3) raises an additional 
important regulatory possibility. It is conceivable that these actively polling lipoate residues 
are not merely reporting their results to their individual complexes but also to other 
mitochondrial consumers of regulatory information.  
Collectively, these considerations suggest that thioctoid lipoate analogs may achieve their 
dramatic inhibition of tumor cell mitochondrial metabolism by addressing multiple, 
essential metabolic regulatory processes in a tumor-specific fashion. The promising pre-
clinical and early clinical properties of thioctoid CPI-613 indicate that it will be of interest to 
explore this possibility in detail going forward. 
8. Conclusions 
The central role of lipoate-dependent dehydrogenases in governing carbon flow through 
mammalian mitochondria is reflected in their extensive regulation. Moreover, both 
empirical evidence and theoretical considerations indicate that the regulation of these 
 
Dehydrogenases 56 
complexes is strongly controlled by the dynamic status of their lipoate residues, reflecting a 
moment-to-moment polling of the mitochondrial matrix. Finally, evidence and theory also 
indicate that some or most of these lipoate-dependent regulatory processes are very 
significantly altered in support of the substantial repurposing of tumor cell mitochondrial 
metabolism relative to its normal cell condition. 
Collectively, these results indicate that the regulatory reprogramming of these 
dehydrogenases may represent a target-rich environment for developing new anti-tumor 
drugs that have the crucial properties that may be required to impart new efficacy to cancer 
chemotherapy – targets that are both essential to the malignant condition and non-
redundant in their function. The preclinical and early clinical properties of agents directed at 
these targets support the possibility of useful promise in this therapeutic domain. 
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1. Introduction 
Glutamate Dehydrogenase (GDH) catalyzes the oxidative conversion of glutamate to alpha 
ketoglutarate and ammonium supplying the TCA cycle with intermediates in support of 
anaplerosis (Figure 1 Rxn1). Conversely GDH catalyzes the reductive amination of alpha 
ketoglutarate and ammonium producing glutamate when the TCA cycle pool is filled. The 
net GDH flux resulting from these bidirectional fluxes can be obtained from the conversion 
of either 15N labeled glutamate and analyzing 15N ammonium or from 15N labeled NH4+ 
and monitoring 15N labeled glutamate. Besides deamination and 15N NH4+ production, 15N 
labeled glutamate can be converted to 15N labeled amino acids, most prominently alanine, 
via transamination reactions (Figure 1, Rxn2). In contrast to glutamate deamination which 
yields net keto acid production for anaplerosis [1], transamination does not yield net keto 
acid production (consuming a keto acid e.g. pyruvate in the process of generating alpha 
ketoglutarate). Under physiological conditions plasma glutamate concentration, 10-20uM, is 
limiting for GDH flux supplying TCA intermediates while plasma glutamine concentration, 
600uM, is not [2]. The conversion of 15N amide labeled glutamine to 15N ammonium 
(Figure1, Rxn1) approximates the net glutaminase flux generating glutamate and 
ammonium, both potential substrates for GDH. Indeed GDH can also incorporate the amide 
derived 15N ammonium and alpha ketoglutarate into glutamate (Figure 1, Rxn3, reductive 
amination) which can subsequently transaminate with pyruvate generating 15N alanine [3]. 
Noteworthy this glutaminolytic anabolic pathway providing glutamate has been proposed 
as the primary metabolic transformation in tumor cells [4]. Figure 1, Rxn 3 also illustrates 
how ammonium production from the 15N amide of glutamine may underestimate the true 
glutaminase flux; to the extent that this occurs, it contributes to differences in estimated net 
glutaminase fluxes between the chemically measured glutamine disappearance and 15N 
amide ammonium appearance. Glutamine labeled with 15N in the amino position provides 
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an assessment of net GDH flux (Figure 1,Rxn1) as 15N NH4+ and, or, ALT flux as 15N 
alanine produced(Figure1,Rxn2).  
 
Figure 1. GDH determines the fate of 15N glutamine. Pathways of glutaminolysis, net keto acid 
production and NH4+ produced per glutamine consumed ratio. [1] Deamidation coupled to GDH 
deamination yielding 2NH4+/Gln and net keto acid (αKG). [2] Deamination coupled to ALT-mediated 
transamination yielding 1 NH4+/Gln and no net acid production. [3] Deamidation coupled to GDH 
reductive amination and transamination yielding < 1 NH4+/Gln and net keto acid 
2. Glutamine is the major source of ammonium produced in  
cultured cells 
Because the bulk (≈90%),[1,3-5] of the ammonium produced by cells in culture derives from 
glutamine’s 2 nitrogen moieties (preformed DMEM media glutamate is <50uM) chemical 
measures of ammonium produced (after subtracting any ammonium produced in the 
absence of glutamine) and glutamine consumed offers an index of the GDH pathway 
activity. A ratio of 1, for example, would be consistent with glutamine metabolized by 
glutaminase with NH4+ released to the media and glutamate either released to the media or 
transaminated to amino acids e.g. alanine (Figure 1, Rxn2). In either case there is no net 
GDH flux and therefore no net generation of keto acids. In contrast a ratio of 2 
NH4+/glutamine (Figure 1, Rxn1) is consistent with glutamine metabolized by glutaminase 
and the glutamate produced metabolized by GDH yielding NH4+ and net keto acid 
(anaplerosis) for the TCA cycle(running in either the normal forward or reverse direction,[ 
6]). On the other hand, an NH4+ produced per glutamine consumed less than 1 (Figure 1, 
Rxn3) is consistent with glutaminase generating NH4+ from the amide nitrogen with 
reductive amination [3,4] catalyzed by GDH reducing the NH4+/Gln ratio to less than 1 
producing glutamate and consuming net keto acid (alpha ketoglutarate); subsequent 
transamination yields amino acids(e.g. alanine, aspartate) consuming keto acids 
(cataplerosis) containing the amide nitrogen of glutamine[3,4]. Normal breast cell line 
exhibits an NH4+/glutamine ratio less than 1[7] whereas cancerous breast cell lines exhibit a 
ratio greater than 1[7] consistent with a quantitative difference in bidirectional GDH fluxes 
between normal (reductive amination) and tumorigenic cells (oxidative deamination). In 
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addition, in vivo administered [2-(14)C] labeled glutamate was taken up by tumors with 14C 
distributed more into protein and lactate than in normal tissues [ 8 ]. In line with this early 
finding, a recent study[9] showed[U-(13)C] glucose contributed less than 50% of the acetyl 
COA pool in human brain tumors consistent with glutaminolysis and GDH’s role in 
maintaining TCA pool homeostasis (anaplerosis).  
3. Intracellular glutamate and alpha ketoglutarate are in near equilibrium 
In most cells intracellular glutamate and alpha ketoglutarate are in near equilibrium[4,10], 
and changes in TCA cycle intermediates(αKG) as well as the redox state(NADPH/NADP), 
energy charge(ADP,GTP) and cell pH shift the GDH catalyzed flux to net production or 
consumption of αKG (Figure 2). Normally pyruvate (glucose) provides the TCA cycle with 
pool intermediates while generated glutamate is transaminated (NH4+/GLN ratio<1, Figure 1 
Rxn3). In cancer cells, glucose is shunted into aerobic glycolysis (Warburg effect, [11]) and 
the TCA cycle intermediates are reduced as the result of cataplerosis as evidenced by lower 
intracellular glutamate [7]. This reduction in TCA cycle intermediates “pulls” glutamate 
through GDH generating αKG as evidenced by the higher steady state NH4+/GLN ratio>1, 
Figure 1, Rxn1 and consistent with glutamate (glutaminolysis) supporting anaplerosis 
(Figure 2). As a corollary, the ammonium to alanine produced ratio increases [7] reflecting 
the increased GDH and decreased ALT flux as the result of reduced intramitochondrial 
pyruvate(metabolized in cytosol to lactate, Figure 2). Thus the increased glutamate flux 
through GDH generates αKG while sparing keto acid consumption (reduced 
transamination).  
4. Glutamate is generated by extra- and intracellular glutaminases  
Glutaminolysis as illustrated in Figure 2 is associated with the increased expression of both 
the  extr ins ic  ce l l  membrane phosphate  independent  g lutaminase/gamma 
glutamyltransferase/gamma glutamyltranspeptidase (PIG, GGT, GGTP) which generates 
extracellular glutamate [2,12] and intracellular phosphate dependent glutaminases, 
Phosphate dependent glutaminases (PDG,GLS1 and GAC, [13,14]) which generates 
glutamate cytosolically [2,13]; extracellular glutamate can be transported(GLAST, Figure2) 
into the cytosol functioning as an inhibitor of the intracellular glutaminases[2]. Noteworthy, 
c-myc signaling up-regulates both the cell membrane glutamine transporter (ASC, Figure 2) 
and the intracellular glutaminases in cancer cells [15]. On the other hand, increased 
expression of the extracellular PIG is also a hallmark of cancer cells [16] and PIG hydrolysis 
of ϒ-glutamyl-tagged fluorescent markers can be used to delineate tumor boundaries [16]. 
However, in contrast to glutamine uptake, cell membrane glutamate transport (GLAST1) is 
shifted from the cell membrane to an intracellular location in breast cancer cells as shown in 
Figure 3, effectively uncoupling extracellular glutamate from inhibiting the intracellular 
glutaminases; this allows full blown expression of intracellular glutamate generation(Figure 
1RXI) and, if the relocated glutamate transporter, GLAST1 transports glutamate from the 
outer surface of inner mitochondrial membrane into the into the mitochondria matrix [17],  
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Figure 2. Central role of GDH flux in cancer cells. Glucose (GLC) derived pyruvate(PYR) is 
metabolized(Warburg effect) to lactic acid(LAC) at the expense of the TCA (tricarboxylic acid) cycle 
intermediate pool(αKG) “pulling” glutamate through GDH to supply anaplerosis. NHE(sodium 
hydrogen ion exchanger 1) mediated acid extrusion is up-regulated coupled to anaerobic glycolysis 
acidifying extracellular milieu while cell membrane glutamate transporter(GLAST1) relocates to 
mitochondria with PIG produced GLU- accumulating extracellularly and contributing with reduced 
pHe to host defense barrier. Glutamine(GLN) transported into cell by ASC and hydrolyzed to 
glutamate on outer surface of inner mitochondrial membrane by GAC [13] coupled with GLAST1. GLC 
removal (dashed line) accentuates GDH flux by “pull” mechanism while NHE mediated acid extrusion 
supported by GDH and accelerated αKG input with cytosolic malate(MAL) conversion to PYR 
supplying anaplerosis. TRO blocks PYR entry into mitochondria and accelerates GDH flux by 
exaggerated pull mechanism in conjunction with reduced pHi as result of NHE1 inhibition (“push” 
mechanism). EGCG inhibits GDH and induces cell death that can be partly rescued with methyl 
pyruvate(CH3-PYR) and restored TCA cycle pool while correction of cellular acidosis requires GDH 
flux pointing to the dual role for GDH in anaplerotic and acid base homeostasis. 
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then it would supply GDH glutamate in support of anaplerosis . Noteworthy  
overexpression of PIG promotes tumorigenesis [16] presumably by building up extracellular 
glutamate and suppressing local immune responses [18] . In addition NHE mediated acid 
extrusion is up-regulated in cancer cells [19,20] importing a Na+ load requiring Na+/K+ 
ATPase - ATP expenditure and ATP regeneration associated with acidogenic aerobic 
glycolysis(Warburg effect) and by substrate level phosphorylation. Because PIG 
(GGT/GGTP), NHE, glutamine transporter and glutaminase activities are all up-regulated in 
rapidly growing tumors, tagging molecular target inhibitors [21-24] with a ϒ-glutamyl 
moiety offers a tumor specific vehicle specific for limiting anaplerosis and preventing 
elevated cell pH, prerequisites for rapid tumor growth. 
 
Figure 3. GLAST localization in normal versus cancer cells. MCF10A and MCF7 cells cultured on 
coverglass were stained with monoclonal antibodies to GLAST-1 . MCF10A demonstrate almost 
complete membrane localization of the transporter, while MCF7 have a cytoplasmic distribution 
pattern. 
5. Glucose removal lowers TCA cycle intermediates and “pulls” 
glutamate through GDH       
Removal of glucose from the media (Figure 2, dotted gray line from GLC) deprives cells of 
pyruvate input into the TCA cycle and a fall in the intermediate (αKG) pool level[5] as reflected 
by a drop in glutamate [7]. As a consequence, GDH flux (Figure 1, Rxn1) increases [5] supplying 
anaplerosis as malate exits the cycle forming pyruvate which in turn supports citrate formation 
(Figure 2). Noteworthy this increased glutamate flux through GDH(“pulling” effect) is 
maintained by 2 responses:1] by a small increase in glutaminase flux [5,7] and, 2] a large fall in 
glutamate transamination [5,7,25].Under glucose deprivation cell survival is dependent on GDH 
flux at least in part to supply anaplerosis [5,26]. Surprisingly cell number actually increase in the 
glutamine (1.3mM) alone compared to the glucose(5mM) plus glutamine media (Figure 4A) 
because of reduced cell death; this increased survival is attributed to the increased GDH flux [26] 
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which besides supporting anaplerosis also enhances NHE mediated acid extrusion (Figure 4D) 
although proliferation rate decreases (Figure 4B). Noteworthy is the increase in cell 
biomass(protein, nucleic acids and lipid) dependent upon glutaminolysis supported anaplerosis 
as shown by the increased incorporation of 14C-U-glutamine into cell biomass (Figure 4C).The 
critical role of GDH flux in cell survival is evident from the massive cell death induced by GDH 
inhibition under glucose depleted conditions with 100uM EGCG [5,26], an inhibitor of GDH [5]. 
Although supplying TCA cycle intermediates e.g. methyl pyruvate (10mM,Figure 2) rescued 
cells with GDH inhibited [5,26], a significant fraction of the population succumbed associated 
with a reduced cell pH [26]. Parenthetically, methylpyruvate is a strong acid constituting a large 
acid load which requires supplementing the media with equal moles of bicarbonate (10mM). 
Nevertheless, even after the above base compensation, supplying anaplerotic substrates does not 
restore NHE activity [26] pointing to an important dual role for GDH in maintaining both 
anaplerosis and pH homeostasis [22] for cell survival.  
 
Figure 4. Physiological(1.3mM) glutamine concentration alone supports breast cancer cell survival 
associated with increased anaplerotic and acid extrusion function. 4A GLN increased cell number and 
decreased cell death compared to GLN plus 5mM glucose; 4B Gln slows cell proliferation compared 
with GLC+GLN; 4C GLN supports anaplerotic function[14C-U-L-glutamine incorporation into TCA 
precipitated cellular protein and lipid 4D GLN supports accelerated NHE activity when assayed with K 
10mM GLN as opposed to 10mM GLC 
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6. Cellular acidosis “pushes” glutamate through GDH 
Glutamate flux through GDH can be also be “pushed” by a fall in intracellular pH [27]. 
Whether this reflects a shift from GHD1 to GDH2 isoform [28] is not known but, if so, this 
“pushing effect” of reduced pH effect could be additive with the above “pulling effect” of a 
reduced TCA pool (Figure 2). Indeed in metabolic acidosis, the ambient condition 
surrounding cancer cells in vivo, kidney cells’ glutaminolysis is both “pushed”(reduced cell 
pHi, [27]) and “pulled”(inhibition of TCA, [29]) as a result of reduced TCA cycle pool size 
associated with true renal growth [30]. Interestingly enough, the in vivo kidney switches 
fuels from lactate to glutamine oxidation in metabolic acidosis[31] so that the anaplerotic 
glutaminolysis-GDH reactions matches [32] the cataplerotic reactions(CO2, biomass 
formation, [30,31] as does acid excretion (2NH4+/glutamine) and base(2HCO3-/glutamine) 
generation. Furthermore the pH-dependent enlistment of GDH2 isoform alone (push 
mechanism) or accompanying GDH 1 flux (anaplerosis driven pull mechanism) would 
provide regulatory options in responding to anaplerotic/cataplerotic and, or, acid /base 
demands in tumors. 
7. Glitazones accelerate GDH flux via the push/pull mechanism:  
A strategy for therapeutic intervention 
Fortuitously there are agents that can be employed to impose this push/pull mechanism on 
the GDH flux in cancer cells and thereby present a window of vulnerability (targeted 
inhibitors). The antihyperglycemic agents, troglitazone (Rezulin) and rosiglitazone 
(Avandia)  block pyruvate entrance into the TCA cycle(25,33] lowering αKG(glutamate,7,25] 
and accelerating GDH flux via this “pull” mechanism (Figure 2). Simultaneously, both 
troglitazone and rosiglitazone directly inhibit NHE [25,34] lowering pHi and driving GDH 
via the “push” mechanism (Figure 2). Noteworthy the glutaminase flux (glutamine 
disappearance) remains unchanged while the NH4+ production increases as the result of the 
increase in deamination flux (GDH Figure 1, Rxn1). Although resembling glucose 
deprivation (“pull” mechanism), troglitazone further increases the NH4+ production 
(additive “push+pull” mechanism) exceeding the fall in alanine production (“pull” 
mechanism alone). More specifically the accelerated GDH flux (“push+pull”) induced by 
troglitazone can be demonstrated using 15N amino labeled glutamine as shown in Figure 5; 
in contrast, another glitazone pioglitazone(Actos) activates GDH flux [34] solely by reducing 
cell pH(“push” mechanism) and consequently does not reduce alanine production [34]. 
Noteworthy troglitazone acutely inhibits GDH flux (0-3hrs) as the result of a fall in 
mitochondrial membrane potential( Ѱm) requiring accelerated GDH flux(3-24hrs) to fully 
restore the Ѱm [7], a response that is PPARγ independent [7,25] and possibly mitoNEET [35] 
dependent. Little recognized is the direct inhibition of NHE[20,34] by both troglitazone and 
rosiglitazone as well as indirect inhibition mediated through PPARγ suppression of NHE 
gene expression[20,36]; in contrast, pioglitazone does not inhibit NHE directly[34] rather 
acts indirectly through PPARγ[36]lowering cell pH[34] and accelerating GDH flux(“push” 
mechanism). In combination, TRO +PIO together exert an additive effect on GDH flux 
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presumably reflecting both TRO’s “pull” action and PIO’s PPARγ- mediated down-
regulation of NHE gene expression. Significantly, the dual effect of glitazones to increase 
GDH flux while reducing NHE activity decreases proliferation(NHE) but increases cell 
survival(GDH) resulting in only a slight decrease in cell number[26]. Nor does adding 
troglitazone to glucose deleted cells induce massive cell death since the effect on GDH flux 
is additive (further reducing TCA intermediates and cell pH, Figure 2) and although 
proliferative rates are decreased, survival is enhanced [26]. Under these conditions, e.g. cell 
survival mechanisms, inhibition of GDH is most effective in causing massive cell death as 
occurs with the GDH inhibitor EGCG [5] combined with troglitazone [26]. Although rescue 
of cells is partly possible by restoring anaplerosis with methyl pyruvate, failure to restore 
NHE activity and the cellular acidosis preclude full recovery underlining the importance of 
both GDH and NHE in cell survival[26].  
 
 
 
 
 
 
 
Figure 5. Ammonium production from amino nitrogen of glutamine. Cells were incubated for 18 
hours in [2-15N] glutamine. TRO was used at  20 uM, PIO 10 uM. Results are from 3 experiments.  
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